

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 1 022 286 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:

**26.07.2000 Bulletin 2000/30**

(21) Application number: **98945638.9**

(22) Date of filing: **06.10.1998**

(51) Int. Cl.<sup>7</sup>: **C07K 14/47, C12N 15/12,  
C12P 21/02, C12P 21/08,  
C07K 16/18, A61K 39/395,  
A61K 38/17, A61K 48/00**

(86) International application number:

**PCT/JP98/04514**

(87) International publication number:

**WO 99/18126 (15.04.1999 Gazette 1999/15)**

(84) Designated Contracting States:

**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL  
PT SE**

(30) Priority: **07.10.1997 JP 27467497**

(71) Applicant:

**ONO PHARMACEUTICAL CO., LTD.  
Osaka-shi, Osaka 541-8526 (JP)**

(72) Inventors:

- **FUKUSHIMA, Dalkichi;  
Minase Res. Inst., Ono Phar.  
Mishima-gun Osaka 618-8585 (JP)**

• **SHIBAYAMA, Shiro;**

**Minase Res. Inst., Ono Pharm.  
Mishima-gun Osaka 618-8585 (JP)**

• **TADA, Hideaki;**

**Minase Res. Inst., Ono Pharm. Co.,  
Mishima-gun Osaka 618-8585 (JP)**

(74) Representative:

**Henkel, Feiler, Hänzel  
Möhlstrasse 37  
81675 München (DE)**

(54) **POLYPEPTIDE, cDNA ENCODING THE POLYPEPTIDE, AND USE OF THE BOTH**

(57) A novel polypeptide obtained from a human library by the SST technique; a process for producing the polypeptide; a cDNA encoding the polypeptide; a fragment selectively hybridizing with the sequence of the cDNA; a replication or expression plasmid having the cDNA integrated therein; a host cell transformed with the plasmid; an antibody against the polypeptide; and a pharmaceutical composition containing the polypeptide or the antibody.

**EP 1 022 286 A1**

**Description****Technical Field**

- 5 **[0001]** The present invention relates to novel polypeptides, a method for preparation of them, a cDNA encoding it, a vector containing it, a host cell transformed with the vector, an antibody against the peptide, and a pharmaceutical composition containing the polypeptide or the antibody.

**Technical Background**

- 10 **[0002]** Until now, when a man skilled in the art intends to obtain a particular polypeptide or a cDNA encoding it, he generally utilizes methods by confirming an aimed biological activity in a tissue or in a cell medium, isolating and purifying the polypeptide and then cloning a gene or methods by "expression-cloning" with the guidance of the said biological activity. However, physiologically active polypeptides in living body have often many kinds of activities. Therefore, it happens increasingly that after cloning a gene, the isolated gene is found to be identical to that encoding a polypeptide already known. In addition, some factors could be generated in only a very slight amount and/or under specific conditions and it makes difficult to isolate and to purify the factor and to confirm its biological activity.

- 15 **[0003]** Recent rapid developments in techniques for constructing cDNAs and sequencing techniques have made it possible to quickly sequence a large amount of cDNAs. By utilizing these techniques, a process, which comprises constructing cDNAs library using various cells or tissues, cloning the cDNA at random, identifying the nucleotide sequences thereof, expressing novel polypeptides encoded by them, is now in progress. Although this process is advantageous in that a gene can be cloned and information regarding its nucleotide sequence can be obtained without any biochemical or genetic analysis, the target gene can be discovered thereby only accidentally in many cases.

- 20 **[0004]** The present inventors have studied cloning method to isolate genes encoding proliferation and/or differentiation factors functioning in hematopoietic systems and immune systems. Focusing their attention on the fact that most of the secretory proteins such as proliferation and/or differentiation factors (for example various cytokines) and membrane proteins such as receptors thereof (hereafter these proteins will be referred to generally as secretory proteins and the like) have sequences called signal peptides in the N-termini, the inventors have conducted extensive studies on a process for efficiently and selectively cloning a gene encoding for a signal peptide. Finally, we have successfully developed a screening method for the signal peptides (signal sequence trap (SST)) by using mammalian cells (See Japanese Patent Application No. Hei 6-13951). We also developed yeast SST method on the same concept. By the method based on the same conception using yeast (yeast SST method), genes including sequence encoding signal peptide can be identified more easily and efficiently (See USP No. 5,536, 637).

**Disclosure of the present invention**

- 35 **[0005]** The present inventors et al. have diligently performed certain investigation in order to isolate novel factors (polypeptides) useful for treatment, diagnosis and/or study, particularly, secretory proteins containing secretory signal and membrane protein.

- 40 **[0006]** From the result, the present inventors achieved to find novel secretory proteins and membrane proteins produced from cell lines and tissue, for example, human placenta, human adult brain tissue, cell lines derived from human brain tissue, human bone, cell line derived from human bone marrow, and endothelial cell line of vein derived from human umbilical cord and cDNAs encoding them, and then completed the present invention.

- 45 **[0007]** The present invention provides the cDNA sequences identified as done ON056, ON034, OX003 which were isolated by the said yeast SST method using cDNA libraries prepared from human placenta tissue. Clone ON056, ON034, OX003 were full-length cDNA including full cDNA sequences encoding secretory proteins (Each protein is represented as ON056, ON034, OX003 protein, respectively).

- 50 **[0008]** It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of ON056, ON034, OX003 of the present invention. From the above, it was proved that polypeptides of the present invention were new secretory proteins.

- 55 **[0009]** The present invention provides the cDNA sequences identified as clone OA052, OC004, OM017, OM101, OM126, OM160, OMA016a, OMA016b, OMB130, OMB142, OVB100 which were isolated by the said yeast SST method using cDNA libraries prepared from human adult brain tissue and cell lines derived from human brain tissue (T98G, IMR-32, and CCF-STTG1). Clone OA052, OC004, OM017, OM101, OM126, OM160, OMA016a, OMA016b, OMB130, OMB142, OVB100003 were full-length cDNA including full cDNA sequences encoding secretory protein (Each protein is represented as OA052, OC004, OM017, OM101, OM126, OM160, OMA016a, OMA016b, OMB130,

OMB142, OVB100 protein, respectively).

[0010] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OA052, OC004, OM017, OM101, OM126, OM160, OMA016a, OMA016b, OMB130, OMB142, OVB100 of the present invention. From these results, it was proved that polypeptides of the present invention were new secretory proteins.

[0011] The present invention provides the cDNA sequences identified as clone OAF062, OAF075, OAG119 which were isolated by the said yeast SST method using cDNA libraries prepared from human bone and bone marrow cell line (HAS303, LP101). Clone OAF062, OAF075, OAG119003 were full-length cDNA including full cDNA sequences encoding secretory protein (Each protein is represented as OAF062, OAF075, OAG119 protein, respectively).

[0012] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAF062, OAF075, OAG119 of the present invention. From these results, it was proved that polypeptides of the present invention were new secretory proteins.

[0013] The present invention provides the cDNA sequences identified as clone OAH040, OAH058 which were isolated by the said yeast SST method using cDNA libraries prepared from epithelial cell line of human umbilical vein (HUV-EC-C). Clone OAH040, OAH058003 were full-length cDNA including full cDNA sequences encoding secretory protein (Each protein is represented as OAH040, OAH058 protein, respectively).

[0014] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAH040, OAH058 of the present invention. From these results, it was proved that polypeptides of the present invention were new secretory proteins.

[0015] The present invention provides the cDNA sequences identified as clone OM011, OM028, OMB092, OMB108, OT007 which were isolated by the said yeast SST method using cDNA libraries prepared from human adult brain tissue and cell lines derived from human brain tissue (IMR-32). Clone OM011, OM028, OMB092, OMB108,

### OT007 は

membrane protein (Each protein is represented as OM011, OM028, OMB092, OMB108, OT007 protein, respectively).

[0016] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM011, OM028, OMB092, OMB108, OT007 of the present invention. From these results, it was proved that polypeptides of the present invention were new secretory proteins.

[0017] The present invention provides the cDNA sequences identified as clone OAG051, OUB068 which were isolated by the said yeast SST method using cDNA libraries prepared from human bone and bone marrow cell line (LP101 and U-2OS). Clone OAG051,

### OUB068 は

membrane protein (Each protein is represented as OAG051, OUB068 protein, respectively).

[0018] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAG051, OUB068 of the present invention. From these results, it was proved that polypeptides of the present invention were new secretory proteins.

[0019] That is to say, the present invention relates to

(1) a polypeptide comprising an amino acid sequence of SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79,

(2) a cDNA encoding the polypeptide described in (1),

(3) a cDNA comprising a nucleotide sequence of SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77 or 80, and

(4) a cDNA comprising a nucleotide sequence of SEQ ID NOS. 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42,

45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81.

### Brief Description of the Drawing

5 [0020]

Fig. 1 is a printed data of electrophoresis (SDS-PAGE). Each prepared fraction and the solubilized fraction obtained from insoluble fraction by urea described in Example 1 were subjected to SDS-PAGE. The proteins on the gel were detected by image analyzer (BAS2000) as shown in the Fig. 1. The expression of ON056 in *E. coli* is shown at the arrowhead in the figure.

### Detailed Description of the present invention

[0021] The present invention relates to a substantially purified form of the polypeptide comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79, homologue thereof, fragment thereof or homologue of the fragment.

[0022] Further, the present invention relates to cDNAs encoding the above peptides. More particularly the invention is provided cDNAs comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81, and cDNA containing a fragment which is selectively hybridizing to the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 46, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81. A said cDNA capable for hybridizing to the cDNA includes the contemporary sequence of the above sequence.

[0023] A polypeptide comprising amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79 in substantially purified form will generally comprise the polypeptide in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is that of the SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79.

[0024] A homologue of polypeptide comprising amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79 will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the polypeptide comprising the said amino acid sequence over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 more contiguous amino acids. Such a polypeptide homologue will be referred to a polypeptide of the present invention.

[0025] Generally, a fragment of polypeptide comprising amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79 or its homologues will be at least 10, preferably at least 15, for example 20, 25, 30, 40, 50 or 60 amino acids in length.

[0026] A cDNA capable of selectively hybridizing to the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the cDNA comprising the said nucleotide sequence over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 or more contiguous nucleotides. Such a cDNA will be referred to "a cDNA of the present invention".

[0027] Fragments of the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 will be at least 10, preferably at least 15, for example 20, 25, 30 or 40 nucleotides in length, and will be also referred to "a cDNA of the present invention" as used herein.

[0028] A further embodiment of the present invention provides replication and expression vectors carrying cDNA of the present invention. The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said cDNA and optionally a regulator of the promoter. The vector may contain one or more selectable marker genes, for example ampicillin resistance gene. The vector may be used in vitro, for example of the production of RNA corresponding to the cDNA, or used to transfect a host cell.

[0029] A further embodiment of the present invention provides host cells transformed, with the vectors for the replication and expression of the cDNA of the present invention, including the cDNA comprising nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 or the open reading frame thereof. The cells will be chosen to be compatible with the vector and may for example be bacterial, yeast, insect cells or mammalian cells.

- [0030]** A further embodiment of the present invention provides a method of producing a polypeptide which comprises culturing host cells of the present invention under conditions effective to express a polypeptide of the present invention. Preferably, in addition, such a method is carried out under conditions in which the polypeptide of the present invention is expressed and then produced from the host cells.
- 5 **[0031]** cDNA of the present invention may also be inserted into the vectors described above in an antisense orientation in order to prove for the production of antisense RNA. Such antisense RNA may be used in a method of controlling the levels of a polypeptide of the present invention in a cell.
- [0032]** The invention also provides monoclonal or polyclonal antibodies against a polypeptide of the present invention. The invention further provides a process for the production of monoclonal or polyclonal antibodies to the polypeptides of the present invention. Monoclonal antibodies may be prepared by common hybridoma technology using polypeptides of the present invention or fragments thereof, as an immunogen. Polyclonal antibodies may also be prepared by common means which comprise inoculating host animals, (for example a rat or a rabbit etc.), with polypeptides of the present invention and recovering immune serum.
- 10 **[0033]** The present invention also provides pharmaceutical compositions containing a polypeptide of the present invention, or an antibody thereof, in association with a pharmaceutically acceptable diluent and/or carrier.
- [0034]** The polypeptide of the present invention specified in (1) includes that which a part of their amino acid sequence is lacking (e.g., a polypeptide comprised of the only essential sequence for revealing a biological activity in an amino acid sequence shown in SEQ ID NO. 1), that which a part of their amino acid sequence is replaced by other amino acids (e.g., those replaced by an amino acid having a similar property) and that which other amino acids are added or inserted into a part of their amino acid sequence, as well as those comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79.
- 20 **[0035]** As known well, there are one to six kinds of codon as that encoding one amino acid (for example, one kind of codon for Methionine (Met), and six kinds of codon for Leucine (Leu) are known). Accordingly, the nucleotide sequence of cDNA can be changed in order to encode the polypeptide having the same amino acid sequence.
- 25 **[0036]** The cDNA of the present invention, specified in (2) includes a group of every nucleotide sequence encoding polypeptides (1) shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79. There is a probability that yield of a polypeptide is improved by changing a nucleotide sequence.
- [0037]** The cDNA specified in (3) is the embodiment of the cDNA shown in (2), and indicate the sequence of natural form.
- 30 **[0038]** The cDNA shown in (4) indicates the sequence of the cDNA specified in (3) with natural non-translational region.
- [0039]** cDNA carrying nucleotide sequence shown in SEQ ID NOS. 3 is prepared by the following method:
- [0040]** Brief description of Yeast SST method (see USP No. 5, 536, 637) is as follows.
- [0041]** Yeast such as *Saccharomyces cerevisiae* should secrete invertase into the medium in order to take sucrose or raffinose as a source of energy or carbon. (Invertase is an enzyme to cleave raffinose into sucrose and melibiose, sucrose into fructose and glucose.). It is known that many known mammalian signal sequence make yeast secrete its invertase. From these knowledge, SST method was developed as a screening method to find novel signal peptide which make it possible can to secrete yeast invertase from mammalian cDNA library. SST method uses yeast growth on raffinose medium as a marker. Non-secretory type invertase gene SUC2 (GENBANK Accession No. V 01311) lacking initiation codon ATG was inserted to yeast expression vector to prepare yeast SST vector pSUC2. In this expression vector, ADH promoter, ADH terminator (both were derived from AAH5 plasmid (Gammerer, Methods in Enzymol. 101, 192-201, 1983)), 2m ori (as a yeast replication origin), TRP1 (as a yeast selective marker), ColE1 ori (as a E. Coli replication origin) and ampicillin resistance gene (as a drug resistance marker) were inserted. Mammalian cDNA was inserted into the upstream of SUC2 gene to prepare yeast SST cDNA library. Yeast lacking secretory type invertase, was transformed with this library. If inserted mammalian cDNA encodes a signal peptide, yeast could survive in raffinose medium as a result of restoring secretion of invertase. Only to culture yeast colonies, prepare plasmids and determine the nucleotide sequence of the insert cDNAs, it is possible to identify novel signal peptide rapidly and easily.
- 45 **[0042]** Preparation of yeast SST cDNA library is as follows:
- 50 (1) mRNA is isolated from the targeted cells, double-strand synthesis is performed by using random primer with certain restriction enzyme (enzyme I) recognition site,  
 (2) obtained double-strand cDNA is ligated to adapter containing certain restriction endonuclease (enzyme II) recognition site, differ from enzyme I, digested with enzyme I and fractionated in a appropriate size,  
 (3) obtained cDNA fragment is inserted into yeast expression vector on the upstream region of invertase gene  
 55 which signal peptide is deleted and the library was transformed.

**[0043]** Detailed description of each step is as follows:

(1) mRNA is isolated from mammalian organs and cell lines stimulate them with appropriate stimulator if necessary by known methods (Molecular Cloning (Sambrook, J., Fritsch, E. F. and Maniatis, T., Cold Spring Harbor Laboratory Press, 1989) or Current Protocol in Molecular Biology (F. M. Ausubel et al, John Wiley & Sons, Inc.) if not remark especially).

5 TG98G (human glioblastoma cell line: ATCC No. CRL-1690), IMR-32 (human neuroblastoma cell line: ATCC No. CCL-127), U-2OS (human osteosarcoma cell line: ATCC No. HTB-96), CCF-STTG1 (human astrocytoma cell line: ATCC No. CRL-1718), HAS303 (human bone marrow stroma cell line: provide from Professor Keisuke Sotoyama, Dr. Makoto Aizawa of First Medicine, Tokyo Medical College; see J. Cell. Physiol., 148, 245-251, 1991 and Experimental Hematol., 22, 482-487, 1994), LP101 (human bone marrow stroma cell line: provide from Professor Keisuke Sotoyama, Dr. Makoto Aizawa of First Medicine, Tokyo Medical College; see J. Cell. Physiol., 148, 245-251, 1991 and Experimental Hematol., 22, 482-487, 1994) and HUV-EC-C (endothelial cell of vein derived from human umbilical cord: ATCC No. CRL-1730) are chosen as a cell line. Human placenta and human adult brain are chosen as a tissue source. Double-strand cDNA synthesis using random primer is performed by known methods.

15 Any sites may be used as restriction endonuclease recognition site I which is linked to adapter and restriction endonuclease recognition site II which is used in step (2), if both sites are different each other. Preferably, XhoI is used as enzyme I and EcoRI as enzyme II.

In step (2), cDNA is created blunt-ends with T4 DNA polymerase, ligated enzyme II adapter and digested with enzyme I. Fragment cDNA is analyzed with agarose-gel electrophoresis (AGE) and is selected cDNA fraction ranging in size from 300 to 800 bp. As mentioned above, any enzyme may be used as enzyme II if it is not same the enzyme I.

20 In step (3), cDNA fragment obtained in step (2) is inserted into yeast expression vector on the upstream region of invertase gene which signal peptide is deleted. E. Coli was transformed with the expression vector. Many vectors are known as yeast expression plasmid vector. For example, YEp24 is also functioned in E. Coli. Preferably pSUC2 as described above is used.

**[0044]** Many host E. Coli strains are known for transformation, preferably DH10B competent cell is used. Any known transformation method is available, preferably it is performed by electroporation method. Transformant is cultured by conventional methods to obtain cDNA library for yeast SST method.

30 **[0045]** However not every all of the clones do not contain cDNA fragment Further all of the gene fragments do not encode unknown signal peptides. It is therefore necessary to screen a gene fragment encoding for an unknown signal peptide from the library.

**[0046]** Therefore, screening of fragments containing a sequence encoding an appropriate signal peptide is performed by transformation of the cDNA library into *Saccharomyces cerevisiae* (e.g. YTA455 strain) which lack invertase (it may be prepared by known methods.). Transformation of yeast is performed by known methods, e.g. lithium acetate method. Transformant is cultured in a selective medium, then transferred to a medium containing raffinose as a carbon source. Survival colonies are selected and then prepared plasmid. Survival colonies on a raffinose-medium indicates that some signal peptide of secretory protein was inserted to this done.

**[0047]** As for isolated positive clones, the nucleotide sequence is determined. As to a cDNA encodes unknown protein, full-length clone may be isolated by using cDNA fragment as a probe and then determined to obtain full-length nucleotide sequence. These manipulation is performed by known methods.

**[0048]** Once the nucleotide sequences shown in SEQ ID NO. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 are determined partially or preferably fully, it is possible to obtain DNA encode mammalian protein itself, homologue or subset. cDNA library or mRNA derived from mammals was screened by PCR with any synthesized oligonucleotide primers or by hybridization with any fragment as a probe. It is possible to obtain DNA encodes other mammalian homologue protein from other mammalian cDNA or genome library.

**[0049]** If a cDNA obtained above contains a nucleotide sequence of cDNA fragment obtained by SST (or consensus sequence thereof), it will be thought that the cDNA encodes signal peptide. So it is clear that the cDNA will be full-length or almost full. (All signal peptides exist at N-termini of a protein and are encoded at 5'-termini of open reading frame of cDNA.)

**[0050]** The confirmation may be carried out by Northern analysis with the said cDNA as a probe. It is thought that the cDNA is almost complete length, if length of the cDNA is almost the same length of the mRNA obtained in the hybridizing band.

55 **[0051]** Once the nucleotide sequences shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77, 80, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 are determined, DNAs of the invention are obtained by chemical synthesis, or by hybridization making use of nucleotide fragments which are chemically synthesized as a probe. Furthermore, DNAs of the

invention are obtained in desired amount by transforming a vector that contains the DNA into a proper host, and culturing the transformant.

**[0052]** The polypeptides of the present invention may be prepared by:

- 5 (1) isolating and purifying from an organism or a cultured cell,
- (2) chemically synthesizing, or
- (3) using recombinant cDNA technology,

preferably, by the method described in (3) in an industrial production.

10 **[0053]** Examples of expression system (host-vector system) for producing a polypeptide by using recombinant cDNA technology are the expression systems of bacteria, yeast, insect cells and mammalian cells.

**[0054]** In the expression of the polypeptide, for example, in *E. Coli*, the expression vector is prepared by adding the initiation codon (ATG) to 5' end of a cDNA encoding mature peptide, connecting the cDNA thus obtained to the downstream of a proper promoter (e.g., trp promoter, lac promoter,  $\lambda$ PL promoter, T7 promoter etc.), and then inserting it into a vector (e.g., pBR322, pUC18, pUC19 etc.) which functions in an *E. coli* strain.

15 **[0055]** Then, an *E. coli* strain (e.g., *E. coli* DH1 strain, *E. coli* JM109 strain, *E. coli* HB101 strain, etc.) which is transformed with the expression vector described above may be cultured in a appropriate medium to obtain the desired polypeptide. When a signal sequence of bacteria (e.g., signal sequence of pel B) is utilized, the desired polypeptide may be also released in periplasm. Furthermore, a fusion protein with other polypeptide may be also produced readily.

20 **[0056]** In the expression of the polypeptide, for example, in a mammalian cells, for example, the expression vector is prepared by inserting the cDNA encoding nucleotide shown in SEQ ID NOS. 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 into the downstream of a proper promoter (e.g., SV40 promoter, LTR promoter, metallothionein promoter etc.) in a proper vector (e.g., retrovirus vector, papilloma virus vector, vaccinia virus vector, SV40 vector, etc.). A proper mammalian cell (e.g., monkey COS-7 cell, Chinese hamster CHO cell, mouse L cell etc.) is transformed with the expression vector thus obtained, and then the transformant is cultured in a proper medium to express the aimed secretory protein and membrane protein of the present invention by the following method.

**[0057]** In case of secretory protein as for the present invention, the aimed polypeptide was expressed in the supernatant of the cells. In addition, fusion protein may be prepared by conjugating cDNA fragment encoding the other polypeptide, for example, Fc portion of antibody.

30 **[0058]** On the other hand, in case of membrane protein as for the present invention, the aimed polypeptide was expressed on the cell membrane. A cDNA encoding the nucleotide sequence of SEQ ID NOS. 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81 with deletion of extracellular region was inserted into the said vector, transfected into the an adequate mammalian cells to secret the aimed soluble polypeptide in the culture medium. In addition, fusion protein may be prepared by conjugating cDNA fragment encoding the said mutant with deletion of extracellular region and other polypeptide, for example, Fc portion of antibody.

35 **[0059]** The polypeptide available by the way described above can be isolated and purified by conventional biochemical method.

#### 40 Industrial Applicability

**[0060]** It is considered that the polypeptide of the present invention and a cDNA which encodes the polypeptide will show one or more of the effects or biological activities (including those which relates to the assays cited below) The effects or biological activities described in relation to the polypeptide of the present invention are provided by administration or use of the polypeptide or by administration or use of a cDNA molecule which encodes the polypeptide (e.g., vector suitable for gene therapy or cDNA introduction).

[Cytokine activity and cell proliferation/differentiation activity]

50 **[0061]** The protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a polypeptide of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines.

[Immune stimulating/suppressing activity]

**[0062]** The protein of the present invention may also exhibit immune stimulating or immune suppressing activity. The protein of the present invention may be useful in the treatment of various immune deficiencies and disorders (inducing severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral infection such as HIV as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using the polypeptide of the present invention, including infections by HIV, hepatitis viruses, herpes viruses, mycobacteria, leishmania, malaria and various fungal infections such as candida. Of course, in this regard, the protein of the present invention may also be useful where a boost to the immune system generally would be indicated, i.e., in the treatment of cancer.

**[0063]** The protein of the present invention may be useful in the treatment of allergic reactions and conditions, such as asthma or other respiratory problems. The protein of the present invention may also be useful in the treatment of the other conditions required to suppress the immune system (for example, asthma or respiratory disease.)

**[0064]** The protein of the present invention may also suppress chronic or acute inflammation, such as, for example, that associated with infection such as septic shock or systemic inflammatory response syndrome (SIRS), inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1 wherein the effect was demonstrated by IL-11.

[Hematopoiesis regulating activity]

**[0065]** The protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis. The said biological activities are concerned with the following all or some example(s). e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemia or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complementary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vitro or ex-vivo (i.e. in conjunction with bone marrow transplantation) as normal cells or genetically manipulated for gene therapy.

**[0066]** The activity of the protein of the present invention may, among other means, be measured by the following methods :

[Tissue generation/regeneration activity]

**[0067]** The protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, Ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair, and in the treatment of burns, incisions and ulcers.

**[0068]** The protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, may be applied to the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing the protein of the present invention may have prophylactic use in dosed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

**[0069]** The protein of the present invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. The protein of the present invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.



**[0070]** Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. The protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, may be applied to the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing the protein inducing a tendon/Ligament-like tissue may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon Ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the present invention may also be useful in the treatment of tendinitis, Carnal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

**[0071]** The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue. i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, the protein of the present invention may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using the polypeptide of the present invention.

**[0072]** It is expected that the protein of the present invention may also exhibit activity for generation of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the proliferation of cells comprising such tissues. Part of the desired effects may be by inhibition of fibrotic scarring to allow normal tissue to regenerate.

**[0073]** The protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

#### [Activin/Inhibin activity]

**[0074]** The protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, the protein of the present invention alone or in heterodimers with a member of the inhibin \*a family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the present invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-\*b group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary (See USP 4,798,885). The protein of the present invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

#### [Chemotactic/chemokinetic activity]

**[0075]** The protein of the present invention may have chemotactic or chemokinetic activity e.g., functioning as a chemokine, for mammalian cells, including, for example, monocytes, neutrophils, T-cells, mast cells, eosinophils and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

**[0076]** If a protein or peptide can stimulate, directly or indirectly, the directed orientation or movement of such cell population, it has chemotactic activity for a particular cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of

cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

[Hemostatic and thrombolytic activity]

- 5 **[0077]** The protein of the present invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the present invention may also be useful for dissolving or inhibiting formation of thrombo-

10

[Receptor/ligand activity]

- [0078]** The protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including cellular adhesion molecules such as Selectins, Integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and develop-  
15 ment of cellular and humoral immune responses. Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. The protein of the present invention  
20 (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

[Other activity]

- 25 **[0079]** The protein of the present invention may also exhibit one or more of the following additional activities or effects: inhibiting growth of or killing the infecting agents including bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) body characteristics including height, weight, hair color, eye color, skin, other tissue pigmentation, or organ or body part size or shape such as, for example, breast augmentation or diminution etc.; effecting elimination of dietary fat, protein, carbohydrate; effecting behavioral characteristics including appetite, libido, stress, cognition (including cognitive disorders), depression and violent behaviors; providing analgesic effects or other pain  
30 reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases.

- [0080]** The protein with above activities, is suspected to have following functions by itself or interaction with its ligands or receptors or association with other molecules. For example, proliferation or cell death of B cells, T cells and/or mast cells; specific induction by promotion of class switch of immunoglobulin genes; differentiation of B cells to antibody-forming cells; proliferation, differentiation, or cell death of precursors of granulocytes; proliferation, differentiation, or cell death of precursors of monocytes-macrophages; proliferation, or up regulation or cell death of neutrophils, monocytes-macrophages, eosinophils and/or basophils; proliferation, or cell death of precursors of megakaryocytes; proliferation, differentiation, or cell death of precursors of neutrophils; proliferation, differentiation, or cell death of precursors of T cells and B cells; promotion of production of erythrocytes; sustainment of proliferation of erythrocytes, neutrophils, eosinophils, basophils, monocytes-macrophages, mast cells, precursors of megakaryocyte; promotion of migration of neutrophils, monocytes-macrophages, B cells and/or T cells; proliferation or cell death of thymocytes; suppression of differentiation of adipocytes; proliferation or cell death of natural killer cells; proliferation or cell death of hematopoietic stem cells; suppression of proliferation of stem cells and each hematopoietic precursor cells; promotion of differentiation from mesenchymal stem cells to osteoblasts or chondrocytes, proliferation or cell death of mesenchymal stem cells, osteoblasts or chondrocytes and promotion of bone absorption by activation of osteoclasts and promotion of differentiation from monocytes to osteoclasts.

- [0081]** The polypeptide of the present invention is also suspected to function to nervous system, so expected to have functions below; differentiation to kinds of neurotransmitter-responsive neurons, survival or cell death of these cells; promotion of proliferation or cell death of glial cells; spread of neural dendrites; survival or cell death of ganglionocytes; proliferation, promotion of differentiation, or cell death of astrocytes; proliferation, survival or cell death of peripheral neurons; proliferation or cell death of Schwann cells; proliferation, survival or cell death of motoneurons.

- [0082]** Furthermore, in the process of development of early embryonic, the polypeptide of the present invention is expected to promote or inhibit the organogenesis of epidermis, brain, backbone, and nervous system by induction of ectoderm, that of notochord connective tissues (bone, muscle, tendon), hemocytes, heart, kidney, and genital organs by induction of mesoderm, and that of digestive apparatus (stomach, intestine, liver, pancreas), respiratory apparatus (lung, trachea) by induction of endoderm. In adult, also, this polypeptide is thought to proliferate or inhibit the above organs.

**[0083]** Therefore, the polypeptide of the present invention itself is expected to be used as an agent for the prevention or treatment of disease of progression or suppression of immune, nervous, or bone metabolic function, hypoplasia or overgrowth of hematopoietic cells: for example, inflammatory disease (rheumatism, ulcerative colitis, etc.), decrease of hematopoietic stem cells after bone marrow transplantation, decrease of leukocytes, platelets, B-cells, or T-cells after radiation exposure or chemotherapeutic dosage against cancer or leukemia, anemia, infectious disease, cancer, leukemia, AIDS, bone metabolic disease (osteoporosis etc.), various degenerative disease (Alzheimer's disease, multiple sclerosis, etc.), or nervous lesion.

**[0084]** In addition, since the polypeptide of the present invention is thought to induce the differentiation or growth of organs derived from ectoderm, mesoderm, and endoderm, this polypeptide is expected to be an agent for tissue repair (epidermis, bone, muscle, tendon, heart, kidney, stomach, intestine, liver, pancreas, lung, and trachea, etc.).

**[0085]** By using polyclonal or monoclonal antibodies against the polypeptide of the present invention, quantitation of the said polypeptide in the body can be performed. It can be used in the study of relationship between this polypeptide and disease or diagnosis of disease, and so on. Polyclonal and monoclonal antibodies can be prepared using this polypeptide or its fragment as an antigen by conventional methods.

**[0086]** Identification, purification or molecular cloning of known or unknown proteins which bind the polypeptide of the present invention (preferably polypeptide of extracellular domain) can be performed using the polypeptide of the present invention by, for example, preparation of the affinity-column.

**[0087]** Identification of the downstream signal transmission molecules which interact with the polypeptide of the present invention in cytoplasm and molecular cloning of the gene can be performed by west-western method using the polypeptide of the present invention (preferably polypeptide of transmembrane region or intracellular domain), or by yeast two-hybrid system using the cDNA (preferably cDNA encoding transmembrane region or cytoplasmic domain of the polypeptide).

**[0088]** Agonists/antagonists of this receptor polypeptide and inhibitors between receptor and signal transduction molecules can be screened using the polypeptide of the present invention.

**[0089]** cDNAs of the present invention are useful not only the important and essential template for the production of the polypeptide of the present invention which is expected to be largely useful, but also be useful for diagnosis or therapy (for example, treatment of gene lacking, treatment to stop the expression of the polypeptide by antisense cDNA (mRNA)). Genomic cDNA may be isolated with the cDNA of the present invention, as a probe. As the same manner, a human gene encoding which can be highly homologous to the cDNA of the present invention, that is, which encodes a polypeptide highly homologous to the polypeptide of the present invention and a gene of animals excluding mouse which can be highly homologous to the cDNA of the present invention, also may be isolated.

#### [Application to Medicaments]

**[0090]** The polypeptide of the present invention or the antibody specific for the polypeptide of the present invention is administered systemically or topically and in general orally or parenterally, preferably parenterally, intravenously and intraventricularly, for preventing or treating the said diseases.

**[0091]** The doses to be administered depend upon age, body weight, symptom, desired therapeutic effect, route of administration, and duration of the treatment etc. In human adults, one dose per person is generally between 100 µg and 100 mg, by oral administration, up to several times per day, and between 10 µg and 100 mg, by parental administration up to several times per day.

**[0092]** As mentioned above, the doses to be used depend upon various conditions. Therefore, there are cases in which doses lower than or greater than the ranges specified above may be used.

**[0093]** The compounds of the present invention, may be administered as solid compositions, liquid compositions or other compositions for oral administration, as injections, liniments or suppositories etc. for parental administration.

**[0094]** Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders, and granules. Capsules include soft or hard capsules.

**[0095]** In such compositions, one or more of the active compound(s) is or are admixed with at least one inert diluent (such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, magnesium metasilicate aluminate, etc.). The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents (such as magnesium stearate etc.), disintegrating agents (such as cellulose calcium glycolate, etc.), stabilizing agents (such as human serum albumin, lactose etc.), and assisting agents for dissolving (such as arginine, asparaginic add etc.).

**[0096]** The tablets or pills may, if desired, be coated with a film of gastric or enteric materials (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate, etc.), or be coated with more than two films. And then, coating may include containment within capsules of absorbable materials such as gelatin.

**[0097]** Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, syrups and elixirs. In such compositions, one or more of the active compound(s) is or are contained in inert diluent(s) com-

monly used (purified water, ethanol etc.). Besides inert diluents, such compositions may also comprise adjuvants (such as wetting agents, suspending agents, etc.), sweetening agents, flavoring agents, perfuming agents, and preserving agents.

[0098] Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents (sodium sulfite etc.), isotonic buffer (sodium chloride, sodium citrate, citric acid, etc.). For preparation of such spray compositions, for example, the method described in the United States Patent No. 2,868,691 or 3,095,355 (herein incorporated in their entireties by reference) may be used.

[0099] Injections for parental administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. In such compositions, one or more active compound(s) is or are admixed with at least one inert aqueous diluent(s) (distilled water for injection, physiological salt solution, etc.) or inert non-aqueous diluents(s) (propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSOLBATE 80 (Trade mark) etc.).

[0100] Injections may comprise additional compound other than inert diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agent (such as human serum albumin, lactose, etc.), and assisting agents such as assisting agents for dissolving (arginine, asparaginic acid, etc.).

#### Best Mode carrying out the invention

[0101] The invention is illustrated by the following examples, but not limit the invention.

Example 1: Clone ON056

##### (1) Preparation of Poly(A)\*RNA

[0102] Total RNA was prepared from human placenta tissue by TRIzol reagent (Trade Mark, marketed by GIBCO BRL Co.). Poly(A)\*RNA was purified from the total RNA by mRNA Purification Kit (Trade name, marketed by Pharmacia Co.).

##### (2) Preparation of yeast SST cDNA library

[0103] Double strand cDNA was synthesized by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning (Trade name, marketed by GIBCO BRL Co.) with above poly(A)\*RNA as template and random 9mer as primer which was containing XhoI site:

5'-CGA TTG AAT TCT AGA CCT GCC TCG AGN NNN NNN NN-3' (SEQ ID NO. 82).

cDNA was ligated EcoRI adapter by DNA ligation kit ver. 2 (Trade name, marketed by Takara Shuzo Co.; this kit was used in all ligating steps hereafter.) and digested by XhoI. cDNAs were separated by agarose-gel electrophoresis. 300-800 bp cDNAs were isolated and were ligated to EcoRI/NotI site of pSUC2 (see US Patent No. 5, 536, 637). E. Coli DH10B strains were transformed by pSUC2 with electroporation to obtain yeast SST cDNA library.

##### (3) Screening by SST method and determination of nucleotide sequence of SST positive clone

[0104] Plasmids of the said cDNA library were prepared. Yeast YTK12 strains were transformed by the plasmids with lithium acetate method (Current Protocols In Molecular Biology 13.7.1). The transformed yeast were plated on triptan-free medium (CMD-Trp medium) for selection. The plate was incubated for 48 hour at 30°C. Replica of the colony (transformant) which was obtained by Accutran Replica Plater (Trade name, marketed by Schleicher & Schuell) were placed onto YPR plate containing raffinose for carbon source, and the plate was incubated for 14 days at 30°C. After 3 days, each colony appeared was streaked on YPR plate again. The plates were incubated for 48 hours at 30°C. Single colony was inoculated to YPD medium and was incubated for 48 hours at 30°C. Then plasmids were prepared. Insert cDNA was amplified by PCR with two kind primers which exist end side of cloning site on pSUC2 (sense strand primers were biotinylated). Biotinylated single strand of cDNAs were purified with Dynabeads (Trade name, marketed by DYNAL Co.) and the nucleotide sequences were determined. Sequencing was performed by Dye Terminator Cycle Sequencing Ready Reaction with DNA Sequencing kit (Trade name, marketed by Applied Biosystems Inc.) and sequence was determined by DNA sequencer 373 (Applied Biosystems Inc.) (All sequencing hereafter was carried out with this method.).

[0105] We tried to carry out cloning of full-length cDNA which was proved to be new one according to the homology search for the obtained nucleotide sequences and deduced amino acid sequences in data base. We also confirmed that each cDNA contains signal peptide in view of function and structure, by comparison with known peptide which has signal peptide and deduced amino acid sequence.

## (4) Cloning of a full-length cDNA and determination of nucleotide sequence

[0106] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System (marketed by GIBCO BRL Co.). First, dT-primed cDNA library was prepared from poly (A)\*RNA in human placenta tissue using pSPORT1 plasmid (marketed by GIBCO BRL Co.), as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer ON056-F1 (27mer):

5' biotin-AACATGAATCTTTCGCTCGTCCTGGCT-3' (SEQ ID NO. 83)

based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. Coli DH10B. Colony hybridization with ON056 SST cDNA which was labeled with <sup>32</sup>P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit (Trade name, marketed by Takara Shuzo Co.) according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequences of 5'-end were determined, and the existence of nucleotide sequence ON056 SST cDNA was confirmed. Nucleotide sequence of full-length ON056 SST cDNA was determined and then sequence shown in SEQ ID NO. 3 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS: 1 and 2, respectively, were obtained.

[0107] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of ON056 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

[0108] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone ON056 (region of 1st-334th amino acid in SEQ ID NO. 1) and Human Cathepsin L (Swiss Prot Accession P07711) (region of 1st-334th amino acid) or between clone ON056 (region of 22nd- 334th amino acid in SEQ ID NO. 1) and Human Cathepsin K (Swiss Prot Accession P43235) (region of 19th-329th amino acid). Based on these homologies, clone ON056 and Human Cathepsin L family were expected to share at least some activity.

## (5) Expression of protein using E. Coli

[0109] The coding region cDNA fragments without sequence encoding signal peptide were amplified by PCR and inserted into the downstream of initiation codon ATG in pET expression vector (marketed by Novagen Co.) for E. Coli inframe to construct the plasmid for expression. The obtained plasmids were transfected into E. Coli BL21 (DE3) and the transformant was cultured with IPTG to induce the expression of protein. The obtained E. Coli was harvested and lysed with ultra-sonication or detergent. The insoluble fraction was solubilized with urea and subjected to SDS-PAGE. The expression of ON056 protein was confirmed by Coomassie staining (arrow in Fig. 1).

## (6) Expression of the protein using mammalian cell

[0110] Thus obtained full-length cDNA was conjugated into XhoI (or EcoRI)-NotI site of the pED6 expression vector of mammalian cells (See Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991)) to construct plasmid to express the secretory protein or membrane protein. The obtained plasmids were transfected into Cos 7 cells using Lypofectine (Trade name, marketed by GIBCO BRL Co.). After 24 hours, the transfection mixture was removed. The cells were cultured in the Met and Cys-free medium with <sup>35</sup>S-labeled Met and <sup>35</sup>S-labeled Cys for 5 hours. The supernatants were harvested and 10-fold concentrated with Centricon-10 (Trade name, marketed by Amicon Co.). The samples were separated on SDS-PAGE gels. After drying the acrylamidogel, the expression of <sup>35</sup>S-labeled protein was detected using BAS2000 (marketed by Fuji Film Co.).

## Example 2: Clone ON034

[0111] In Example relating to clone ON034 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

## (1) Preparation of Poly(A)\*RNA

[0112] Total RNA was prepared from human placenta tissue by TRIzol reagent. Poly(A)\*RNA was purified from the total RNA by mRNA Purification Kit.

## (2) Cloning of a full-length cDNA and determination of nucleotide sequence

**[0113]** A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)+RNA in human placenta tissue using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer ON034-F1 (28mer):

5' biotin-TGAAGCCCATCACTACATCGCCATTACG-3' (SEQ ID NO.: 84)

based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. Coli DH10B. Colony hybridization with ON034 SST cDNA which was labeled with 32P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequence of full-length ON034 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 6 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 4 and 5, respectively, were obtained.

**[0114]** It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of ON034 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

## Example 3: Clone OX003

**[0115]** In Example relating to clone OX003 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

**[0116]** Total RNA was prepared from human placenta tissue by TRIzol reagent. Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

## (2) Cloning of a full-length cDNA and determination of nucleotide sequence

**[0117]** A full-length cDNA was cloned using Marathon cDNA Amplification Kit (Trade name, marketed by Clontech Co.) according to 3' RACE (Rapid Amplification of cDNA End) method. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA in human placenta tissue. 27mer primer OX003-F1:

5'-CAAAACCCACAAGAAATTCACCAAGGC-3' (SEQ ID NOS. 85)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 23mer primer OX003-F2:

5'-TCACCAAGGCTAACATGGTGGCC-3' (SEQ ID NOS. 86)

was prepared additionally at 3' end of OX003-F1 primer and then nested PCR was performed. cDNA which was amplified with clone OX003 specifically was separated with agarose-gel electrophoresis, ligated to pT7 Blue-2 T-Vector (Trade name, marketed by Novagen Co.) and transfected into E. Coli DH5a to prepare the plasmid. First, Nucleotide sequences of 5'-end were determined, and the existence of nucleotide sequence OX003 SST cDNA was confirmed. Nucleotide sequence of full-length OX003 SST cDNA was determined and then sequence shown in SEQ ID NO. 9 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 7 and 8, respectively, were obtained.

**[0118]** It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OX003 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

## Example 4: Clone OA052

**[0119]** In Example relating to clone OA052 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

**[0120]** Total RNA was prepared from human glioblastoma cell line T98G (ATCC No. CRL-1690) by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

## (2) Cloning of a full-length cDNA and determination of nucleotide sequence

**[0121]** A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA conjugating adapter was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA in human glioblastoma cell line T98G according to the method of the said kit 27mer primer OA052-F1:

5'-ATGCCTAGAAGAGGACTGATTCTTCAC-3' (SEQ ID NO. 87)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. cDNA which was amplified with done OA052 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 12 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 10 and 11, respectively, were obtained.

**[0122]** It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OA052 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

## Example 5: Clone OC004

**[0123]** In Example relating to clone OC004 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

**[0124]** Total RNA was prepared from human adult brain tissue by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

## (2) Cloning of a full-length cDNA and determination of nucleotide sequence

**[0125]** A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA in human adult brain tissue. 27mer primer OC004-F1:

5'-ATGAGGAAAGGGAACCTTCTGCTGAGC-3' (SEQ ID NOS. 88)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 18mer primer OC004-F2:

5'-TGAGCTTCCAGAGCTGTC-3' (SEQ ID NOS. 89)

was prepared additionally at 3' end of OC004-F1 primer and then nested PCR was performed. cDNA which was amplified with done OC004 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 15 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 13 and 14, respectively, were obtained.

**[0126]** It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OC004 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

## Example 6: Clone OM017

**[0127]** In Example relating to clone OM017 of the present invention, the same procedure as in Example of ON056

was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

- 5 [0128] Total RNA was prepared from human adult brain tissue by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

(2) Cloning of a full-length cDNA and determination of nucleotide sequence

- 10 [0129] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA in human adult brain tissue. 27mer primer OM017-F3:

5'-GGGAAATGAAACATTTCTGTAACTGC-3' (SEQ ID NOS. 90)

- 15 containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 27mer primer OM017-F1:

5'-ATGAAACATTTCTGTAACTGCTTTGT-3' (SEQ ID NOS. 91)

- 20 was prepared additionally at 3' end of OM017-F3 primer and then nested PCR was performed. cDNA which was amplified with clone OM017 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 18 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 16 and 17, respectively, were obtained.

- 25 [0130] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM017 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

- 30 [0131] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OM017 (region of 433th~709th, 42nd~225th, 170th~399th and 1st~224th amino add in SEQ ID NO. 16) and Human DXS6673E (Candidate gene for Mental Retardation) (PRF Code 2218282A (Genbank Accession X95808)) (region of 1083rd~1358th, 758th~932nd, 850th~1081st and 739th~965th amino add) Based on these homologies, clone OM017 and Human DXS6673E were expected to share at least some activity.

Example 7: Clone OM101

- 35 [0132] In Example relating to clone OM101 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

- 40 [0133] Total RNA was prepared from human adult brain tissue by TRIzol reagent. Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

(2) Cloning of a full-length cDNA and determination of nucleotide sequence

- 45 [0134] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA in human adult brain tissue. 27mer primer OM101-F3:

5'-TGAAGTTGCAGATAATGAGGACTTACC-3' (SEQ ID NOS. 92)

- 50 containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 27mer primer OM101-F1:

5'-ATGAGGACTTACCATTATATACCATTA-3' (SEQ ID NOS. 93)

- 55 was prepared additionally at 3' end of OM101-F3 primer and then nested PCR was performed. cDNA which was amplified with clone OM101 specifically was separated with redoning by the same method as Example of OX003. Full nucleotide sequence, was determined and then sequence shown in SEQ ID NO. 21 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 19 and 20, respectively, were obtained.



[0135] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM101 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0136] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between done OM101 (region of 1st~77th amino acid in SEQ ID NO. 19), and a lot of Cadherin family such as Human Cadherin-6 (Swiss Prot Accession P55285) (region of 1st~77th amino acid) and Human Brain-Cadherin (Swiss Prot Accession P55289) (region of 1st~78th amino acid). Based on these homologies, done OM101 and Human Cadherin-6 and the other Cadherin family were expected to share at least some activity.

#### Example 8: Clone OM126

[0137] In Example relating to clone OM126 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

##### (1) Preparation of Poly(A)<sup>+</sup>RNA

[0138] Total RNA was prepared from human adult brain tissue by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

##### (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0139] Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA in human adult brain tissue. 27mer primer OM126-F3:

5'-AGGAAGGATGAGGAAGACCAGGCTCTG-3' (SEQ ID NOS. 94)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with done OM126 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 24 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 22 and 23, respectively, were obtained.

[0140] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM126 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretary protein.

[0141] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OM126 (region of 25th~115th amino acid in SEQ ID NO. 22), and immunoglobulin domain. Based on these homologies, clone OM126 and immunoglobulin superfamily were expected to share at least some activity.

#### Example 9: Clone OM160

[0142] In Example relating to clone OM160 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

##### (1) Preparation of Poly(A)<sup>+</sup>RNA

[0143] Total RNA was prepared from human adult brain tissue by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

##### (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0144] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)<sup>+</sup>RNA in human adult brain tissue using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer ON160-F1 (27mer):

5' biotin-ATGCTTCAGTGGAGGAGAAGACACTGC-3' (SEQ ID NO. 95)

based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated

primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. Coli DH10B. Colony hybridization with OM160 SST cDNA which was labeled with  $^{32}\text{P}$ -dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequence of full-length OM160 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 27 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 25 and 26, respectively, were obtained.

[0145] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM160 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

[0146] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OM160 (region of 153rd~395th amino acid in SEQ ID NO. 25) and *Drosophila* neurogenic secreted signaling protein (Genepept Accession U41449) (region of 80th~317th amino acid). Based on these homologies, clone OM160 and *Drosophila* neurogenic secreted signaling protein were expected to share at least some activity.

#### Example 10: Clone OMA016

[0147] In Example relating to clone OMA016 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

##### (1) Preparation of Poly(A)<sup>+</sup>RNA

[0148] Total RNA was prepared from human adult brain tissue by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

##### (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0149] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA in human adult brain tissue. 27mer primer OMA016-F1:

5'-AGAAATGGTGAATGCCTGCTGGTGTGG-3' (SEQ ID NOS. 96)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. There existed two kinds of cDNAs which were amplified with clone OMA016 specifically and which were named OMA016a and OMA016b. These two were separated with recloning by the same method as Example of OX003. Full nucleotide sequences were determined and then sequences shown in SEQ ID NOS. 30 and 33 were obtained. Each open reading frame was determined and reduced amino acid sequences and nucleotide sequences shown in SEQ ID NOS. 28, 31 and SEQ ID NOS. 29, 32, respectively, were obtained.

[0150] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OMA016a and OMA016b of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

#### Example 11: Clone OMB130

[0151] In Example relating to clone OMB130 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

##### (1) Preparation of Poly(A)<sup>+</sup>RNA

[0152] Total RNA was prepared from human adult brain tissue by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

## (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0153] Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA in human adult brain tissue. 27mer primer OMB130-F1:

5 5'-TCCTCTGACTTTTCTTCTGCAAGCTCC-3' (SEQ ID NOS. 97)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with done OMB130 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 36 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence

10 shown in SEQ ID NOS. 34 and 35, respectively, were obtained.  
[0154] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OMB130 of the present invention. From these results, it was proved that polypeptide of the present invention was new

15 secretory protein.  
[0155] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OMB130 (region of 10th-177th amino acid in SEQ ID NO. 34), and Monkey Hepatitis A virus receptor (PRF Code 2220266A (Genbank Accession X98252) (region of 6th-173rd amino acid. Based on these homologies, clone OMB130 and Monkey Hepatitis A virus receptor were expected to share at least some activity.

20

## Example 12: Clone OMB142

[0156] In Example relating to clone OMB142 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

25

(1) Preparation of Poly(A)<sup>+</sup>RNA

[0157] Total RNA was prepared from human adult brain tissue by TRizol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

30

## (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0158] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA in

35 human adult brain tissue. 27mer primer OMB142-F2:

5'-GCCCAAGGTCAAGGAGATGGTACGGAT-3' (SEQ ID NOS. 98)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 28mer primer OMB142-F1:

40 5'-GGAGATGGTACGGATCTTAAGGACTGTG-3' (SEQ ID NOS. 99)

was prepared additionally at 3' end of OMB142-F2 primer and then nested PCR was performed. cDNA which was amplified with done OMB142 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 39 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 37 and 38,

45

respectively, were obtained.  
[0159] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OMB142 of the present invention. From these results, it was proved that polypeptide of the present invention was new

50

## Example 13: Clone OTB033

[0160] In Example relating to clone OTB033 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

55

(1) Preparation of Poly(A)<sup>+</sup>RNA

[0161] Total RNA was prepared from human neuroblastoma cell line IMR-32 (ATCC No. CCL-127) by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

## (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0162] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA of IMR-32. 27mer primer OTB033-F1:

5'-TGCACTATCCAAAAGCTCCATGTACAC-3' (SEQ ID NOS. 100)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 19mer primer OTB003-F2:

5'-CCATGTACACAGTGGGGGC-3' (SEQ ID NOS. 101)

was prepared additionally at 3' end of OTB033-F1 primer and then nested PCR was performed. cDNA which was amplified with clone OTB033 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 42 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 40 and 41, respectively, were obtained.

[0163] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OTB033 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

## Example 14: Clone OVB100

[0164] In Example relating to clone OVB100 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

[0165] Total RNA was prepared from human astrocytoma cell line CCF-STTG1 (ATCC No. CRL-1718) by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

## (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0166] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA of CCF-STTG1. 27mer primer OVB100-F1:

5'-CACTTGGTGTTTGATTACCTAAGCAC-3' (SEQ ID NOS. 102)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OVB100 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 45 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 43 and 44, respectively, were obtained.

[0167] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OVB100 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

## Example 15: Clone OAF062

[0168] In Example relating to clone OAF062 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

[0169] Total RNA was prepared from human bone marrow stroma cell line HAS303 (provided from Prof. Keisuke Sotoyama, Dr. Makoto Aizawa, First Medicine, Tokyo Medical College) by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

## (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0170] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA of HAS303. 27mer primer OAF062-F2:

5'-GAGTTTCGTAAGCAAAATAGAGGACAG-3' (SEQ ID NOS. 103)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 27mer primer OAF062-F3:

5'-TAGAGGACAGAAATGCAGTTCATGAAC-3' (SEQ ID NOS. 104)

was prepared additionally at 3' end of OAF062-F2 primer and then nested PCR was performed. cDNA which was amplified with clone OAF062 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 48 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 46 and 47, respectively, were obtained.

[0171] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAF062 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

## Example 16: Clone OAF075

[0172] In Example relating to clone OAF075 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

[0173] Total RNA was prepared from human bone marrow stroma cell line HAS303 (provided from Prof. Keisuke Sotoyama, Dr. Makoto Aizawa, First Medicine, Tokyo Medical College) by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit

## (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0174] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA of HAS303. 28mer primer OAF075-F1:

5'-GACATGAGGTGGATACTGTTTCATTGGGG-3' (SEQ ID NOS. 105)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OAF075 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 51 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 49 and 50, respectively, were obtained.

[0175] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAF075 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

[0176] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OAF075 (region of 1st-421st amino acid in SEQ ID NO. 49), and Human Carboxypeptidase A2 (Swiss Prot Accession P48052) (region of 1st-417th amino acid), Human Carboxypeptidase A1 (Swiss Prot Accession P15085) (region of

1st-417th amino acid), Human Carboxypeptidase B (Swiss Prot Accession P15086) (region of 5th-416th amino acid) and Human Mast Cell Carboxypeptidase A (Swiss Prot Accession P15088) (region of 1st-412th amino acid). Based on these homologies, clone OAF075 and Carboxypeptidase family were expected to share at least some activity.

5 Example 17: Clone OAG119

[0177] In Example relating to clone OAG119 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

10 (1) Preparation of Poly(A)\*RNA

[0178] Total RNA was prepared from human bone marrow stroma cell line LP101 (provided from Prof. Keisuke Sotoyama, Dr. Makoto Aizawa, First Medicine, Tokyo Medical College) by TRIzol reagent Poly(A)\*RNA was purified from the total RNA by mRNA Purification Kit.

15

(2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0179] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)\*RNA of LP101. 28mer primer OAG119-F1:

5'-TGGCGTGTAACATGCTCATCATTGTTC-3' (SEQ ID NOS. 106)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OAG119 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 54 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 52 and 53, respectively, were obtained.

[0180] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAG119 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

Example 18: Clone OAH040

35 [0181] In Example relating to clone OAH040 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)\*RNA

40 [0182] Total RNA was prepared from endothelial cell line of vein derived from human umbilical cord UV-EC-C (ATCC No. CRL-1730) by TRIzol reagent Poly(A)\*RNA was purified from the total RNA by mRNA Purification Kit.

(2) Cloning of a full-length cDNA and determination of nucleotide sequence

45 [0183] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)\*RNA of HUV-EC-C. 28mer primer OAH040-F1:

5'-TTAGCCCAACCATGTTGATAGAACACCC-3' (SEQ ID NOS. 107)

50 containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OAH040 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 57 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 55 and 56, respectively, were obtained.

[0184] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAH040 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

## Example 19: Clone OAH058

[0185] In Example relating to clone OAH058 of the present invention, the same procedure as in Example of OAH056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

[0186] Total RNA was prepared from endothelial cell line of vein derived from human umbilical cord HUV-EC-C (ATCC No. CRL-1730) by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

(2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0187] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA of HUV-EC-C. 28mer primer OAH058-F1:

5'-ACAATGTTGGCCTGTC TGCAAGCTTGTG-3' (SEQ ID NOS. 108)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with done OAH058 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 60 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 58 and 59, respectively, were obtained.

[0188] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAH058 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

## Example 20: Clone OM011

[0189] In Example relating to clone OM011 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

[0190] Total RNA was prepared from human adult brain tissue by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

(2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0191] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)<sup>+</sup>RNA in human adult brain tissue using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer OM011-F1 (27mer):

5' biotin-GAAGTGACTCTTCTCTAGTTTGCCAC-3' (SEQ ID NOS. 109)

based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. Coli DH10B. Colony hybridization with OM011 SST cDNA which was labeled with 32P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequence of full-length OM011 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 63 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 61 and 62, respectively, were obtained.

[0192] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM011 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

[0193] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone

OM011 (region of 26th–396th amino acid in SEQ ID NO. 61) and Human Plasma-cell Glycoprotein PC-1 (Alkaline Phosphodiesterase I) (Swiss Prot Accession P22413) (region of 158th–543rd amino acid). Based on these homologies, done OM011 and Human Plasma-cell Glycoprotein PC-1 were expected to share at least some activity.

5 Example 21: Clone OM028

[0194] In Example relating to done OM028 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

10 (1) Preparation of Poly(A)<sup>+</sup>RNA

[0195] Total RNA was prepared from human adult brain tissue by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

15 (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0196] A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)<sup>+</sup>RNA in human adult brain tissue using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer OM028-F1 (27mer):

5' biotin-ATGAAGGACATGCCACTCCGAATTCAT-3' (SEQ ID NOS. 110)

based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. Coli DH10B. Colony hybridization with OM028 SST cDNA which was labeled with 32P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive done and to prepare the plasmid. Nucleotide sequence of full-length OM028 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 66 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 64 and 65, respectively, were obtained.

[0197] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OM028 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

[0198] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OM028 (region of 1st–708th amino acid in SEQ ID NO. 64) and many proteins containing Leu-rich repeat such as Mouse Leu-rich repeat protein (PRF Code 2212307A (GENBANK Accession D49802) (region of 1st–707th amino acid). Based on these homologies, clone OM028 and certain proteins containing Leu-rich repeat were expected to share at least some activity.

40 Example 22: Clone OMB092

[0199] In Example relating to clone OMB092 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

45 (1) Preparation of Poly(A)<sup>+</sup>RNA

[0200] Total RNA was prepared from human adult brain tissue by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

50 (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0201] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA in human adult brain tissue. 27mer primer OMB092-F1:

5'-ACTCACCTGGATCCCTAAGGGCACAGC-3' (SEQ ID NOS. 111)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient ampli-



fication of cDNA by only one-time PCR, 28mer primer OMB092-F2:

5'-AGAATGAGCTATTACGGCAGCAGCTATC-3' (SEQ ID NOS. 112)

was prepared additionally at 3' end of OMB092-F1 primer and then nested PCR was performed. cDNA which was amplified with clone OMB092 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 69 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 67 and 68, respectively, were obtained.

[0202] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OMB092 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

[0203] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OMB092 (region of 1st-254th amino acid in SEQ ID NO. 67) and many Potassium Channels family such as Rat Inward Rectifier Potassium Channel BIR9 (Swiss Prot Accession P52191) (region of 1st-254th amino acid). Based on these homologies, clone OMB092 and Potassium Channel were expected to share at least some activity.

#### Example 23: Clone OMB108

[0204] In Example relating to clone OMB108 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

#### (1) Preparation of Poly(A)<sup>+</sup>RNA

[0205] Total RNA was prepared from human adult brain tissue by TRIzol reagent Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

#### (2) Cloning of a full-length cDNA and determination of nucleotide sequence

[0206] A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA in human adult brain tissue. 27mer primer OMB108-F1:

5'-CTCTCTCCATCTGCTGTGGTTATGGCC-3' (SEQ ID NOS. 113)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. PCR was performed with the said primer and adapter primer attached in the kit. Due to insufficient amplification of cDNA by only one-time PCR, 22mer primer OMB108-F2:

5'-TGGTTATGGCCTGTCGCTGGAG-3' (SEQ ID NOS. 114)

was prepared additionally at 3' end of OMB108-F1 primer and then nested PCR was performed. cDNA which was amplified with clone OMB108 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 72 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 70 and 71, respectively, were obtained.

[0207] It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OMB108 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

[0208] However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OMB108 (region of 164th-256th and 374th-487th amino acid in SEQ ID NO. 70) and LDL-repeat region of many LDL receptors family such as Human Low-Density Lipoprotein Receptor Related Protein 10 (Swiss Prot Accession Q07954) or OMB108 (region of 47th-158th and 259th-370th amino acid in SEQ ID NO. 70) and CUB domain included in Human Bone Morphogenetic Protein 1 (Swiss Prot Accession P13497). That is to say, clone OMB108 proved to possess the common sequences of two parts of CUB domain and five parts of LDL-repeat at the extracellular domain. Based on these homologies, clone OMB108, protein including LDL-repeat and protein including CUB domain were expected to share at least some activity.

## Example 24: Clone OT007

**[0209]** In Example relating to clone OT007 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

**[0210]** Total RNA was prepared from human neuroblastoma cell line IMR-32 (ATCC No. CCL-127) by TRIzol reagent. Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

(2) Cloning of a full-length cDNA and determination of nucleotide sequence

**[0211]** A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)<sup>+</sup>RNA in IMR-32 using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer OT007-F1 (27mer):

5' biotin-AAAATGACTCCCCAGTCGCTGCTGCAG-3' (SEQ ID NOS. 115)

based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. Coli DH10B. Colony hybridization with OT007 SST cDNA which was labeled with 32P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequence of full-length OT007 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 75 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 73 and 74, respectively, were obtained.

**[0212]** It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OT007 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

**[0213]** However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OT007 (region of 217th-660th amino acid in SEQ ID NO. 73) and transmembrane region of Secretin/Vasoactive Intestinal Peptide receptor superfamily such as Human Seven Transmembrane-domain receptor (Genepept Accession X82892), Rat Latrophilin-related protein 1 (Genepept Accession U78105), Human CD97 (Swiss Prot Accession P48960) etc. Based on these homologies, clone OT007 and certain proteins containing seven transmembrane region type of Secretin/Vasoactive Intestinal Peptide were expected to share at least some activity.

## Example 25: Clone OAG051

**[0214]** In Example relating to clone OAG051 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

**[0215]** Total RNA was prepared from human bone marrow stroma cell line LP101 (provided from Prof. Kaisukey Sotoyama, Dr. Makoto Aizawa, First Medicine, Tokyo Medical College) by TRIzol reagent. Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

(2) Cloning of a full-length cDNA and determination of nucleotide sequence

**[0216]** A full-length cDNA was cloned using Marathon cDNA Amplification Kit according to 3' RACE method as described in Example of OX003. Double strand cDNA was prepared from the origin of each clone, i.e., poly (A)<sup>+</sup>RNA of LP101. 27mer primer OAG051-F1:

5'-GGAAATGTTTACATTTT GTTGACGTG-3' (SEQ ID NOS. 116)

containing the deduced initiation ATG codon region based on the information of nucleotide sequence obtained by SST, was prepared. cDNA which was amplified with clone OAG051 specifically was separated with recloning by the same method as Example of OX003. Full nucleotide sequence was determined and then sequence shown in SEQ ID NO. 78 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 76 and 77, respectively, were obtained.

**[0217]** It was indicated from the results of homology search for the public database of the nucleic acid sequences

by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OAG051 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

- 5 **[0218]** However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OAG051 and many Frizzled family, for example, clone OAG051 (region of 4th~703rd amino acid in SEQ ID NO. 76) and Mouse Frizzled-6 (PRF Code 2208383E (Genebank Accession U43319) (region of 6th~708th amino acid) or clone OAG051 (region of 1st~627th amino acid in SEQ ID NO. 76) and Mouse Frizzled-3 (PRF Code 2208383E (Genebank Accession U43205) (region of 7th~618th amino acid). Based on these homologies, clone OAG051 and Frizzled family were expected to share at least some activity.

Example 26: Clone OUB068

- [0219]** In Example relating to clone OUB068 of the present invention, the same procedure as in Example of ON056 was used except for the following points.

(1) Preparation of Poly(A)<sup>+</sup>RNA

- [0220]** Total RNA was prepared from human osteosarcoma cell line U-2OS (ATCC No. HTB-96) by TRizol reagent. Poly(A)<sup>+</sup>RNA was purified from the total RNA by mRNA Purification Kit.

(2) Cloning of a full-length cDNA and determination of nucleotide sequence

- [0221]** A full-length cDNA was cloned using GENETRAPPER cDNA Positive Selection System. First, dT-primed cDNA library was prepared from poly (A)<sup>+</sup>RNA in U-2OS using pSPORT1 plasmid, as a vector, by Super Script Plasmid System for cDNA Synthesis and Plasmid Cloning. Next, after preparing biotinylated primer OUB068-F1 (27mer):

5' biotin-CACTCATGAAGGAAATTCAGCGCTGC-3' (SEQ ID NOS. 117)

- based on the information of nucleotide sequence obtained by SST, plasmid hybridized specifically with the biotinylated primer were recovered from the cDNA library according to the method of Gene Trapper Kit and then transfected into E. Coli DH10B. Colony hybridization with OUB068 SST cDNA which was labeled with 32P-dCTP, as a probe, was performed by using Random Primer DNA Labeling kit according to known method to isolate the positive clone and to prepare the plasmid. Nucleotide sequence of full-length OUB068 SST cDNA was determined by the same procedure as ON056 and then sequence shown in SEQ ID NO. 81 was obtained. An open reading frame was determined and deduced amino acid sequence and nucleotide sequence shown in SEQ ID NOS. 79 and 80, respectively, were obtained.

- [0222]** It was indicated from the results of homology search for the public database of the nucleic acid sequences by using BLASTN and FASTA, and for the public database of the amino acid sequences by using BLASTX, BLASTP and FASTA, that there was no sequence identical to the polypeptide sequence and the nucleotide sequence of OUB068 of the present invention. From these results, it was proved that polypeptide of the present invention was new secretory protein.

- [0223]** However, the search using BLASTX, BLASTP and FASTA revealed a significant homology between clone OUB068 (region of 5th~386th amino acid in SEQ ID NO. 79) and Xenopus Unknown Transmembrane Protein (Genepept Accession X92871) (region of 3rd~407th amino acid). Based on these homologies, clone OUB068 and Xenopus Unknown Transmembrane Protein were expected to share at least some activity.

## Sequence Listing

5 <110> ONO Pharmaceutical Co., Ltd.

<120> Novel polypeptide, cDNA coding the polypeptide and use thereof

10 <130> ONF-2794PCT

<150> JP 9-274674

15 <151> 1997-10-7

<160> 117

20 <210> 1

<211> 334

<212> PRT

25 <213> Homo sapiens

<400> 1

30 Met Asn Leu Ser Leu Val Leu Ala Ala Phe Cys Leu Gly Ile Ala Ser  
 -17 -15 -10 -5  
 Ala Val Pro Lys Phe Asp Gln Asn Leu Asp Thr Lys Trp Tyr Gln Trp  
 1 5 10 15  
 35 Lys Ala Thr His Arg Arg Leu Tyr Gly Ala Asn Glu Glu Gly Trp Arg  
 20 25 30  
 Arg Ala Val Trp Glu Lys Asn Met Lys Met Ile Glu Leu His Asn Gly  
 35 40 45  
 40 Glu Tyr Ser Gln Gly Lys His Gly Phe Thr Met Ala Met Asn Ala Phe  
 50 55 60  
 Gly Asp Met Thr Asn Glu Glu Phe Arg Gln Met Met Gly Cys Phe Arg  
 45 65 70 75  
 Asn Gln Lys Phe Arg Lys Gly Lys Val Phe Arg Glu Pro Leu Phe Leu  
 80 85 90 95  
 50 Asp Leu Pro Lys Ser Val Asp Trp Arg Lys Lys Gly Tyr Val Thr Pro  
 100 105 110  
 Val Lys Asn Gln Lys Gln Cys Gly Ser Cys Trp Ala Phe Ser Ala Thr

55

115 120 125  
 Gly Ala Leu Glu Gly Gln Met Phe Arg Lys Thr Gly Lys Leu Val Ser  
 5 130 135 140  
 Leu Ser Glu Gln Asn Leu Val Asp Cys Ser Arg Pro Gln Gly Asn Gln  
 145 150 155  
 10 Gly Cys Asn Gly Gly Phe Met Ala Arg Ala Phe Gln Tyr Val Lys Glu  
 160 165 170 175  
 Asn Gly Gly Leu Asp Ser Glu Glu Ser Tyr Pro Tyr Val Ala Val Asp  
 180 185 190  
 15 Glu Ile Cys Lys Tyr Arg Pro Glu Asn Ser Val Ala Asn Asp Thr Gly  
 195 200 205  
 Phe Thr Val Val Ala Pro Gly Lys Glu Lys Ala Leu Met Lys Ala Val  
 210 215 220  
 20 Ala Thr Val Gly Pro Ile Ser Val Ala Met Asp Ala Gly His Ser Ser  
 225 230 235  
 Phe Gln Phe Tyr Lys Ser Gly Ile Tyr Phe Glu Pro Asp Cys Ser Ser  
 240 245 250 255  
 25 Lys Asn Leu Asp His Gly Val Leu Val Val Gly Tyr Gly Phe Glu Gly  
 260 265 270  
 30 Ala Asn Ser Asn Asn Ser Lys Tyr Trp Leu Val Lys Asn Ser Trp Gly  
 275 280 285  
 Pro Glu Trp Gly Ser Asn Gly Tyr Val Lys Ile Ala Lys Asp Lys Asn  
 290 295 300  
 35 Asn His Cys Gly Ile Ala Thr Ala Ala Ser Tyr Pro Asn Val  
 305 310 315  
  
 40 <210> 2  
 <211> 1002  
 <212> DNA  
 <213> Homo sapiens  
  
 45 <400> 2  
 atgaatcttt cgtcgtctct ggcagccitt tgcctgggaa tgcctccgc tgcaccaaa 60  
 tttagcnaa attggatac aaatgggtac catggagagc caacacacag aagattat 120  
 50 ggcgcgaatg aagaaggatg gaggagagca gtagagaaa agaatatgaa atgattgaa 180  
 ctgcacatg kgaatcacg caagagaaa catgcttcn catgkccat gantgcitt 240  
  
 55

ggagacaaga ccaatgaaga attcaggcag atgatgggtt gctttcgaaa ccagaaattc 300  
 aggaagggga aagtgliccg tgagcctctg ttctctgac ttcccaaatc tgtggatigg 360  
 5 agaagaag gctacgtgac gccagtgaag aatcagaaac agtgtgggtc ttgttgggtc 420  
 tttagtgca ctggtgctct tgaaggacag atgttccgga aaactgggaa acttgtctca 480  
 ctgagcgagc agaactcgtt ggactgttct cgctctcaag gcaatcaggc ctgcaatggt 540  
 ggcttcatgg ctagggcctt ccagtatgtc aaggagaacg gaggccttga ctctgaggaa 600  
 10 tctatccat atgtagcagt ggaigaaatc tgtaagtaca gacctgagaa ttctgttctc 660  
 aatgacactg gcttcacagt ggtcgcacct ggaaaggaga aggcctctgat gaaagcagtc 720  
 gcaactgttg ggcccatctc cgttgcctat gatgcaggcc attcgtctt ccagttctac 780  
 15 aaatcaggca ttatcttga accagactgc agcagcaaaa acctggatca tgggtgtctg 840  
 gtgtgttggt acggttga aggagcaaat tcgaataaca gcaagtattg gctcgtcaaa 900  
 aacagctggg gtccagaatg gggctcgaat ggctatgtaa aaatagccaa agacaagaac 960  
 20 aaccactgtg gaatgccac agcagccagc taccccaatg tg 1002

<210> 3

<211> 1370

25

<212> DNA

<213> Homo sapiens

<220>

30

<221> CDS

<222> (60)..(1061)

<220>

35

<221> sig peptide

<222> (60)..(110)

<220>

40

<221> mat peptide

<222> (111)..(1061)

45

<400> 3

ctacagggt tgtttgtga gggcgctgc gcagctgcga cggctgctgg ttltgnaac 59  
 ntg aat ctt tgg etc gtc ctg gct gcc ttt tgc tlg gga ala gcc tcc 107  
 Met Asn Leu Ser Leu Val Leu Ala Ala Phe Cys Leu Gly Ile Ala Ser  
 50 -17 -15 -10 -5  
 gct gtt cca aaa ttt gac cca aat ttg gnt acn ang tgg tac cag tgg 155

55

	Ala Val Pro Lys Phe Asp Gln Asn Leu Asp Thr Lys Trp Tyr Gln Trp	
	1 5 10 15	
5	aag gca aca cac aga aga tta tat ggc gcg aat gaa gaa gga tgg agg	203
	Lys Ala Thr His Arg Arg Leu Tyr Gly Ala Asn Glu Glu Gly Trp Arg	
	20 25 30	
10	aga gca gtg tgg gaa aag aat atg aaa atg att gaa ctg cac aat ggg	251
	Arg Ala Val Trp Glu Lys Asn Met Lys Met Ile Glu Leu His Asn Gly	
	35 40 45	
15	gaa tac agc caa ggg aaa cat ggc ttc aca atg gcc atg aat gct ttt	299
	Glu Tyr Ser Gln Gly Lys His Gly Phe Thr Met Ala Met Asn Ala Phe	
	50 55 60	
20	ggg gac atg acc aat gaa gaa ttc agg cag atg atg ggt tgc ttt cga	347
	Gly Asp Met Thr Asn Glu Glu Phe Arg Gln Met Met Gly Cys Phe Arg	
	65 70 75	
25	aac cag aaa ttc agg aag ggg aaa gtg ttc cgt gag cct ctg ttt ctt	395
	Asn Gln Lys Phe Arg Lys Gly Lys Val Phe Arg Glu Pro Leu Phe Leu	
	80 85 90 95	
30	gat ctt ccc aaa tct gtg gat tgg aga aag aaa ggc tac gtg acg cca	443
	Asp Leu Pro Lys Ser Val Asp Trp Arg Lys Lys Gly Tyr Val Thr Pro	
	100 105 110	
35	gtg aag aat cag aaa cag tgt ggt tct tgt tgg gct ttt agt gcg act	491
	Val Lys Asn Gln Lys Gln Cys Gly Ser Cys Trp Ala Phe Ser Ala Thr	
	115 120 125	
40	ggg gct ctt gaa gga cag atg ttc cgg aaa act ggg aaa ctt gtc tca	539
	Gly Ala Leu Glu Gly Gln Met Phe Arg Lys Thr Gly Lys Leu Val Ser	
	130 135 140	
45	ctg agc gag cag aat ctg gtc gac tgt tgg cgt cct caa ggc aat cag	587
	Leu Ser Glu Gln Asn Leu Val Asp Cys Ser Arg Pro Gln Gly Asn Gln	
	145 150 155	
50	ggc tgc aat ggt ggc ttc atg gct agg gcc ttc cag tat gtc aag gag	635
	Gly Cys Asn Gly Gly Phe Met Ala Arg Ala Phe Gln Tyr Val Lys Glu	
	160 165 170 175	
55	aac gga ggc ctg gac tct gag gaa tcc tat cca tat gln gca gtg gat	683
	Asn Gly Gly Leu Asp Ser Glu Glu Ser Tyr Pro Tyr Val Ala Val Asp	
	180 185 190	
	gaa atc tgt aag tac aga cct aag aat tct gtt gct aat gac act ggc	731

Glu Ile Cys Lys Tyr Arg Pro Glu Asn Ser Val Ala Asn Asp Thr Gly  
 195 200 205  
 5 ttc aca gtg gtc gca cct gga aag gag aag gcc ctg atg aaa gca gtc 779  
 Phe Thr Val Val Ala Pro Gly Lys Glu Lys Ala Leu Met Lys Ala Val  
 210 215 220  
 10 gca act gtg ggg ccc atc tcc gtt gct atg gat gca ggc cat tgc tcc 827  
 Ala Thr Val Gly Pro Ile Ser Val Ala Met Asp Ala Gly His Ser Ser  
 225 230 235  
 15 ttc cag ttc tac aaa tca ggc att tat ttt gaa cca gac tgc agc agc 875  
 Phe Gln Phe Tyr Lys Ser Gly Ile Tyr Phe Glu Pro Asp Cys Ser Ser  
 240 245 250 255  
 20 aaa aac ctg gat cat ggt gtt ctg gtg gtt ggc tac ggc ttt gaa gga 923  
 Lys Asn Leu Asp His Gly Val Leu Val Val Gly Tyr Gly Phe Glu Gly  
 260 265 270  
 gca aat tgc aat aac agc aag tat tgg ctc gtc aaa aac agc tgg ggt 971  
 Ala Asn Ser Asn Asn Ser Lys Tyr Trp Leu Val Lys Asn Ser Trp Gly  
 275 280 285  
 25 cca gaa tgg ggc tgc aat ggc tat gta aaa ata gcc aaa gac aag aac 1019  
 Pro Glu Trp Gly Ser Asn Gly Tyr Val Lys Ile Ala Lys Asp Lys Asn  
 290 295 300  
 30 aac cac tgt gga atc gcc aca gca gcc agc tac ccc aat gtg 1061  
 Asn His Cys Gly Ile Ala Thr Ala Ala Ser Tyr Pro Asn Val  
 305 310 315  
 35 tggcgtgatg gatggtaggg aggaaggact taaggacagc atgtctgagg aaattttatc 1121  
 ttgaaactga ccaaaccgtt attgtgtang ataaaccagt tgaatcatgg aggatccaag 1181  
 ttgagatttt aattctgtga catttttaca agggtaaaat gttaccacta ctttaattat 1241  
 40 tgttatcac agctttatga tatcanagac tcattgetta attctaugac ttltgaattt 1301  
 tcatttttta aaagatgta caaancagtt tgaataaat ttaatttct atataaaaaa 1361  
 aaaaaaaa 1370  
 45 <210> -  
 <211> III  
 <212> PRT  
 50 <213> Homo sapiens  
 <100> -  
 55



Met Leu Pro Leu Cys Ser Leu Phe Leu Phe Gly Ser Ser Ser Val Gly  
 -14 -10 -5 1  
 5 Val Lys Gln Tyr Gln Ala Leu Glu Leu Pro Leu Val Val Phe Val Thr  
 5 10 15  
 Tyr Leu Lys Met Ala Ala Cys Phe Leu Arg Ile Ser Gly Ser Ala Leu  
 10 20 25 30  
 Pro Val Phe Ile Cys Thr Phe Phe Ser His Cys Ala Ser Cys Thr His  
 35 40 45 50  
 15 Thr Pro Leu Pro His His Leu Pro Asn Leu Arg Leu Phe Gln Gln Phe  
 55 60 65  
 Leu Phe Arg Ala Gly Pro Cys Trp Asp Met Ile Ser Ile Lys Ser Glu  
 70 75 80  
 20 Gly Pro Asn Cys Ser Cys Pro Cys Ser Pro Tyr His Arg Pro Leu  
 85 90 95  
  
 <210> 5  
 25 <211> 333  
 <212> DNA  
 <213> Homo sapiens  
  
 30 <400> 5  
 atgttaccac ttgtttcttt attctctttt ggaatcatctt cagtgagggtt aanacagiat 60  
 caagctctag agctccctct ggtagttttt gtagacatatt tgaagatggc agcttgcttt 120  
 35 ttgagaattt ctggctctgc tctccctggt ttatctctga ctttttttc tcattgtgcc 180  
 tcttgacac acacaccct tcccccctt ctacccaatt tgcgctgtt ccagcagttt 240  
 ctcttcaggg cagggccgtg ttgggacatg attctatta agagttaggg cccaattgc 300  
 40 tcttgccctt gcagccctta tcacagacc ctc 333  
  
 <210> 6  
 <211> 1086  
 45 <212> DNA  
 <213> Homo sapiens  
  
 50 <220>  
 <221> CDS  
 <222> (151).. (183)  
 55

&lt;220&gt;

&lt;221&gt; sig peptide

&lt;222&gt; (151)..(192)

&lt;220&gt;

&lt;221&gt; nat peptide

&lt;222&gt; (193)..(483)

&lt;400&gt; 6

ttaaattttaa actttgacac ctttaccctg ctaaacaata cagtacagtg accttcaaac 60

atttcagcag ccttcgggtt gtacatatt tattcttttt tgaagcccat cactacatcg 120

ccattacggtt ttacactgtg tatgtaacaa atg tta cca ctt tgt tct tta ttc 174

Met Leu Pro Leu Cys Ser Leu Phe

-14 -10

ctt ttt gga tca tct tca gtg ggg gta aaa cag tat caa gct cta gag 222

Leu Phe Gly Ser Ser Ser Val Gly Val Lys Gln Tyr Gln Ala Leu Glu

-5 1 5 10

ctc cct ctg gtg gtt ttt gtg aca tat ttg aag atg gca gct tgc ttt 270

Leu Pro Leu Val Val Phe Val Thr Tyr Leu Lys Met Ala Ala Cys Phe

15 20 25

ttg aga att tct ggc tct gct ctc cct gtt ttt atc tgt act ttt ttt 318

Leu Arg Ile Ser Gly Ser Ala Leu Pro Val Phe Ile Cys Thr Phe Phe

30 35 40

tct cat tgt gcc tct tgc aca cac aca ccc ctt ccc cac cat cta ccc 366

Ser His Cys Ala Ser Cys Thr His Thr Pro Leu Pro His His Leu Pro

45 50 55

aat ttg cgc ctg ttc cag cag ttt ctc ttc agg gca ggg ccg tgt tgg 414

Asn Leu Arg Leu Phe Gln Gln Phe Leu Phe Arg Ala Gly Pro Cys Trp

60 65 70

gac atg att tct att aag agt gac ggc cca aat tgc tct tgc ccc tgc 462

Asp Met Ile Ser Ile Lys Ser Glu Gly Pro Asn Cys Ser Cys Pro Cys

75 80 85 90

agc cct tat cac aga ccc ctg tggcattat tggacatgc tggctctggg 513

Ser Pro Tyr His Arg Pro Leu

95

cctgcctttc tcagtcactg gagttctcca gtttgtaaga cggctcctcg cctccccct 573  
 gcttcttccct gtacaaaggc cgtcacccctg caagccttgt tgcctctaac atgggttgtc 633  
 5 tctacttggt cctatcttag agttactgca gaalgccctg ccatctagct tggttgtagc 693  
 tggtaaccat aggtttttgt ttttttgcta tctttatgc actatgtttt atggaacaat 753  
 tggagaagat taaaaattca cctgcccac tgggcgtggt ggctcacgcc tgaatccca 813  
 10 gctctttggg aggccgaggc aggcagatca cgaggtcagg agatcgagac catcgtggct 873  
 aatacagtga aaccccgctt ctactaaaaa tgcaaaaaaa attagccggg catggtgggt 933  
 ggcccttgta gtcccagcta ctggggaggc tgaggcagga gaatggcatg aattcgggag 993  
 gcggaagctt cagttagcca agatcacgcc actgtactcc agcctgggca acagagcgag 1053  
 15 actccgtctc aaaaaaaaaa aaaaaaaaaa aaa 1086

<210> 7

20 <211> 111

<212> PRT

<213> Homo sapiens

25 <400> 7

Met Val Ala Thr Ser Thr Ala Val Ile Ser Gly Val Met Ser Leu Leu  
 -26 -25 -20 -15  
 30 Gly Leu Ala Leu Ala Pro Ala Thr Gly Gly Gly Ser Leu Leu Leu Ser  
 -10 -5 1 5  
 Thr Ala Gly Gln Gly Leu Ala Thr Ala Ala Gly Val Thr Ser Ile Val  
 10 15 20  
 35 Ser Gly Thr Leu Glu Arg Ser Lys Asn Lys Glu Ala Gln Ala Arg Ala  
 25 30 35  
 Glu Asp Ile Leu Pro Thr Tyr Asp Gln Glu Asp Arg Glu Asp Glu Glu  
 40 40 45 50  
 Glu Lys Ala Asp Tyr Val Thr Ala Ala Gly Lys Ile Ile Tyr Asn Leu  
 55 60 65 70  
 45 Arg Asn Thr Leu Lys Tyr Ala Lys Lys Asn Val Arg Ala Phe Trp  
 75 80 85

<210> 8

50 <211> 333

<212> DNA

<213> Homo sapiens

55

&lt;400&gt; 8

atgggtggcca cctctactgc tgcatactct ggagtgatga gcctcctggg tttagccctt 60  
 5 gccccagcaa caggaggagg aagcctgclg ctctccaccg ctggtaagg tttggcaaca 120  
 gcagctgggg tcaccagcat cgtgagtggt acgttgggaac gctccaaaaa taaagaagcc 180  
 caagcacggg cggaagacat actgcccacc tacgaccaag aggacaggga ggatgaggaa 240  
 10 gagaaggcag actatgtcac agctgcigga aagattatct ataacttttag aaacaccttg 300  
 aagtatgcca agaaaaacgt ccgtgcattt tgg 333

&lt;210&gt; 9

15

&lt;211&gt; 2604

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

20

&lt;220&gt;

&lt;221&gt; CDS

25

&lt;222&gt; (173)..(505)

&lt;220&gt;

&lt;221&gt; sig peptide

30

&lt;222&gt; (173)..(250)

&lt;220&gt;

35

&lt;221&gt; mat peptide

&lt;222&gt; (251)..(505)

&lt;400&gt; 9

40

cgctcctcig tgtgaagacg tggagctach agacggagat ctgtcccccg aagaaaaaal 60  
 atttttgaga gaatttccca gattgaanag agatctgaaa gggaacattg acaagctccg 120  
 tgccctcgca gacgatattg acnnnnccca cnagaaattc accaaggcta ac atg 175

45

Met

-26

glg gcc acc tct act gct gtc atc tct gga gtg atg agc ctc ctg ggt 223  
 Val Ala Thr Ser Thr Ala Val Ile Ser Gly Val Met Ser Leu Leu Gly  
 50 -25 -20 -15 -10  
 tta gcc ctt gcc cca gca acn gga gga gga ogc ctg ctg ctc tcc acc 271

55

Leu Ala Leu Ala Pro Ala Thr Gly Gly Gly Ser Leu Leu Leu Ser Thr  
 -5 1 5  
 5 gct ggt caa ggt ttg gca aca gca gct ggg gtc acc agc atc gtg agt 319  
 Ala Gly Gln Gly Leu Ala Thr Ala Ala Gly Val Thr Ser Ile Val Ser  
 10 15 20  
 10 ggt acg ttg gaa cgc tcc aaa aat aaa gaa gcc caa gca cgg gcg gaa 367  
 Gly Thr Leu Glu Arg Ser Lys Asn Lys Glu Ala Gln Ala Arg Ala Glu  
 25 30 35  
 15 gac ata ctg ccc acc tac gac caa gag gac agg gag gat gag gaa gag 415  
 Asp Ile Leu Pro Thr Tyr Asp Gln Glu Asp Arg Glu Asp Glu Glu Glu  
 40 45 50 55  
 aag gca gac tat gtc aca gct gct gga aag att atc tat aat ctt aga 463  
 Lys Ala Asp Tyr Val Thr Ala Ala Gly Lys Ile Ile Tyr Asn Leu Arg  
 20 60 65 70  
 aac acc ttg aag tat gcc aag aaa aac gtc cgt gca ttt tgg 505  
 Asn Thr Leu Lys Tyr Ala Lys Lys Asn Val Arg Ala Phe Trp  
 25 75 80 85  
 taactcagag ccaacccacg ctccggccaat gctaccaagc gtcttctgac cactggccaa 565  
 gtctctctcc ggagccgctg gcagggtcaa aaggcccttg cgggaacnac actggcgatg 625  
 accaaaaatg ctgcgctgct gggagggttg atgtccgctt tctcccttgg ctatgacttg 685  
 30 gccactctct caaaggaatg gaagcaccig aaggaaggag caaggacaaa gtitcgggaa 745  
 gaggtagag ccaaggcctt ggagctggag aggaacatca cagaactcac ccagctctac 805  
 aagagcttgc agcagaaagl gaggtcaagg gccagagggg tggggaagxa tttaactggg 865  
 35 acctcgaaa ccgaggctta ctggaaggag ttaaggagac atgtgtggat gttgctgttg 925  
 ctgtgtgtgt gtctgtgtgt ctgtgtgtat gtacagttaa catgaatgtt cctcaggaca 985  
 tggcatataa tggccttgga ggtccaaata atatcaagta catcttggag atgagggtgc 1045  
 ctgtcttga cagacctcgg catgccttct gtctctctt caatgcctct taaggcctat 1105  
 40 gtgtctggaa aagggtcttc cctgttgtt tttgttgtt tttgttgtt tttgttgtt 1165  
 cgggtctct gtgtcactcc agtctgggtg tcagaatgag acccctctc aaaaaaaaaa 1225  
 aaaaaaaaaa aaaaagaaga gaatacagtc atgtatctct tggtagacag gncgcattct 1285  
 45 gataaalgag tcattaggca attgcatgtt agtgtgatta tcacagattg tacttataca 1345  
 aaacttagat ggcatagcct actgcatacc taggtatata gggagagcct atgtctccca 1405  
 ggctacgcac ctgtacagca tgtactact gaatactata ggcaattgca gcacaatggg 1465  
 aantatttgt gtatctaanc atnigtanac agaghaaag gnaughtana utatggcata 1525  
 50 aagataaga attggctctc ctgtacaggg cacttaclac gaatggagct tgcagggttg 1585  
 agagltctc cagatgagtc agtgaatgtt gaatgaatgtt gaaggcctag ggcattactg 1645

55

tatactactg taggccttat aaacacagca cacttaggtt acacaaaatg catattaaaa 1705  
 catcttcttc ctccagatata ttaggcaata ggaatttttc aagtcacta taaatcttat 1765  
 5 caaacatgg ttgtatatgc agttagcga aacattgita ttggacacat aactatagtt 1825  
 gaaagaataa gcaaaaagtc tatctagggtg tgcgtctctg agcaactttt aattattctc 1885  
 ccgtcctgca atatgagtta atcttctctg atcgaigtat attccaggaa ggggigicca 1945  
 10 ggacaattac cticcttctg gagaaattc ccttaataca alaagagaac ticaaagaaa 2005  
 atccctccct gtgcttllga aggggaaggga ggtgggcagc agtgggtcag agatagacct 2065  
 ttgttctctt atttctgagg ccttcagtc tctttattc aaagcactca gcatgccaaa 2125  
 gcacctatt ttagggatc ttttctgag ccttaaacac tgtgtgggg atgtcaactg 2185  
 15 tgacaggaaa ataacttggg gccccagaat cactaaggaa aactcaagct tagggaaact 2245  
 tcttagggca aaccacctc ccactctatt caaagtatc tctctgctca ctgagataga 2305  
 tacatatctg attgcctctt ttggaaggc taatcagaaa ctcaaaagaa tgcaactgtt 2365  
 tgtgtctcac ctatcttga cctggaagct cctcctccac tgaaccaatg tcttcttacc 2425  
 20 atatatgtat taatgtctta tgcctccca aaatgtataa aaccaaggta tgccccaacc 2485  
 atcttggta catgcatca ggacttctg agtctgtgtc acagtgtgtc ctcaaccttg 2545  
 gcaaaataaa ctttctaact taacaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2604

25

&lt;210&gt; 10

&lt;211&gt; 542

&lt;212&gt; PRT

30

&lt;213&gt; Homo sapiens

&lt;400&gt; 10

35

Met Pro Arg Arg Gly Leu Ile Leu His Thr Arg Thr His Trp Leu Leu

-34 -30 -25 -20

Leu Gly Leu Ala Leu Leu Cys Ser Leu Val Leu Phe Met Tyr Leu Leu

-15 -10 -5

40

Glu Cys Ala Pro Gln Thr Asp Gly Asn Ala Ser Leu Pro Gly Val Val

1 5 10

Gly Glu Asn Tyr Gly Lys Glu Tyr Tyr Gln Ala Leu Leu Gln Glu Gln

45

15 20 25 30

Glu Glu His Tyr Gln Thr Arg Ala Thr Ser Leu Lys Arg Gln Ile Ala

35 40 45

Gln Leu Lys Gln Glu Leu Gln Glu Met Ser Glu Lys Met Arg Ser Leu

50

50 55 60

Gln Glu Arg Arg Asn Val Gly Ala Asn Gly Ile Gly Tyr Gln Ser Asn

55

	65	70	75
	Lys Glu Gln Ala Pro Ser Asp Leu Leu Glu Phe Leu His Ser Gln Ile		
5	80	85	90
	Asp Lys Ala Glu Val Ser Ile Gly Ala Lys Leu Pro Ser Glu Tyr Gly		
	95	100	105
	Val Ile Pro Phe Glu Ser Phe Thr Leu Met Lys Val Phe Gln Leu Glu		
10	115	120	125
	Met Gly Leu Thr Arg His Pro Glu Glu Lys Pro Val Arg Lys Asp Lys		
	130	135	140
15	Arg Asp Glu Leu Val Glu Val Ile Glu Ala Gly Leu Glu Val Ile Asn		
	145	150	155
	Asn Pro Asp Glu Asp Asp Glu Gln Glu Asp Glu Glu Gly Pro Leu Gly		
20	160	165	170
	Glu Lys Leu Ile Phe Asn Glu Asn Asp Phe Val Glu Gly Tyr Tyr Arg		
	175	180	185
	Thr Glu Arg Asp Lys Gly Thr Gln Tyr Glu Leu Phe Phe Lys Lys Ala		
25	195	200	205
	Asp Leu Thr Glu Tyr Arg His Val Thr Leu Phe Arg Pro Phe Gly Pro		
	210	215	220
30	Leu Met Lys Val Lys Ser Glu Met Ile Asp Ile Thr Arg Ser Ile Ile		
	225	230	235
	Asn Ile Ile Val Pro Leu Ala Glu Arg Thr Glu Ala Phe Val Gln Phe		
	240	245	250
35	Met Gln Asn Phe Arg Asp Val Cys Ile His Gln Asp Lys Lys Ile His		
	255	260	265
	Leu Thr Val Val Tyr Phe Gly Lys Glu Gly Leu Ser Lys Val Lys Ser		
	275	280	285
40	Ile Leu Glu Ser Val Thr Ser Glu Ser Asn Phe His Asn Tyr Thr Leu		
	290	295	300
	Val Ser Leu Asn Glu Glu Phe Asn Arg Gly Arg Gly Leu Asn Val Gly		
45	305	310	315
	Ala Arg Ala Trp Asp Lys Gly Glu Val Leu Met Phe Phe Cys Asp Val		
	320	325	330
	Asp Ile Tyr Phe Ser Ala Glu Phe Leu Asn Ser Cys Arg Leu Asn Ala		
50	335	340	345
	Glu Pro Gly Lys Lys Val Phe Tyr Pro Val Val Phe Ser Leu Tyr Asn		

55

355 360 365  
 Pro Ala Ile Val Tyr Ala Asn Gln Glu Val Pro Pro Pro Val Glu Gln  
 5 370 375 380  
 Gln Leu Val His Lys Lys Asp Ser Gly Phe Trp Arg Asp Phe Gly Phe  
 385 390 395  
 10 Gly Met Thr Cys Gln Tyr Arg Ser Asp Phe Leu Thr Ile Gly Gly Phe  
 400 405 410  
 Asp Met Glu Val Arg Gly Trp Gly Gly Glu Asp Val His Leu Tyr Arg  
 415 420 425 430  
 15 Lys Tyr Leu His Gly Asp Leu Ile Val Ile Arg Thr Pro Val Pro Gly  
 435 440 445  
 Pro Phe His Leu Trp His Glu Lys Arg Cys Ala Asp Glu Leu Thr Pro  
 20 450 455 460  
 Glu Gln Tyr Arg Met Cys Ile Gln Ser Lys Ala Met Asn Glu Ala Ser  
 465 470 475  
 His Ser His Leu Gly Met Leu Val Phe Arg Glu Glu Ile Glu Thr His  
 25 480 485 490  
 Leu His Lys Gln Ala Tyr Arg Thr Asn Ser Glu Ala Val Gly  
 495 500 505  
 30  
 <210> 11  
 <211> 1626  
 <212> DNA  
 35 <213> Homo sapiens  
 <400> 11  
 40 atgcctagaa gaggactgat tcttcacacc cggaccact ggttgcgttt gggccttgc 60  
 ttgctctgca gtttgggtatt atttatgtac ctcttggaal gtgccccca gactgatgga 120  
 aatgcatttc ttcttggtgt tgttggggaa atttatgga aagagtatta tcaagccctc 180  
 ctacaggaac aagaagaaca ttatcagacc agggcnnccn gcttgaaacg ccaaatggcc 240  
 caactaanac aagaattaca agaatgagt gagaagttgc ggtcactgca agaaagaagg 300  
 aatgtagggg ctatggcat aggtatcag agcncanaag agcaagcacc tagtgatctt 360  
 ttagagtttc ttatttccca aattgacana gctgagttta gcataggggc caaactaccc 420  
 agtgagtatg gggtcattcc ctltganngt ttacctttna tgnnagtatt tcnatlggaa 480  
 50 atgggtctca ctgcccattc tgaagaaatc ccagttagaa agacaaacg agatgatttg 540  
 agggagttta ttgagcggg cttaggggc atttatatc ctgatgaaga tgatgancan 600

55



gaagatgagg aggggtcccct tggagagaaa ctgatattta atgaaaatga ctctgtagaa 660  
 gggtattatc gcactgagag ag taagggc acacagiatg aactcttttt taagaaagca 720  
 5 gaccttacgg aatatagaca tgtgacccct ttcgcccctt ttggacctct catgaaagtg 780  
 aagagtgaga tgattgacat cactagatca attattaata tcatlgtgcc actlgtctgaa 840  
 agaactgaag catttgtaca atttatgcag aacttcaggg atgtlgtat tcatcaagac 900  
 10 aagaagattc atctcacagt ggtgtatttt ggtaaagaag gactgtctaa ggtcaagict 960  
 atcctagaat ctgtcaccag tgagtctaatt tttcacaatt acaccttggc ctcattgaat 1020  
 gaagaattta atcgtggacg aggactaaat gtgggtgccc gagcttggga caaggagag 1080  
 gtcttgatgt tttctgtga tgttgatc ttttctcag ccgaattcct taacagctgc 1140  
 15 cggttaaatg ctgagccagg taagaagggt tttaccctg tgggtgtcag tctttacaat 1200  
 cctgccattg tttatgcaa ccaggagtg ccaccacctg tggagcagca gcigtgtcac 1260  
 aaaaaggatt ctggcttttg gcgagatttt ggcttggaa tgacttgtca gtatcgttca 1320  
 20 gatttctga ccattggigg atttgacatg gaagttagag gttgggtgg agaagatgtt 1380  
 catctttatc gaaaatactt acatgggtgac ctcatlgtga ttggactcc ggttcttgg 1440  
 cctttccacc tctggcatga aaagcgtgt gctgatgagc tgacccccga gcagtaccgc 1500  
 25 atgtgcatcc agtctaaagc catgaatgag gcctctcact cccacctggg aatgtctgtc 1560  
 ttcaggaggg aatatagagc gcattctcat aaacaggcat acaggacaaa cagtgaaagt 1620  
 gttagt 1626

30 <210> 12  
 <211> 3451  
 <212> DNA  
 35 <213> Homo sapiens

<220>  
 <221> CDS  
 40 <222> (41)..(1666)

<220>  
 45 <221> sig peptide  
 <222> (41)..(112)

50 <220>  
 <221> mat peptide  
 <222> (143)..(1666)

55

<400> 12

	aggcctagcg attttgttag gcaaatacac attaataaga atg cct aga aga gga	55
5	Met Pro Arg Arg Gly	
	-34 -30	
	ctg att ctt cac acc cgg acc cac tgg ttg ctg ttg ggc ctt gct ttg	103
10	Leu Ile Leu His Thr Arg Thr His Trp Leu Leu Leu Gly Leu Ala Leu	
	-25 -20 -15	
	ctc tgc agt ttg gta tta ttt atg tac ctc ctg gaa tgt gcc ccc cag	151
15	Leu Cys Ser Leu Val Leu Phe Met Tyr Leu Leu Glu Cys Ala Pro Gln	
	-10 -5 1	
	act gat gga aat gca tct ctt cct ggt gtt gtt ggg gaa aat tat ggt	199
20	Thr Asp Gly Asn Ala Ser Leu Pro Gly Val Val Gly Glu Asn Tyr Gly	
	5 10 15	
	aaa gag tat tat caa gcc ctc cta cag gaa caa gaa gaa cat tat cag	247
25	Lys Glu Tyr Tyr Gln Ala Leu Leu Gln Glu Gln Glu Glu His Tyr Gln	
	20 25 30 35	
	acc agg gca acc agt ctg aaa cgc caa att gcc caa cta aaa caa gaa	295
30	Thr Arg Ala Thr Ser Leu Lys Arg Gln Ile Ala Gln Leu Lys Gln Glu	
	40 45 50	
	tta caa gaa atg agt gag aag atg cgg tca ctg caa gaa aga agg aat	343
35	Leu Gln Glu Met Ser Glu Lys Met Arg Ser Leu Gln Glu Arg Arg Asn	
	55 60 65	
	gta ggg gct aat ggc ata ggc tat cag agc aac aaa gag caa gca cct	391
40	Val Gly Ala Asn Gly Ile Gly Tyr Gln Ser Asn Lys Glu Gln Ala Pro	
	70 75 80	
	agt gat ctt tta gag ttt ctt cat tcc caa att gac aaa gct gaa gtt	439
45	Ser Asp Leu Leu Glu Phe Leu His Ser Gln Ile Asp Lys Ala Glu Val	
	85 90 95	
	agc ata ggg gcc aaa cta ccc agt gag tat ggg gtc att ccc ttt gaa	487
50	Ser Ile Gly Ala Lys Leu Pro Ser Glu Tyr Gly Val Ile Pro Phe Glu	
	100 105 110 115	
	agt ttt acc tta atg aat gta ttt caa ttg gaa atg ggt ctc act cgc	535
	Ser Phe Thr Leu Met Lys Val Phe Gln Leu Glu Met Gly Leu Thr Arg	
	120 125 130	
	ent cct gaa gaa aag cca gtt hga aat gac aaa cga gat gaa ttg gtc	583
55	His Pro Glu Glu Lys Pro Val Arg Lys Asp Lys Arg Asp Glu Leu Val	

	135	140	145	
5	gaa gtt att gaa gcg ggc ttg gag gtc att aat aat cct gat gaa gat			631
	Glu Val Ile Glu Ala Gly Leu Glu Val Ile Asn Asn Pro Asp Glu Asp			
	150	155	160	
10	gat gaa caa gaa gat gag gag ggt ccc ctt gga gag aaa ctg ata ttt			679
	Asp Glu Gln Glu Asp Glu Glu Gly Pro Leu Gly Glu Lys Leu Ile Phe			
	165	170	175	
15	aat gaa aat gac ttc gta gaa ggt tat tat cgc act gag aga gat aag			727
	Asn Glu Asn Asp Phe Val Glu Gly Tyr Tyr Arg Thr Glu Arg Asp Lys			
	180	185	190	195
	ggc aca cag tat gaa ctc ttt ttt aag aaa gca gac ctt acg gaa tat			775
	Gly Thr Gln Tyr Glu Leu Phe Phe Lys Lys Ala Asp Leu Thr Glu Tyr			
20	200	205	210	
	aga cat gtg acc ctc ttc cgc cct ttt gga cct ctc atg aaa gtg aag			823
	Arg His Val Thr Leu Phe Arg Pro Phe Gly Pro Leu Met Lys Val Lys			
	215	220	225	
25	agt gag atg att gac atc act aga tca att att aat atc att gtg cca			871
	Ser Glu Met Ile Asp Ile Thr Arg Ser Ile Ile Asn Ile Ile Val Pro			
	230	235	240	
30	ctt gct gaa aga act gaa gca ttt gta caa ttt atg cag aac ttc agg			919
	Leu Ala Glu Arg Thr Glu Ala Phe Val Gln Phe Met Gln Asn Phe Arg			
	245	250	255	
35	gat gtt tgt att cat caa gac aag aag att cat ctc aca glg glg tal			967
	Asp Val Cys Ile His Gln Asp Lys Lys Ile His Leu Thr Val Val Tyr			
	260	265	270	275
	ttt ggt aaa gaa gga ctg tct aag gtc aag tct atc cta gaa tct gtc			1015
40	Phe Gly Lys Glu Gly Leu Ser Lys Val Lys Ser Ile Leu Glu Ser Val			
	280	285	290	
	acc agt gag tct aat ttt cac aat tac acc ttg gtc tca ttg aat gan			1063
	Thr Ser Glu Ser Asn Phe His Asn Tyr Thr Leu Val Ser Leu Asn Glu			
45	295	300	305	
	gaa ttt aat cgt gga cga gga cta aat glg ggt gcc cga gct tgg gac			1111
	Glu Phe Asn Arg Gly Arg Gly Leu Asn Val Gly Ala Arg Ala Trp Asp			
	310	315	320	
50	aag gga gag gtc ttg atg ttt ttc tgt gat gtt gat atc tat ttc tca			1159
	Lys Gly Glu Val Leu Met Phe Phe Cys Asp Val Asp Ile Tyr Phe Ser			

55

325                      330                      335  
 gcc gaa ttc ctt aac agc tgc cgg tta aat gct gag cca ggt aag aag 1207  
 5 Ala Glu Phe Leu Asn Ser Cys Arg Leu Asn Ala Glu Pro Gly Lys Lys  
 340                      345                      350                      355  
 gtg ttt tac cct gtg gtg ttc agt ctt tac aat cct gcc att gtt tat 1255  
 10 Val Phe Tyr Pro Val Val Phe Ser Leu Tyr Asn Pro Ala Ile Val Tyr  
 360                      365                      370  
 gcc aac cag gaa gtg cca cca cct gig gag cag cag ctg gtt cac aaa 1303  
 15 Ala Asn Gln Glu Val Pro Pro Pro Val Glu Gln Gln Leu Val His Lys  
 375                      380                      385  
 aag gat tct ggc ttt tgg cga gat ttt ggc ttt gga atg act tgt cag 1351  
 Lys Asp Ser Gly Phe Trp Arg Asp Phe Gly Phe Gly Met Thr Cys Gln  
 390                      395                      400  
 20 tat cgt tca gat ttc ctg acc att ggt gga ttt gac atg gaa gtg aga 1399  
 Tyr Arg Ser Asp Phe Leu Thr Ile Gly Gly Phe Asp Met Glu Val Arg  
 405                      410                      415  
 25 ggt tgg ggt gga gaa gat gtt cat ctt tat cga aaa tac tta cat ggt 1447  
 Gly Trp Gly Gly Glu Asp Val His Leu Tyr Arg Lys Tyr Leu His Gly  
 420                      425                      430                      435  
 30 gac ctc att gtg att cgg act ccg gtt cct ggt cct ttc cac ctc tgg 1495  
 Asp Leu Ile Val Ile Arg Thr Pro Val Pro Gly Pro Phe His Leu Trp  
 440                      445                      450  
 cat gaa aag cgc tgt gct gat gag ctg acc ccc gag cag tac cgc atg 1543  
 35 His Glu Lys Arg Cys Ala Asp Glu Leu Thr Pro Glu Gln Tyr Arg Met  
 455                      460                      465  
 tgc atc cag tct aac gcc atg aat gag gcc tct cac tcc cac ctg gga 1591  
 40 Cys Ile Gln Ser Lys Ala Met Asn Glu Ala Ser His Ser His Leu Gly  
 470                      475                      480  
 atg ctg gtc ttc agg gag gaa ata gag acg cat ctt cat aac cag gca 1639  
 Met Leu Val Phe Arg Glu Glu Ile Glu Thr His Leu His Lys Gln Ala  
 485                      490                      495  
 45 tac agg aca aac agt gaa gct gtt ggt tgaatcata attaatgcgt 1686  
 Tyr Arg Thr Asn Ser Glu Ala Val Gly  
 500                      505  
 50 taatgtatga aacacaaac agcaatatt aattagcctt acttctactt ccagatgcag 1716  
 tgcctctttt ggaagagaca tgttatattt tcatgttctt tctgacatta cttagcctat 1806  
 55

tcaacttgat gtagaagaa aaaacaaatg ttcaacaca aaatctctgt ttgtgagaa 1866  
 tactgcacta tggataaatt gacaaattga aatctcatat ttgtcccaa agttgttttg 1926  
 5 agttagtctt acctgggtgcc catgttctga ttgtgtgtgg gattgcatgg tgtccigatt 1986  
 gcatctaggt ggagcggatg gaatgtgtgt ggccactgtt gggtagagag cagcacattc 2046  
 ttacagagga gatggagcgt tatgagcata gtagtggat aggtatcttc acctgcccc 2106  
 10 ccttgagtca gccctcttga ctgatagct tgaagaatcc ttltccactg aaatagagga 2166  
 taattaattg acacatctga aatcccaat caatcaatca agagaaggt agaaactaaa 2226  
 actccttaac ttactgttgc ttacacccct gaaagtctgt tttaagcaa atgggttaata 2286  
 gtagaaaata ggttagaatt tatggcttga ttaaaaatat gttattacat tatcaigtic 2346  
 15 aggtattagga ttagtagtca gtgtgtgtga actattttga acaaacagaa aagaacacgg 2406  
 aaacattttt aacagagcat ttaattatgt tggataacag gatcctagct ctgtctggga 2466  
 acattagctt atgtgagcca gctctatcag ggtcttccca tgggtgttca gaatagatga 2526  
 gcatagcatg gttttgtttg tttttgcttt caattttcta atttggcatg gatccatag 2586  
 20 tatttactat cttttttcta atatatatat atatgttaca ttgtatttg cattactata 2646  
 atactttgag ttgaaaaaga gtttcattgt ggagagaaaa agcaaatggt atgccacaag 2706  
 atcacttga tttagaaaaa gggaggaggg gaagatagtc tgaatggaaa tctgaaatc 2766  
 25 ggaatgtttt agagaatat gtcacttga tatagaagt tttaattgag gtataaatta 2826  
 atgagacaaa gtgaaaaaga aattatattc agataggact gcactacatt attgttcaca 2886  
 catggatctg ttaccatcag gtcaattcct agtatgcata aattttttta ccttttttaa 2946  
 agagacctat gttgaaaacc cctgaaaatt cactgaagaa aaatcattac tctttttc 3006  
 30 agtaaatcat alcatctga atattacaaa ttcaaatl ctagggtcta tattantica 3066  
 atattacaat aactcttacc taattattct tacaagtltt aagtgtgtgt agtttagtga 3126  
 tttttttaaa agatgttga aatgttctct gcaaaatat tcaggccact gtcctttt 3186  
 35 atatattatt ataattattt attatgaaga ccagigaatt ccgalmllh maglmgaga 3246  
 acttaattat ttgcaaggt aagttacagc ttgtttttg agngaattca atgatttac 3306  
 tttgttctt gtgtttttta actagcttta agtttaaga tggagctaa gcattgkaa 3366  
 40 tgcatacgt ttttgacatt tattaaatgg taccaataaa gtattttatt accaaaaaa 3426  
 aaaaaaaaa aaaaaaaaa aaaa 3451

<210> 13

<211> 119

<212> PRT

<213> Homo sapiens

<400> 13

Met Arg Lys Gly Asn Leu Leu Leu Ser Trp Leu Leu Gly Pro Glu Leu

-17      -15                      -10                      -5  
 Pro Glu Leu Ser Pro Arg Ala Arg Lys Ala Asp Leu Lys Asp Glu Asn  
 5                      1                      5                      10                      15  
 Leu Lys Phe Ser Cys Trp Trp Glu Pro Arg Lys Thr Ala Gly Val Leu  
                                  20                      25                      30  
 10      Thr Trp Pro Phe Leu Ala Glu Leu Ala Glu Val Gly Val Leu Ala Asp  
                                  35                      40                      45  
 Gly Met Tyr Leu Gly Ala Val Ser Val Ala Gln Gln Arg Cys Arg Ala  
                                  50                      55                      60  
 15      Asp Trp Leu Ser His Trp Val Leu Pro Ala Gly Ser Pro Leu His Trp  
                                  65                      70                      75  
 Ala Phe Thr Gln Pro Cys Ser Trp Val Ser Leu Pro Cys Lys Gln Ser  
 20      80                      85                      90                      95  
 His Asn Asn Thr Arg Ile Val  
                                  100  
  
 25      <210> 14  
          <211> 357  
          <212> DNA  
 30      <213> Homo sapiens  
  
          <400> 14  
 35      atgaggnaag ggaaccttct gctgagctgg ctctcggggc ctgagcttcc agagctgtcc 60  
          ccaagggtta ggaaggccga cctgaaggat gagaacctca aattcagttg ctgggtggag 120  
          ccaagganga cggcgggtgt tctaactggg ccccttctgg ctgagctggc ggaagtgggc 180  
          gtlttggccg atgggatgta tctcggcgct gtgtctgtgg cccagcaag gtcagggct 240  
 40      gactggctga gccactgggt tctaccgcga ggctccccac tgcactgggc ttacacacag 300  
          ccatgtcttt gggtttccct ccttgtlaag cagagtcata ataacacacg aatagtc 357  
  
          <210> 15  
 45      <211> 814  
          <212> DNA  
          <213> Homo sapiens  
  
 50      <220>  
          <221> CDS  
  
 55

&lt;222&gt; (62).. (418)

5

&lt;200&gt;

&lt;221&gt; sig peptide

&lt;222&gt; (62).. (112)

10

&lt;200&gt;

&lt;221&gt; mat peptide

&lt;222&gt; (113).. (418)

15

&lt;400&gt; 15

caaaaatata agcatcagct gaggtgatat tagttcagtc acctaacaaac tcttagaaga 60

20

g atg agg aaa ggg aac ctt ctg ctg agc tgg ctt ctg ggg cct gag 106

Met Arg Lys Gly Asn Leu Leu Leu Ser Trp Leu Leu Gly Pro Glu

-17 -15 -10 -5

ctt cca gag ctg tcc cca agg gct agg aag gcc gac ctg aag gat gag 154

25

Leu Pro Glu Leu Ser Pro Arg Ala Arg Lys Ala Asp Leu Lys Asp Glu

1 5 10

aac ctc aaa ttc agt tgc tgg tgg gag cca agg aag acg gcg ggt gtt 202

30

Asn Leu Lys Phe Ser Cys Trp Trp Glu Pro Arg Lys Thr Ala Gly Val

15 20 25 30

cta acg tgg ccc ttt ctg gct gag ctg gcg gaa gtg ggc gtt ttg gcc 250

Leu Thr Trp Pro Phe Leu Ala Glu Leu Ala Glu Val Gly Val Leu Ala

35

35 40 45

gat ggg atg tat ctc ggc gct gtg tct gtg gcc cag caa agg tgc agc 298

Asp Gly Met Tyr Leu Gly Ala Val Ser Val Ala Gln Gln Arg Cys Arg

40

50 55 60

gct gac tgg ctg agc cac tgg gtt cta ccc gca ggc tcc cca ctg cac 346

Ala Asp Trp Leu Ser His Trp Val Leu Pro Ala Gly Ser Pro Leu His

65 70 75

45

tgg gct ttc aca cag cca tgc tct tgg gtt tcc ctc cct tgl aag cag 394

Trp Ala Phe Thr Gln Pro Cys Ser Trp Val Ser Leu Pro Cys Lys Gln

80 85 90

50

ngt cat aat aac aca cga ata gtc taacgtcggg tttctcgtc agcagaggtc 118

Ser His Asn Asn Thr Arg Ile Val

95 100

55

cttaggtcac agtgttactg aaatgggtct gagcctgaga atctctttgg cctctgaaag 508  
 ggcagggcag gtgggcaccg acttctgcc agtctttca ggtttcctgt tcaaagccag 568  
 5 tccgtttggt ggaggggac accgagagtg tcgtatcat ttgtagccc ttltctcgn 628  
 cgttttctgg tagaaaatgt ccttctcaa aatgctaata attatcataa taatctgctt 688  
 tccaaccaac ttccacaagt gacaacctgt gtagaactgt gataaaggtt tgcataaagt 748  
 10 aggttttcta ccaagtgtgt gtaagtctct gtaaaataaa aagctgtttt ccaaaaaaaaa 808  
 aaaaaa 814

<210> 16

15 <211> 714

<212> PRT

<213> Homo sapiens

20

<400> 16

Met Lys His Phe Cys Asn Leu Leu Cys Ile Leu Met Phe Cys Asn Gln  
 -16 -15 -10 -5  
 25 Gln Ser Val Cys Asp Pro Pro Ser Gln Asn Asn Ala Ala Asn Ile Ser  
 1 5 10 15  
 Met Val Gln Ala Ala Ser Ala Gly Pro Pro Ser Leu Arg Lys Asp Ser  
 20 25 30  
 30 Thr Pro Val Ile Ala Asn Val Val Ser Leu Ala Ser Ala Pro Ala Ala  
 35 40 45  
 Gln Pro Thr Val Asn Ser Asn Ser Val Leu Gln Gly Ala Val Pro Thr  
 35 50 55 60  
 Val Thr Ala Lys Ile Ile Gly Asp Ala Ser Thr Gln Thr Asp Ala Leu  
 65 70 75 80  
 Lys Leu Pro Pro Ser Gln Pro Pro Arg Leu Leu Lys Asn Lys Ala Leu  
 40 85 90 95  
 Leu Cys Lys Pro Ile Thr Gln Thr Lys Ala Thr Ser Cys Lys Pro His  
 100 105 110  
 45 Thr Gln Asn Lys Glu Cys Gln Thr Glu Asp Thr Pro Ser Gln Pro Gln  
 115 120 125  
 Ile Ile Val Val Pro Val Pro Val Pro Val Phe Val Pro Ile Pro Leu  
 130 135 140  
 50 His Leu Tyr Thr Gln Tyr Ala Pro Val Pro Phe Gly Ile Pro Val Pro  
 145 150 155 160

55



	Met Pro Val Pro Met Leu Ile Pro Ser Ser Met Asp Ser Glu Asp Lys		
	165	170	175
5	Val Thr Glu Ser Ile Glu Asp Ile Lys Glu Lys Leu Pro Thr His Pro		
	180	185	190
	Phe Glu Ala Asp Leu Leu Glu Met Ala Glu Met Ile Ala Glu Asp Glu		
10	195	200	205
	Glu Lys Lys Thr Leu Ser Gln Gly Glu Ser Gln Thr Ser Glu His Glu		
	210	215	220
	Leu Phe Leu Asp Thr Lys Ile Phe Glu Lys Asp Gln Gly Ser Thr Tyr		
15	225	230	235
	Ser Gly Asp Leu Glu Ser Glu Ala Val Ser Thr Leu His Ser Trp Glu		
	245	250	255
20	Glu Glu Leu Asn His Tyr Ala Leu Lys Ser Asn Ala Val Gln Glu Ala		
	260	265	270
	Asp Ser Glu Leu Lys Gln Phe Ser Lys Gly Glu Thr Glu Gln Asp Leu		
	275	280	285
25	Glu Ala Asp Phe Pro Ser Asp Ser Phe Asp Pro Leu Asn Lys Gly Gln		
	290	295	300
	Gly Ile Gln Ala Arg Ser Arg Thr Arg Arg Arg His Arg Asp Gly Phe		
30	305	310	315
	Pro Gln Pro Arg Arg Arg Gly Arg Lys Lys Ser Ile Val Ala Val Glu		
	325	330	335
	Pro Arg Ser Leu Ile Gln Gly Ala Phe Gln Gly Cys Ser Val Ser Gly		
35	340	345	350
	Met Thr Leu Lys Tyr Met Tyr Gly Val Asn Ala Trp Lys Asn Trp Val		
	355	360	365
40	Gln Trp Lys Asn Ala Lys Glu Glu Gln Gly Asp Leu Lys Cys Gly Gly		
	370	375	380
	Val Glu Gln Ala Ser Ser Ser Pro Arg Ser Asp Pro Leu Gly Ser Thr		
	385	390	395
45	Gln Asp His Ala Leu Ser Gln Glu Ser Ser Glu Pro Gly Cys Arg Val		
	405	410	415
	Arg Ser Ile Lys Leu Lys Glu Asp Ile Leu Ser Cys Thr Phe Ala Glu		
50	420	425	430
	Leu Ser Leu Gly Leu Cys Gln Phe Ile Gln Glu Val Arg Arg Pro Asn		
	435	440	445

55

Gly Glu Lys Tyr Asp Pro Asp Ser Ile Leu Tyr Leu Cys Leu Gly Ile  
 450 455 460  
 5 Gln Gln Tyr Leu Phe Glu Asn Gly Arg Ile Asp Asn Ile Phe Thr Glu  
 465 470 475 480  
 Pro Tyr Ser Arg Phe Met Ile Glu Leu Thr Lys Leu Leu Lys Ile Trp  
 485 490 495  
 10 Glu Pro Thr Ile Leu Pro Asn Gly Tyr Met Phe Ser Arg Ile Glu Glu  
 500 505 510  
 Glu His Leu Trp Glu Cys Lys Gln Leu Gly Ala Tyr Ser Pro Ile Val  
 515 520 525  
 Leu Leu Asn Thr Leu Leu Phe Phe Asn Thr Lys Tyr Phe Gln Leu Lys  
 530 535 540  
 20 Asn Val Thr Glu His Leu Lys Leu Ser Phe Ala His Val Met Arg Arg  
 545 550 555 560  
 Thr Arg Thr Leu Lys Tyr Ser Thr Lys Met Thr Tyr Leu Arg Phe Phe  
 565 570 575  
 25 Pro Pro Leu Gln Lys Gln Glu Ser Glu Pro Asp Lys Leu Thr Val Gly  
 580 585 590  
 Lys Arg Lys Arg Asn Glu Asp Asp Glu Val Pro Val Gly Val Glu Met  
 595 600 605  
 30 Ala Glu Asn Thr Asp Asn Pro Leu Arg Cys Pro Val Arg Leu Tyr Glu  
 610 615 620  
 Phe Tyr Leu Ser Lys Cys Ser Glu Ser Val Lys Gln Arg Asn Asp Val  
 35 625 630 635 640  
 Phe Tyr Leu Gln Pro Glu Arg Ser Cys Val Pro Asn Ser Pro Met Trp  
 645 650 655  
 40 Tyr Ser Ala Phe Pro Ile Asp Pro Gly Thr Leu Asp Thr Met Leu Thr  
 660 665 670  
 Arg Ile Leu Met Val Arg Glu Val His Glu Glu Leu Ala Lys Ala Lys  
 675 680 685  
 45 Ser Glu Asp Ser Asp Val Glu Leu Ser Asp  
 690 695  
 50 <210> 17  
 <211> 2142  
 <212> DNA  
 55

&lt;213&gt; Homo sapiens

&lt;400&gt; 17

5

10

15

20

25

30

35

40

45

50

55

atgaacatt tctgaacct gcttgtatc ttgatgtct gtaacagca aagtgtatgt 60  
 gacccgcctt cacaataaa tgcagcaaat atttccalgg ttcaagctgc ttcagcagga 120  
 ccccatctc tgagaaaaga ttgactcca gttatagcca atgtagtatc attggcaagt 180  
 gccccgtctg ctacagctac agtgaattct aacagtgtct tacaaggctc agttccaaca 240  
 gtaacagcga aatcatcgg tgatgaagt actcaaacag atgccccgaa actgccacct 300  
 tcccaacctc caaggctttt gaagaacaaa gctttatlat gcaaaccctat cacacagact 360  
 aaagccacct ctgcaaac acatacccaa aacaaagaat gccagacaga agacactcca 420  
 agtcagcccc agattattgt ggigccagtt cccgtaccag tgttgttcc catacctctt 480  
 caccittata ctcaatatgc tccagtcca ttggaattc cagtccaat gccgttccct 540  
 atgcttattc catcttcaat gtagagtga gataaagta cagagagtat tgaagacatt 600  
 aaagaaaagc tccccacaca tccatttga gctgactcc ttgagatggc agaattgatt 660  
 gcagaagatg aagagaagaa gactctatct caggagaggt cccaaacttc tgaacacgaa 720  
 ctctttctag acaccaagat attgaaaaa gaccaaggaa gtacatacag tggtagcttt 780  
 gaatcagagg cagtatctac tctacatagc tgggaggaag agctgaatca ctatgcctta 840  
 aagtcacatg ctgtgcaaga ggctgattca gaattgaagc agttctcaa aggggaaact 900  
 gaacaggacc tggagcaga ttttccatca gactccttgc acccacttaa taaaggacag 960  
 ggaatccagg caggttcccg aacaagcga cgacacagag atggcttccc ccaaccaga 1020  
 cgaagaggac ggaagaagtc tatagtggtc tggagccca ggaacttlat tcaaggagcc 1080  
 tticaaggct gctcagtgic cgggagaca ctgaatata tgtatgggtt aatgcttgg 1140  
 aagaacttgg ttcatggaa aatgcccaag gaagagcagc ggaacttlat atgtggagg 1200  
 gtgaacagg cctcatctag cccacgttct gaccccttag gaagtactca agaccatgca 1260  
 ctcttcaag aatcctcagc gccaggctgt agagtcggtc ctatcaagct gaaggaagac 1320  
 attctgtct gcacttgc tgagtgagt ttggcttlat gccagtlat ccaagagggt 1380  
 cggagaccan atggigaaaa atatgatcca gacagtatct tatacttgc ctttgggaatt 1440  
 caacagtacc tgttgaaat tggtagaata gataacatt ttactgagcc ctattccaga 1500  
 ttatgattg aacttaccna actctlgaaa atalggaac ctacatact tctaatgtt 1560  
 tcatgttct ctgcattga ggaagagcat ttgtggagt kcaaacagct gggcgcttac 1620  
 tcaccaatcg tctttttaa cccctcctt tcttcaata ccaaatact ccaactaaag 1680  
 aatgttactg agcacttga gctttcttt gcccttga tgagacgac caggactctg 1740  
 aagtacagta ccaagatgac atatctgagg tcttccac ctttacaga gcaggagica 1800  
 gaaccagata aactgactgt tggcagaggc aacgaaatg aagtgatga ggttccagt 1860  
 gggctggaga tggcagagat tctgacat ccaacttact gccagtcg actttatgag 1920  
 tttactgt cnaatgtc tgggtgtg aagcaagga atgatgttt ttacttcan 1980

cctgagcgt cctgtgtccc gaatagcccc atgttgtact ccgcattccc gatagaccct 2040  
 ggaaccttgg acaccatgtt aacacgtatt ctcatggta gggaggtaca tgaagaactt 2100  
 5 gccaagcca aatctgaaga ctctgatgtt gaattatcag at 2142

<210> 18

10 <211> 2662

<212> DNA

<213> Homo sapiens

15 <200>

<221> CDS

<222> (6).. (2147)

20

<220>

<221> sig peptide

<222> (6).. (53)

25

<220>

<221> mat peptide

30

<222> (54).. (2147)

<400> 18

35 gggaa atg aau cat ttc tgt aac ctg ctt tgt atc ttg atg ttc tgt 47  
 Met Lys His Phe Cys Asn Leu Leu Cys Ile Leu Met Phe Cys  
 -16 -15 -10 -5

40 aat cag cua agt gta tgt gac cag cct tca caa aat aat gca gca aat 95  
 Asn Gln Gln Ser Val Cys Asp Pro Pro Ser Gln Asn Asn Ala Ala Asn  
 1 5 10

45 att tcc atg gtt caa gct gct tca gca gga ccc cca tct ctg aga aaa 143  
 Ile Ser Met Val Gln Ala Ala Ser Ala Gly Pro Pro Ser Leu Arg Lys  
 15 20 25 30

50 gat tgg act cca gtt ata gcc aat gta gta tca ttg gca agt gcc cct 191  
 Asp Ser Thr Pro Val Ile Ala Asn Val Val Ser Leu Ala Ser Ala Pro  
 35 40 45

55 gct gct cag cct aca gta aat tct aac agt gtc tta caa ggt gca gtt 239  
 Ala Ala Gln Pro Thr Val Asn Ser Asn Ser Val Leu Gln Gly Ala Val

	50	55	60	
5	cca aca gta aca gcg aaa atc atc ggt gat gca agt act caa aca gat	287		
	Pro Thr Val Thr Ala Lys Ile Ile Gly Asp Ala Ser Thr Gln Thr Asp			
	65	70	75	
10	gcc ctg aaa ctg cca cct tcc caa cct cca agg ctt ttg aag aac aaa	335		
	Ala Leu Lys Leu Pro Pro Ser Gln Pro Pro Arg Leu Leu Lys Asn Lys			
	80	85	90	
	gct tta tta tgc aaa ccc atc aca cag act aaa gcc acc tct tgc aaa	383		
	Ala Leu Leu Cys Lys Pro Ile Thr Gln Thr Lys Ala Thr Ser Cys Lys			
15	95	100	105	110
	cca cat acc caa aac aaa gaa tgc cag aca gaa gac act cca agt cag	431		
	Pro His Thr Gln Asn Lys Glu Cys Gln Thr Glu Asp Thr Pro Ser Gln			
	115	120	125	
20	ccc cag att att gtg gtg cca gtt ccc gta cca gtg ttt gtt ccc ata	479		
	Pro Gln Ile Ile Val Val Pro Val Pro Val Pro Val Phe Val Pro Ile			
	130	135	140	
25	cct ctt cac ctt tat act caa tat get cca gtc cca ttt gga att cca	527		
	Pro Leu His Leu Tyr Thr Gln Tyr Ala Pro Val Pro Phe Gly Ile Pro			
	145	150	155	
30	glt cca atg cct gtc cct atg ctt att cca tct tca atg gat agt gaa	575		
	Val Pro Met Pro Val Pro Met Leu Ile Pro Ser Ser Met Asp Ser Glu			
	160	165	170	
35	gat aaa gtc aca gag agt att gaa gac att aaa gaa aag ctt ccc aca	623		
	Asp Lys Val Thr Glu Ser Ile Glu Asp Ile Lys Glu Lys Leu Pro Thr			
	175	180	185	190
	cat cca ttt gaa gct gat ctc ctt gag atg gca gaa atg att gca gaa	671		
	Ile Pro Phe Glu Ala Asp Leu Leu Glu Met Ala Glu Met Ile Ala Glu			
40	195	200	205	
	gat gaa gag aag aag act cta tct cag gga gag tcc can act tct gaa	719		
	Asp Glu Glu Lys Lys Thr Leu Ser Gln Gly Glu Ser Gln Thr Ser Glu			
45	210	215	220	
	cac gaa ctc ttt cta gac acc aag ata ttt gaa aaa gac caa gga agt	767		
	Ile Glu Leu Phe Leu Asp Thr Lys Ile Phe Glu Lys Asp Gln Gly Ser			
	225	230	235	
50	aca tac agt ggt gat ctt gaa tca gag gca gta tct act cta cat agc	815		
	Thr Tyr Ser Gly Asp Leu Glu Ser Glu Ala Val Ser Thr Leu His Ser			

	240	245	250	
5	tgg gag gaa gag ctg aat cac tat gcc tta aag tca aat gct gtg caa			863
	Trp Glu Glu Glu Leu Asn His Tyr Ala Leu Lys Ser Asn Ala Val Gln			
	255	260	265	270
10	gag gct gat tca gaa ttg aag cag ttc tca aaa ggg gaa act gaa cag			911
	Glu Ala Asp Ser Glu Leu Lys Gln Phe Ser Lys Gly Glu Thr Glu Gln			
	275	280	285	
15	gac ctg gaa gca gat ttt cca tca gac tcc ttt gac cca ctt aat aaa			959
	Asp Leu Glu Ala Asp Phe Pro Ser Asp Ser Phe Asp Pro Leu Asn Lys			
	290	295	300	
20	gga cag gga atc cag gca cgt tcc cga aca aga cga cga cac aga gat			1007
	Gly Gln Gly Ile Gln Ala Arg Ser Arg Thr Arg Arg Arg His Arg Asp			
	305	310	315	
25	ggc ttc ccc caa ccc aga cga aga gga cgg aag aag tct ata gtg gct			1055
	Gly Phe Pro Gln Pro Arg Arg Arg Gly Arg Lys Lys Ser Ile Val Ala			
	320	325	330	
30	gtg gag ccc agg agt ctt att caa gga gcc ttt caa ggc tgc tca gtg			1103
	Val Glu Pro Arg Ser Leu Ile Gln Gly Ala Phe Gln Gly Cys Ser Val			
	335	340	345	350
35	tcc ggg atg aca ctg aaa tac atg tat ggg gta aat gct tgg aag aac			1151
	Ser Gly Met Thr Leu Lys Tyr Met Tyr Gly Val Asn Ala Trp Lys Asn			
	355	360	365	
40	tgg gtt cag tgg aaa aat gcc aag gaa gag cag ggg gat cta aaa tgt			1199
	Trp Val Gln Trp Lys Asn Ala Lys Glu Glu Gln Gly Asp Leu Lys Cys			
	370	375	380	
45	gga ggg gtt gaa cag gcc tca tct agc ccn cgt tct gnc ccc tta gga			1247
	Gly Gly Val Glu Gln Ala Ser Ser Ser Pro Arg Ser Asp Pro Leu Gly			
	385	390	395	
50	agt act caa gac cat gca ctc tct caa gaa tcc tca gag ccn ggc tgt			1295
	Ser Thr Gln Asp His Ala Leu Ser Gln Glu Ser Ser Glu Pro Gly Cys			
	400	405	410	
55	aga gtc cgc tct atc aag ctg aag gaa gac att ctg tcc tgc act ttt			1343
	Arg Val Arg Ser Ile Lys Leu Lys Glu Asp Ile Leu Ser Cys Thr Phe			
	415	420	425	430
	gct gag tlg agt ttg ggc tta tgc cag ttt atc caa gac gtg cga agt			1391
	Ala Glu Leu Ser Leu Gly Leu Cys Gln Phe Ile Gln Glu Val Arg Arg			

	435	440	445	
5	cca aat ggt gaa aaa tat gat cca gac agt atc tta tac ttg tgc ctt			1439
	Pro Asn Gly Glu Lys Tyr Asp Pro Asp Ser Ile Leu Tyr Leu Cys Leu			
	450	455	460	
10	gga att caa cag tac ctg ttt gaa aat ggt aga ata gat aac att ttt			1487
	Gly Ile Gln Gln Tyr Leu Phe Glu Asn Gly Arg Ile Asp Asn Ile Phe			
	465	470	475	
15	act gag ccc tat tcc aga ttt atg att gaa ctt acc aaa ctc ttg aaa			1535
	Thr Glu Pro Tyr Ser Arg Phe Met Ile Glu Leu Thr Lys Leu Leu Lys			
	480	485	490	
20	ata tgg gaa cct aca ata ctt cct aat ggt tac atg ttc tct cgc att			1583
	Ile Trp Glu Pro Thr Ile Leu Pro Asn Gly Tyr Met Phe Ser Arg Ile			
	495	500	505	510
	gag gaa gag cat ttg tgg gag tgc aaa cag ctg ggc gct tac tca cca			1631
	Glu Glu Glu His Leu Trp Glu Cys Lys Gln Leu Gly Ala Tyr Ser Pro			
	515	520	525	
25	atc gtc ctt tta aac acc ctc ctt ttc ttc aat acc aaa tac ttc caa			1679
	Ile Val Leu Leu Asn Thr Leu Leu Phe Phe Asn Thr Lys Tyr Phe Gln			
	530	535	540	
30	cta aag aat gtt act gag cac ttg aag ctt tcc ttt gcc cat gtg atg			1727
	Leu Lys Asn Val Thr Glu His Leu Lys Leu Ser Phe Ala His Val Met			
	545	550	555	
35	aga cgg acc agg act ctg aag tac agt acc aag atg aca tat ctg agg			1775
	Arg Arg Thr Arg Thr Leu Lys Tyr Ser Thr Lys Met Thr Tyr Leu Arg			
	560	565	570	
40	ttc ttc cca cct tta cag aag cag gag tca gaa cca gat aaa ctg act			1823
	Phe Phe Pro Pro Leu Gln Lys Gln Glu Ser Glu Pro Asp Lys Leu Thr			
	575	580	585	590
	gtt ggc aag agg aaa cga aat gaa gat gat gag gtt cca glg ggc glg			1871
	Val Gly Lys Arg Lys Arg Asn Glu Asp Asp Glu Val Pro Val Gly Val			
45	595	600	605	
	gag atg gca gng aat act gac aat cca cta agn tgc cca gtc cga ctt			1919
	Glu Met Ala Glu Asn Thr Asp Asn Pro Leu Arg Cys Pro Val Arg Leu			
	610	615	620	
50	tat gag ttt tac ctg tca naa tgt tct gaa agt glg aag cna agg aat			1967
	Tyr Glu Phe Tyr Leu Ser Lys Cys Ser Glu Ser Val Lys Gln Arg Asn			

55

625                      630                      635  
 gat gtg ttt tac ctt caa cct gag cgc tcc tgt gtc ccg aat agc ccc 2015  
 5 Asp Val Phe Tyr Leu Gln Pro Glu Arg Ser Cys Val Pro Asn Ser Pro  
 640                      645                      650  
 atg tgg tac tcc gca ttc ccg ata gac cct gga acc ctg gac acc atg 2063  
 10 Met Trp Tyr Ser Ala Phe Pro Ile Asp Pro Gly Thr Leu Asp Thr Met  
 655                      660                      665                      670  
 tta aca cgt att ctc atg gtg agg gag gta cat gaa gaa ctt gcc aaa 2111  
 15 Leu Thr Arg Ile Leu Met Val Arg Glu Val His Glu Glu Leu Ala Lys  
 675                      680                      685  
 gcc aaa tct gaa gac tct gat gtt gaa tta tca gat taaaacggaa 2157  
 Ala Lys Ser Glu Asp Ser Asp Val Glu Leu Ser Asp  
 690                      695  
 20 gtgaggttct tattttcata catatttgta tgcaccaaac tgtgaatgca tccagctggt 2217  
 ggaaaatgat gtataagtct aagtcctctt gacttgacca taagatcatg gaaaacagat 2277  
 gacttgtgaa cccacacgtg tggatgtgca aatgaaaatt gaaggaauga atatgaactg 2337  
 25 agaaatgttc ttitggcagt atatatgtct tagacatctt cagaaigact aatttctccg 2397  
 agtgggtgat aatcttattt tgtttgggag taacaaatcg tggaaatatt ttaaggaaaa 2457  
 ctgttgtata aaactttacc atagtaacct tagaccttag aguggtagct ttggagttaa 2517  
 actttggctg caataggcta cltttgcaag ccttccgtaa aagtcagagg agagatcagt 2577  
 30 acagagctaa gagtgcacac aatgaggac tttgggaccc agatttgaag acccaataaa 2637  
 aatactcaac tttttaaaaa aaaaa 2662  
 35 <210> 19  
 <211> 81  
 <212> PRT  
 40 <213> Homo sapiens  
 <400> 19  
 Met Arg Thr Tyr His Tyr Ile Pro Leu Phe Ile Trp Thr Tyr Met Phe  
 45 -21                      -20                      -15                      -10  
 His Thr Val Asp Thr Ile Leu Leu Gln Glu Lys Pro Asn Ser Tyr Leu  
 -5                      1                      5  
 Ser Ser Lys Lys Ile Ala Gly Leu Thr Lys Asp Asp Gly Lys Met Leu  
 50 10                      15                      20  
 Arg Arg Thr Lys Arg Gly Trp Met Trp Asn Gln Phe Phe Leu Leu Glu  
 55



	25	30	35	40
	Glu Tyr Thr Gly Thr Asp Thr Gln Tyr Val Gly Lys Val Arg Ile Phe			
5		45	50	55
	Val			
10	<210> 20			
	<211> 243			
	<212> DNA			
	<213> Homo sapiens			
15	<400> 20			
	atgaggactt accattatat accattattc atctggacct atatgttcca tacagttgac	60		
20	accatcctat tacaagaaaa acctaacagt tatttatcaa gcaaaaagat agcgggtctg	120		
	acaaaagatg acggtaaaat gctacgtcgc accaagcgtg gctggatgtg gaatcagttc	180		
	ttcttatgg aagagttcac aggtactgac acacaatatg taggcaaggt aagaattttt	240		
25	gta	243		
30	<210> 21			
	<211> 630			
	<212> DNA			
	<213> Homo sapiens			
35	<200>			
	<221> CDS			
	<222> (160)..(402)			
40	<200>			
	<221> sig peptide			
	<222> (160)..(231)			
45	<200>			
	<221> mat peptide			
	<222> (232)..(402)			
50	<400> 21			
	aagatcagct gtgaagatgc tataaaagc gtagggaagg accgagacag aagcaaacac	60		
55				

ggaaacigtcn gtgcggagta gggctaaact cagttccatt gtttagcaag gaaaaacaaa 120  
 caatacatig aatttgacaa cccactgaag ttgcagata atg agg act tac cat 174  
 5 Met Arg Thr Tyr His  
 -24 -20  
 tat ata cca tta ttc atc tgg acc tat atg ttc cat aca gtt gac acc 222  
 10 Tyr Ile Pro Leu Phe Ile Trp Thr Tyr Met Phe His Thr Val Asp Thr  
 -15 -10 -5  
 atc cta tta caa gaa aaa cct aac agt tat tta tca agc aaa aag ata 270  
 15 Ile Leu Leu Gln Glu Lys Pro Asn Ser Tyr Leu Ser Ser Lys Lys Ile  
 1 5 10  
 gcg ggt ctg aca aaa gat gac ggt aaa atg cta cgt cgc acc aag cgt 318  
 Ala Gly Leu Thr Lys Asp Asp Gly Lys Met Leu Arg Arg Thr Lys Arg  
 20 15 20 25  
 ggc tgg atg tgg aat cag ttc ttc tta ttg gaa gag tac aca ggt act 366  
 Gly Trp Met Trp Asn Gln Phe Phe Leu Leu Glu Glu Tyr Thr Gly Thr  
 30 35 40 45  
 25 gac aca caa tat gta ggc aag gta aga att ttt gta tgagaaatct 412  
 Asp Thr Gln Tyr Val Gly Lys Val Arg Ile Phe Val  
 50 55  
 30 aaaagcigan agtgcagct atttatitit ttcagcaac tttctitit actagtatt 472  
 attaaaaat atttaactaa ttatgtitig aaggtgtgat atigcaact attitagtgg 532  
 ggaagaaan ggaacatat ttgggtcta aalgtaaac aalgtcaata alaagcgtaa 592  
 gctactaagt catagttga tggatgtgat callatta 630  
 35  
 <210> 22  
 <211> 150  
 40 <212> PRT  
 <213> Homo sapiens  
 <400> 22  
 45 Met Arg Lys Thr Arg Leu Trp Gly Leu Leu Trp Met Leu Phe Val Ser  
 -20 -15 -10 -5  
 Glu Leu Arg Ala Ala Thr Lys Leu Thr Glu Glu Lys Tyr Glu Leu Lys  
 50 1 5 10  
 Glu Gly Gln Thr Leu Asp Val Lys Cys Asp Tyr Thr Leu Glu Lys Phe  
 15 20 25  
 55

Ala Ser Ser Gln Lys Ala Trp Gln Ile Ile Arg Asp Gly Glu Met Pro  
 30 35 40  
 5 Lys Thr Leu Ala Cys Thr Glu Arg Pro Ser Lys Asn Ser His Pro Val  
 45 50 55 60  
 Gln Val Gly Arg Ile Ile Leu Glu Asp Tyr His Asp His Gly Leu Leu  
 65 70 75  
 10 Arg Val Arg Met Val Asn Leu Gln Val Glu Asp Ser Gly Leu Tyr Gln  
 80 85 90  
 Cys Val Ile Tyr Gln Pro Pro Lys Glu Pro His Met Leu Phe Asp Arg  
 95 100 105  
 15 Ile Arg Leu Val Val Thr Lys Gly Phe Arg Cys Ser Thr Leu Ser Phe  
 110 115 120  
 20 Ser Trp Leu Val Asp Ser  
 125 130

25 <210> 23  
 <211> 450  
 <212> DNA  
 <213> Homo sapiens

30 <400> 23  
 atgaggaaga ccaggctctg ggggctgctg tggatgcctt ttgtctcaga actccgagct 60  
 gcaactaaat taactgagga aaagtaagaa ctgaagagg ggcagaccct ggatgtaaa 120  
 35 tgtgactaca cgtagagaa gtttccagc agccagaaag ctggcagat aataagggnc 180  
 ggagagnlgt ccaagaccct ggcatgcaca gagaggcctt caaagaattc ccatccagtc 240  
 caagtggggg ggaatcact agaagactac catgatcatg gtttactgct cgctccgaatg 300  
 40 gtcaaccttc aagtgaaga ttctggactg tatcagtgtg tgatctacca gccctccaaag 360  
 gagcctcaca tctgttctga tgcctccgc ttggtggiga ccaaggggtt ccggtgttca 420  
 acattgtcat tctccagct agtgaattcc 450

45 <210> 24  
 <211> 701  
 <212> DNA  
 50 <213> Homo sapiens

55 <200>

&lt;221&gt; CDS

&lt;222&gt; (19)..(468)

5

&lt;200&gt;

&lt;221&gt; sig peptide

10

&lt;222&gt; (19)..(78)

&lt;200&gt;

&lt;221&gt; mat peptide

15

&lt;222&gt; (79)..(468)

&lt;400&gt; 24

20

agctgggtgca caggaagg atg agg aag acc agg ctc tgg ggg ctg ctg tgg 51

Met Arg Lys Thr Arg Leu Trp Gly Leu Leu Trp

-20

-15

-10

25

atg ctc ttt gtc tca gaa ctc cga gct gca act aaa tta act gag gaa 99

Met Leu Phe Val Ser Glu Leu Arg Ala Ala Thr Lys Leu Thr Glu Glu

-5

1

5

30

aag tat gaa ctg aaa gag ggg cag acc ctg gat gtg aaa tgt gac tac 147

Lys Tyr Glu Leu Lys Glu Gly Gln Thr Leu Asp Val Lys Cys Asp Tyr

10

15

20

35

acg cta gag aag ttt gcc agc agc cag aaa gct tgg cag ata ata agg 195

Thr Leu Glu Lys Phe Ala Ser Ser Gln Lys Ala Trp Gln Ile Ile Arg

25

30

35

40

gac gga gag atg ccc aag acc ctg gca tgc acg gag agg cct tca aag 243

Asp Gly Glu Met Pro Lys Thr Leu Ala Cys Thr Glu Arg Pro Ser Lys

40

45

50

55

50

aat tcc cat cca gtc caa gtg ggg agx atc ata cta gaa gac tac cat 291

Asn Ser His Pro Val Gln Val Gly Arg Ile Ile Leu Glu Asp Tyr His

60

65

70

45

gat cat ggt tta ctg cgc gtc cga atg gtc aac ctt caa gtg gaa gat 339

Asp His Gly Leu Leu Arg Val Arg Met Val Asn Leu Gln Val Glu Asp

75

80

85

tct gga ctg tat cag tgt gtg atc tac cug cct ccc aag gag cct cnc 387

Ser Gly Leu Tyr Gln Cys Val Ile Tyr Gln Pro Pro Lys Glu Pro His

90

95

100

55

atg ctg ttc gat cgc atc cgc ttg gtg gtg acc aag ggg ttc cgg tgt 435  
 Met Leu Phe Asp Arg Ile Arg Leu Val Val Thr Lys Gly Phe Arg Cys  
 5 105 110 115  
 tca aca ttg tca ttc tcc tgg ctg gtg gat tcc tgagtaagag cctggctctc 488  
 Ser Thr Leu Ser Phe Ser Trp Leu Val Asp Ser  
 10 120 125 130  
 tctgtcctgt ttgctgicac gctgaggica ttgtaccct aggcccacga acccagcaga 548  
 atgtcctctg acticcagcc acatccalcct ggcagttgtg ccaagggagg agggaggagg 608  
 taaaaggcag ggagttaata acatgaatta aatctgtaat caccagctaa agaaaaaaaa 668  
 15 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 701

<210> 25  
 <211> 422  
 20 <212> PRT  
 <213> Homo sapiens

25 <400> 25  
 Met Leu Gln Trp Arg Arg Arg His Cys Cys Phe Ala Lys Met Thr Trp  
 -38 -35 -30 -25  
 30 Asn Ala Lys Arg Ser Leu Phe Arg Thr His Leu Ile Gly Val Leu Ser  
 -20 -15 -10  
 Leu Val Phe Leu Phe Ala Met Phe Leu Phe Phe Asn His His Asp Trp  
 -5 1 5 10  
 35 Leu Pro Gly Arg Ala Gly Phe Lys Glu Asn Pro Val Thr Tyr Thr Phe  
 15 20 25  
 Arg Gly Phe Arg Ser Thr Lys Ser Glu Thr Asn His Ser Ser Leu Arg  
 30 35 40  
 40 Asn Ile Trp Lys Glu Thr Val Pro Gln Thr Leu Arg Pro Gln Thr Ala  
 45 50 55  
 Thr Asn Ser Asn Asn Thr Asp Leu Ser Pro Gln Gly Val Thr Gly Leu  
 45 60 65 70  
 Glu Asn Thr Leu Ser Ala Asn Gly Ser Ile Tyr Asn Glu Lys Gly Thr  
 75 80 85 90  
 50 Gly His Pro Asn Ser Tyr His Phe Lys Tyr Ile Ile Asn Glu Pro Glu  
 95 100 105  
 Lys Cys Gln Glu Lys Ser Pro Phe Leu Ile Leu Leu Ile Ala Ala Glu

55

	110	115	120
5	Pro Gly Gln Ile Glu Ala Arg Arg Ala Ile Arg Gln Thr Trp Gly Asn		
	125	130	135
	Glu Ser Leu Ala Pro Gly Ile Gln Ile Thr Arg Ile Phe Leu Leu Gly		
	140	145	150
10	Leu Ser Ile Lys Leu Asn Gly Tyr Leu Gln Arg Ala Ile Leu Glu Glu		
	155	160	165
	Ser Arg Gln Tyr His Asp Ile Ile Gln Gln Glu Tyr Leu Asp Thr Tyr		
	175	180	185
15	Tyr Asn Leu Thr Ile Lys Thr Leu Met Gly Met Asn Trp Val Ala Thr		
	190	195	200
	Tyr Cys Pro His Ile Pro Tyr Val Met Lys Thr Asp Ser Asp Met Phe		
20	205	210	215
	Val Asn Thr Glu Tyr Leu Ile Asn Lys Leu Leu Lys Pro Asp Leu Pro		
	220	225	230
25	Pro Arg His Asn Tyr Phe Thr Gly Tyr Leu Met Arg Gly Tyr Ala Pro		
	235	240	245
	Asn Arg Asn Lys Asp Ser Lys Trp Tyr Met Pro Pro Asp Leu Tyr Pro		
	255	260	265
30	Ser Glu Arg Tyr Pro Val Phe Cys Ser Gly Thr Gly Tyr Val Phe Ser		
	270	275	280
	Gly Asp Leu Ala Glu Lys Ile Phe Lys Val Ser Leu Gly Ile Arg Arg		
35	285	290	295
	Leu His Leu Glu Asp Val Tyr Val Gly Ile Cys Leu Ala Lys Leu Arg		
	300	305	310
	Ile Asp Pro Val Pro Pro Pro Asn Glu Phe Val Phe Asn His Trp Arg		
40	315	320	325
	Val Ser Tyr Ser Ser Cys Lys Tyr Ser His Leu Ile Thr Ser His Gln		
	335	340	345
45	Phe Gln Pro Ser Glu Leu Ile Lys Tyr Trp Asn His Leu Gln Gln Asn		
	350	355	360
	Lys His Asn Ala Cys Ala Asn Ala Ala Lys Glu Lys Ala Gly Arg Tyr		
50	365	370	375
	Arg His Arg Lys Leu His		
	380		

55

<210> 26  
 <211> 1266  
 <212> DNA  
 <213> Homo sapiens

5

10

15

20

25

30

35

40

<400> 26  
 atgcttcagt ggaggagaag acactgcigc ttigcaaaga tgacctggaa tgccaaaagg 60  
 tctctgttcc gcactcatct tatlggagta ctllclctag tgtttctttt tgctatgttt 120  
 ttgtttttca atcatcatga ctggctgccg ggcagagctg gattcaaaga aaacctgtgt 180  
 acatacactt tccgaggatt tgggtcaaca aaaagtgaga caaaccacag ctcccttcgg 240  
 aacatttgga aagaaacagt cctcaaac ctgaggcctc aaacagcaac taactctaact 300  
 aacacagacc tgtcaccaca aggagtlaca ggccgggaga atacacttag tgccaatgga 360  
 agtatttaca atgaaaaagg tactggacat ccaaattctt accatttcaa atatatattt 420  
 aatgagcctg aaaaatgccg agagaaaagt ccttttttaa tactactaat agctgcagag 480  
 cctggacaaa tagaagctag aagagctatt cggcaaat ttgggcaatga aagtctagca 540  
 ccctgtattc aaatcacaaag aatatttttg ttgggcttaa gtattaagct aaatggctac 600  
 ctccaacgtg caatactgga agaaagcaga caatctcatg atataattca acaggaatac 660  
 ttagatacgt actataattt gaccattaaa acactaaagg gcatgaactg ggttgcaaca 720  
 tactgtccac atattccata tgttatgaaa acigacagtg acatgtttgt caacacigaa 780  
 tatttaatca ataagttact gaagccagat ctgcccccga gacataacta ttacaciggt 840  
 tacctaatgc gaggatctgc acccattcgn ancaaugata gcaagtggta catgccacca 900  
 gacctctacc caagtgagcg ttatctgtgc ttctgttctg gaactgggta tgtttttct 960  
 ggagatcttg cagaanagat tttaaagtt tctttaggtt tccgccgttt gcacttggaa 1020  
 gatgtatag tagggatctg tcttgcctang ttgaganttg atcctgtacc ccttcccaat 1080  
 gatttttgtt tcaatcacgt gcgagtcctt tcttcgagct gtaaatacag ccacctaat 1140  
 acctctatc agttccagcc tagtgaactg ataaaatact ggaaccattt acaacaaaat 1200  
 aagcacantg cctgtgccaa cgcagcaaan gaaagggcag gcaggtatcg ccaccgtaaa 1260  
 ctacat 1266

45

<210> 27  
 <211> 2420  
 <212> DNA  
 <213> Homo sapiens

50

<200>  
 <221> CDS

55

&lt;222&gt; (698).. (1963)

5

&lt;200&gt;

&lt;221&gt; sig peptide

&lt;222&gt; (698).. (811)

10

&lt;200&gt;

&lt;221&gt; mat peptide

&lt;222&gt; (812).. (1963)

15

&lt;400&gt; 27

gccgtgtcag cagctgagga accgtggatt tcatattata gactaaanacc ccattaaaac 60  
 20 tgcacaaaat ccttcctgca gctgccaggc aacaacgaaa gaagagaggt aaatccattt 120  
 cttttccaat acaactgaag cactacattt tagctctggc tgccttacct tgcagctcag 180  
 tgttattagt agaatatgg atactgagac gagaacacag cactgcattg tccagccagg 240  
 25 aaaatagcag atglaaaaag cttcaatgca tcaactgtcg ggaagagtca acagtgcctac 300  
 aagcagaacg ggcaactaca gctcttttgt ttaacgaaag agagaanaatg aaagaaaggg 360  
 aaaatttcag aagactagga cccatatgaa caaggagggt aactcgaaga caagcagaca 420  
 gatggacact tiggatctg tgaaaagcaa tgcaggaggc cagactgttg ggggatgtgc 480  
 30 gcatgttcga tagcatcttt ttgtctgaag tgaigggcgt ccaaaagtat tttcagtggt 540  
 cataatcctc ttacataaaa tggcctgacc aaggaagaal gactacaaga gagacaatgt 600  
 gactgaatta gaaaatgalt gccaaagaat agtattnagg agaagaaanac atttttggtc 660  
 35 accaatctct catataccac tactggatat tlacaac atg ctt cag tgg agg aga 715  
 Met Leu Gln Trp Arg Arg  
 -38 -35  
 aga cac tgc tgc ttt gca ang atg acc tgg aat gcc aaa agg tct ctg 763  
 40 Arg His Cys Cys Phe Ala Lys Met Thr Trp Asn Ala Lys Arg Ser Leu  
 -30 -25 -20  
 ttc cgc act cat ctt att gga gta ctt tct cta gtg ttt ctt ttt gct 811  
 Phe Arg Thr His Leu Ile Gly Val Leu Ser Leu Val Phe Leu Phe Ala  
 45 -15 -10 -5  
 atg ttt ttg ttt ttc ant cat cat gac tgg ctg cca ggc aca gct gga 859  
 Met Phe Leu Phe Phe Asn His His Asp Trp Leu Pro Gly Arg Ala Gly  
 50 1 5 10 15  
 ttc aaa gaa aac cct gtg aca tac act ttc cga gga ttt cgg tca aca 907  
 Phe Lys Glu Asn Pro Val Thr Tyr Thr Phe Arg Gly Phe Arg Ser Thr

55



	20	25	30	
5	aaa agt gag aca aac cac agc tcc ctt cgg aac att tgg aaa gaa aca			955
	Lys Ser Glu Thr Asn His Ser Ser Leu Arg Asn Ile Trp Lys Glu Thr			
	35	40	45	
10	gtc cct caa acc ctg agg cct caa aca gca act aac tct aat aac aca			1003
	Val Pro Gln Thr Leu Arg Pro Gln Thr Ala Thr Asn Ser Asn Asn Thr			
	50	55	60	
15	gac ctg tca cca caa gga gtt aca ggc ctg gag aat aca ctt agt gcc			1051
	Asp Leu Ser Pro Gln Gly Val Thr Gly Leu Glu Asn Thr Leu Ser Ala			
	65	70	75	80
	aat gga agt att tac aat gaa aaa ggt act gga cat cca aat tct tac			1099
	Asn Gly Ser Ile Tyr Asn Glu Lys Gly Thr Gly His Pro Asn Ser Tyr			
	85	90	95	
20	cat ttc aaa tat att att aat gag cct gaa aaa tgc caa gag aaa agt			1147
	His Phe Lys Tyr Ile Ile Asn Glu Pro Glu Lys Cys Gln Glu Lys Ser			
	100	105	110	
25	cct ttt tta ata cta cta ata gct gca gag cct gga caa ata gaa gct			1195
	Pro Phe Leu Ile Leu Leu Ile Ala Ala Glu Pro Gly Gln Ile Glu Ala			
	115	120	125	
30	aga aga gct att cgg caa act tgg ggc aat gaa agt cta gca cct ggt			1243
	Arg Arg Ala Ile Arg Gln Thr Trp Gly Asn Glu Ser Leu Ala Pro Gly			
	130	135	140	
35	att caa atc aca aga ata ttt ttg ttg ggc tta agt att aag cta ant			1291
	Ile Gln Ile Thr Arg Ile Phe Leu Leu Gly Leu Ser Ile Lys Leu Asn			
	145	150	155	160
	ggc tac ctt caa cgt gca ata ctg gaa gaa agc aga caa tat cat gat			1339
	Gly Tyr Leu Gln Arg Ala Ile Leu Glu Glu Ser Arg Gln Tyr His Asp			
40	165	170	175	
	ala att cna cag gaa tac tta gat acg tac tat aat ttg acc att aaa			1387
	Ile Ile Gln Gln Glu Tyr Leu Asp Thr Tyr Tyr Asn Leu Thr Ile Lys			
45	180	185	190	
	aca cta atg ggc atg aac tgg gtt gca aca tac tgt cca cat att cca			1435
	Thr Leu Met Gly Met Asn Trp Val Ala Thr Tyr Cys Pro His Ile Pro			
	195	200	205	
50	tat gtt atg aam act gac ngt gac atg ttt gtc aac act gaa tat tta			1483
	Tyr Val Met Lys Thr Asp Ser Asp Met Phe Val Asn Thr Glu Tyr Leu			

55

210 215 220  
 atc aat aag tta ctg aag cca gat ctg cct ccc aga cat aac tat ttc 1531  
 5 Ile Asn Lys Leu Leu Lys Pro Asp Leu Pro Pro Arg His Asn Tyr Phe  
 225 230 235 240  
 act ggt tac cta atg cga gga tat gca ccc aat cga aac aaa gat agc 1579  
 10 Thr Gly Tyr Leu Met Arg Gly Tyr Ala Pro Asn Arg Asn Lys Asp Ser  
 245 250 255  
 aag tgg tac atg cca cca gac ctc tac cca agt gag cgt tat cct gtc 1627  
 Lys Trp Tyr Met Pro Pro Asp Leu Tyr Pro Ser Glu Arg Tyr Pro Val  
 15 260 265 270  
 ttc tgt tct gga act ggt tat gtt ttt tct gga gat ctg gca gaa aag 1675  
 Phe Cys Ser Gly Thr Gly Tyr Val Phe Ser Gly Asp Leu Ala Glu Lys  
 20 275 280 285  
 att ttt aaa gtt tct tta ggt atc cgc cgt ttg cac ttg gaa gat gta 1723  
 Ile Phe Lys Val Ser Leu Gly Ile Arg Arg Leu His Leu Glu Asp Val  
 290 295 300  
 25 tat gta ggg atc tgt ctt gcc aag ttg aga att gat cct gta ccc cct 1771  
 Tyr Val Gly Ile Cys Leu Ala Lys Leu Arg Ile Asp Pro Val Pro Pro  
 305 310 315 320  
 30 ccc aat gag ttt gtg ttc aat cac tgg cga gtc tct tat tgc agc tgt 1819  
 Pro Asn Glu Phe Val Phe Asn His Trp Arg Val Ser Tyr Ser Ser Cys  
 325 330 335  
 35 aaa tac agc cac cta att acc tct cat cag ttc cag cct agt gaa ctg 1867  
 Lys Tyr Ser His Leu Ile Thr Ser His Gln Phe Gln Pro Ser Glu Leu  
 340 345 350  
 ata aaa tac tgg aac cat tta can cun aat aag cac aat gcc tgt gcc 1915  
 40 Ile Lys Tyr Trp Asn His Leu Gln Gln Asn Lys His Asn Ala Cys Ala  
 355 360 365  
 aac gca gca aaa gaa aag gca ggc agg tat cgc cac cgt aaa cta cat 1963  
 Asn Ala Ala Lys Glu Lys Ala Gly Arg Tyr Arg His Arg Lys Leu His  
 45 370 375 380  
 tagaaagac aattttttt chaatgtgen atttgtaaat attgctaaaa gcaigtatag 2023  
 ttgaactga ttacatccgt aggcacagtt ttngttnaaa ctcatcacat aaagaaattc 2083  
 50 aagangtatt tttttattt ctgaagaggt taattcttaa aactatnaca ttatntaucha 2113  
 aaaaagggtt cccanacua tctattttaa nancigtata agggattct gtgtattaac 2203  
 atgcantanc angcatgcat nnaicmigg ticaagtctt ctgttagggk ccaataaunt 2263



gtatctgcat atgttttcca cataaatlll aallcaagaa atgacagica aaagatccit 2323  
 cattttagat taagcttttc attttaatat ataatttaac gaaataaaa catcactatc 2383  
 5 aattttaagg aaaaaaaaaa aaaaaaaaaa aaaaaaa 2420

<210> 28  
 <211> 521  
 <212> PRT  
 <213> Homo sapiens

15 <400> 28  
 Met Val Asn Ala Cys Trp Cys Gly Leu Leu Ala Ala Leu Ser Leu Leu  
 -21 -20 -15 -10  
 20 Leu Asp Ala Ser Thr Asp Glu Val Ala Thr Glu Asn Ile Leu Lys Ala  
 -5 1 5 10  
 Glu Leu Thr Met Ala Ala Leu Cys Gly Arg Leu Gly Leu Val Thr Ser  
 15 20 25  
 25 Arg Asp Ala Phe Ile Thr Ala Ile Cys Lys Gly Ser Leu Pro Pro His  
 30 35 40  
 Tyr Ala Leu Thr Val Leu Asn Thr Thr Thr Ala Ala Thr Leu Ser Asn  
 45 50 55  
 30 Lys Ser Tyr Ser Val Gln Gly Gln Ser Val Met Met Ile Ser Pro Ser  
 60 65 70 75  
 Ser Glu Ser His Gln Gln Val Val Ala Val Gly Gln Pro Leu Ala Val  
 35 80 85 90  
 Gln Pro Gln Gly Thr Val Met Leu Thr Ser Lys Asn Ile Gln Cys Met  
 95 100 105  
 40 Arg Thr Leu Leu Asn Leu Ala His Cys His Gly Ala Val Leu Gly Thr  
 110 115 120  
 Ser Trp Gln Leu Val Leu Ala Thr Leu Gln His Leu Val Trp Ile Leu  
 125 130 135  
 45 Gly Leu Lys Pro Ser Ser Gly Gly Ala Leu Lys Pro Gly Arg Ala Val  
 140 145 150 155  
 Glu Gly Pro Ser Thr Val Leu Thr Thr Ala Val Met Thr Asp Leu Pro  
 160 165 170  
 50 Val Ile Ser Asn Ile Leu Ser Arg Leu Phe Glu Ser Ser Gln Tyr Leu  
 175 180 185

55

	Asp	Asp	Val	Ser	Leu	His	His	Leu	Ile	Asn	Ala	Leu	Cys	Ser	Leu	Ser
	190							195					200			
5	Leu	Glu	Ala	Met	Asp	Met	Ala	Tyr	Gly	Asn	Asn	Lys	Glu	Pro	Ser	Leu
	205							210					215			
	Phe	Ala	Val	Ala	Lys	Leu	Leu	Glu	Thr	Gly	Leu	Val	Asn	Met	His	Arg
	220					225					230					235
10	Ile	Glu	Ile	Leu	Trp	Arg	Pro	Leu	Thr	Gly	His	Leu	Leu	Glu	Lys	Val
						240					245					250
	Cys	Gln	His	Pro	Asn	Ser	Arg	Met	Gly	Glu	Trp	Gly	Ala	Glu	Ala	Leu
15						255					260					265
	Thr	Ser	Leu	Ile	Lys	Ala	Gly	Leu	Thr	Phe	Asn	His	Asp	Pro	Pro	Leu
						270					275					280
	Ser	Gln	Asn	Gln	Arg	Leu	Gln	Leu	Leu	Leu	Leu	Asn	Pro	Leu	Lys	Glu
20						285										295
	Met	Ser	Asn	Ile	Asn	His	Pro	Asp	Ile	Arg	Leu	Lys	Gln	Leu	Glu	Cys
	300					305					310					315
25	Val	Leu	Gln	Ile	Leu	Gln	Ser	Gln	Gly	Asp	Asn	Leu	Gly	Pro	Gly	Trp
						320					325					330
	Pro	Leu	Val	Leu	Gly	Val	Met	Gly	Ala	Ile	Arg	Asn	Asp	Gln	Gly	Glu
						335					340					345
30	Ser	Leu	Ile	Arg	Thr	Ala	Phe	Gln	Cys	Leu	Gln	Leu	Val	Val	Thr	Asp
						350					355					360
	Phe	Leu	Pro	Thr	Met	Pro	Cys	Thr	Cys	Leu	Gln	Ile	Val	Val	Asp	Val
35						365										375
	Ala	Gly	Ser	Phe	Gly	Leu	His	Asn	Gln	Glu	Leu	Asn	Ile	Ser	Leu	Thr
	380					385							390			395
	Ser	Ile	Gly	Leu	Leu	Trp	Asn	Ile	Ser	Asp	Tyr	Phe	Phe	Gln	Arg	Gly
40						400							405			410
	Glu	Thr	Ile	Glu	Lys	Glu	Leu	Asn	Lys	Glu	Glu	Ala	Ala	Gln	Gln	Lys
						415					420					425
45	Gln	Ala	Glu	Glu	Lys	Gly	Val	Val	Leu	Asn	Arg	Pro	Phe	His	Pro	Ala
						430					435					440
	Pro	Pro	Phe	Asp	Cys	Leu	Trp	Leu	Cys	Leu	Tyr	Ala	Lys	Leu	Gly	Glu
						445					450					455
50	Leu	Cys	Val	Asp	Pro	Arg	Pro	Ala	Val	Arg	Lys	Ser	Ala	Gly	Gln	Thr
						460					465					470
																475

55

Leu Phe Ser Thr Ile Gly Ala His Gly Thr Leu Leu Gln His Ser Thr  
 480 485 490  
 5 Trp Arg Thr Val Ile Trp Lys Val Leu  
 495 500

10 <210> 29

<211> 1563

<212> DNA

15 <213> Homo sapiens

<400> 29

atggatgaatg cctgctggg tggtcttctt gctgcactct cactccttct tgaigccagc 60  
 acagatgaag ttgccactga gaatatatta aaagctgaac tgactatggc tgccttttgt 120  
 20 ggaagactgg gccttgtaac ttcaagagat gccattataa ctgcaataig caaagggtcc 180  
 ctgccicccc attatgctct tactgtattg aataccacca ctgcagctac actttccaac 240  
 aaatcatatt ccttcaggc ccaangtgtt atgatgataa gtccatcaag tgaatcicac 300  
 25 caacaagtig tggcagtggt tcaaccttta gcagtcacgc ctcaaggagc agtaatgctg 360  
 acttccnaaa atatccagtg tatgaggact ttacttaact tggcgcttg ccatggggct 420  
 gltctiggaa catcatggca acttgtcttg gcaactcttc agcatcttgt gttgattctg 480  
 30 ggattaaagc ctgtagtggc cggtagcttg aaacctggga gagctgtaga aggaccagc 540  
 acagtctta caacagcagt gatgacagat ttaccagtga ttccaatat actttcaaga 600  
 ttgttllhan gctcacagta tcttgatgat gtatcactgc atcatltaat aaalgacat 660  
 tgcctcttgi ctctagaagc aatggatag gccatlgga atataaagga accatctctt 720  
 35 ttgtctgttg ccaaatgtt agaaactgtt ttagttaata tgcaccgaat agaaattctg 780  
 tggagaccic tgaatggcca tctacttgag aaggcttgcc agcatccaaa ctctcgaatg 840  
 ggagaalggt gagcagaagc tttaacttct ctatttaaag caggattaac attaaacct 900  
 40 gatcccccac tctcacaaaa ccagaggctg cagtgtctt tatgaaccg gttaaaggag 960  
 atgtccaata ttaatcatcc agatattcga ctcaagcagt tagaatgcgt gtgcagatt 1020  
 ctgcagagtc agggagacaa tcttgggctt ggalggccat tagtgcttgg agtcatggga 1080  
 gcaatcagan atgatcaagg agaactcttg atcgaacig catlccagtg tcttcagtig 1140  
 45 gtgtgncng atttctacc aacaatgctt tgaacttgc tgaantagt ttagatgtt 1200  
 gcaggtagct ttggcctcca taaccaagaa ctcatatta gtttaacttc aataggttta 1260  
 ttgttgatla tticagatta tttttccaa agaggggaaa ctatgaaan agnactaaat 1320  
 50 aaggagagag cagcacagca aaagcagca gaggagagag gagtgttll aaatcggtcc 1380  
 ttccaccttg caccgccatt tgaatgctt tggatgtg tttatgcaan attgggtgaa 1440  
 ctatgtgttg atccccgctc tgcgtcagg aagagtgag gxcnaactct gtttctact 1500

55

atgggtgcgc atggaacttt attacagcat tcaacctggc gcactgltat ctggaaggta 1560  
 ttg 1563

5

&lt;210&gt; 30

&lt;211&gt; 1768

&lt;212&gt; DNA

10

&lt;213&gt; Homo sapiens

&lt;200&gt;

15

&lt;221&gt; CDS

&lt;222&gt; (8)..(1570)

&lt;200&gt;

20

&lt;221&gt; sig peptide

&lt;222&gt; (8)..(70)

25

&lt;200&gt;

&lt;221&gt; mat peptide

&lt;222&gt; (71)..(1570)

30

&lt;400&gt; 30

ggaagaa alg gtg aat gcc tgc tgg tgl ggt ctt ctt gct gca ctc tca 49

Met Val Asn Ala Cys Trp Cys Gly Leu Leu Ala Ala Leu Ser

35

-21 -20

-15

-10

ctc ctt ctt gat gcc agc acn gat gaa gll gcc act gag aat att tta 97

Leu Leu Leu Asp Ala Ser Thr Asp Glu Val Ala Thr Glu Asn Ile Leu

40

-5

1

5

aaa gct gaa ctg act atg gct gct ctt tgl gga aga ctg ggc ctt gta 145

Lys Ala Glu Leu Thr Met Ala Ala Leu Cys Gly Arg Leu Gly Leu Val

10

15

20

25

45

act tca aga gat gcc ttt ata act gca ata tgc aaa ggt tcc ctg cct 193

Thr Ser Arg Asp Ala Phe Ile Thr Ala Ile Cys Lys Gly Ser Leu Pro

30

35

40

50

ccc cat tat gct ctt act gta ttg aat acc acc act gca gct aca ctt 241

Pro His Tyr Ala Leu Thr Val Leu Asn Thr Thr Thr Ala Ala Thr Leu

45

50

55

55

	tcc aac aaa tca tat tcc gtt cag ggc caa agt gtt atg atg ala agt	289
	Ser Asn Lys Ser Tyr Ser Val Gln Gly Gln Ser Val Met Met Ile Ser	
5	60 65 70	
	cca tca agt gaa tct cac caa caa gtt gtg gca gtg ggt caa cct tta	337
	Pro Ser Ser Glu Ser His Gln Gln Val Val Ala Val Gly Gln Pro Leu	
10	75 80 85	
	gca gtc cag cct caa ggg aca gta atg ctg act tcc aaa aat atc cag	385
	Ala Val Gln Pro Gln Gly Thr Val Met Leu Thr Ser Lys Asn Ile Gln	
	90 95 100 105	
15	tgt atg agg act tta ctt aac ttg gcg cat tgc cat ggg gct gtt ctt	433
	Cys Met Arg Thr Leu Leu Asn Leu Ala His Cys His Gly Ala Val Leu	
	110 115 120	
20	gga aca tca tgg caa ctt gtc ttg gca act ctt cag cat ctt gtg tgg	481
	Gly Thr Ser Trp Gln Leu Val Leu Ala Thr Leu Gln His Leu Val Trp	
	125 130 135	
	att ctg gga tta aag cct agt agt ggc ggt gcc ttg aaa cct ggg aga	529
25	Ile Leu Gly Leu Lys Pro Ser Ser Gly Gly Ala Leu Lys Pro Gly Arg	
	140 145 150	
	gct gta gaa gga ccc agt aca gtt cta aca aca gca gtg atg aca gat	577
30	Ala Val Glu Gly Pro Ser Thr Val Leu Thr Thr Ala Val Met Thr Asp	
	155 160 165	
	tta cca gtg att tcc aat ata ctt tca aga ttg ttt gaa agc tca cag	625
	Leu Pro Val Ile Ser Asn Ile Leu Ser Arg Leu Phe Glu Ser Ser Gln	
35	170 175 180 185	
	tat ctt gat gat gta tca ctg cat cat tta ata aat gca ctt tgc tcc	673
	Tyr Leu Asp Asp Val Ser Leu His His Leu Ile Asn Ala Leu Cys Ser	
40	190 195 200	
	ttg tct cta gaa gca atg gnt atg gcc tat gga aat aat aag gaa cca	721
	Leu Ser Leu Glu Ala Met Asp Met Ala Tyr Gly Asn Asn Lys Glu Pro	
	205 210 215	
45	tct ctt ttt gct gtt gcc ann ttg tta gaa act ggt tta gtt aat atg	769
	Ser Leu Phe Ala Val Ala Lys Leu Leu Glu Thr Gly Leu Val Asn Met	
	220 225 230	
50	cnc cga ata gaa att ctg tgg aga cct ctg act ggc cat cta ctt gag	817
	His Arg Ile Glu Ile Leu Trp Arg Pro Leu Thr Gly His Leu Leu Glu	
	235 240 245	
55		



	aag gtc tgc cag cnt cca aac tct cga atg gga gaa tgg gga gca gaa	865
	Lys Val Cys Gln His Pro Asn Ser Arg Met Gly Glu Trp Gly Ala Glu	
5	250                      255                      260                      265	
	gct tta act tct ctt att aaa gca gga tta aca ttt aac cat gat cct	913
	Ala Leu Thr Ser Leu Ile Lys Ala Gly Leu Thr Phe Asn His Asp Pro	
10	270                      275                      280	
	cca ctc tca caa aac cag agg ctg cag ttg ctt tta ttg aac ccg tta	961
	Pro Leu Ser Gln Asn Gln Arg Leu Gln Leu Leu Leu Asn Pro Leu	
	285                      290                      295	
15	aag gag atg tcc aat att aat cat cca gat att cga ctc aag cag tta	1009
	Lys Glu Met Ser Asn Ile Asn His Pro Asp Ile Arg Leu Lys Gln Leu	
	300                      305                      310	
20	gaa tgc gtg ttg cag att ctg cag agt cag gga gac aat ctt ggg cct	1057
	Glu Cys Val Leu Gln Ile Leu Gln Ser Gln Gly Asp Asn Leu Gly Pro	
	315                      320                      325	
	gga tgg cca tta gtg ctt gga gtc atg gga gca atc aga aat gat caa	1105
25	Gly Trp Pro Leu Val Leu Gly Val Met Gly Ala Ile Arg Asn Asp Gln	
	330                      335                      340                      345	
	gga gaa tcc ttg ala cga act gca ttc cag tgt ctt cag ttg gtt gtg	1153
30	Gly Glu Ser Leu Ile Arg Thr Ala Phe Gln Cys Leu Gln Leu Val Val	
	350                      355                      360	
	aca gat ttt cta cca aca atg cct tgt act tgc ctg caa ata gtt gta	1201
	Thr Asp Phe Leu Pro Thr Met Pro Cys Thr Cys Leu Gln Ile Val Val	
35	365                      370                      375	
	gat gtt gca ggt agc ttt ggc ctc cat aac caa gaa ctc aat att agt	1249
	Asp Val Ala Gly Ser Phe Gly Leu His Asn Gln Glu Leu Asn Ile Ser	
40	380                      385                      390	
	tta act tca atn ggt tta ttg tgg aat att tca gat tat ttt ttc caa	1297
	Leu Thr Ser Ile Gly Leu Leu Trp Asn Ile Ser Asp Tyr Phe Phe Gln	
	395                      400                      405	
45	aga ggg gaa act att gaa ana gaa cta aat aag gaa gag gca gca cag	1345
	Arg Gly Glu Thr Ile Glu Lys Glu Leu Asn Lys Glu Glu Ala Ala Gln	
	410                      415                      420                      425	
50	caa nag cag gcg gnn gag nna gnn gtt gtt tta aat cgg cca ttc cac	1393
	Gln Lys Gln Ala Glu Glu Lys Gly Val Val Leu Asn Arg Pro Phe His	
	430                      435                      440	

55

55

Gln Pro Gln Gly Thr Val Met Leu Thr Ser Lys Asn Ile Gln Cys Met  
 95 100 105  
 5 Arg Thr Leu Leu Asn Leu Ala His Cys His Gly Ala Val Leu Gly Thr  
 110 115 120  
 Ser Trp Gln Leu Val Leu Ala Thr Leu Gln His Leu Val Trp Ile Leu  
 10 125 130 135  
 Gly Leu Lys Pro Ser Ser Gly Gly Ala Leu Lys Pro Gly Arg Ala Val  
 140 145 150 155  
 Glu Gly Pro Ser Thr Val Leu Thr Thr Ala Val Met Thr Asp Leu Pro  
 15 160 165 170  
 Val Ile Ser Asn Ile Leu Ser Arg Leu Phe Glu Ser Ser Arg Tyr Leu  
 175 180 185  
 20 Asp Asp Val Ser Leu His His Leu Ile Asn Ala Leu Cys Ser Leu Ser  
 190 195 200  
 Leu Glu Ala Met Asp Met Ala Tyr Gly Asn Asn Lys Glu Pro Ser Leu  
 205 210 215  
 25 Phe Ala Val Ala Lys Leu Leu Glu Thr Gly Leu Val Asn Met His Arg  
 220 225 230 235  
 Ile Glu Ile Leu Trp Arg Pro Leu Thr Gly His Leu Leu Glu Val Cys  
 240 245 250  
 30 Gln His Pro Asn Ser Arg Met Arg Glu Trp Gly Ala Glu Ala Leu Thr  
 255 260 265  
 Ser Leu Ile Lys Ala Gly Leu Thr Phe Asn His Asp Pro Pro Leu Ser  
 270 275 280  
 35 Gln Asn Gln Arg Leu Gln Leu Leu Leu Leu Asn Pro Leu Lys Glu Met  
 285 290 295  
 Ser Asn Ile Asn His Pro Asp Ile Arg Leu Lys Gln Leu Glu Cys Val  
 300 305 310 315  
 Leu Gln Ile Leu Gln Ser Gln Gly Asp Ser Leu Gly Pro Gly Trp Pro  
 320 325 330  
 45 Leu Val Leu Gly Val Met Gly Ala Ile Arg Asn Asp Gln Gly Glu Ser  
 335 340 345  
 Leu Ile Arg Thr Ala Phe Gln Cys Leu Gln Leu Val Val Thr Glu Ile  
 350 355 360  
 50 Ile Phe Val Leu Lys Ala Val Ser Thr Leu Ile Asp Ser Leu Lys Lys  
 365 370 375

55

Thr Gln Pro Glu Asn Val Asp Gly Asn Thr Trp Ala Gln Val Ile Ala  
 380 385 390 395  
 5 Leu Tyr Pro Thr Leu Val Glu Cys Ile Ala Cys Pro Ser Ser Glu Val  
 400 405 410  
 Cys Ser Ala Leu Lys Glu Ala Leu Val Pro Phe Lys Asp Phe Met Gln  
 10 415 420 425  
 Pro Pro Ala Ser Arg Val Gln Asn Gly Glu Ser  
 430 435  
 15 <210> 32  
 <211> 1377  
 <212> DNA  
 20 <213> Homo sapiens  
 <400> 32  
 atggatgaatg cctgctgggtg tggctctctt gctgcactct cactccttct tgaatgccagc 60  
 25 acagatgaag ttgccactga gaatatttta aaagctgaac tgactatggc tgetctttgt 120  
 ggaagacttg gccttgtaac ttcaagagat gccctttataa ctgcaataag caaaggctcc 180  
 ctgcctcccc attatgctct tacttgattg aataccacca ctgcagctac actttccaac 240  
 30 aaacatatt cgttcaggc ccaagtggt atgatgataa gtccatcaag tgaatctcac 300  
 caacaagttg tggcagtggt tcaaccttta gcagtcaccg ctcaaggagc agtaatgctg 360  
 acttccaaaa atatccagt tatgaggact ttacttaact tggcgcatg ccaatgggct 420  
 gtctttggaa catcatggca acttgcttg gcaactctc agcatcttgt gttgattctg 480  
 35 ggattaaagc ctatgtagtg cggcgcttg aaacctggga gagctttaga aggaccaggt 540  
 acagttctaa caacagcagt gatgacagat ttaccagtga ttccaatat actttcaaga 600  
 ttgtttgaaa gctcaggta tcttgatgat gtatcactgc atcatttaat aaatgcactt 660  
 40 tgetccttgt ctctagaagc aatggataag gccatggaa ataataagga accatctctt 720  
 ttgtctgtg ccaaattgtt agaaactggt ttagttaata tgcaccgaat agaantctg 780  
 tggagacctc tgactggcca tctacttgag gtctgccagc atccaaactc tgaatgaga 840  
 gaatggggag cagaagcttt aacttctctt attaaagcag gattaacatt taacctgat 900  
 45 cctccactct cacaaacca gaggcctgag ttgcttttat tgaacctggt aaaggagatg 960  
 tccnatatta atcatccaga taticgactc aagcagtag aatgcgtgtt gcagattctg 1020  
 cagagtcagg gagacagtct tgggccttga tggccattag tgcctgaggt catgggagca 1080  
 50 atcagaaatg atcaaggaga atccttgata cgaactgcat tccgtgtctt tcaattgggt 1140  
 gtacacagaa ttatatttgt tttaaaagca gtctgactc ttatgtttt acttaagaaa 1200  
 actcagcctg agatgttga tggaaatacc tgggcacag taattgctt ataccaact 1260

55

ttagtagaat gcatcgccctg tccctcttca gaagtcctgtt ctgcacttaa agaggcacta 1320  
gttcccttta aggaattcat gcagccacca gcatccagag ttcaaatgg agaattct 1377

5

<210> 33

<211> 2009

10

<212> DNA

<213> Homo sapiens

15

<200>

<221> CDS

<222> (8)..(1384)

20

<220>

<221> sig peptide

<222> (8)..(70)

25

<220>

<221> mat peptide

<222> (71)..(1384)

30

<400> 33

ggaagna atg gta aat gcc tgc tgg tgt ggt ctt ctt gct gca ctc tca 49

Met Val Asn Ala Cys Trp Cys Gly Leu Leu Ala Ala Leu Ser

35

-21 -20 -15 -10

ctc ctt ctt gat gcc agc acn gat gaa gtt gcc act gag aat att tta 97

Leu Leu Leu Asp Ala Ser Thr Asp Glu Val Ala Thr Glu Asn Ile Leu

40

-5 1 5

aaa gct gaa ctg act atg gct gct ctt tgt gga aga ctg ggc ctt gta 145

Lys Ala Glu Leu Thr Met Ala Ala Leu Cys Gly Arg Leu Gly Leu Val

10 15 20 25

45

act tca aga gat gcc ttt ata act gcn ata tgc aan ggt tcc ctg cct 193

Thr Ser Arg Asp Ala Phe Ile Thr Ala Ile Cys Lys Gly Ser Leu Pro

30 35 40

50

ccc cat tat gct ctt act gta ttg aat acc acc act gcn gct aca ctt 211

Pro His Tyr Ala Leu Thr Val Leu Asn Thr Thr Thr Ala Ala Thr Leu

15 50 55

55

	tcc aac aaa tca tat tcc gtt cag ggc caa agt gtt atg atg ata agt	289
	Ser Asn Lys Ser Tyr Ser Val Gln Gly Gln Ser Val Met Met Ile Ser	
5	60 65 70	
	cca tca agt gaa tct cac caa caa gtt gtg gca gtg ggt caa cct tta	337
	Pro Ser Ser Glu Ser His Gln Gln Val Val Ala Val Gly Gln Pro Leu	
10	75 80 85	
	gca gtc cag cct caa ggg aca gta atg ctg act tcc aaa aat atc cag	385
	Ala Val Gln Pro Gln Gly Thr Val Met Leu Thr Ser Lys Asn Ile Gln	
	90 95 100 105	
15	tgt atg agg act tta ctt aac ttg gcg cat tgc cat ggg gct gtt ctt	433
	Cys Met Arg Thr Leu Leu Asn Leu Ala His Cys His Gly Ala Val Leu	
	110 115 120	
20	gga aca tca tgg caa ctt gtc ttg gca act ctt cag cat ctt gtg tgg	481
	Gly Thr Ser Trp Gln Leu Val Leu Ala Thr Leu Gln His Leu Val Trp	
	125 130 135	
	att ctg gga tta aag cct agt agt ggc ggt gcc ttg aaa cct ggg aga	529
25	Ile Leu Gly Leu Lys Pro Ser Ser Gly Gly Ala Leu Lys Pro Gly Arg	
	140 145 150	
	gct gta gaa gga ccc agt aca gtt cta aca aca gca gtg atg aca gat	577
30	Ala Val Glu Gly Pro Ser Thr Val Leu Thr Thr Ala Val Met Thr Asp	
	155 160 165	
	tta cca gtg att tcc aat ata ctt tca aga ttg ttt gaa agc tca cgg	625
	Leu Pro Val Ile Ser Asn Ile Leu Ser Arg Leu Phe Glu Ser Ser Arg	
35	170 175 180 185	
	tat ctt gat gat gta tca ctg cat cat tta ata aat gca ctt tgc tcc	673
	Tyr Leu Asp Asp Val Ser Leu His His Leu Ile Asn Ala Leu Cys Ser	
	190 195 200	
40	ttg tct cta gaa gca atg gat atg gcc tat gga aat aat aag gaa cca	721
	Leu Ser Leu Glu Ala Met Asp Met Ala Tyr Gly Asn Asn Lys Glu Pro	
	205 210 215	
45	tct ctt ttt gct gtt gcc aaa ttg tta gaa act ggt tta gtt aat atg	769
	Ser Leu Phe Ala Val Ala Lys Leu Leu Glu Thr Gly Leu Val Asn Met	
	220 225 230	
50	cac cga ata gaa att ctg tgg aga cct ctg act ggc cat cta ctt gag	817
	His Arg Ile Glu Ile Leu Trp Arg Pro Leu Thr Gly His Leu Leu Glu	
	235 240 245	

gtc tgc cag cat cca aac tct cga atg aga gaa tgg gga gca gaa gct 865  
 Val Cys Gln His Pro Asn Ser Arg Met Arg Glu Trp Gly Ala Glu Ala  
 5 250 255 260 265  
 Leu Thr Ser Leu Ile Lys Ala Gly Leu Thr Phe Asn His Asp Pro Pro  
 270 275 280  
 10 ctc tca caa aac cag agg ctg cag ttg ctt tta ttg aac ccg tta aag 961  
 Leu Ser Gln Asn Gln Arg Leu Gln Leu Leu Leu Leu Asn Pro Leu Lys  
 285 290 295  
 15 gag atg tcc aat att aat cat cca gat att cga ctc aag cag tta gaa 1009  
 Glu Met Ser Asn Ile Asn His Pro Asp Ile Arg Leu Lys Gln Leu Glu  
 300 305 310  
 20 tgc gtg ttg cag att ctg cag agt cag gga gac agt ctt ggg cct gga 1057  
 Cys Val Leu Gln Ile Leu Gln Ser Gln Gly Asp Ser Leu Gly Pro Gly  
 315 320 325  
 25 tgg cca tta gtg ctt gga gtc atg gga gca atc aga aat gat caa gga 1105  
 Trp Pro Leu Val Leu Gly Val Met Gly Ala Ile Arg Asn Asp Gln Gly  
 330 335 340 345  
 gaa tcc ttg ata cga act gca ttc cag tgt ctt cag ttg gtt gta aca 1153  
 Glu Ser Leu Ile Arg Thr Ala Phe Gln Cys Leu Gln Leu Val Val Thr  
 350 355 360  
 30 gaa att ala ttt gtt tta aaa gca gtc agt act ctt att gat tca ctt 1201  
 Glu Ile Ile Phe Val Leu Lys Ala Val Ser Thr Leu Ile Asp Ser Leu  
 365 370 375  
 35 aag aaa act cag cct gag aat gtt gat gga aat acc tgg gca caa gla 1249  
 Lys Lys Thr Gln Pro Glu Asn Val Asp Gly Asn Thr Trp Ala Gln Val  
 380 385 390  
 40 att gcc tta tac cca act tta gta gaa tgc atc gcc tgt cct tct tca 1297  
 Ile Ala Leu Tyr Pro Thr Leu Val Glu Cys Ile Ala Cys Pro Ser Ser  
 395 400 405  
 45 gaa gtc tgt tct gca ctt aaa gag gca cta gtt cct ttt aag gat ttc 1315  
 Glu Val Cys Ser Ala Leu Lys Glu Ala Leu Val Pro Phe Lys Asp Phe  
 410 415 420 425  
 atg cag cca cca gca tcc aga gtt can aat gga gaa tct tgaccggcta 1391  
 Met Gln Pro Pro Ala Ser Arg Val Gln Asn Gly Glu Ser  
 430 435  
 caatatatt gaagcagga agatagctca aaaaatgitt gctccatatt gattctcttg 1451

5      tgagaaggac atttcttact gcagataatt ctggcagct gtgttgcc tcttttaaat 1514  
       tctacttacc tgagttcagt aattcatatt acaggcttgc acatcaacaa aggcctccga 1574  
       atgaacagca gtgcaaggct ttaataaatt aaactgatgg gagggataat taacactaca 1634  
       gtatacatgc taccatatct ccagttgggtg atttaaagtg agcttatgta cagtttgg 1694  
       tgtatgtgtt aatgatgtac tttttaaaaa gaaagaagag atatttcaat tcagtcagat 1754  
 10     ttattagtct ggtgttttgg cacccttttt caagtacaaa atcgtactag aattttatgc 1814  
       aagatggtag tgtaacattc catattatct ataaccagcc tcgtttaaca aagggaaatg 1874  
       atatacttgt gtgtataata aatggtagag ttctgtataa aatagtgcac ttattttaa 1934  
       tttaaaagta ttgataatgt taaatgctta aagctctatt tattactaaa aaaaaaaaaa 1994  
 15     aaaaaaaaaa aaaaaa 2009

<210> 34

<211> 185

<212> PRT

<213> Homo sapiens

<400> 34

Met Phe Ser His Leu Pro Phe Asp Cys Val Leu Leu Leu Leu Leu Leu  
 -21 -20                      -15                      -10  
 Leu Leu Thr Arg Ser Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Gln  
 -5                      1                      5                      10  
 Asn Ala Tyr Leu Pro Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu  
                     15                      20                      25  
 Val Pro Val Cys Trp Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly  
                     30                      35                      40  
 Asn Val Val Leu Arg Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser  
                     45                      50                      55  
 Arg Tyr Trp Leu Asn Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr  
                     60                      65                      70                      75  
 Ile Glu Asn Val Thr Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile  
                     80                      85                      90  
 Gln Ile Pro Gly Ile Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val  
                     95                      100                      105  
 Ile Lys Pro Ala Lys Val Thr Pro Ala Pro Thr Leu Gln Arg Asp Phe  
                     110                      115                      120  
 Thr Ala Ala Phe Pro Arg Met Leu Thr Thr Arg Gly His Gly Pro Ala



125                      130                      135  
 Glu Thr Gln Thr Leu Gly Ser Leu Pro Asp Ile Asn Leu Thr Gly Ile  
 5                      140                      145                      150                      155  
 Leu Ile Ala Lys Arg Arg Tyr Arg Ile  
                          160  
 10  
 <210> 35  
 <211> 555  
 <212> DNA  
 15                      <213> Homo sapiens  
  
 <400> 35  
 20                      atgttttcaac atcttccctt tgactgtgtc ctgctgtctgc tgcctgtact acttacaagg 60  
                          tcttcagaag tggaaatcac agcggaggtc ggtcagaatg cctatctgcc ctgcttctac 120  
                          accccagccg ccccagggaa cctcgtgccg gtcctgtggg gcaaaggagc ctgtccigtg 180  
 25                      ttlgaatgtg gcaacgtggt gctcaggact gatgaaaggg atgtgaattt tiggacalcc 240  
                          agatactggc taaatgggga ttccgcgaaa ggagatgtgt ccttgaccat agagaalgtg 300  
                          actctagcag acagtgggat ctactgtctg cggatccaaa tcccaggcat aatgaatgat 360  
                          gaaaaattta acctgaagtt ggcatcaaaa ccagccaagg tcacccctgc accgactctg 420  
 30                      cagagagact tcactgcagc ctttccaagg atgcttacca ccaggggaca tggcccagca 480  
                          gagacacaga cuciggggag cctccctgat ataatctaa caggatctct catagcnaag 540  
                          agaagalaca gantt 555  
 35  
 <210> 36  
 <211> 2091  
 <212> DNA  
 40                      <213> Homo sapiens  
  
 <200>  
 45                      <221> CDS  
                          <222> (53)..(607)  
  
 <220>  
 50                      <221> sig peptide  
                          <222> (53)..(115)  
 55

**<220>**

<221> mat peptide

**<222> (116).. (607)**

<400> 36

gttaaaactg tgccaaacag aggtgtcttc tgacititct tctgcagct cc atg 55

Met

-21

ttt tca cat ctt ccc ttt gac tgt gtc ctg ctg ctg ctg ctg cta cta 103

Phe Ser His Leu Pro Phe Asp Cys Val Leu Leu Leu Leu Leu Leu Leu

-20                      -15                      -10                      -5

ctt aca agg tcc tca gaa gtg gaa tac aga gcg gag gtc ggt cag aat. 151

Leu Thr Arg Ser Ser Glu Val Glu Tyr Arg Ala Glu Val Gly Cln Asn

10

gcc tat ctg ccc tgc ttc tac acc cca gcc gcc cca ggg aac ctc gtg 199

Ala Tyr Leu Pro Cys Phe Tyr Thr Pro Ala Ala Pro Gly Asn Leu Val

**15                      20                      25**

ccc gtc tgc tgg ggc aaa gga gcc tgt cct gtg ttt gaa tgt ggc aac 247

Pro Val Cys Trp Gly Lys Gly Ala Cys Pro Val Phe Glu Cys Gly Asn

**30                      35                      40**

gig gig cic agg act gat gaa agg gat gig aal tat tgg aca lcc aga 295

Val Val Leu Arg Thr Asp Glu Arg Asp Val Asn Tyr Trp Thr Ser Arg

**45                      50                      55                      60**

tac tgg cta aat ggg gat ttc cgc aaa gga gat gtg tcc ctg acc ala 343

Tyr Trp Leu Asn Gly Asp Phe Arg Lys Gly Asp Val Ser Leu Thr Ile

65                      70                      75

gag aai gtg act cta gca gac agt ggg atc tac tgc tgc cgg atc caa 391

Glu Asn Val Thr Leu Ala Asp Ser Gly Ile Tyr Cys Cys Arg Ile Gln

80                      85                      90

atc ccn ggc ata atg aat gat gaa aaa ttt aac ctg aag ttg gtc atc 439

Ile Pro Gly Ile Met Asn Asp Glu Lys Phe Asn Leu Lys Leu Val Ile

95                      100                      105

aaa cca gcc aag gtc acc ccl gca ccg acf clg cng aga gac ttc acf .487

Lys Pro Ala Lys Val Thr Pro Ala Pro Thr Leu Gln Arg Asp Phe Thr

110 115 120

gca gcc tll cca agg atg cll acc acc agg gga cat ggc cca gca gag 535

Ala Ala Phe Pro Arg Met Leu Thr Thr Arg Gly His Gly Pro Ala Glu  
 125 130 135 140  
 5 aca cag aca ctg ggg agc ctc cct gat ata aat cta aca ggt att ctc 583  
 Thr Gln Thr Leu Gly Ser Leu Pro Asp Ile Asn Leu Thr Gly Ile Leu  
 145 150 155  
 10 ata gca aag aga aga tac aga att taagcctcat ctccttggcc aaccctccctc 637  
 Ile Ala Lys Arg Arg Tyr Arg Ile  
 160  
 15 cctcaggatt ggcaaatgca gtagcagagg gaattcgctc agaagaaaac atctatacca 697  
 ttgaagagaa cgtatagaa gtggaggagc ccaatgagta ttattgctat gtcagcagca 757  
 ggcagcaacc ctacaaacct ttgggttgct gctttgcaat gccatagatc caaccacctt 817  
 atttttgagc ttggtgtttt gcttttttca gaaactatga gctgtgtcac ctgactgggt 877  
 20 ttggaggttc tgtccactgc taaggagcag agttttccca ttttcagaag ataatactc 937  
 acatgggaat tgaactggga cctgcactga acttaaacag gcatgtcatt gcctctgtat 997  
 ttaagccaac agagttaccc aaccagagaa ctgttaatca tggatgttag agctcaaacg 1057  
 ggcttttata tacactagga attcttgacg tgggtctctt ggagctccag gaaattcggg 1117  
 25 cacatcatal gtccatgaaa cticagataa actagggaag actgggtgct gaggtagaag 1177  
 cataactttt ttggcacaga aagctaaag gggccactga ttttcaaaga gatctgtgat 1237  
 ccccttttgt tttttgtttt tgagatggag tcttgctctg ttgccaggc tggagtcaa 1297  
 30 tggcacaalc tgggtcact gcaagccccg cctcctgggt tcaagcgatt ctcttgctc 1357  
 agctctcga gggctggga ttacaggcct gcaccacct gccagctaa ttgttgtat 1417  
 ttttagtaga gacaggtttt caccatgtg gccagtgtg tctcaaacct ctgacctcat 1477  
 gatttgctg cctcgcccc ccaagcactl gggattacag gcgtgagcca ccacatccag 1537  
 35 ccagtcatc ttannagat aagagtgctc tggactaggt ctacctgat ctgaagatt 1597  
 ccccttgaat gttagatllt aggtctatllt gacactacc tgcctaacctg tcatgtccag 1657  
 tgcatagccc ttcttttgic tcccttaaga agactgcctt gcagggtga gatgtggcag 1717  
 gagctcccag ggaaaaagga agtgcatllg attggtgtgt attggccaag ttltgttgt 1777  
 40 tgtgtgtllg aaagaaatla tctctgacca acttctgtat tctggacca aactgaagct 1837  
 atattttica cagaagaaga agcagtgacg yggacacaaa ttctgttgc tggtaggaug 1897  
 aaggcaaug ccttcagca tctatllt cagcgttga tctttgaca gagagtgtc 1957  
 45 cctaancila ntttcaaga cgttatggc tigtctgtc ttgtttllg ttgccccctg 2017  
 cgcctagcuc ntttctgaca cactttgga acttactaaa anttttttt actgaauuaa 2077  
 aaaaaaana aaaa 2091  
 50  
 <210> 37  
 <211> 98  
 55

<212> PRT

<213> Homo sapiens

5

<400> 37

Met Val Arg Ile Leu Arg Thr Val Pro Phe Leu Pro Leu Leu Gly Gly  
 -16 -15 -10 -5  
 Cys Ile Asp Asp Thr Ile Leu Ser Arg Gln Gly Phe Ile Asn Tyr Ser  
 1 5 10 15  
 Lys Leu Pro Ser Leu Pro Leu Val Gln Gly Glu Leu Val Gly Gly Leu  
 15 20 25 30  
 Thr Cys Leu Thr Ala Gln Thr His Ser Leu Leu Gln His Gln Pro Leu  
 35 40 45  
 Gln Leu Thr Thr Leu Leu Asp Gln Tyr Ile Arg Glu Gln Arg Glu Lys  
 20 50 55 60  
 Asp Ser Val Met Ser Ala Asn Gly Lys Pro Asp Pro Asp Thr Val Pro  
 65 70 75 80  
 25 Asp Ser

<210> 38

30

<211> 294

<212> DNA

<213> Homo sapiens

35

<400> 38

atggtagga tcttaaggac tggccalc ctgcgcctgc taggtggcctg cattgatgac 60  
 accatctca gcaggcagg cttatcanc tactccaagc tccccagccl gcccttggtg 120  
 40 cagggggagc ttgtaggagg cctcacctgc ctcacagccc agucccactc cctgcctcag 180  
 caccagcccc tcagctgac caccctgttg gaccagtnca tcagagagca acgcgagaag 240  
 gattcigtca tgcggccna tgggaagcca gatccigaca cgttccgga ctcg 294

45

<210> 39

<211> 1094

<212> DNA

50

<213> Homo sapiens

<200>

55

&lt;221&gt; CDS

&lt;222&gt; (22).. (315)

5

&lt;220&gt;

&lt;221&gt; sig peptide

10

&lt;222&gt; (22).. (69)

&lt;220&gt;

&lt;221&gt; mat peptide

15

&lt;222&gt; (70).. (315)

&lt;400&gt; 39

20

gaagagccca aggtcaagga g atg gta cgg atc tta agg act gtg cca ttc 51

Met Val Arg Ile Leu Arg Thr Val Pro Phe

-16 -15 -10

25

ctg ccg ctg cta ggt ggc tgc att gat gac acc atc ctc agc agg cag 99

Leu Pro Leu Leu Gly Gly Cys Ile Asp Asp Thr Ile Leu Ser Arg Gln

-5 1 5 10

30

ggc ttt atc aac tac tcc aag ctc ccc agc ctg ccc ctg gtg cag ggg 147

Gly Phe Ile Asn Tyr Ser Lys Leu Pro Ser Leu Pro Leu Val Gln Gly

15 20 25

35

gag ctt gta gga ggc ctc acc tgc ctc aca gcc cag acc cac tcc ctg 195

Glu Leu Val Gly Gly Leu Thr Cys Leu Thr Ala Gln Thr His Ser Leu

30 35 40

40

ctc cag cac cag ccc ctc cag ctg acc acc ctg ttg gac cag tac atc 243

Leu Gln His Gln Pro Leu Gln Leu Thr Thr Leu Leu Asp Gln Tyr Ile

45 50 55

aga gag caa cgc gag aag gat tct gtc atg tgc gcc aat ggg aag cca 291

Arg Glu Gln Arg Glu Lys Asp Ser Val Met Ser Ala Asn Gly Lys Pro

60 65 70

45

gat cct gac act gtt ccg gac tgc tagccagcct gtttagccag ccttgccat 345

Asp Pro Asp Thr Val Pro Asp Ser

75 80

50

anatacactc tgcgttatig gcigtgcctt cctcaatggg acatgtggaa gaacttggg -105

tcgaggagtg tgtttgtenc ttgttttten ctagttaatga tatgttcagg tataggacca -165

cttgagatg cagtggnlle catttcagat gtcagtcacc ggttttgttcc ttgttttcc 525

55

caacttggga cgtgatagga gcaaagtcic tccattctcc aggtccaagg cagagatcct 585  
 gaaaagatag ggctattgtc ccttgcctcc ttggctactg cctcttgcig caggggtccc 645  
 5 tgagcccacc ccttgggggc acaaccigcc actgccacag tagctcaacc aagcagttgt 705  
 gctgagaatg gcacctggig agagcctgct gtgtgccagg ctttgtgctg agtgcgtgtac 765  
 atgtattagt tcccttactg ctgaccacat tgtaccatt tcacagagaa ggagcagaga 825  
 aattaagtgg ctgtctcaag gtcatgcagt tagtaagtgg cagaacaggg acttgggaacc 885  
 10 aagccctcig ccttgaagac cgcgtcctga atttcttcac tagagcttcc tcatacaggt 945  
 acccagaagt gggccccatc caccatccag gtgtgcttgg atgttagttc tccaccctcg 1005  
 aggtgtacgc tgtgaaaagt ttgggagcac tgccttataa taaatgaaa tatattataa 1065  
 15 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1094

<210> 40

<211> 474

<212> PRT

<213> Homo sapiens

25 <400> 40  
 Met Tyr Thr Val Gly Ala Pro His Thr Trp Pro His Ile Val Ala Ala  
 -23 -20 -15 -10  
 30 Leu Val Trp Leu Ile Asp Cys Ile Lys Ile His Thr Ala Met Lys Glu  
 -5 1 5  
 Ser Ser Pro Leu Phe Asp Asp Gly Gln Pro Trp Gly Glu Glu Thr Glu  
 10 15 20 25  
 35 Asp Gly Ile Met His Asn Lys Leu Phe Leu Asp Tyr Thr Ile Lys Cys  
 30 35 40  
 Tyr Glu Ser Phe Met Ser Gly Ala Asp Ser Phe Asp Glu Met Asn Ala  
 45 50 55  
 40 Glu Leu Gln Ser Lys Leu Lys Asp Leu Phe Asn Val Asp Ala Phe Lys  
 60 65 70  
 Leu Glu Ser Leu Glu Ala Lys Asn Arg Ala Leu Asn Glu Gln Ile Ala  
 45 75 80 85  
 Arg Leu Glu Gln Glu Arg Glu Lys Glu Pro Asn Arg Leu Glu Ser Leu  
 90 95 100 105  
 50 Arg Lys Leu Lys Ala Ser Leu Gln Gly Asp Val Gln Lys Tyr Gln Ala  
 110 115 120  
 Tyr Met Ser Asn Leu Glu Ser His Ser Ala Ile Leu Asp Gln Lys Leu

55

	125	130	135
	Asn Gly Leu Asn Glu Glu Ile Ala Arg Val Glu Leu Glu Cys Glu Thr		
5	140	145	150
	Ile Lys Gln Glu Asn Thr Arg Leu Gln Asn Ile Ile Asp Asn Gln Lys		
	155	160	165
10	Tyr Ser Val Ala Asp Ile Glu Arg Ile Asn His Glu Arg Asn Glu Leu		
	170	175	180
	Gln Gln Thr Ile Asn Lys Leu Thr Lys Asp Leu Glu Ala Glu Gln Gln		
	190	195	200
15	Lys Leu Trp Asn Glu Glu Leu Lys Tyr Ala Arg Gly Lys Glu Ala Ile		
	205	210	215
	Glu Thr Gln Leu Ala Glu Tyr His Lys Leu Ala Arg Lys Leu Lys Leu		
20	220	225	230
	Ile Pro Lys Gly Ala Glu Asn Ser Lys Gly Tyr Asp Phe Glu Ile Lys		
	235	240	245
	Phe Asn Pro Glu Ala Gly Ala Asn Cys Leu Val Lys Tyr Arg Ala Gln		
25	250	255	260
	Val Tyr Val Pro Leu Lys Glu Leu Leu Asn Glu Thr Glu Glu Glu Ile		
	270	275	280
30	Asn Lys Ala Leu Asn Lys Lys Met Gly Leu Glu Asp Thr Leu Glu Gln		
	285	290	295
	Leu Asn Ala Met Ile Thr Glu Ser Lys Arg Ser Val Gly Thr Leu Lys		
	300	305	310
35	Glu Glu Val Gln Lys Leu Asp Asp Leu Tyr Gln Gln Lys Ile Lys Glu		
	315	320	325
	Ala Glu Glu Glu Asp Glu Lys Cys Ala Ser Glu Leu Glu Ser Leu Glu		
40	330	335	340
	Lys His Lys His Leu Leu Glu Ser Thr Val Asn Gln Gly Leu Ser Glu		
	350	355	360
	Ala Met Asn Glu Leu Asp Ala Val Gln Arg Glu Tyr Gln Leu Val Val		
45	365	370	375
	Gln Thr Thr Thr Glu Glu Arg Arg Lys Val Gly Asn Asn Leu Gln Arg		
	380	385	390
	Leu Leu Glu Met Val Ala Thr His Val Gly Ser Val Glu Lys His Leu		
50	395	400	405
	Glu Glu Gln Ile Ala Lys Val Asp Arg Glu Tyr Glu Glu Cys Met Ser		

55

410                      415                      420                      425  
 Glu Asp Leu Ser Glu Asn Ile Lys Glu Ile Arg Asp Lys Tyr Glu Lys  
 5                      430                      435                      440  
 Lys Ala Thr Leu Ile Lys Ser Ser Glu Glu  
                     445                      450

10                      <210> 41  
                     <211> 1422  
                     <212> DNA  
 15                      <213> Homo sapiens

                    <400> 41  
 20                      atgtacacag tgggggctcc tcatacatgg cctcacattg tggcagccit agtttggcta 60  
                     atagactgca tcaagataca tactgccatg aaagaaagct cacctttatt tgaigatggg 120  
                     cagcccttggg gagaagaaac tgaagatgga attatgcata ataagtigt tttggactac 180  
                     accataaaat gctatgagag ttttatgagt ggtgccgaca gctttgaiga gatgaatgca 240  
 25                      gagctgcagt caaaactgaa ggattttatt aatgtggatg ctittlaagct ggaatcatta 300  
                     gaagcaaaaa acagagcatt gaatgaacag attgcaagat tggacaaga aagagaaaaa 360  
                     gaaccgaatc gcttagagtc gttgagaaaa ctgaaggctt ccttacaagg agatgttcaa 420  
                     aagtatcagg catacatgag caatttggag tctcattcag ccattcttga ccagaaalla 480  
 30                      aatggcttca atgaggaaat tgctagagta gaactagaat gigaahcaat aaaacaggag 540  
                     aacactcgac tacagaatat caltgacaac cagaaglaet cagltgcaga catlgagcga 600  
                     ataaatcatg aaagaaatga attgcagcag actatlaata aallaaccaa ggccttggaa 660  
 35                      gctgaacaac agaagtgtg gaatgaggag tlaaaatatg ccagagacca agaagcgatt 720  
                     gaaacacaat tagcagagta tcacaaattg gctagaaaaa laaaacttnt tcttaagggt 780  
                     gctgagaatt ccaaaggtaa tgaattttaa attlaagttta atcccagagg tgggtccaac 840  
                     tgccttgtca aatacagggc tcaagtttat gtacctctta aggaactcct gaatgaact 900  
 40                      gaagaagaaa ttaataaagc cctaataaaa aaaaatgggt tggaggatcc tttagaahca 960  
                     ttgaatgcaa tgataacaga aagcaagaga agltgtggaa ctctganaga ngaagttaa 1020  
                     aagctggatg atctttacca acaaaualt aaghuagcag aggaahgagg tgaahhgt 1080  
 45                      gccagtgcgc ttgagtcctt ggagaacac aagcacctgc tagaagtlac ttttaaccag 1140  
                     gggctcagtg aagctatgaa tgaattagat gctgttcagc gggaatacca actagtgtg 1200  
                     caaaccacgn ctgaaganag acgaadagtg ggnataact tgaacgtct gttaghgtg 1260  
                     gttgtacac atgttgggtc tglagagaaa catcttngk agcaghtgc thungtght 1320  
 50                      agagaatalg aghaatgcat gtcaguagat ctctcgghaa ataltaaagk gatttghgt 1380  
                     anglatgaga agnaagctac tctaatlaug tctctghag an 1422

55



<210> 42  
 <211> 1613  
 5 <212> DNA  
 <213> Homo sapiens

10 <200>  
 <221> CDS  
 <222> (99)..(1520)

15 <220>  
 <221> sig peptide  
 <222> (99)..(167)

20 <220>  
 <221> mat peptide  
 25 <222> (168)..(1520)

<400> 42  
 tgtgccccctc atacgaactt cctgacacaa agttgaaga agagggtcca agaattctta 60  
 30 aagaccttgg gtaaccttll gcactatcca aaagctcc atg tac aca gtg ggg 113  
 Met Tyr Thr Val Gly  
 -23 -20  
 35 gct cct cat acn tgg cct cac att gtg gca gcc tta gtt tgg cta ata 161  
 Ala Pro His Thr Trp Pro His Ile Val Ala Ala Leu Val Trp Leu Ile  
 -15 -10 -5  
 40 gac tgc atc aag ata cat act gcc atg aaa gaa agc tca cct tta ttt 209  
 Asp Cys Ile Lys Ile His Thr Ala Met Lys Glu Ser Ser Pro Leu Phe  
 1 5 10  
 45 gat gat ggg cag cct tgg gga gaa gaa act gaa gat gga att atg cat 257  
 Asp Asp Gly Gln Pro Trp Gly Glu Glu Thr Glu Asp Gly Ile Met His  
 15 20 25 30  
 aat aag ttg ttt ttg gac tac acc ata aaa tgc tat gag agt ttt atg 305  
 Asn Lys Leu Phe Leu Asp Tyr Thr Ile Lys Cys Tyr Glu Ser Phe Met  
 50 35 40 45  
 agt ggt gcc gac agc ttt gat gag atg aat gca gag ctg cag tca ana 353

55

Ser Gly Ala Asp Ser Phe Asp Glu Met Asn Ala Glu Leu Gln Ser Lys  
 50 55 60  
 5 ctg aag gat tta ttt aat gtg gat gct ttt aag ctg gaa tca tta gaa 401  
 Leu Lys Asp Leu Phe Asn Val Asp Ala Phe Lys Leu Glu Ser Leu Glu  
 65 70 75  
 10 gca aaa aac aga gca ttg aat gaa cag att gca aga ttg gaa caa gaa 449  
 Ala Lys Asn Arg Ala Leu Asn Glu Gln Ile Ala Arg Leu Glu Gln Glu  
 80 85 90  
 15 aga gaa aaa gaa ccg aat cgt cta gag tcg ttg aga aaa ctg aag gct 497  
 Arg Glu Lys Glu Pro Asn Arg Leu Glu Ser Leu Arg Lys Leu Lys Ala  
 95 100 105 110  
 TCC TTA CAA GGA GAT GTT CAA AAG TAT CAG GCA TAC ATG AGC AAT TTG 545  
 20 Ser Leu Gln Gly Asp Val Gln Lys Tyr Gln Ala Tyr Met Ser Asn Leu  
 115 120 125  
 gag tct cat tca gcc att ctt gac cag aaa tta aat ggt ctc aat gag 593  
 Glu Ser His Ser Ala Ile Leu Asp Gln Lys Leu Asn Gly Leu Asn Glu  
 25 130 135 140  
 gaa att gct aga gta gaa cta gaa tgt gaa aca ata aaa cag gag aac 641  
 Glu Ile Ala Arg Val Glu Leu Glu Cys Glu Thr Ile Lys Gln Glu Asn  
 30 145 150 155  
 act cga cta cag aat atc att gac aac cag aag tac tca gtt gca gac 689  
 Thr Arg Leu Gln Asn Ile Ile Asp Asn Gln Lys Tyr Ser Val Ala Asp  
 160 165 170  
 35 att gag cga ala aat cat gaa aga aat gaa ttg cag cag nct att aat 737  
 Ile Glu Arg Ile Asn His Glu Arg Asn Glu Leu Gln Gln Thr Ile Asn  
 175 180 185 190  
 40 aaa tta acc aag gac ctg gaa gct gaa caa cag aag ttg tgg aat gag 785  
 Lys Leu Thr Lys Asp Leu Glu Ala Glu Gln Gln Lys Leu Trp Asn Glu  
 195 200 205  
 gag tta aaa tat gcc aga gcc aan gaa gcg att gaa aca caa tta gca 833  
 45 Glu Leu Lys Tyr Ala Arg Gly Lys Glu Ala Ile Glu Thr Gln Leu Ala  
 210 215 220  
 gag tat cac aaa ttg gct aga aaa tta aat att cct aaa ggt gct 881  
 Glu Tyr His Lys Leu Ala Arg Lys Leu Lys Leu Ile Pro Lys Gly Ala  
 50 225 230 235  
 gng aat tcc aua ggt tat gac ttt gaa att aag ttt aat ccc gng gct 929

	Glu Asn Ser Lys Gly Tyr Asp Phe Glu Ile Lys Phe Asn Pro Glu Ala	
	240	245 250
5	ggg gcc aac tgc ctt gtc aaa tac agg gct caa gtt tat gta cct ctt	977
	Gly Ala Asn Cys Leu Val Lys Tyr Arg Ala Gln Val Tyr Val Pro Leu	
	255 260 265 270	
10	aag gaa ctc ctg aat gaa act gaa gaa gaa att aat aaa gcc cta aat	1025
	Lys Glu Leu Leu Asn Glu Thr Glu Glu Glu Ile Asn Lys Ala Leu Asn	
	275 280 285	
15	aaa aaa atg ggt ttg gag gat act tta gaa caa ttg aat gca atg ata	1073
	Lys Lys Met Gly Leu Glu Asp Thr Leu Glu Gln Leu Asn Ala Met Ile	
	290 295 300	
20	aca gaa agc aag aga agt gtg gga act ctg aaa gaa gaa gtt caa aag	1121
	Thr Glu Ser Lys Arg Ser Val Gly Thr Leu Lys Glu Glu Val Gln Lys	
	305 310 315	
25	ctg gat gat ctt tac caa caa aaa att aag gaa gca gag gaa gag gat	1169
	Leu Asp Asp Leu Tyr Gln Gln Lys Ile Lys Glu Ala Glu Glu Glu Asp	
	320 325 330	
30	gaa aaa tgt gcc agt gag ctt gag tcc ttg gag aaa cac aag cac ctg	1217
	Glu Lys Cys Ala Ser Glu Leu Glu Ser Leu Glu Lys His Lys His Leu	
	335 340 345 350	
35	cta gaa agt act gtt aac cag ggg ctc agt gaa gct atg aat gaa tta	1265
	Leu Glu Ser Thr Val Asn Gln Gly Leu Ser Glu Ala Met Asn Glu Leu	
	355 360 365	
40	gat gct gtt cag cgg gaa tac caa cta gtt gtg caa acc acg act gaa	1313
	Asp Ala Val Gln Arg Glu Tyr Gln Leu Val Val Gln Thr Thr Thr Glu	
	370 375 380	
45	gaa aga cga aaa gtg gga aat aac ttg caa cgt ctg tta gag atg gtt	1361
	Glu Arg Arg Lys Val Gly Asn Asn Leu Gln Arg Leu Leu Glu Met Val	
	385 390 395	
50	gct aca cat gtt ggg tct gta gag aaa cat ctt gag gag cag att gct	1409
	Ala Thr His Val Gly Ser Val Glu Lys His Leu Glu Glu Gln Ile Ala	
	400 405 410	
55	aaa gtt gat aga gaa tat gaa gaa tgc atg tca gaa gat ctc tcg gaa	1457
	Lys Val Asp Arg Glu Tyr Glu Glu Cys Met Ser Glu Asp Leu Ser Glu	
	415 420 425 430	
	aat att aaa gag att aga gat aag tat gag aag aaa gct act cta att	1505

Asn Ile Lys Glu Ile Arg Asp Lys Tyr Glu Lys Lys Ala Thr Leu Ile  
435 440 445  
5 aag tct tct gaa gaa tgaagataaa atgttgatca tgtatatata tccatagta 1560  
Lys Ser Ser Glu Glu  
450  
10 ataaaaattgt ctcagtaaag taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa 1613  
  
<210> 43  
<211> 78  
15 <212> PRT  
<213> Homo sapiens  
  
<400> 43  
20 Met Tyr Tyr Ile Leu Ile Tyr Pro Phe Pro Leu Phe Leu Phe Leu Leu  
-22 -20 -15 -10  
Ser Leu Leu Ile Tyr Asn Gln Lys Met Lys Lys Ser Val His Leu Val  
25 -5 1 5 10  
Phe Asp Leu Pro Lys His Leu Val Asn Leu Ile Phe Val Thr Leu Trp  
15 20 25  
30 Met Val Asn Leu Thr Phe Thr Gln Val Gly Phe Cys Phe Val Glu Asn  
30 35 40  
Asp Leu Leu Gly Gly Thr Thr Thr Thr Glu Arg Thr Lys Leu  
45 50 55  
35  
<210> 44  
<211> 234  
40 <212> DNA  
<213> Homo sapiens  
  
<400> 44  
45 atgtattata ttttaactta tccctttccct ttgtttttgt tcttattalc tcttcigata 60  
tataaccaa aatgaaaaa atcgttacac ttgggttttg atttacctaa gcacctagtt 120  
aatttaact ttgtaacact ttggatgggt aacttaacct ttactcangt tggtttttgt 180  
50 ttgttgaaa atgacttact tggttggacc tctactnctg aungnngn anct 234  
  
<210> 45  
55

<211> 511  
 <212> DNA  
 5 <213> Homo sapiens

<200>  
 <221> CDS  
 10 <222> (49)..(282)

<220>  
 15 <221> sig peptide  
 <222> (49)..(114)

<220>  
 20 <221> mat peptide  
 <222> (115)..(282)

25 <400> 45  
 attttatcaa ttgtttgtat tttcccttttaa ggtaacattt taaatgaa atg tat tat 57  
 Met Tyr Tyr  
 -22 -20

30 att tta atc tat cct ttt cct ttg ttt ttg ttc tta tta tct ctt ctg 105  
 Ile Leu Ile Tyr Pro Phe Pro Leu Phe Leu Phe Leu Ser Leu Leu  
 -15 -10 -5

35 ata tat aac caa aaa atg aaa aaa tct gta cac ttg gtg ttt gat tta 153  
 Ile Tyr Asn Gln Lys Met Lys Lys Ser Val His Leu Val Phe Asp Leu  
 1 5 10

40 cct aag cac cta gtt aat tta atc ttt gta aca ctt tgg atg gtt aac 201  
 Pro Lys His Leu Val Asn Leu Ile Phe Val Thr Leu Trp Met Val Asn  
 15 20 25

45 tta acc ttt act caa gtt ggt ttt tgt ttt gtt gaa aat gac tta ctt 249  
 Leu Thr Phe Thr Gln Val Gly Phe Cys Phe Val Glu Asn Asp Leu Leu  
 30 35 40 45

ggt gga acc act act act gaa uga acg aaa ctt tgaatttaca ttgttaangta 302  
 Gly Gly Thr Thr Thr Thr Glu Arg Thr Lys Leu  
 50 55

tcagagctgt tacagagcna gtccctttta agagatgtan aaattangta cctgtgcca 362

55

actgattttt attagaaacc ctgttttctt taagtaaaag tatattctac cagcatggct 422  
 tggtaagaaa aatcccttat cttttttccc ctgtccctcaa aattcagaat ttttccggaa 482  
 5 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 511

<210> 46  
 10 <211> 73  
 <212> PRT  
 <213> Homo sapiens

15 <400> 46  
 Met Gln Phe Met Asn Leu Leu Val Gly Phe Ser Cys Ser Trp Gly Asn  
 -15 -10 -5 1  
 20 Thr Cys Ala Cys His Thr Arg Pro Phe Leu Ala Pro Ser Val Phe Ser  
 5 10 15  
 Leu Cys Asp Gly Gly Leu Ile Val Ser Val Phe Thr Gln Gly Trp Phe  
 20 25 30  
 25 Pro Gly Cys Thr Ala Pro Val Pro Thr Pro Thr Val Pro Leu Ile Arg  
 35 40 45  
 Cys His Asp Phe Ser Ala Thr Ser Pro  
 30 50 55

<210> 47  
 <211> 219  
 35 <212> DNA  
 <213> Homo sapiens

40 <400> 47  
 atgcagttca tgaacttgcg ggltgggttt tctgtctcct ggggtaacac atgcgcttgt 60  
 catacacgcc ccttccttgc ccttcagla ttctctcttt gcgatggagg tctcatagt 120  
 agtgccttca ctcaagggtg gtttcttggc tgcacggcac ctgttccaac acctactgtg 180  
 45 cctctcatca gggtgcacga tttttctgca ncttccct 219

<210> 48  
 50 <211> 903  
 <212> DNA  
 <213> Homo sapiens

55

**<200>**

&lt;221&gt; CDS

5

<222> (31)..(249)

**<220>**

10

&lt;221&gt; sig peptide

<222> (31).. (75)

(220)

15

<221> mat peptide

(222) (76).. (249)

20

&lt;400&gt; 48

ggagtttcgt aagcaaaata gaggacagaa atg cag ttc atg aac ttg ctg gtt 54

Met Gln Phe Met Asn Leu Leu Val

-15                      -10

25

ggg ttt tcc tgc tcc tgg ggt aac aca tgc gct tgt cat aca cgc ccc 102

Gly Phe Ser Cys Ser Trp Gly Asn Thr Cys Ala Cys His Thr Arg Pro

-5 1 5

30

ttc ctt gcc cct tca gla ttc tct ctt tgc gal gga ggt ctc ata gtg 150

Phe Leu Ala Pro Ser Val Phe Ser Leu Cys Asp Gly Gly Leu Ile Val

**10                      15                      20                      25**

35

agt gtc ttc act caa ggg tgg ttt cct ggc tgc acg gca cct gtt cca 198

Ser Val Phe Thr Gln Gly Trp Phe Pro Gly Cys Thr Ala Pro Val Pro

**30                      35                      40**

40

aca cct act gtg cct ctc alc agg lgl cac gat ttt tct gcc act tca 246

Thr Pro Thr Val Pro Leu Ile Arg Cys His Asp Phe Ser Ala Thr Ser

**45                      50                      55**

cct tagggagcct ccagtgatg atlltaggag gccacgcca agctccccag 299

45

**Pro**

gnaalgactg ccttccttgg gaccaaggac cgttccnacc gcatttcactg ccngllctaa 359

laggcgagga aaatgcccgaggcgctgtct tctgtccccc acacglacca gaaggtgaa 419

50

aatgcagcga gtcctctggg cggltatgag cctccaggcg catgctgtcc agttagacgg -179

aacatctggc ggttggllga ttgcctcctt ttgtcttggg cgcctgcttc agaatctatg 539

caggggatag cagtgggtc agaatctlll cccgggagag agatggccctg ggtlatal 599

gctgatagct ttggctgcat gagtggggt tcccttacc cagggtgca cagccagggtg 659  
 tgggggtcac cggcaggtag gctgggtggt gcagctcag agccctcca ggttgctgt 719  
 5 gttccagtg aatcacattt cgtcattga agccatgag gaccattgtg tggatccatg 779  
 gtgattctag acttcagata tatttaggaa ggcgcagatt tcaaactgtt gtttgattt 839  
 ctgtaataag agaaatccaa ttgtaaac ttgaaaaaa aaaaaaaaaa aaaaaaaaaa 899  
 10 aaaa 903

<210> 49

<211> 421

15 <212> PRT

<213> Homo sapiens

20 <400> 49

Met Arg Trp Ile Leu Phe Ile Gly Ala Leu Ile Gly Ser Ser Ile Cys  
 -16 -15 -10 -5  
 Gly Gln Glu Lys Phe Phe Gly Asp Gln Val Phe Arg Ile Asn Val Arg  
 25 1 5 10 15  
 Asn Gly Asp Glu Ile Ser Lys Leu Ser Gln Leu Val Asn Ser Asn Asn  
 20 25 30  
 30 Leu Lys Leu Asn Phe Trp Lys Ser Pro Ser Ser Phe Asn Arg Pro Val  
 35 40 45  
 Asp Val Leu Val Pro Ser Val Ser Leu Gln Ala Phe Lys Ser Phe Leu  
 50 55 60  
 35 Arg Ser Gln Gly Leu Glu Tyr Ala Val Thr Ile Glu Asp Leu Gln Ala  
 65 70 75 80  
 Leu Leu Asp Asn Glu Asp Asp Glu Met Gln His Asn Glu Gly Gln Glu  
 40 85 90 95  
 Arg Ser Ser Asn Asn Phe Asn Tyr Gly Ala Tyr His Ser Leu Glu Ala  
 100 105 110  
 Thr Tyr His Glu Met Asp Asn Ile Ala Ala Asp Phe Pro Asp Leu Ala  
 45 115 120 125  
 Arg Arg Val Lys Ile Gly His Ser Phe Glu Asn Arg Thr Met Tyr Val  
 130 135 140  
 50 Leu Lys Phe Ser Thr Gly Lys Gly Val Arg Arg Pro Ala Val Trp Leu  
 145 150 155 160  
 Asn Ala Gly Ile His Ser Arg Glu Trp Ile Ser Gln Ala Thr Ala Ile

55



	165	170	175
5	Trp Thr Ala Arg Lys Ile Val Ser Asp Tyr Gln Arg Asp Pro Ala Ile		
	180	185	190
	Thr Ser Ile Leu Glu Lys Met Asp Ile Phe Leu Leu Pro Val Ala Asn		
	195	200	205
10	Pro Asp Gly Tyr Val Tyr Thr Gln Thr Gln Asn Arg Leu Trp Arg Lys		
	210	215	220
	Thr Arg Ser Arg Asn Pro Gly Ser Ser Cys Ile Gly Ala Asp Pro Asn		
	225	230	235
15	Arg Asn Trp Asn Ala Ser Phe Ala Gly Lys Gly Ala Ser Asp Asn Pro		
	245	250	255
	Cys Ser Glu Val Tyr His Gly Pro His Ala Asn Ser Glu Val Glu Val		
20	260	265	270
	Lys Ser Val Val Asp Phe Ile Gln Lys His Gly Asn Phe Lys Gly Phe		
	275	280	285
	Ile Asp Leu His Ser Tyr Ser Gln Leu Leu Met Tyr Pro Tyr Gly Tyr		
25	290	295	300
	Ser Val Lys Lys Ala Pro Asp Ala Glu Glu Leu Asp Lys Val Ala Arg		
	305	310	315
30	Leu Ala Ala Lys Ala Leu Ala Ser Val Ser Gly Thr Glu Tyr Gln Val		
	325	330	335
	Gly Pro Thr Cys Thr Thr Val Tyr Pro Ala Ser Gly Ser Ser Ile Asp		
	340	345	350
35	Trp Ala Tyr Asp Asn Gly Ile Lys Phe Ala Phe Thr Phe Glu Leu Arg		
	355	360	365
	Asp Thr Gly Thr Tyr Gly Phe Leu Leu Pro Ala Asn Gln Ile Ile Pro		
40	370	375	380
	Thr Ala Glu Glu Thr Trp Leu Gly Leu Lys Thr Ile Met Glu His Val		
	385	390	395
	Arg Asp Asn Leu Tyr		400
45	-105		

&lt;210&gt; 50

50 &lt;211&gt; 1263

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

55

&lt;400&gt; 50

atgaggtgga tactgttcat tggggccctt attgggtcca gcatctgttg ccaagaaaaa 60  
 5 ttttttgggg accaagtttt taggattaat gtcagaaatg gagacgagat cagcaaatg 120  
 agtcaactag tgaattcaaa caactigaag ctcaatttct ggaaatctcc ctcttctctc 180  
 aatcggcctg tggatgtcct ggtcccatct gtcagtctgc aggcatttaa atccitctctg 240  
 10 agatcccagg gcttagagta cgcagtgaac attaggacc tgcaggccct tttagacaat 300  
 gaagatgatg aaatgcaaca caatgaaggg caagaacgga gcagtaataa ctcaactac 360  
 ggggcttacc attccctgga agctacttac cagcagatgg acaacatlgc cgcagacttt 420  
 cctgacctgg cgaggagggt gaagatigga cattctgttg aaaaccggac gatgtatgta 480  
 15 ctgaagtcca gcactgggaa aggcgtgagg cggccggccg ttggcigaa tgcaggcatc 540  
 cattcccgag agtggatctc ccaggccact gcaatctgga cggcaaggaa gattgtatct 600  
 gattaccaga gggatccagc tatcacctcc atctiggaga aaatggatat tttcttgttg 660  
 20 cctgtggcca atctgtatgg atagtgtat actcaaaactc aaaaccgatt atggaggaag 720  
 acgcgtccc gaaatcctgg aagctcctgc attgtgtctg acccaaatag aaactgggac 780  
 gctagttttg caggaaaggg agccagcgac aaccttgct ccgaagtga ccatggaccc 840  
 25 cagccaatt cggaagtiga ggtgaaatca gtggtagatt tcatccaaaa acatgggaat 900  
 ttcaagggtt tcatcgacct gcacagctac tgcagctgc tgatgtatcc atatgggiac 960  
 tcagtcaaaa aggcccccaga tgcgaggaa ctgcacaagg tggcagggtt tgcggccaaa 1020  
 gctctggctt ctgtgtcggg cactgagtag caagtgggic ccactgcac cactgtctat 1080  
 30 ccagctagcg ggagcagcat cgactgggag tatgacaacg gcatcaattt tgcattcaca 1140  
 tttgagltga gagataccgg gacctatggc ttcttctgc cagctaacca gatcatcccc 1200  
 actgcagagg agacgtggct ggggctgaug accatcatgg agcatgtgcg ggacaaccic 1260  
 35 tac 1263

&lt;210&gt; 51

&lt;211&gt; 2796

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;200&gt;

&lt;221&gt; CDS

&lt;222&gt; (11)..(1273)

&lt;220&gt;

&lt;221&gt; sig peptide

&lt;222&gt; (11)..(58)

5

&lt;220&gt;

&lt;221&gt; mat peptide

&lt;222&gt; (59)..(1273)

10

&lt;400&gt; 51

15

ccccggggac atg agg tgg ata ctg ttc att ggg gcc ctt att ggg tcc 49

Met Arg Trp Ile Leu Phe Ile Gly Ala Leu Ile Gly Ser

-16 -15 -10 -5

agc atc tgt ggc caa gaa aaa ttt ttt ggg gac caa gtt ttt agg att 97

Ser Ile Cys Gly Gln Glu Lys Phe Phe Gly Asp Gln Val Phe Arg Ile

1 5 10

20

aat gtc aga aat gga gac gag atc agc aaa ttg agt caa cta gtg aat 145

Asn Val Arg Asn Gly Asp Glu Ile Ser Lys Leu Ser Gln Leu Val Asn

15 20 25

25

tca aac aac ttg aag ctc aat ttc tgg aaa tct ccc tcc tcc ttc aat 193

Ser Asn Asn Leu Lys Leu Asn Phe Trp Lys Ser Pro Ser Ser Phe Asn

30 35 40 45

30

cgg cct gtg gat gtc ctg gtc cca tct gtc agt ctg cag gca ttt aaa 241

Arg Pro Val Asp Val Leu Val Pro Ser Val Ser Leu Gln Ala Phe Lys

50 55 60

35

tcc ttc ctg aga tcc cag ggc tta gag tac gca gtg acn att gag gac 289

Ser Phe Leu Arg Ser Gln Gly Leu Glu Tyr Ala Val Thr Ile Glu Asp

65 70 75

ctg cag gcc ctt tta gac aat gaa gat gat gaa atg caa cac aat gaa 337

Leu Gln Ala Leu Leu Asp Asn Glu Asp Asp Glu Met Gln His Asn Glu

80 85 90

40

ggg caa gaa cgg agc agt aat aac ttc aac tac ggg gct tac cat tcc 385

Gly Gln Glu Arg Ser Ser Asn Asn Phe Asn Tyr Gly Ala Tyr His Ser

95 100 105

45

ctg gaa gct act tac cac gag atg gac aac att gcc gca gac ttt cct 433

Leu Glu Ala Thr Tyr His Glu Met Asp Asn Ile Ala Ala Asp Phe Pro

110 115 120 125

50

gac ctg gca agc agc gtg aac att gga cat tcc ttt gaa aac cgg acg 481

Asp Leu Ala Arg Arg Val Lys Ile Gly His Ser Phe Glu Asn Arg Thr

55

	130	135	140	
	atg tat gta ctg aag ttc agc act ggg aaa ggc gtg agg cgg ccg gcc	529		
5	Met Tyr Val Leu Lys Phe Ser Thr Gly Lys Gly Val Arg Arg Pro Ala			
	145	150	155	
	gtt tgg ctg aat gca ggc atc cat tcc cga gag tgg atc tcc cag gcc	577		
10	Val Trp Leu Asn Ala Gly Ile His Ser Arg Glu Trp Ile Ser Gln Ala			
	160	165	170	
	act gca atc tgg acg gca agg aag att gta tct gat tac cag agg gat	625		
	Thr Ala Ile Trp Thr Ala Arg Lys Ile Val Ser Asp Tyr Gln Arg Asp			
15	175	180	185	
	cca gct atc acc tcc atc ttg gag aaa atg gat att ttc ttg ttg cct	673		
	Pro Ala Ile Thr Ser Ile Leu Glu Lys Met Asp Ile Phe Leu Leu Pro			
20	190	195	200	205
	gtg gcc aat cct gat gga tat gtg tat act caa act caa aac cga tta	721		
	Val Ala Asn Pro Asp Gly Tyr Val Tyr Thr Gln Thr Gln Asn Arg Leu			
	210	215	220	
25	tgg agg aag acg cgg tcc cga aat cct gga agc tcc tgc att ggt gct	769		
	Trp Arg Lys Thr Arg Ser Arg Asn Pro Gly Ser Ser Cys Ile Gly Ala			
	225	230	235	
30	gac cca aat aga aac tgg aac gct agt ttt gca gga aag gga gcc agc	817		
	Asp Pro Asn Arg Asn Trp Asn Ala Ser Phe Ala Gly Lys Gly Ala Ser			
	240	245	250	
	gac aac cct tgc tcc gaa gtg tac cat gga ccc cac gcc aat tcc gaa	865		
35	Asp Asn Pro Cys Ser Glu Val Tyr His Gly Pro His Ala Asn Ser Glu			
	255	260	265	
	gtg gag gtg aaa tca gtg gla gat ttc atc caa aaa cat ggg aat ttc	913		
40	Val Glu Val Lys Ser Val Val Asp Phe Ile Gln Lys His Gly Asn Phe			
	270	275	280	285
	aag ggc ttc atc gac ctg cac agc tac tcc cag ctg ctg atg tat cca	961		
	Lys Gly Phe Ile Asp Leu His Ser Tyr Ser Gln Leu Leu Met Tyr Pro			
45	290	295	300	
	tat ggg tac tca gtc aaa aag gcc cca gat gcc gag gaa ctg gac aag	1009		
	Tyr Gly Tyr Ser Val Lys Lys Ala Pro Asp Ala Glu Glu Leu Asp Lys			
50	305	310	315	
	gtg gcg agg ctt gcg gcc aaa gct ctg gct tct gtg tcc ggc act gag	1057		
	Val Ala Arg Leu Ala Ala Lys Ala Leu Ala Ser Val Ser Gly Thr Glu			

55

320 325 330  
 tac caa gtg ggt ccc acc tgc acc act gtc tat cca gct agc ggg agc 1105  
 Tyr Gln Val Gly Pro Thr Cys Thr Thr Val Tyr Pro Ala Ser Gly Ser  
 335 340 345  
 agc atc gac tgg gcg tat gac aac ggc atc aaa ttt gca ttc aca ttt 1153  
 Ser Ile Asp Trp Ala Tyr Asp Asn Gly Ile Lys Phe Ala Phe Thr Phe  
 350 355 360 365  
 gag ttg aga gat acc ggg acc tat ggc ttc ctc ctg cca gct aac cag 1201  
 Glu Leu Arg Asp Thr Gly Thr Tyr Gly Phe Leu Leu Pro Ala Asn Gln  
 370 375 380  
 atc atc ccc act gca gag gag acg tgg ctg ggg ctg aag acc atc atg 1249  
 Ile Ile Pro Thr Ala Glu Glu Thr Trp Leu Gly Leu Lys Thr Ile Met  
 385 390 395  
 gag cat gtg cgg gac aac ctc tac taggcgatgg ctctgctctg tctacattta 1303  
 Glu His Val Arg Asp Asn Leu Tyr  
 400 405  
 ttgtaccca cactgcacg cactgagcc atgttaaag gagctcttc ctacctgtgt 1363  
 gactcagagc cctctgggtt tgtggagcac acaggccctgc cctctccag ccagctccct 1423  
 ggagtcgtgt gtcctggcgg tgcctctgca agaactggtt ctgccagcct gctcaatttt 1483  
 ggctcctgtg ttttgatga gccttttgc tgtttcctt tccaccctgc tggctgggcg 1543  
 gctgcactca genicacccc ttcctgggtg gcctgtctct ctctacctca tttttagAAC 1603  
 caaagaacat ctgagatgat tctctacct calccacatc tagccaagcc agtgaccttg 1663  
 ctctgggtgc actgtgggag acaccacttg tctttagggt ggctcAaag atgatgtaga 1723  
 atttcttla atttctgca gcttctctgg aaataattt cctttgagca gcaaatcttg 1783  
 tagggataic agtgaaggic tctctctccc tctctctctg tttttttt tgagacagag 1843  
 tttgtctt gttgccaga ctggagtgt atggctcgac ctggctcnc cacaacctct 1903  
 gccctctggg ttcaagcaat tctctgctt cagcctcttg agtagcttgg tttataggcg 1963  
 catgccacca tgcctggcta attttgtt tttagtagag acagggttc tccatgttg 2023  
 tchggctgtt ctcaactcc caacctcag tgaictgcc tcttggcct cccagagtgc 2083  
 tgggtatca agtgtgacc actgtgccc tccgtcccc tcttttlla ggctgaata 2143  
 caaagtagna gactccttc ctctacttg ctgagaattt ctgatactca cagtcttacc 2203  
 tctctcttc ccttggat tcaagtgtac caggatggcg ggaggggac tgtctactg 2263  
 taggtactgt gcccggaug gctgggtgaa gtagcatct aatttcagc atggtgaaat 2323  
 tctcccttc tgcctaatg ggttacct ctcttggct ttgactca ctctaaagt 2383  
 ctaggctca tcttchgtt cctaaactc tctctggcc tggataatct cactgcccgt 2443  
 gcacttccc attgtactg tgggtatcc tgttttct tgcctgttt tgtgtgtg 2503

**5**

10

20

40

50

55

ctgggctgta gaaagaagac accaaaggca aaglacatgt atctggcgca ggagctcttg 240  
 gttgatccag aatggccacc aaaacctcag acaaccacag aagctaangc tllagttaag 300  
 5 gagaatggat catgtcaat catcaccata aca 333

<210> 54  
 <211> 3635  
 10 <212> DNA  
 <213> Homo sapiens

15 <200>  
 <221> CDS  
 <222> (36)..(368)

20 <220>  
 <221> sig peptide  
 <222> (36)..(77)

25 <220>  
 <221> mat peptide  
 30 <222> (78)..(368)

<400> 5-1  
 agatagtg tgtagcatat cagtgccgtg taact atg ctc atc att gtt ctt 53  
 Met Leu Ile Ile Val Leu  
 -14 -10  
 gtc aat gcc ttt gtg tct atc aca gtg gag aac ttc ttc ctt gac atg 101  
 Val Asn Ala Phe Val Ser Ile Thr Val Glu Asn Phe Phe Leu Asp Met  
 -5 1 5  
 gtc ctt tgg aaa gtt gtg ttc aac cga gac aaa caa gga gng tal cgg 149  
 Val Leu Trp Lys Val Val Phe Asn Arg Asp Lys Gln Gly Glu Tyr Arg  
 10 15 20  
 ttc agc acc aca cag cca ccg cag gag tca gtg gat cgg tgg gga aaa 197  
 Phe Ser Thr Thr Gln Pro Pro Gln Glu Ser Val Asp Arg Trp Gly Lys  
 25 30 35 40  
 tgc tgc tta ccc tgg gcc ctg gcc tgt aga aag aag aca cca aag gca 245  
 Cys Cys Leu Pro Trp Ala Leu Gly Cys Arg Lys Lys Thr Pro Lys Ala

55

45 50 55  
 aag tac atg tat ctg gcg cag gag ctc ttg gtt gat cca gaa tgg cca 293  
 5 Lys Tyr Met Tyr Leu Ala Gln Glu Leu Leu Val Asp Pro Glu Trp Pro  
 60 65 70  
 cca aaa cct cag aca acc aca gaa gct aaa gct tta gtt aag gag aat 341  
 10 Pro Lys Pro Gln Thr Thr Thr Glu Ala Lys Ala Leu Val Lys Glu Asn  
 75 80 85  
 gga tca tgt caa atc atc acc ata aca tagcagtcaa tcagtcctcag 388  
 15 Gly Ser Cys Gln Ile Ile Thr Ile Thr  
 90 95  
 tggatattgt gatagcagta ttcaggaata tgtgatitaa ggagtittctg atcctgtgtg 448  
 tcagaatggc actagttcag tttatgtccc ttctgatata gtacattati tgacagcttt 508  
 20 gctcttccctt aaaataaaaa cagaaaaata tatcgtccta acagttaaat taacaatcaa 568  
 tccataaagt cctatatctt caticagcaa cccaaatatt acatacatit ccagaattit 628  
 ctigtattgt actttcagtg atattcttta tatigggtag aggagaagtt tgggttttgg 688  
 taggtttttc aacattagtt ttgagacta gtttacctct tcacatttat gctcacaacc 748  
 25 ctcttgtag aaaagtctgt gtttatatac aggcgtgaag ttigtgattg ataaaaagaa 808  
 gatgagtggt aattagcctc cagtgaanaa atactgaag cctgttttca ttgattcca 868  
 atgtttcttc caaagaattc tgtalaaaca tatgccaatt ccttatgatg gcttagagtt 928  
 30 aggaatgagt gtttatgtgt ttgcttatag aacaactcag gtaacttcca ttcttggttt 988  
 tataatttct glacaaactg cctgggtttt atttttctaa tcagcaaggt gcttcactgc 1048  
 ctcttgaga gccttctcaa agctctttaa tggctctctg gctatgtgtg gtttggtcag 1108  
 tctaatgtgc ttctgtttaa tgtgttagaa cctttttcac taggaataaa gattcatitc 1168  
 35 ttctggcag agatgtgat tcatctttaa agctttcttc aaatttggtt ctgtcaggct 1228  
 ttgtgttatt ttaaatgtgt ttttaaaatt ttcttctatg ttctcaatla cctaaagaca 1288  
 taggataaah gtttttttta agtlagaatt ttaccicata aaattttttg aggttttgat 1348  
 tatgtctctg tcttatcaat aatgaggctt aaaaaatact ggtattgaat ggtgtccgtt 1408  
 40 ttltcaagc aatatgaatt tgatgagttt gttttatgcc attaggtggc gccagaggic 1468  
 agaacatgic tattttgaat tggatcgtta caaatgagca tatttgatgc ggaattttct 1528  
 gggagaaana aaattgagga aataaagttt aaaaattgac attcattgag ccaaaagaga 1588  
 45 tgttgagaa cattttttac ctltctgttt ggcttgatla ncatltaaat tcttgccaaa 1648  
 attnaggtta ctlttaaaaa cactltttat aggttgatcc agcagctctg caacgccctc 1708  
 agttaccnca acacagaaaa ctgactgtgc tataaatg agcttaact atgaaaacag 1768  
 tgttcatttg ttctctgttc ttccagagcc agtaacatgc ttgcctgtgc ttcttacttc 1828  
 50 tagctgaten ttcttttccc nactatatt tactaatlla ccmatttita cctagaattt 1888  
 taggtccaaa tggctctenc tctttatgt gcaagacct ggtatgagtt tggtaactat 1948

55



agaaaaatag aaattacact caggatcact gttactgcta ttgccactga tgattcctgc 2008  
 aaaatataat cgaagtttcc catcaaatgt ataatatgct attaatcacac attagatgat 2068  
 5 aacagtgtgt ccatgaatga ttctatgaag ctatgcatct tagaccctct gagctgtgaa 2128  
 ttagcactat ttcttatagt tacttatctt ctggatcatt ttataatttc catattaatt 2188  
 tcaaatatgc tegtgttatt cticagtgtt tccacaatt gtgcatttta ttctttggtt 2248  
 taagtactga agcatataat gaaaglaatt gctaagtagc agcttaaaaa ttcaattatc 2308  
 10 cgattgtatt taacatcttt aagagcatga tcataaagag ctatttttga ccccccccc 2368  
 cactttttta acatttagag ttaataaggg ttttatatct ctctcgtcca tattgttttc 2428  
 aaaggaatga ggtgttttagg tggcctggaaa agcatttgta ggaagttaga ttigaatata 2488  
 15 gacaaggtgg gttattcacg ttgagaatgt tatttgaaga atgctctgta agccagggtg 2548  
 gggttctact cagtgcata galagactga gtcttctctc gtaggtcacc attacatagt 2608  
 aattttgatt ctgaatttca caltaaatia tttagttta tacagacctt aattttaaaa 2668  
 tctgtacata tattattttg atgtatttaag atgaatattg ctgattttaa ttttatttat 2728  
 20 gcacatactt aaaggacaga aatgctcggg aaagtaattg ttaataatg atattgaact 2788  
 ttttaacttt ttaataaat aacaagattt ttaatgtgtg tctcctcag ggttgtttta 2848  
 agtttttttt ctccctcaag tataaatagt ggtaactata tgttttgtat ctcttagcac 2908  
 25 caactgctgt aaagcaatgc tgcataat ccttgaatc aagtggctaa gccacaaca 2968  
 gaataaatat ttttatagta gtittatant cctgaattc gaaagctttc ccaattgcac 3028  
 ttgcaactaa acaaaactgt tgcagttttt actctattta ttltgttccc catgtttatg 3088  
 aaagtccctc acagtttcaa aggcattgga aataatata caatgtttat gtagtctgtt 3148  
 30 acagaaacag ctatagatan callatccag tgaagagcaa aattcaagct ttganaata 3208  
 ttcatgcatg canlttgac atatctanaa ataggttttt gtatatitat ggtgggaggt 3268  
 ggttgggaac tttaacaaa atgggtgtgt aatttttgta cagtcctgtg gcatttacac 3328  
 35 atttttaag tatlaaaatt tggltttttt gttacatta aattatata agttacttct 3388  
 agttatgatt tgtgaattcc cttagacctt ggattttttt aaglaacttt atatcagaaa 3448  
 tgatactgca tctttatatt tttaaatgtt tatgtctgtt caagaatgtt acctcttgtt 3508  
 40 caaaaaggca tacattcata attgtacatt cagcattgta aataatctta tgaacctttt 3568  
 ttgtattgaa gctattcaaa ataaatattt taatgaacga aaaaaaaaaa aaaaaaaaaa 3628  
 aaaaaaa 3635

45 <210> 55  
 <211> 1109  
 <212> PRT  
 50 <213> Homo sapiens

<400> 55

55

55

Glu Lys Gln His Leu Glu Asn Val Thr Glu Glu His Val Val Thr Phe  
 275 280 285  
 5 Thr Phe Thr Gln Lys Ile Ser Lys Pro Gly Glu Ala Pro Lys Asn Ser  
 290 295 300  
 Pro Ser Ile Leu Ala Met Leu Glu Thr Leu Gln Asn Ala Pro Tyr Leu  
 305 310 315  
 10 Glu Val His Lys Asp Met Ile Arg Trp Ile Leu Lys Thr Phe Asn Ala  
 320 325 330  
 Val Lys Lys Met Arg Glu Ser Ser Pro Thr Ser Pro Val Ala Glu Thr  
 15 335 340 345 350  
 Glu Gly Thr Ile Met Glu Glu Ser Ser Arg Asp Lys Asp Lys Ala Glu  
 355 360 365  
 20 Arg Lys Arg Lys Ala Glu Ile Ala Arg Leu Arg Arg Glu Lys Ile Met  
 370 375 380  
 Ala Gln Met Ser Glu Met Gln Arg His Phe Ile Asp Glu Asn Lys Glu  
 385 390 395  
 25 Leu Phe Gln Gln Thr Leu Glu Leu Asp Ala Ser Thr Ser Ala Val Leu  
 400 405 410  
 Asp His Ser Pro Val Ala Ser Asp Met Thr Leu Thr Ala Leu Gly Pro  
 415 420 425 430  
 30 Ala Gln Thr Gln Val Pro Glu Gln Arg Gln Phe Val Thr Cys Ile Leu  
 435 440 445  
 Cys Gln Glu Glu Gln Glu Val Lys Val Glu Ser Arg Ala Met Val Leu  
 35 450 455 460  
 Ala Ala Phe Val Gln Arg Ser Thr Val Leu Ser Lys Asn Arg Ser Lys  
 465 470 475  
 40 Phe Ile Gln Asp Pro Glu Lys Tyr Asp Pro Leu Phe Met His Pro Asp  
 480 485 490  
 Leu Ser Cys Gly Thr His Thr Ser Ser Cys Gly His Ile Met His Ala  
 495 500 505 510  
 45 His Cys Trp Gln Arg Tyr Phe Asp Ser Val Gln Ala Lys Glu Gln Arg  
 515 520 525  
 Arg Gln Gln Arg Leu Arg Leu His Thr Ser Tyr Asp Val Glu Asn Gly  
 530 535 540  
 50 Glu Phe Leu Cys Pro Leu Cys Glu Cys Leu Ser Asn Thr Val Ile Pro  
 545 550 555

55

Leu Leu Leu Ser Pro Arg Asn Ile Phe Asn Asn Arg Leu Asn Phe Ser  
 560 565 570  
 5 Asp Gln Pro Asn Leu Thr Gln Trp Ile Arg Thr Ile Ser Gln Gln Ile  
 575 580 585 590  
 Lys Ala Leu Gln Phe Leu Arg Lys Glu Glu Ser Thr Pro Asn Asn Ala  
 595 600 605  
 10 Ser Thr Lys Asn Ser Glu Asn Val Asp Glu Leu Gln Leu Pro Glu Gly  
 610 615 620  
 Phe Arg Pro Asp Phe Arg Pro Lys Ile Pro Tyr Ser Glu Ser Ile Lys  
 625 630 635  
 15 Glu Met Leu Thr Thr Phe Gly Thr Ala Thr Tyr Lys Val Gly Leu Lys  
 640 645 650  
 Val His Pro Asn Glu Glu Asp Pro Arg Val Pro Ile Met Cys Trp Gly  
 655 660 665 670  
 20 Ser Cys Ala Tyr Thr Ile Gln Ser Ile Glu Arg Ile Leu Ser Asp Glu  
 675 680 685  
 25 Asp Lys Pro Leu Phe Gly Pro Leu Pro Cys Arg Leu Asp Asp Cys Leu  
 690 695 700  
 Arg Ser Leu Thr Arg Phe Ala Ala Ala His Trp Thr Val Ala Ser Val  
 705 710 715  
 30 Ser Val Val Gln Gly His Phe Cys Lys Leu Phe Ala Ser Leu Val Pro  
 720 725 730  
 Asn Asp Ser His Glu Glu Leu Pro Cys Ile Leu Asp Ile Asp Met Phe  
 735 740 745 750  
 35 His Leu Leu Val Gly Leu Val Leu Ala Phe Pro Ala Leu Gln Cys Gln  
 755 760 765  
 40 Asp Phe Ser Gly Ile Ser Leu Gly Thr Gly Asp Leu His Ile Phe His  
 770 775 780  
 Leu Val Thr Met Ala His Ile Ile Gln Ile Leu Leu Thr Ser Cys Thr  
 785 790 795  
 45 Glu Glu Asn Gly Met Asp Gln Glu Asn Pro Pro Cys Glu Glu Glu Ser  
 800 805 810  
 Ala Val Leu Ala Leu Tyr Lys Thr Leu His Gln Tyr Thr Gly Ser Ala  
 815 820 825 830  
 50 Leu Lys Glu Ile Pro Ser Gly Trp His Leu Trp Arg Ser Val Arg Ala  
 835 840 845

55

Gly Ile Met Pro Phe Leu Lys Cys Ser Ala Leu Phe Phe His Tyr Leu  
 850 855 860  
 5 Asn Gly Val Pro Ser Pro Pro Asp Ile Gln Val Pro Gly Thr Ser His  
 865 870 875  
 Phe Glu His Leu Cys Ser Tyr Leu Ser Leu Pro Asn Asn Leu Ile Cys  
 10 880 885 890  
 Leu Phe Gln Glu Asn Ser Glu Ile Met Asn Ser Leu Ile Glu Ser Trp  
 895 900 905 910  
 15 Cys Arg Asn Ser Glu Val Lys Arg Tyr Leu Glu Gly Glu Arg Asp Ala  
 915 920 925  
 Ile Arg Tyr Pro Arg Glu Ser Asn Lys Leu Ile Asn Leu Pro Glu Asp  
 930 935 940  
 20 Tyr Ser Ser Leu Ile Asn Gln Ala Ser Asn Phe Ser Cys Pro Lys Ser  
 945 950 955  
 Gly Gly Asp Lys Ser Arg Ala Pro Thr Leu Cys Leu Val Cys Gly Ser  
 960 965 970  
 25 Leu Leu Cys Ser Gln Ser Tyr Cys Cys Gln Thr Glu Leu Glu Gly Glu  
 975 980 985 990  
 Asp Val Gly Ala Cys Thr Ala His Thr Tyr Ser Cys Gly Ser Gly Val  
 995 1000 1005  
 30 Gly Ile Phe Leu Arg Val Arg Glu Cys Gln Val Leu Phe Leu Ala Gly  
 1010 1015 1020  
 Lys Thr Lys Gly Cys Phe Tyr Ser Pro Pro Tyr Leu Asp Asp Tyr Gly  
 1025 1030 1035  
 35 Glu Thr Asp Gln Gly Leu Arg Arg Gly Asn Pro Leu His Leu Cys Lys  
 1040 1045 1050  
 40 Glu Arg Phe Lys Lys Ile Gln Lys Leu Trp His Gln His Ser Val Thr  
 1055 1060 1065 1070  
 Glu Glu Ile Gly His Ala Gln Glu Ala Asn Gln Thr Leu Val Gly Ile  
 1075 1080 1085  
 45 Asp Trp Gln His Leu  
 1090  
 50 <210> 56  
 <211> 3327  
 <212> DVA  
 55

&lt;213&gt; Homo sapiens

5

&lt;400&gt; 56

10

15

20

25

30

35

40

45

50

55

atgttgatag aacacccctct tagatgtctt gtictgtgtg cccaagtaca tgccggaatg 60  
 tggagaagaa atgggttctc tctagtaaac cagatttatt actaccataa tgtgaatgc 120  
 agacgtgaga tgttggacaa ggaatgtaga atgcttcaga cagggtgtctc catgaatgat 180  
 ccaaatacatt tccgatgat catgctcagc cgctttgaac tttatcagat tticagtact 240  
 ccagactatg gaaaaagatt tagttctgag attaccata aggatgttgt tcagcagaac 300  
 aatactctaa tagaagaat gctatacctc attataatgc ttgttggaga gagatttagt 360  
 ccaggagtig gacaggtaaa tgcacagat gaaatcaagc gagagattat ccatcagtig 420  
 aglatcaagc ctatggctca tagtgaattg gtaagtcctt tacctgaaga tgagaacaag 480  
 gagactggca tggagagtgt aatcgaagca gtigccatt tcaagaacc tggattaaca 540  
 ggacgaggca tgtatgaact gaaaccagaa tgtgcaaag agttcaactt gtatttctat 600  
 cacttttcaa gggcagaaca gtccaaggca gaagaagcgc aacggaaat gaaaagacaa 660  
 aalagagaag atacagcact ccacctccg gtgttgctc cattctgccc tctgtttgca 720  
 agcctgggta acattttgca gtcagatgtc atgtttgtga tcatgggaac aattctgcaa 780  
 tgggctgtgg aacataatgg atatgcctgg tcagagtcca tgcgcaaag gggtttacat 840  
 tlaattggca tggcactaca agaagaaaa caacatttag agaatgtcac ggaagagcat 900  
 gtaglaaat ttaccttcac tcagaagata tcaaaacctg gtgaagcgcc aaaaaattct 960  
 cctagcalac tagctatgct ggaacacta caaaatgctc cctacctaga agtccacaaa 1020  
 gacatgatic ggtggatatt gaagactttt aatgctgta aaaagatgag ggagagttca 1080  
 cctaccagtc ccgtggcaga gacagaagga accataatgg aagagagttc aagggacaaa 1140  
 gacuaagctg aguggaagag aaaagcagag atlgccagac tgcgcagagn aaagatcatg 1200  
 gctcagaigt ctgaatgca cgggcatttt attgatgaa acnaagaaact ctltcagcag 1260  
 acattagnac tggatgctc aacctctgct gttcttgatc atagccctgt ggcttcagat 1320  
 atgacactta cagcactggg ccccgacaa actcaggtic ctgaacnaag acaattcgtt 1380  
 acatgtatgt tgtgtcaaga ggagcaagaa gttaaagtg aaagcagggc aatggctttg 1440  
 gcagcatttg ttcagagatc aactgtatta tcaaaaaca gaagtaatt tattcaagat 1500  
 ccagaaaaat atgatccatt attcatgcac cctgatctgt ctigtggaa acacactagt 1560  
 agctgtgggc acattatgca tgccctttgt tggcaagggt attttgatt cgttcaagct 1620  
 aaagaacnxc gaaggcaaca gagattacgc ttacatacga gctatgatgt agaaaacgga 1680  
 gatttccitt gccccctttg tgaatgcttg agtattactg ttattccctc gctgctttct 1740  
 ccuaguuua tttttaaca caggttaatt ttltcagacc aaccaatct gactcagttg 1800  
 attagacaa tatctcaga aatuuagca ttacgtttc ttaggaaaga agnaagtact 1860  
 cctaatatg cctctacnaa gaattcagaa natgiggatg aattacagct ccttgnaagg 1920  
 ttacggcttg attttgtec taagatccct taltctgga genluuagaa atgtctnec 1980

acatttggaa ctgctaccta caaggtggga cttaaagggtc atcccaatga agaggatcct 2040  
 cgtgttccca taatgtgttg gggtagctgc gcgtacacca tccaaagcat agaaagaatt 2100  
 5 ttgagtgatg aagataaacc attgtttgtt cctttacctt gcagactgga tgactgtctt 2160  
 aggtcatlga cgagatttgc cgcagcacac tggacagtgg catcagtttc agtgggtgcaa 2220  
 ggacattttt gtaaacittt tgcattcactg gtgcctaatt acagccatga ggaacttcca 2280  
 10 tgcattatag atattgacat gtttcatlta ttgggtgggt tgggtcttgc atttcttgcg 2340  
 ttgcagtgc aggtattttc agggatcagc ctggcactg gagaccttca caltttccat 2400  
 ctggttacta tggcacacat catacagatc ttacttacct catgtacaga agagaatggc 2460  
 atggatcaag aaaatccccc ttgtgaagaa gaatcagcag ttcttgcitt gtataaaca 2520  
 15 cttcaccagt atacgggaag tgccttgaag gaaataccat cgggttggca tctgtggagg 2580  
 agtgtcagag ctggaatcat gcttttcttg aaggttcttg ctttattttt tcatlactta 2640  
 aatggagtgc cttccccacc cgacattcaa gttccttggaa caagccattt tgaacattta 2700  
 20 tgtagctatc ttcccttacc aaacaacctc atttgccttt ttcaagaaaa tagtgagata 2760  
 atgaattcac tgattgaag ttggtgccgt aacagtgaag ttaaaagata tctagaaggt 2820  
 gaaagagatg ctataagata tccaagagaa tctaacaat taataaacct tccagaggat 2880  
 tacagcagcc tcattaatca agcatccaat ttctctgtcc cgaatcagg tggtgataag 2940  
 25 agcagagccc caactctgtg ccttgtgtgc ggaictctgc tgtgtccca gatttactgc 3000  
 tgcagactg aactggaagg ggaggatgta ggagcctgca cagctcacac ctactcctgt 3060  
 ggctctggag tgggcatctt cctgagagta cgggaatgic aggtgtctat tttagctggc 3120  
 30 aaaaccaaag gctgttttta ttctctctct taccttgatg actatggggn gaccgaccag 3180  
 ggactcagac ggggaaatcc ttacattta tgcagagagc gattcagaa gattcagaag 3240  
 ctctggcacc aacacagtgt cacagaggaa atlggacatg cacaggagac caatcagaca 3300  
 ctgggtggca ttgactggca acattta 3327

35

&lt;210&gt; 57

&lt;211&gt; 3502

40

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

50

&lt;200&gt;

45

&lt;221&gt; CDS

&lt;222&gt; (56).. (3382)

&lt;220&gt;

&lt;221&gt; sig peptide

&lt;222&gt; (56).. (109)

55

&lt;220&gt;

&lt;221&gt; mat peptide

5

&lt;222&gt; (110).. (3382)

&lt;400&gt; 57

10

tttttgtttt ctgttttttt attttttgta tatatagagt gaacttagcc caccc atg 58  
Met

-18

15

ttg ata gaa cac cct ctt aga tgt ctt gtt ctg tgt gcc caa gta cat 106  
Leu Ile Glu His Pro Leu Arg Cys Leu Val Leu Cys Ala Gln Val His

-15

-10

-5

20

gcc gga atg tgg aga aga aat ggg ttc tct cta gta aac cag att tat 154  
Ala Gly Met Trp Arg Arg Asn Gly Phe Ser Leu Val Asn Gln Ile Tyr

1

5

10

15

25

tac tac cat aat gtg aaa tgc aga cgt gag atg ttt gac aag gat gta 202  
Tyr Tyr His Asn Val Lys Cys Arg Arg Glu Met Phe Asp Lys Asp Val

20

25

30

30

gta atg ctt cag aca ggt gtc tcc atg atg gat cca aat cat ttc ctg 250  
Val Met Leu Gln Thr Gly Val Ser Met Met Asp Pro Asn His Phe Leu

35

40

45

35

atg atc atg ctc agc cgc ttt gaa ctt tat cng att ttc agt act cca 298  
Met Ile Met Leu Ser Arg Phe Glu Leu Tyr Gln Ile Phe Ser Thr Pro

50

55

60

40

gac tat gga aaa aga ttt agt tct gag att acc cat aag gat gtt gtt 346  
Asp Tyr Gly Lys Arg Phe Ser Ser Glu Ile Thr His Lys Asp Val Val

65

70

75

45

cag cag aac aat act cta ata gaa gaa atg cta tac ctc att ata atg 394  
Gln Gln Asn Asn Thr Leu Ile Glu Glu Met Leu Tyr Leu Ile Ile Met

80

85

90

95

ctt gtt gga gag aga ttt agt cct gga gtt gga cag gla aat gct aca 442  
Leu Val Gly Glu Arg Phe Ser Pro Gly Val Gly Gln Val Asn Ala Thr

100

105

110

50

ggt gaa atc aag cga gag att atc cat cag ctg agt atc aag cct atg 490  
Asp Glu Ile Lys Arg Glu Ile Ile His Gln Leu Ser Ile Lys Pro Met

115

120

125

55



	gct cat agt gaa ttg gta aag tct tta cct gaa gat gag aac aag gag	538
	Ala His Ser Glu Leu Val Lys Ser Leu Pro Glu Asp Glu Asn Lys Glu	
5	130 135 140	
	act ggc atg gag agt gta atc gaa gca gtt gcc cat ttc aag aaa cct	586
	Thr Gly Met Glu Ser Val Ile Glu Ala Val Ala His Phe Lys Lys Pro	
10	145 150 155	
	gga tta aca gga cga ggc atg tat gaa ctg aaa cca gaa tgt gcc aaa	634
	Gly Leu Thr Gly Arg Gly Met Tyr Glu Leu Lys Pro Glu Cys Ala Lys	
	160 165 170 175	
15	gag ttc aac ttg tat ttc tat cac ttt tca agg gca gaa cag tcc aag	682
	Glu Phe Asn Leu Tyr Phe Tyr His Phe Ser Arg Ala Glu Gln Ser Lys	
	180 185 190	
20	gca gaa gaa gcg caa cgg aaa ttg aaa aga caa aat aga gaa gat aca	730
	Ala Glu Glu Ala Gln Arg Lys Leu Lys Arg Gln Asn Arg Glu Asp Thr	
	195 200 205	
	gca ctc cca cct ccg gtg ttg cct cca ttc tgc cct ctg ttt gca agc	778
25	Ala Leu Pro Pro Pro Val Leu Pro Pro Phe Cys Pro Leu Phe Ala Ser	
	210 215 220	
	ctg gtt aac att ttg cag tca gat gtc atg ttg tgc atc atg gga aca	826
30	Leu Val Asn Ile Leu Gln Ser Asp Val Met Leu Cys Ile Met Gly Thr	
	225 230 235	
	att ctg caa tgg gct gtg gaa cat aat gga tat gcc tgg tca gag tcc	874
	Ile Leu Gln Trp Ala Val Glu His Asn Gly Tyr Ala Trp Ser Glu Ser	
35	240 245 250 255	
	atg ctg caa agg gtg tta cat tta att ggc atg gca cta caa gaa gaa	922
	Met Leu Gln Arg Val Leu His Leu Ile Gly Met Ala Leu Gln Glu Glu	
	260 265 270	
40	aaa caa cnt tta gag aat gtc acg gaa gag cat gta gta acn ttt acc	970
	Lys Gln His Leu Glu Asn Val Thr Glu Glu His Val Val Thr Phe Thr	
	275 280 285	
45	ttc act cag aag ala tca aan cct ggt gaa gcg cca aaa aat tct cct	1018
	Phe Thr Gln Lys Ile Ser Lys Pro Gly Glu Ala Pro Lys Asn Ser Pro	
	290 295 300	
50	ngc ata cta gct atg ctg gaa acn cta cam aat gct ccc tnc cta gaa	1066
	Ser Ile Leu Ala Met Leu Glu Thr Leu Gln Asn Ala Pro Tyr Leu Glu	
	305 310 315	
55		

	gtc cac aaa gac atg att cgg tgg ata ttg aag act ttt aat gct gtt	1114
	Val His Lys Asp Met Ile Arg Trp Ile Leu Lys Thr Phe Asn Ala Val	
5	320                      325                      330                      335	
	aaa aag atg agg gag agt tca cct acc agt ccc gtg gca gag aca gaa	1162
	Lys Lys Met Arg Glu Ser Ser Pro Thr Ser Pro Val Ala Glu Thr Glu	
10	340                      345                      350	
	gga acc ata atg gaa gag agt tca agg gac aaa gac aaa gct gag agg	1210
	Gly Thr Ile Met Glu Glu Ser Ser Arg Asp Lys Asp Lys Ala Glu Arg	
	355                      360                      365	
15	aag aga aaa gca gag att gcc aga ctg cgc aga gaa aag atc atg gct	1258
	Lys Arg Lys Ala Glu Ile Ala Arg Leu Arg Arg Glu Lys Ile Met Ala	
	370                      375                      380	
20	cag atg tct gaa atg cag cgg cat ttt att gat gaa aac aaa gaa ctc	1306
	Gln Met Ser Glu Met Gln Arg His Phe Ile Asp Glu Asn Lys Glu Leu	
	385                      390                      395	
	ttt cag cag aca tta gaa ctg gat gcc tca acc tct gct gtt ctt gat	1354
25	Phe Gln Gln Thr Leu Glu Leu Asp Ala Ser Thr Ser Ala Val Leu Asp	
	400                      405                      410                      415	
	cat agc cct gtg gct tca gat atg aca ctt aca gca ctg ggc ccc gca	1402
	His Ser Pro Val Ala Ser Asp Met Thr Leu Thr Ala Leu Gly Pro Ala	
30	420                      425                      430	
	caa act cag gtt cct gaa caa aga caa ttc gtt aca tgt ata ttg tgt	1450
	Gln Thr Gln Val Pro Glu Gln Arg Gln Phe Val Thr Cys Ile Leu Cys	
35	435                      440                      445	
	caa gag gag caa gaa gtt aaa gtg gaa agc agg gca atg gtc ttg gca	1498
	Gln Glu Glu Gln Glu Val Lys Val Glu Ser Arg Ala Met Val Leu Ala	
	450                      455                      460	
40	gca ttt gtt cag aga tca act gta tta tca aaa aac aga agt aaa ttt	1546
	Ala Phe Val Gln Arg Ser Thr Val Leu Ser Lys Asn Arg Ser Lys Phe	
	465                      470                      475	
45	att caa gat ccn gaa aaa tat gat cca tta ttc atg cac cct gat ctg	1594
	Ile Gln Asp Pro Glu Lys Tyr Asp Pro Leu Phe Met His Pro Asp Leu	
	480                      485                      490                      495	
50	tct tgt gga nca cnc act agt agc tgt ggc cnc att atg cct gcc cat	1642
	Ser Cys Gly Thr His Thr Ser Ser Cys Gly His Ile Met His Ala His	
	500                      505                      510	
55		

	tgt tgg caa agg tat ttt gat tcc gtt caa gct aaa gaa cag cga agg	1690
	Cys Trp Gln Arg Tyr Phe Asp Ser Val Gln Ala Lys Glu Gln Arg Arg	
5	515 520 525	
	caa cag aga tta cgc tta cat acg agc tat gat gla gaa aac gga gaa	1738
	Gln Gln Arg Leu Arg Leu His Thr Ser Tyr Asp Val Glu Asn Gly Glu	
	530 535 540	
10	ttc ctt tgc ccc ctt tgt gaa tgc ttg agt aat act gtt att cct ctg	1786
	Phe Leu Cys Pro Leu Cys Glu Cys Leu Ser Asn Thr Val Ile Pro Leu	
	545 550 555	
15	ctg ctt tct cca aga aat att ttt aac aac agg tta aat ttt tca gac	1834
	Leu Leu Ser Pro Arg Asn Ile Phe Asn Asn Arg Leu Asn Phe Ser Asp	
	560 565 570 575	
20	caa cca aat ctg act cag tgg att aga aca ata tct cag caa ata aaa	1882
	Gln Pro Asn Leu Thr Gln Trp Ile Arg Thr Ile Ser Gln Gln Ile Lys	
	580 585 590	
25	gca tta cag ttt ctt agg aaa gaa gaa agt act cct aat aat gcc tct	1930
	Ala Leu Gln Phe Leu Arg Lys Glu Glu Ser Thr Pro Asn Asn Ala Ser	
	595 600 605	
30	aca aag aat tca gaa aat gtg gat gaa tta cag ctc cct gaa ggg ttc	1978
	Thr Lys Asn Ser Glu Asn Val Asp Glu Leu Gln Leu Pro Glu Gly Phe	
	610 615 620	
35	agg cct gat ttt cgt cct aag atc cct tat tct gag agc ata aaa gaa	2026
	Arg Pro Asp Phe Arg Pro Lys Ile Pro Tyr Ser Glu Ser Ile Lys Glu	
	625 630 635	
40	atg cta acg aca ttt gga act gct acc tac aag gtg gga cta aag gtt	2074
	Met Leu Thr Thr Phe Gly Thr Ala Thr Tyr Lys Val Gly Leu Lys Val	
	640 645 650 655	
45	cat ccc aat gaa gag gat cct cgt gtt ccc ata atg tgt tgg ggt agc	2122
	His Pro Asn Glu Glu Asp Pro Arg Val Pro Ile Met Cys Trp Gly Ser	
	660 665 670	
50	tgc gcg tac acc atc caa agc ata gaa aga att ttg agt gat gaa gat	2170
	Cys Ala Tyr Thr Ile Gln Ser Ile Glu Arg Ile Leu Ser Asp Glu Asp	
	675 680 685	
55	aaa cca ttg ttt ggt cct tta cct tgc aga ctg gat gac tgt ctt agg	2218
	Lys Pro Leu Phe Gly Pro Leu Pro Cys Arg Leu Asp Asp Cys Leu Arg	
	690 695 700	



	tca ttg acg aga ttt gcc gca gca cac tgg aca gtg gca tca gtt tca	2266
	Ser Leu Thr Arg Phe Ala Ala Ala His Trp Thr Val Ala Ser Val Ser	
5	705                      710                      715	
	gtg gtg caa gga cat ttt tgt aaa ctt ttt gca tca ctg gtg cct aat	2314
	Val Val Gln Gly His Phe Cys Lys Leu Phe Ala Ser Leu Val Pro Asn	
10	720                      725                      730                      735	
	gac agc cat gag gaa ctt cca tgc ata tta gat att gac atg ttt cat	2362
	Asp Ser His Glu Glu Leu Pro Cys Ile Leu Asp Ile Asp Met Phe His	
	740                      745                      750	
15	tta ttg gtg ggc ttg gtg ctt gca ttt cct gcg ttg cag tgt cag gat	2410
	Leu Leu Val Gly Leu Val Leu Ala Phe Pro Ala Leu Gln Cys Gln Asp	
	755                      760                      765	
20	ttt tca ggg atc agc ctt ggc act gga gac ctt cac att ttc cat ctg	2458
	Phe Ser Gly Ile Ser Leu Gly Thr Gly Asp Leu His Ile Phe His Leu	
	770                      775                      780	
	gtt act atg gca cac atc ata cag atc tta ctt acc tca tgt aca gaa	2506
25	Val Thr Met Ala His Ile Ile Gln Ile Leu Leu Thr Ser Cys Thr Glu	
	785                      790                      795	
	gag aat ggc atg gat caa gaa aat ccc cct tgt gaa gaa gaa tca gca	2554
30	Glu Asn Gly Met Asp Gln Glu Asn Pro Pro Cys Glu Glu Glu Ser Ala	
	800                      805                      810                      815	
	gtt ctt gct ttg tat aaa acn ctt cac cag tat acg gga agt gcc ttg	2602
	Val Leu Ala Leu Tyr Lys Thr Leu His Gln Tyr Thr Gly Ser Ala Leu	
35	820                      825                      830	
	aaa gaa ata cca tcc ggc tgg cat ctg tgg agg agt gtc aga gct ggn	2650
	Lys Glu Ile Pro Ser Gly Trp His Leu Trp Arg Ser Val Arg Ala Gly	
40	835                      840                      845	
	atc atg cct ttc ctg aag tgt tct gct tta ttt ttt cat tac tta aat	2698
	Ile Met Pro Phe Leu Lys Cys Ser Ala Leu Phe Phe His Tyr Leu Asn	
	850                      855                      860	
45	gga gtt cct tcc cca ccc gac att caa gtt cct gga acn agc cat ttt	2746
	Gly Val Pro Ser Pro Pro Asp Ile Gln Val Pro Gly Thr Ser His Phe	
	865                      870                      875	
50	gaa cat tta tgt agc tat ctt tcc cta cca aac nac ctc att tgc ctt	2794
	Glu His Leu Cys Ser Tyr Leu Ser Leu Pro Asn Asn Leu Ile Cys Leu	
	880                      885                      890                      895	

55

	ttt caa gaa aat agt gag ata atg aat tca ctg att gaa agt tgg tgc	2842
	Phe Gln Glu Asn Ser Glu Ile Met Asn Ser Leu Ile Glu Ser Trp Cys	
5	900 905 910	
	cgt aac agt gaa gtt aaa aga tat cta gaa ggt gaa aga gat gct ata	2890
	Arg Asn Ser Glu Val Lys Arg Tyr Leu Glu Gly Glu Arg Asp Ala Ile	
10	915 920 925	
	aga tat cca aga gaa tct aac aaa tta ata aac ctt cca gag gat tac	2938
	Arg Tyr Pro Arg Glu Ser Asn Lys Leu Ile Asn Leu Pro Glu Asp Tyr	
	930 935 940	
15	agc agc ctc att aat caa gca tcc aat ttc tgc tgc ccg aaa tca ggt	2986
	Ser Ser Leu Ile Asn Gln Ala Ser Asn Phe Ser Cys Pro Lys Ser Gly	
	945 950 955	
20	ggc gat aag agc aga gcc cca act ctg tgc ctt gtg tgc gga tct ctg	3034
	Gly Asp Lys Ser Arg Ala Pro Thr Leu Cys Leu Val Cys Gly Ser Leu	
	960 965 970 975	
	ctg tgc tcc cag agt tac tgc tgc cag act gaa ctg gaa ggg gag gat	3082
25	Leu Cys Ser Gln Ser Tyr Cys Cys Gln Thr Glu Leu Glu Gly Glu Asp	
	980 985 990	
	gta gga gcc tgc aca gct cac acc tac tcc tgt ggc tct gga gtg ggc	3130
30	Val Gly Ala Cys Thr Ala His Thr Tyr Ser Cys Gly Ser Gly Val Gly	
	995 1000 1005	
	atc ttc ctg aga gta cgg gaa tgt cag gtg cta ttt tta gct ggc aaa	3178
	Ile Phe Leu Arg Val Arg Glu Cys Gln Val Leu Phe Leu Ala Gly Lys	
35	1010 1015 1020	
	acc aaa ggc tgt ttt tat tct cct cct tac ctt gat gac tat ggg gag	3226
	Thr Lys Gly Cys Phe Tyr Ser Pro Pro Tyr Leu Asp Asp Tyr Gly Glu	
40	1025 1030 1035	
	acc gac cag gga ctc aga cgg gga aat cct tta cat tta tgc aaa gag	3274
	Thr Asp Gln Gly Leu Arg Arg Gly Asn Pro Leu His Leu Cys Lys Glu	
	1040 1045 1050 1055	
45	cga ttc aag aag att cag aag ctc tgg cac caa cac agt gtc aca gag	3322
	Arg Phe Lys Lys Ile Gln Lys Leu Trp His Gln His Ser Val Thr Glu	
	1060 1065 1070	
50	gaa att gaa ctt gca cag gaa gcc aat cag acu ctg gtt ggc att gac	3370
	Glu Ile Gly His Ala Gln Glu Ala Asn Gln Thr Leu Val Gly Ile Asp	
	1075 1080 1085	
55		

tgg caa cat tta taattattgc accaccaaaa aacacaaact tggatttttt 3422  
 Trp Gln His Leu  
 5 1090  
 taaccagttt ggcttttttaa gaaagaanga agttctgctg aatttgaaa taaattcttt 3482  
 atttaaacit taaaaaaaaa 3502  
 10  
 <210> 58  
 <211> 1726  
 <212> PRT  
 15 <213> Homo sapiens  
 <400> 58  
 20 Met Leu Ala Cys Leu Gln Ala Cys Ala Gly Ser Val Ser Gln Glu Leu  
 -13 -10 -5 1  
 Ser Glu Thr Ile Leu Thr Met Val Ala Asn Cys Ser Asn Val Met Asn  
 5 10 15  
 25 Lys Ala Arg Gln Pro Pro Pro Gly Val Met Pro Lys Gly Arg Pro Pro  
 20 25 30 35  
 Ser Ala Ser Ser Leu Asp Ala Ile Ser Pro Val Gln Ile Asp Pro Leu  
 40 45 50  
 30 Ala Gly Met Thr Ser Leu Ser Ile Gly Gly Ser Ala Ala Pro His Thr  
 55 60 65  
 Gln Ser Met Gln Gly Phe Pro Pro Asn Leu Gly Ser Ala Phe Ser Thr  
 70 75 80  
 35 Pro Gln Ser Pro Ala Lys Ala Phe Pro Pro Leu Ser Thr Pro Asn Gln  
 85 90 95  
 Thr Thr Ala Phe Ser Gly Ile Gly Gly Leu Ser Ser Gln Leu Pro Val  
 40 100 105 110 115  
 Gly Gly Leu Gly Thr Gly Ser Leu Thr Gly Ile Gly Thr Gly Ala Leu  
 120 125 130  
 45 Gly Leu Pro Ala Val Asn Asn Asp Pro Phe Val Gln Arg Lys Leu Gly  
 135 140 145  
 Thr Ser Gly Leu Asn Gln Pro Thr Phe Gln Gln Ser Lys Met Lys Pro  
 150 155 160  
 50 Ser Asp Leu Ser Gln Val Trp Pro Glu Ala Asn Gln His Phe Ser Lys  
 165 170 175

55

Glu Ile Asp Asp Glu Ala Asn Ser Tyr Phe Gln Arg Ile Tyr Asn His  
 180 185 190 195  
 5 Pro Pro His Pro Thr Met Ser Val Asp Glu Val Leu Glu Met Leu Gln  
 200 205 210  
 Arg Phe Lys Asp Ser Thr Ile Lys Arg Glu Arg Glu Val Phe Asn Cys  
 215 220 225  
 10 Met Leu Arg Asn Leu Phe Glu Glu Tyr Arg Phe Phe Pro Gln Tyr Pro  
 230 235 240  
 Asp Lys Glu Leu His Ile Thr Ala Cys Leu Phe Gly Gly Ile Ile Glu  
 15 245 250 255  
 Lys Gly Leu Val Thr Tyr Met Ala Leu Gly Leu Ala Leu Arg Tyr Val  
 260 265 270 275  
 20 Leu Glu Ala Leu Arg Lys Pro Phe Gly Ser Lys Met Tyr Tyr Phe Gly  
 280 285 290  
 Ile Ala Ala Leu Asp Arg Phe Lys Asn Arg Leu Lys Asp Tyr Pro Gln  
 295 300 305  
 25 Tyr Cys Gln His Leu Ala Ser Ile Ser His Phe Met Gln Phe Pro His  
 310 315 320  
 His Leu Gln Glu Tyr Ile Glu Tyr Gly Gln Gln Ser Arg Asp Pro Pro  
 325 330 335  
 30 Val Lys Met Gln Gly Ser Ile Thr Thr Pro Gly Ser Ile Ala Leu Ala  
 340 345 350 355  
 Gln Ala Gln Ala Gln Ala Gln Val Pro Ala Lys Ala Pro Leu Ala Gly  
 35 360 365 370  
 Gln Val Ser Thr Met Val Thr Thr Ser Thr Thr Thr Thr Val Ala Lys  
 375 380 385  
 40 Thr Val Thr Val Thr Arg Pro Thr Gly Val Ser Phe Lys Lys Asp Val  
 390 395 400  
 Pro Pro Ser Ile Asn Thr Thr Asn Ile Asp Thr Leu Leu Val Ala Thr  
 405 410 415  
 45 Asp Gln Thr Glu Arg Ile Val Glu Pro Pro Glu Asn Ile Gln Glu Lys  
 420 425 430 435  
 Ile Ala Phe Ile Phe Asn Asn Leu Ser Gln Ser Asn Met Thr Gln Lys  
 440 445 450  
 50 Val Glu Glu Leu Lys Glu Thr Val Lys Glu Glu Phe Met Pro Trp Val  
 455 460 465  
 55



Ser Gln Tyr Leu Val Met Lys Arg Val Ser Ile Glu Pro Asn Phe His  
 470 475 480  
 5 Ser Leu Tyr Ser Asn Phe Leu Asp Thr Leu Lys Asn Pro Glu Phe Asn  
 485 490 495  
 Lys Met Val Leu Asn Glu Thr Tyr Arg Asn Ile Lys Val Leu Leu Thr  
 10 500 505 510 515  
 Ser Asp Lys Ala Ala Ala Asn Phe Ser Asp Arg Ser Leu Leu Lys Asn  
 520 525 530  
 Leu Gly His Trp Leu Gly Met Ile Thr Leu Ala Lys Asn Lys Pro Ile  
 15 535 540 545  
 Leu His Thr Asp Leu Asp Val Lys Ser Leu Leu Leu Glu Ala Tyr Val  
 550 555 560  
 Lys Gly Gln Gln Glu Leu Leu Tyr Val Val Pro Phe Val Ala Lys Val  
 20 565 570 575  
 Leu Glu Ser Ser Ile Arg Ser Val Val Phe Arg Pro Pro Asn Pro Trp  
 580 585 590 595  
 25 Thr Met Ala Ile Met Asn Val Leu Ala Glu Leu His Gln Glu His Asp  
 600 605 610  
 Leu Lys Leu Asn Leu Lys Phe Glu Ile Glu Val Leu Cys Lys Asn Leu  
 30 615 620 625  
 Ala Leu Asp Ile Asn Glu Leu Lys Pro Gly Asn Leu Leu Lys Asp Lys  
 630 635 640  
 Asp Arg Leu Lys Asn Leu Asp Glu Gln Leu Ser Ala Pro Lys Lys Asp  
 35 645 650 655  
 Val Lys Gln Pro Glu Glu Leu Pro Pro Ile Thr Thr Thr Thr Thr Ser  
 660 665 670 675  
 Thr Thr Pro Ala Thr Asn Thr Thr Cys Thr Ala Thr Val Pro Pro Gln  
 40 680 685 690  
 Pro Gln Tyr Ser Tyr His Asp Ile Asn Val Tyr Ser Leu Ala Gly Leu  
 695 700 705  
 45 Ala Pro His Ile Thr Leu Asn Pro Thr Ile Pro Leu Phe Gln Ala His  
 710 715 720  
 Pro Gln Leu Lys Gln Cys Val Arg Gln Ala Ile Glu Arg Ala Val Gln  
 725 730 735  
 50 Glu Leu Val His Pro Val Val Asp Arg Ser Ile Lys Ile Ala Met Thr  
 740 745 750 755

55

Thr Cys Glu Gln Ile Val Arg Lys Asp Phe Ala Leu Asp Ser Glu Glu  
 760 765 770  
 5 Ser Arg Met Arg Ile Ala Ala His His Met Met Arg Asn Leu Thr Ala  
 775 780 785  
 Gly Met Ala Met Ile Thr Cys Arg Glu Pro Leu Leu Met Ser Ile Ser  
 790 795 800  
 10 Thr Asn Leu Lys Asn Ser Phe Ala Ser Ala Leu Arg Thr Ala Ser Pro  
 805 810 815  
 Gln Gln Arg Glu Met Met Asp Gln Ala Ala Ala Gln Leu Ala Gln Asp  
 15 820 825 830 835  
 Asn Cys Glu Leu Ala Cys Cys Phe Ile Gln Lys Thr Ala Val Glu Lys  
 840 845 850  
 20 Ala Gly Pro Glu Met Asp Lys Arg Leu Ala Thr Glu Phe Glu Leu Arg  
 855 860 865  
 Lys His Ala Arg Gln Glu Gly Arg Arg Tyr Cys Asp Pro Val Val Leu  
 870 875 880  
 25 Thr Tyr Gln Ala Glu Arg Met Pro Glu Gln Ile Arg Leu Lys Val Gly  
 885 890 895  
 Gly Val Asp Pro Lys Gln Leu Ala Val Tyr Glu Glu Phe Ala Arg Asn  
 30 900 905 910 915  
 Val Pro Gly Phe Leu Pro Thr Asn Asp Leu Ser Gln Pro Thr Gly Phe  
 920 925 930  
 Leu Ala Gln Pro Met Lys Gln Ala Trp Ala Thr Asp Asp Val Ala Gln  
 35 935 940 945  
 Ile Tyr Asp Lys Cys Ile Thr Glu Leu Glu Gln His Leu His Ala Ile  
 950 955 960  
 Pro Pro Thr Leu Ala Met Asn Pro Gln Ala Gln Ala Leu Arg Ser Leu  
 40 965 970 975  
 Leu Glu Val Val Val Leu Ser Arg Asn Ser Arg Asp Ala Ile Ala Ala  
 980 985 990 995  
 45 Leu Gly Leu Leu Gln Lys Ala Val Glu Gly Leu Leu Asp Ala Thr Ser  
 1000 1005 1010  
 Gly Ala Asp Ala Asp Leu Leu Leu Arg Tyr Arg Glu Cys His Leu Leu  
 1015 1020 1025  
 50 Val Leu Lys Ala Leu Gln Asp Gly Arg Ala Tyr Gly Ser Pro Trp Cys  
 1030 1035 1040

55

	Asn Lys Gln Ile Thr Arg Cys Leu Ile Glu Cys Arg Asp Glu Tyr Lys	
	1045	1050 1055
5	Tyr Asn Val Glu Ala Val Glu Leu Leu Ile Arg Asn His Leu Val Asn	
	1060	1065 1070 1075
	Met Gln Gln Tyr Asp Phe His Leu Ala Gln Ser Met Glu Asn Gly Leu	
	1080	1085 1090
10	Asn Tyr Met Ala Val Ala Phe Ala Met Gln Leu Val Lys Ile Leu Leu	
	1095	1100 1105
	Val Asp Glu Arg Ser Val Ala His Val Thr Glu Ala Asp Leu Phe His	
15	1110	1115 1120
	Thr Ile Glu Thr Leu Met Arg Ile Asn Ala His Ser Arg Gly Asn Ala	
	1125	1130 1135
20	Pro Glu Gly Leu Ser Gln Leu Met Glu Val Val Arg Ser Asn Tyr Glu	
	1140	1145 1150 1155
	Ala Met Ile Asp Arg Ala His Gly Gly Pro Asn Phe Met Met His Ser	
	1160	1165 1170
25	Gly Ile Ser Gln Ala Ser Glu Tyr Asp Asp Pro Pro Gly Leu Arg Glu	
	1175	1180 1185
	Lys Ala Glu Tyr Leu Leu Arg Glu Trp Val Asn Leu Tyr His Ser Ala	
	1190	1195 1200
30	Ala Ala Gly Arg Asp Ser Thr Lys Ala Phe Ser Ala Phe Val Gly Gln	
	1205	1210 1215
	Met His Gln Gln Gly Ile Leu Lys Thr Asp Asp Leu Ile Thr Arg Phe	
35	1220	1225 1230 1235
	Phe Arg Leu Cys Thr Glu Met Cys Val Glu Ile Ser Tyr Arg Ala Gln	
	1240	1245 1250
40	Ala Glu Gln Gln His Asn Pro Ala Ala Asn Pro Thr Met Ile Arg Ala	
	1255	1260 1265
	Lys Cys Tyr His Asn Leu Asp Ala Phe Val Arg Leu Ile Ala Leu Leu	
	1270	1275 1280
45	Val Lys His Ser Gly Glu Ala Thr Asn Thr Val Thr Lys Ile Asn Leu	
	1285	1290 1295
	Leu Asn Lys Val Leu Gly Ile Val Val Gly Val Leu Leu Gln Asp His	
50	1300	1305 1310 1315
	Asp Val Arg Gln Ser Glu Phe Gln Gln Leu Pro Tyr His Arg Ile Phe	
	1320	1325 1330

55

Ile Met Leu Leu Leu Glu Leu Asn Ala Pro Glu His Val Leu Glu Thr  
 1335 1340 1345  
 5 Ile Asn Phe Gln Thr Leu Thr Ala Phe Cys Asn Thr Phe His Ile Leu  
 1350 1355 1360  
 Arg Pro Thr Lys Ala Pro Gly Phe Val Tyr Ala Trp Leu Glu Leu Ile  
 10 1365 1370 1375  
 Ser His Arg Ile Phe Ile Ala Arg Met Leu Ala His Thr Pro Gln Gln  
 1380 1385 1390 1395  
 Lys Gly Trp Pro Met Tyr Ala Gln Leu Leu Ile Asp Leu Phe Lys Tyr  
 15 1400 1405 1410  
 Leu Ala Pro Phe Leu Arg Asn Val Glu Leu Thr Lys Pro Met Gln Ile  
 1415 1420 1425  
 20 Leu Tyr Lys Gly Thr Leu Arg Val Leu Leu Val Leu Leu His Asp Phe  
 1430 1435 1440  
 Pro Glu Phe Leu Cys Asp Tyr His Tyr Gly Phe Cys Asp Val Ile Pro  
 1445 1450 1455  
 25 Pro Asn Cys Ile Gln Leu Arg Asn Leu Ile Leu Ser Ala Phe Pro Arg  
 1460 1465 1470 1475  
 Asn Met Arg Leu Pro Asp Pro Phe Thr Pro Asn Leu Lys Val Asp Met  
 30 1480 1485 1490  
 Leu Ser Glu Ile Asn Ile Ala Pro Arg Ile Leu Thr Asn Phe Thr Gly  
 1495 1500 1505  
 Val Met Pro Pro Gln Phe Lys Lys Asp Leu Asp Ser Tyr Leu Lys Thr  
 35 1510 1515 1520  
 Arg Ser Pro Val Thr Phe Leu Ser Asp Leu Arg Ser Asn Leu Gln Val  
 1525 1530 1535  
 40 Ser Asn Glu Pro Gly Asn Arg Tyr Asn Leu Gln Leu Ile Asn Ala Leu  
 1540 1545 1550 1555  
 Val Leu Tyr Val Gly Thr Gln Ala Ile Ala His Ile His Asn Lys Gly  
 1560 1565 1570  
 45 Ser Thr Pro Ser Met Ser Thr Ile Thr His Ser Ala His Met Asp Ile  
 1575 1580 1585  
 Phe Gln Asn Leu Ala Val Asp Leu Asp Thr Glu Gly Arg Tyr Leu Phe  
 50 1590 1595 1600  
 Leu Asn Ala Ile Ala Asn Gln Leu Arg Tyr Pro Asn Ser His Thr His  
 1605 1610 1615

55

Tyr Phe Ser Cys Thr Met Leu Tyr Leu Phe Ala Glu Ala Asn Thr Glu  
 1620 1625 1630 1635  
 5 Ala Ile Gln Glu Gln Ile Thr Arg Val Leu Leu Glu Arg Leu Ile Val  
 1640 1645 1650  
 Asn Arg Pro His Pro Trp Gly Leu Leu Ile Thr Phe Ile Glu Leu Ile  
 1655 1660 1665  
 10 Lys Asn Pro Ala Phe Lys Phe Trp Asn His Glu Phe Val His Cys Ala  
 1670 1675 1680  
 Pro Glu Ile Glu Lys Leu Phe Gln Ser Val Ala Gln Cys Cys Met Gly  
 1685 1690 1695  
 15 Gln Lys Gln Ala Gln Gln Val Met Glu Gly Thr Gly Ala Ser  
 1700 1705 1710  
 20  
 <210> 59  
 <211> 5178  
 <212> DNA  
 25 <213> Homo sapiens  
  
 <400> 59  
 30 atgttggcct gctgcnaagc ttgtgcaggg agtgtttctc aggagctatc agaaactatc 60  
 ctccaccatgg tagccnnttg cagtaatgtt atgaalaagg ccagacaacc accaccitgga 120  
 gttatgccaa aaggacgtcc tccctagtgct agcagcittag atgccatttc tccctgttcag 180  
 attgaccttc ttgtcggaaat gacatctctc agtatagggtg gticagctgc cccctcacacc 240  
 35 cagagtatgc agggitttcc tccaaatttg ggttctgcat tcagtacccc tcagtcacca 300  
 gcaaaagcni tccacccct ticaaccccc aatcagacca ctgcattcag tgggtattgga 360  
 ggactttcat cacagcttcc agtaggtggt ctggcacag gcagccctgac tgggtalagga 420  
 actgggtgctc ttggactccc tgcagtgaaat aacgaccttt ttgtacagag gaaactgggc 480  
 40 acctctggac tgaatcagcc tacattccag cagaglaaga tgaaccttc ggacttgtct 540  
 caggttggc cagaggaana ccagcacitt agtaaagaga tagatgta agcaaacagc 600  
 tatttccagc gaattatata tcatccacca catccnacca tgtctgttga tgaagtatta 660  
 gaaatgtgc agagattta agactctact aiaangggg aacgagaagt attaacgtt 720  
 45 atgclaagga acttgttga agaatactgt tttttcccc agtatccga taaagugtta 780  
 catataacag ccctccatit tgggtgtata attgagaaag gacttggtcnc ttacatggcn 840  
 ctaggctcgg ctctacgata tttcttga ggcctacgca agccttttgg atccnaattg 900  
 50 tattatttcg gttatgtgc actagataga tttaaaaca gattgaagga ctatccccc 960  
 tatgtcanc atttggcttc tatcagtcac ttatggcni tccacatca ttacaggg 1020

55

5      tataligagl atggacagca gtctagagat cctcctgtga aaatgcaagg ctctatcaca 1080  
 accccigga gttatgcact ggctcaggcc caggctcagg cccaggttcc agcaaaagct 1140  
 cctcttgctg gtcaagttag cactatggta accacctcaa caactaccac tgttgctaaa 1200  
 acgggttacgg tcaccaggcc aactggagtc agctttaaga aagatgtgcc accttctatt 1260  
 aatactacaa atatagatac gttagcttgg gccacagatc aaactgagag aattgtggag 1320  
 10      cccccagaaa atatccagga gaaaattgct tttattttca ataactcttc acagtcacaa 1380  
 atgacacaaa aggttgaaga gctaaaggaa acggtgaaag aagaatttat gccttgggtt 1440  
 tcacagtatc tggttatgaa gagagtcagt attgagccaa actttcatag cctgtattca 1500  
 aacttcttg acacgtcgaa gaactctgaa tttacaaga tggttctgaa tgagacctac 1560  
 15      agaaacatta aagtgtcctt gacctctgat aaagctgcag ccaatttctc agatcgttct 1620  
 ttgctgaaga acttgggaca ttggctagga atgatacat tagctaaaaa caaacccatc 1680  
 ttacacactg acttggatgt gaaatcattg ctgctagagg ctatgttaa aggacaacaa 1740  
 gaattgtctt atgtatgtcc ctttgttgcc aaagctttag aatctagcat tctagtgtg 1800  
 20      gtttttaggc caccaaaccc ttggacaatg gcaattatga atgtattagc tgagctacat 1860  
 caggagcatg acttaaggtt aaacttgaag ttgaaatcg aggttctctg caagaacctt 1920  
 gcattagaca tcaatgagct aaaacctgga aacctcttaa agataaaga tgcctgaag 1980  
 25      aatttagatg agcaactctc tgctccaaag aaagatgtca agcagccaga agaactcctt 2040  
 cccatcaca ccacaacaac ttctactaca ccagctacca acaccacttg tacagccacg 2100  
 gtccaccac agccacagta cagctaccac gacatcaatg tctattccct tgcgggcttg 2160  
 30      gcaccacaca ttacttcgaa tccaacaatt ccttgttctc aggcccatcc acagtgaag 2220  
 cagtggtgct gtcaggcaat tgaacgggct gtccaggagc tggctccatcc tgggttgat 2280  
 cgtacatta agattgccat gactacttgt gagcaaatag tcaggaagga ttttgccctg 2340  
 gattcggagg aatctcgaat gcgaatagca gctatcaca tgaatcgtaa cttagacgtt 2400  
 35      ggaatggcta tgattacatg cagggaacct ttgtctatga gcatactac caacttaaaa 2460  
 aacagtittg cctcagccct tctacttgtt tcccacaaac aaagagaaat gatggatcag 2520  
 gcagctgctc aattagctca ggacaattgt gatttggctt gctgttttat tcagaagact 2580  
 gcagtagaaa aagcaggccc tgagatggac aagagattag caacigaatt tgagctgaga 2640  
 40      aahcatgcta ggcaagaagg acgcagatc tgtgatcctg ttgttttaac atatcaagct 2700  
 gnacggatgc cagagcaaat caggctgann gtgggtgggt tggaccacaa gcagtggctt 2760  
 gtttatgag agtttgcacg caatgttctt ggcttcttac ctacaaatga cttaagtcag 2820  
 45      cccacgggat ttttagccca gcccatgng caagcttggg caacagatga ttagctcag 2880  
 atttatgata agtgtattac agaactggag caacatctac atgcatccc accaactttg 2940  
 gccntgnac ctcaagctca ggctcttcca agtctcttgg aggtttagt tttatctcga 3000  
 auctctcggg atgcatagc tgccttggg ttgcctcann aggcctgaga gggttacta 3060  
 50      gttgcacann gtgtgtcga tgcctacat ctgtctgctt acagggatg ccactcttg 3120  
 gtcctannng ctctgcagga tggcgggca tatgggtctc catgttgcnn caatcagtc 3180

55

5 acaagggtgcc taattgaatg tcgagatgaa tataaatata atgtggaggc tctggagctg 3240  
 ctaattcgca atcatttggc taatatgcag cagtatgatt ttcacctagc gcagtcacg 3300  
 gagaatggct taaactacat ggctgtggca ttgctatgc agttagtaaa aatccigctg 3360  
 gtggatgaaa ggagtgttgc tcatgttact gaggcagatc tgtccacac cattgaaacc 3420  
 ctcattgagga ttaatgctca ttccagaggc aatgctccag aaggattgtc ccagctgatg 3480  
 10 gaagtagtgc gatccaacta tgaagcaatg attgatcgig ctcattggagg cccaaacitl 3540  
 atgaigcatt ctgggatctc tcaagcctca gagtatgatg accctccagg cctgaggag 3600  
 aaggcagagt atcttctgag ggaatgggtg aatctctacc attcagcagc agctggccgc 3660  
 gacagtacca aagctttctc tgcatttgtt ggacagatgc accagcaagg aatactgaag 3720  
 15 accgatgac tcataacaag gttctttcgt ctgtgtactg aatgtgtgt tgaatcagt 3780  
 taccgigctc aggtgagca gcagcacaat cctgtgcca atcccaccat galccgagcc 3840  
 aagtgtatc acaacctgga tgcctttgtt cgactcattg cactgtctgt gaaacacica 3900  
 20 ggggaggcca ccaacactgt cacaagatt aatctgtga scaaggctct tggatatga 3960  
 gtgggagtic tccitcagga tcatgatgtt cgtcagatg aattcagca acttccctac 4020  
 catcgaattt ttatcatgct tctcttgaa ctcaatgcac ctgagcatgt gttggaacc 4080  
 attaatctc agacacttac agctttctgc aatacatcc acatcttgag gcctaccaaa 4140  
 25 gctcctggct ttgtatatgc ctggcttgaa ctgatttccc atcgatatt tatlgcaaga 4200  
 atgtggcac atacgccaca gcagaagggtg tggcctatgt atgcacagct actgattgat 4260  
 ttattcaaat atttagcgc ttctcttga aatgtggaac tcaccaaac tatgcaaac 4320  
 30 ctctacaagg gcactttaag agtgcgtgt gtcttttgc atgatttccc agagttctt 4380  
 tctgattacc attatgggtt ctgtgatgt atcccaccia attgtatcca gttangaat 4440  
 ttgatctga gtcctttcc aagaacatg aggtctcccg acccattcac tctaatcta 4500  
 aagggtgaca ttttagtga aattaacat gtctcccgga ttctaccaaa ttctactgga 4560  
 35 gtaatgccac ctgattcaa aaaggattg gattctatc ttaaaactcg atcaccagtc 4620  
 actttctgt ctgatctgcg cagcaacctc caggatcca atgaacctg gaatcgctac 4680  
 aacctccagc tcatcaatgc actgggtctc tatgtcgga ctacggccat tgcgcacac 4740  
 40 cacaacaagg gcagcacacc ttcaatgagc accatcacac actcagcaca catggatc 4800  
 ttccagaatt tggctgtgga ctggacact gagggtcgt atctctttt gaatgcaat 4860  
 gcaaatcagc tccggtacc aaatagccac actcactact tcagtgcac catgctgtac 4920  
 ctlttgcag aggccaatc ggaagccac caagancaga tcacaagat tcttltgaa 4980  
 45 cggttgattg taataggcc acatcttgg ggtcttcta ttacctcat tgactgatt 5040  
 aanaaccag cgtttaagtt ctggaacct gaatttgc acgtgcccc agaaatcga 5100  
 aagtatccc agtcggtgc acagtgcgc atgggacga ngcaggccca gcaagtatg 5160  
 50 gagggtacag gtcctagt 5178

&lt;210&gt; 60

55

<211> 5457  
 <212> DNA  
 5 <213> Homo sapiens  
  
 <200>  
 10 <221> CDS  
 <222> (8).. (5185)  
  
 <220>  
 15 <221> sig peptide  
 <222> (8).. (46)  
  
 <220>  
 20 <221> mat peptide  
 <222> (47).. (5185)  
  
 25 <400> 60  
 ggcgaca atg ttg gcc tgt ctg caa gct tgt gca ggg agt gtt tct cag 49  
 Met Leu Ala Cys Leu Gln Ala Cys Ala Gly Ser Val Ser Gln  
 -13 -10 -5 1  
 30 gag cta tca gaa act atc ctc acc atg gta gcc aat tgc agt aat gtt 97  
 Glu Leu Ser Glu Thr Ile Leu Thr Met Val Ala Asn Cys Ser Asn Val  
 5 10 15  
 35 atg aat aag gcc aga caa cca cca cct gga gtt atg cca aaa gga cgt 145  
 Met Asn Lys Ala Arg Gln Pro Pro Pro Gly Val Met Pro Lys Gly Arg  
 20 25 30  
 40 cct cct agt gct agc agc tta gat gcc att tct cct gtt cag att gac 193  
 Pro Pro Ser Ala Ser Ser Leu Asp Ala Ile Ser Pro Val Gln Ile Asp  
 35 40 45  
 45 cct ctt gct gga atg aca tct ctt agt ata ggt ggt tca gct gcc cct 241  
 Pro Leu Ala Gly Met Thr Ser Leu Ser Ile Gly Gly Ser Ala Ala Pro  
 50 55 60 65  
 cac acc cag agt atg cag ggt ttt cct cca aat ttg ggt tct gca ttc 289  
 His Thr Gln Ser Met Gln Gly Phe Pro Pro Asn Leu Gly Ser Ala Phe  
 50 70 75 80  
 agt acc cct cag tca cca gca aat gca ttt cca ccc ctt tca acc ccc 337

55



	Ser Thr Pro Gln Ser Pro Ala Lys Ala Phe Pro Pro Leu Ser Thr Pro	
	85 90 95	
5	aat cag acc act gca ttc agt ggt att gga gga ctt tca tca cag ctt	385
	Asn Gln Thr Thr Ala Phe Ser Gly Ile Gly Gly Leu Ser Ser Gln Leu	
	100 105 110	
10	cca gta ggt ggt ctt ggc aca ggc agc ctg act ggt ata gga act ggt	433
	Pro Val Gly Gly Leu Gly Thr Gly Ser Leu Thr Gly Ile Gly Thr Gly	
	115 120 125	
	gct ctt gga ctc cct gca gtg aat aac gac cct ttt gta cag agg aaa	481
15	Ala Leu Gly Leu Pro Ala Val Asn Asn Asp Pro Phe Val Gln Arg Lys	
	130 135 140 145	
	ctg ggc acc tct gga ctg aat cag cct aca ttc cag cag agt aag atg	529
20	Leu Gly Thr Ser Gly Leu Asn Gln Pro Thr Phe Gln Gln Ser Lys Met	
	150 155 160	
	aaa cct tcg gac ttg tct cag gtg tgg cca gag gca aac cag cac ttt	577
	Lys Pro Ser Asp Leu Ser Gln Val Trp Pro Glu Ala Asn Gln His Phe	
25	165 170 175	
	agt aaa gag ata gat gat gaa gca aac agc tat ttc cag cga ata tat	625
	Ser Lys Glu Ile Asp Asp Glu Ala Asn Ser Tyr Phe Gln Arg Ile Tyr	
	180 185 190	
30	aat cat cca cca cat cca acc atg tct gtt gat gag glu tta gaa atg	673
	Asn His Pro Pro His Pro Thr Met Ser Val Asp Glu Val Leu Glu Met	
	195 200 205	
35	ctg cag aga ttt aaa gac tct act ata aag agg gaa cga gaa gta ttt	721
	Leu Gln Arg Phe Lys Asp Ser Thr Ile Lys Arg Glu Arg Glu Val Phe	
	210 215 220 225	
40	aac tgt atg cta agg aac ttg ttt gaa gaa tat cgt ttt ttt ccc cag	769
	Asn Cys Met Leu Arg Asn Leu Phe Glu Glu Tyr Arg Phe Phe Pro Gln	
	230 235 240	
	tat cct gat aaa gag tta cat ata aca gcc tgc cta ttt ggt ggt ata	817
45	Tyr Pro Asp Lys Glu Leu His Ile Thr Ala Cys Leu Phe Gly Gly Ile	
	245 250 255	
	att gag aac gga ctg gtc act tac atg gca cta ggt ctg gct cta cga	865
50	Ile Glu Lys Gly Leu Val Thr Tyr Met Ala Leu Gly Leu Ala Leu Arg	
	260 265 270	
	tat gtt ctt gaa gcc tta cgc aag cct ttt gga tcc aaa atg tat tat	913

Tyr Val Leu Glu Ala Leu Arg Lys Pro Phe Gly Ser Lys Met Tyr Tyr  
 275 280 285  
 5 ttc ggg att gct gca cta gat aga ttt aaa aac aga ttg aag gac tat 961  
 Phe Gly Ile Ala Ala Leu Asp Arg Phe Lys Asn Arg Leu Lys Asp Tyr  
 290 295 300 305  
 10 ccc cag tat tgt caa cat ttg gct tct atc agt cac ttt atg caa ttt 1009  
 Pro Gln Tyr Cys Gln His Leu Ala Ser Ile Ser His Phe Met Gln Phe  
 310 315 320  
 15 cca cat cat tta cag gag tat att gag tat gga cag cag tct aga gat 1057  
 Pro His His Leu Gln Glu Tyr Ile Glu Tyr Gly Gln Gln Ser Arg Asp  
 325 330 335  
 20 cct cct gtg aaa atg caa ggc tct atc aca acc cct gga agt att gca 1105  
 Pro Pro Val Lys Met Gln Gly Ser Ile Thr Thr Pro Gly Ser Ile Ala  
 340 345 350  
 25 ctg gct cag gcc cag gct cag gcc cag gtt cca gca aaa gct cct ctt 1153  
 Leu Ala Gln Ala Gln Ala Gln Ala Gln Val Pro Ala Lys Ala Pro Leu  
 355 360 365  
 30 gct ggt caa gtt agc act atg gta acc acc tca aca act acc act gtt 1201  
 Ala Gly Gln Val Ser Thr Met Val Thr Thr Ser Thr Thr Thr Val  
 370 375 380 385  
 gct aaa acg gtt acg gtc acc agg cca act gga gtc agc ttt aag aaa 1249  
 Ala Lys Thr Val Thr Val Thr Arg Pro Thr Gly Val Ser Phe Lys Lys  
 390 395 400  
 35 gat gtg cca cct tct att aat act aca aat ata gat acg ttg ctt gtg 1297  
 Asp Val Pro Pro Ser Ile Asn Thr Thr Asn Ile Asp Thr Leu Leu Val  
 405 410 415  
 40 gcc aca gat caa act gag aga att gtg gag ccc cca gaa aat atc cag 1345  
 Ala Thr Asp Gln Thr Glu Arg Ile Val Glu Pro Pro Glu Asn Ile Gln  
 420 425 430  
 45 gag aaa att gct ttt att ttc aat aat ctc tca cag tca aat atg aca 1393  
 Glu Lys Ile Ala Phe Ile Phe Asn Asn Leu Ser Gln Ser Asn Met Thr  
 435 440 445  
 50 cna aag gtt gaa gag cta aag gaa acg gtg aaa gaa gaa ttt atg cct 1441  
 Gln Lys Val Glu Glu Leu Lys Glu Thr Val Lys Glu Glu Phe Met Pro  
 450 455 460 465  
 tgg gtt tca cag tat ctg gtt atg aag aga gtc agt att gag cca aac 1489

55

	Trp Val Ser Gln Tyr Leu Val Met Lys Arg Val Ser Ile Glu Pro Asn	
	470 475 480	
5	ttt cat agc ctg tat tca aac ttc ctt gac acg ctg aag aat cct gaa	1537
	Phe His Ser Leu Tyr Ser Asn Phe Leu Asp Thr Leu Lys Asn Pro Glu	
	485 490 495	
10	ttt aac aag atg gtt ctg aat gag acc tac aga aac att aaa gtg ctc	1585
	Phe Asn Lys Met Val Leu Asn Glu Thr Tyr Arg Asn Ile Lys Val Leu	
	500 505 510	
15	ctg acc tct gat aaa gct gca gcc aat ttc tca gat cgt tct ttg ctg	1633
	Leu Thr Ser Asp Lys Ala Ala Ala Asn Phe Ser Asp Arg Ser Leu Leu	
	515 520 525	
	aag aac ttg gga cat tgg cta gga atg atc aca tta gct aaa aac aaa	1681
20	Lys Asn Leu Gly His Trp Leu Gly Met Ile Thr Leu Ala Lys Asn Lys	
	530 535 540 545	
	ccc atc tta cac act gac ttg gat gtg aaa tca ttg ctg cta gag gct	1729
	Pro Ile Leu His Thr Asp Leu Asp Val Lys Ser Leu Leu Leu Glu Ala	
25	550 555 560	
	tat gtt aaa gga caa caa gaa ttg ctc tat gta gtg ccc ttt gtt gcc	1777
	Tyr Val Lys Gly Gln Gln Glu Leu Leu Tyr Val Val Pro Phe Val Ala	
	565 570 575	
30	aaa gtc tta gaa tct agc att cgt hgt xtg gtt ttt agg cca cca aac	1825
	Lys Val Leu Glu Ser Ser Ile Arg Ser Val Val Phe Arg Pro Pro Asn	
	580 585 590	
35		
	cct tgg aca atg gca att atg aat gla tta gct gag cta cat cag gag	1873
	Pro Trp Thr Met Ala Ile Met Asn Val Leu Ala Glu Leu His Gln Glu	
	595 600 605	
40	cat gac tta aag tta aac ttg ang ttt gaa atc gag gtt ctc tgc aag	1921
	His Asp Leu Lys Leu Asn Leu Lys Phe Glu Ile Glu Val Leu Cys Lys	
	610 615 620 625	
45	aac ctt gca tta gac atc aat gag cta aaa cct gga aac ctc cta aag	1969
	Asn Leu Ala Leu Asp Ile Asn Glu Leu Lys Pro Gly Asn Leu Leu Lys	
	630 635 640	
50	ggt aaa ggt cgc ctg nag aat tta ggt gag cat ctc tct gct cca aag	2017
	Asp Lys Asp Arg Leu Lys Asn Leu Asp Glu Gln Leu Ser Ala Pro Lys	
	645 650 655	

55

	aaa gat gtc aag cag cca gaa gaa ctc cct ccc atc aca acc aca aca	2065
	Lys Asp Val Lys Gln Pro Glu Glu Leu Pro Pro Ile Thr Thr Thr Thr	
5	660 665 670	
	act tct act aca cca gct acc aac acc act tgt aca gcc acg gtt cca	2113
	Thr Ser Thr Thr Pro Ala Thr Asn Thr Thr Cys Thr Ala Thr Val Pro	
10	675 680 685	
	cca cag cca cag tac agc tac cac gac atc aat gtc tat tcc ctt gcg	2161
	Pro Gln Pro Gln Tyr Ser Tyr His Asp Ile Asn Val Tyr Ser Leu Ala	
	690 695 700 705	
15	ggc ttg gca cca cac att act ctg aat cca aca att ccc ttg ttt cag	2209
	Gly Leu Ala Pro His Ile Thr Leu Asn Pro Thr Ile Pro Leu Phe Gln	
	710 715 720	
20	gcc cat cca cag ttg aag cag tgt gtg cgt cag gca att gaa cgg gct	2257
	Ala His Pro Gln Leu Lys Gln Cys Val Arg Gln Ala Ile Glu Arg Ala	
	725 730 735	
25	gtc cag gag ctg gtc cat cct gtg gtg gat cga tca att aag att gcc	2305
	Val Gln Glu Leu Val His Pro Val Val Asp Arg Ser Ile Lys Ile Ala	
	740 745 750	
30	atg act act tgt gag caa ata gtc agg aag gat ttt gcc ctg gat tgc	2353
	Met Thr Thr Cys Glu Gln Ile Val Arg Lys Asp Phe Ala Leu Asp Ser	
	755 760 765	
35	gag gaa tct cga atg cga ata gca gct cat cac atg atg cgt aac ttg	2401
	Glu Glu Ser Arg Met Arg Ile Ala Ala His His Met Met Arg Asn Leu	
	770 775 780 785	
	aca gct gga atg gct atg att aca tgc agg gaa cct ttg ctc atg agc	2449
	Thr Ala Gly Met Ala Met Ile Thr Cys Arg Glu Pro Leu Leu Met Ser	
	790 795 800	
40	ata tct acc aac tta aaa aac agt ttt gcc tca gcc ctt cgt act gct	2497
	Ile Ser Thr Asn Leu Lys Asn Ser Phe Ala Ser Ala Leu Arg Thr Ala	
	805 810 815	
45	tcc cca caa caa aga gaa atg atg gat cag gca gct gct caa tta gct	2545
	Ser Pro Gln Gln Arg Glu Met Met Asp Gln Ala Ala Ala Gln Leu Ala	
	820 825 830	
50	cag gac aat tgt ggg ttg gct tgc tgt ttt att cag aag aet gca gln	2593
	Gln Asp Asn Cys Glu Leu Ala Cys Cys Phe Ile Gln Lys Thr Ala Val	
	835 840 845	
55		

	gaa aaa gca ggc cct gag atg gac aag aga tta gca act gaa ttt gag	2641
	Glu Lys Ala Gly Pro Glu Met Asp Lys Arg Leu Ala Thr Glu Phe Glu	
5	850                      855                      860                      865	
	ctg aga aaa cat gct agg caa gaa gga cgc aga tac tgt gat cct gtt	2689
	Leu Arg Lys His Ala Arg Gln Glu Gly Arg Arg Tyr Cys Asp Pro Val	
10	870                      875                      880	
	gtt tta aca tat caa gct gaa cgg atg cca gag caa atc agg ctg aaa	2737
	Val Leu Thr Tyr Gln Ala Glu Arg Met Pro Glu Gln Ile Arg Leu Lys	
	885                      890                      895	
15	gtt ggt ggt gtg gac cca aag cag ttg gct gtt tat gaa gag ttt gca	2785
	Val Gly Gly Val Asp Pro Lys Gln Leu Ala Val Tyr Glu Glu Phe Ala	
	900                      905                      910	
20	cgc aat gtt cct ggc ttc tta cct aca aat gac tta agt cag ccc acg	2833
	Arg Asn Val Pro Gly Phe Leu Pro Thr Asn Asp Leu Ser Gln Pro Thr	
	915                      920                      925	
25	gga ttt tta gcc cag ccc atg aag caa gct tgg gca aca gat gat gta	2881
	Gly Phe Leu Ala Gln Pro Met Lys Gln Ala Trp Ala Thr Asp Asp Val	
	930                      935                      940                      945	
	gct cag att tat gat aag tgt att aca gaa ctg gag caa cat cta cat	2929
	Ala Gln Ile Tyr Asp Lys Cys Ile Thr Glu Leu Glu Gln His Leu His	
30	950                      955                      960	
	gcc atc cca cca act ttg gcc atg aac cct caa gct cag gct ctt cga	2977
	Ala Ile Pro Pro Thr Leu Ala Met Asn Pro Gln Ala Gln Ala Leu Arg	
35	965                      970                      975	
	agt ctc ttg gag gtt gta gtt tta tct cga aac tct cgg gat gcc ata	3025
	Ser Leu Leu Glu Val Val Val Leu Ser Arg Asn Ser Arg Asp Ala Ile	
	980                      985                      990	
40	gct gct ctt gga ttg ctc caa nag gct gta gag ggc tta cta gat gcc	3073
	Ala Ala Leu Gly Leu Leu Gln Lys Ala Val Glu Gly Leu Leu Asp Ala	
	995                      1000                      1005	
45	aca agt ggt gct gat gct gac ctt ctg ctg cgc tac agg gaa tgc cnc	3121
	Thr Ser Gly Ala Asp Ala Asp Leu Leu Leu Arg Tyr Arg Glu Cys His	
	1010                      1015                      1020                      1025	
50	ctc ttg gtc cta aaa gct ctg cag gat ggc cgg gcn tat ggg tct ccu	3169
	Leu Leu Val Leu Lys Ala Leu Gln Asp Gly Arg Ala Tyr Gly Ser Pro	
	1030                      1035                      1040	

	tgg tgc aac aaa cag atc aca agg tgc cta att gaa tgt cga gat gaa	3217
	Trp Cys Asn Lys Gln Ile Thr Arg Cys Leu Ile Glu Cys Arg Asp Glu	
5	1045 1050 1055	
	tat aaa tat aat gtg gag gct gtg gag ctg cta att cgc aat cat ttg	3265
	Tyr Lys Tyr Asn Val Glu Ala Val Glu Leu Leu Ile Arg Asn His Leu	
10	1060 1065 1070	
	glt aat atg cag cag tat gat ttt cac cta gcg cag tca atg gag aat	3313
	Val Asn Met Gln Gln Tyr Asp Phe His Leu Ala Gln Ser Met Glu Asn	
	1075 1080 1085	
15	ggc tta aac tac atg gct gtg gca ttt gct atg cag tta gta aaa atc	3361
	Gly Leu Asn Tyr Met Ala Val Ala Phe Ala Met Gln Leu Val Lys Ile	
	1090 1095 1100 1105	
20	ctg ctg gtg gat gaa agg agt gtt gct cat gtt act gag gca gat ctg	3409
	Leu Leu Val Asp Glu Arg Ser Val Ala His Val Thr Glu Ala Asp Leu	
	1110 1115 1120	
25	ttc cac acc att gaa acc ctc atg agg att aat gct cat tcc aga ggc	3457
	Phe His Thr Ile Glu Thr Leu Met Arg Ile Asn Ala His Ser Arg Gly	
	1125 1130 1135	
30	aat gct cca gaa gga ttg tcc cag ctg atg gaa gta gtg cga tcc aac	3505
	Asn Ala Pro Glu Gly Leu Ser Gln Leu Met Glu Val Val Arg Ser Asn	
	1140 1145 1150	
	tat gaa gca atg att gat cgt gct cat gga ggc cca aac ttt atg atg	3553
	Tyr Glu Ala Met Ile Asp Arg Ala His Gly Gly Pro Asn Phe Met Met	
35	1155 1160 1165	
	cat tct ggg atc tct caa gcc tca gag tat gat gac cct cca ggc ctg	3601
	His Ser Gly Ile Ser Gln Ala Ser Glu Tyr Asp Asp Pro Pro Gly Leu	
40	1170 1175 1180 1185	
	agg gag aag gca gag tat ctt ctg agg gaa tgg gtg aat ctc tac cat	3649
	Arg Glu Lys Ala Glu Tyr Leu Leu Arg Glu Trp Val Asn Leu Tyr His	
	1190 1195 1200	
45	tca gca gca gct ggc cgc gac agt acc aaa gct ttc tct gca ttt gtt	3697
	Ser Ala Ala Ala Gly Arg Asp Ser Thr Lys Ala Phe Ser Ala Phe Val	
	1205 1210 1215	
50	gga cag atg cnc cng cna gga atn ctg aag acc gat gat ctc ata aca	3745
	Gly Gln Met His Gln Gln Gly Ile Leu Lys Thr Asp Asp Leu Ile Thr	
	1220 1225 1230	

5      agg ttc ttt cgt ctg tgt act gaa atg tgt gtt gaa atc agt tac cgt    3793  
       Arg Phe Phe Arg Leu Cys Thr Glu Met Cys Val Glu Ile Ser Tyr Arg  
          1235                      1240                      1245  
 10      gct cag gct gag cag cag cac aat cct gct gcc aat ccc acc atg atc    3841  
       Ala Gln Ala Glu Gln Gln His Asn Pro Ala Ala Asn Pro Thr Met Ile  
          1250                      1255                      1260                      1265  
       cga gcc aag tgc tat cac aac ctg gat gcc ttt gtt cga ctc att gca    3889  
       Arg Ala Lys Cys Tyr His Asn Leu Asp Ala Phe Val Arg Leu Ile Ala  
                          1270                      1275                      1280  
 15      ctg ctc gtg aaa cac tca ggg gag gcc acc aac act gtc aca aag att    3937  
       Leu Leu Val Lys His Ser Gly Glu Ala Thr Asn Thr Val Thr Lys Ile  
                          1285                      1290                      1295  
 20      aat ctg ctg aac aag gtc ctt ggt ata gta gtg gga gtt ctc ctt cag    3985  
       Asn Leu Leu Asn Lys Val Leu Gly Ile Val Val Gly Val Leu Leu Gln  
                          1300                      1305                      1310  
 25      gat cat gat gtt cgt cag agt gaa ttt cag caa ctt ccc tac cat cga    4033  
       Asp His Asp Val Arg Gln Ser Glu Phe Gln Gln Leu Pro Tyr His Arg  
                          1315                      1320                      1325  
 30      att ttt atc atg ctt ctc ttg gaa ctc aat gca cct gag cat gtg ttg    4081  
       Ile Phe Ile Met Leu Leu Leu Glu Leu Asn Ala Pro Glu His Val Leu  
                          1330                      1335                      1340                      1345  
       gaa acc att aat ttc cag aca ctt aca gct ttc tgc aat aca ttc cac    4129  
       Glu Thr Ile Asn Phe Gln Thr Leu Thr Ala Phe Cys Asn Thr Phe His  
                          1350                      1355                      1360  
 35      atc ttg agg cct acc aaa gct cct ggc ttt gta tat gcc tgg ctt gaa    4177  
       Ile Leu Arg Pro Thr Lys Ala Pro Gly Phe Val Tyr Ala Trp Leu Glu  
                          1365                      1370                      1375  
 40      ctg att tcc cat cgg ata ttt att gca aga atg ctg gca cat acg cca    4225  
       Leu Ile Ser His Arg Ile Phe Ile Ala Arg Met Leu Ala His Thr Pro  
                          1380                      1385                      1390  
 45      cag cag aag ggg tgg cct atg tal gca cag cta ctg att gat tta ttc    4273  
       Gln Gln Lys Gly Trp Pro Met Tyr Ala Gln Leu Leu Ile Asp Leu Phe  
                          1395                      1400                      1405  
 50      aaa tal tta gcg cct ttc ctt agn aat gtg gaa ctc acc aaa cct atg    4321  
       Lys Tyr Leu Ala Pro Phe Leu Arg Asn Val Glu Leu Thr Lys Pro Met  
                          1410                      1415                      1420                      1425  
 55

5                   caa atc ctc tac aag ggc act tta aga gtg ctg ctg gtt ctt ttg cat   4369  
                   Gln Ile Leu Tyr Lys Gly Thr Leu Arg Val Leu Leu Val Leu Leu His  
                                   1430                   1435                   1440  
                   gat ttc cca gag ttc ctt tgt gat tac cat tat ggg ttc tgt gat gtg   4417  
                   Asp Phe Pro Glu Phe Leu Cys Asp Tyr His Tyr Gly Phe Cys Asp Val  
                                   1445                   1450                   1455  
 10                   atc cca cct aat tgt atc cag tta aga aat ttg atc ctg agt gcc ttt   4465  
                   Ile Pro Pro Asn Cys Ile Gln Leu Arg Asn Leu Ile Leu Ser Ala Phe  
                                   1460                   1465                   1470  
 15                   cca aga aac atg agg ctc ccc gac cca ttc act cct aat cta aag gtg   4513  
                   Pro Arg Asn Met Arg Leu Pro Asp Pro Phe Thr Pro Asn Leu Lys Val  
                                   1475                   1480                   1485  
 20                   gac atg ttg agt gaa att aac att gct ccc cgg att ctc acc aat ttc   4561  
                   Asp Met Leu Ser Glu Ile Asn Ile Ala Pro Arg Ile Leu Thr Asn Phe  
                                   1490                   1495                   1500                   1505  
 25                   act gga gta atg cca cct cag ttc aaa aag gat ttg gat tcc tat ctt   4609  
                   Thr Gly Val Met Pro Pro Gln Phe Lys Lys Asp Leu Asp Ser Tyr Leu  
                                   1510                   1515                   1520  
 30                   aaa act cga tca cca gtc act ttc ctg tct gat ctg cgc agc aac cta   4657  
                   Lys Thr Arg Ser Pro Val Thr Phe Leu Ser Asp Leu Arg Ser Asn Leu  
                                   1525                   1530                   1535  
 35                   cag gta tcc aat gaa cct ggg aat cgc tac aac ctc cag ctc atc aat   4705  
                   Gln Val Ser Asn Glu Pro Gly Asn Arg Tyr Asn Leu Gln Leu Ile Asn  
                                   1540                   1545                   1550  
 40                   gca ctg gtg ctc tat gtc ggg act cag gcc att gcg cac atc cac aac   4753  
                   Ala Leu Val Leu Tyr Val Gly Thr Gln Ala Ile Ala His Ile His Asn  
                                   1555                   1560                   1565  
 45                   aag ggc agc aca cct tca atg agc acc atc act cac tca gca cac atg   4801  
                   Lys Gly Ser Thr Pro Ser Met Ser Thr Ile Thr His Ser Ala His Met  
                                   1570                   1575                   1580                   1585  
 50                   gnt atc ttc cag aat ttg gct gtg gac ttg gac act gag ggt cgc tat   4849  
                   Asp Ile Phe Gln Asn Leu Ala Val Asp Leu Asp Thr Glu Gly Arg Tyr  
                                   1590                   1595                   1600  
 55                   ctc ttc ttg aat gca att gca aat cag ctc cgg tac cca aat agc cac   4897  
                   Leu Phe Leu Asn Ala Ile Ala Asn Gln Leu Arg Tyr Pro Asn Ser His  
                                   1605                   1610                   1615



act cac tac ttc agt tgc acc atg ctg tac ctt ttt gca gag gcc aat 4945  
 Thr His Tyr Phe Ser Cys Thr Met Leu Tyr Leu Phe Ala Glu Ala Asn  
 5 1620 1625 1630  
 acg gaa gcc atc caa gaa cag atc aca aga gtt ctc ttg gaa cgg ttg 4993  
 Thr Glu Ala Ile Gln Glu Gln Ile Thr Arg Val Leu Leu Glu Arg Leu  
 10 1635 1640 1645  
 att gta aat agg cca cat cct tgg ggt ctt ctt att acc ttc att gag 5041  
 Ile Val Asn Arg Pro His Pro Trp Gly Leu Leu Ile Thr Phe Ile Glu  
 1650 1655 1660 1665  
 15 ctg att aaa aac cca gcg ttt aag ttc tgg aac cat gaa ttt gta cac 5089  
 Leu Ile Lys Asn Pro Ala Phe Lys Phe Trp Asn His Glu Phe Val His  
 1670 1675 1680  
 20 tgt gcc cca gaa atc gaa aag tta ttc cag tgc gtc gca cag tgc tgc 5137  
 Cys Ala Pro Glu Ile Glu Lys Leu Phe Gln Ser Val Ala Gln Cys Cys  
 1685 1690 1695  
 25 atg gga cag aag cag gcc cag caa gta atg gaa ggg aca ggt gcc agt 5185  
 Met Gly Gln Lys Gln Ala Gln Gln Val Met Glu Gly Thr Gly Ala Ser  
 1700 1705 1710  
 tagacgaaac tgcattctctg ttgtactgt cagtctagag gtctcactgc accgagttca 5245  
 30 taaactgact gaagaatcct ttcagctcct cctgactttc ccagcccttt gglttgggg 5305  
 tatctgcccc aactactgtt gggatcagcc tccigtctta tgtgggcacg tttccaaagt 5365  
 taaatgcatt ttttgcact ttggccaaaa tttagagat gcctggnata tcaatttgaa 5425  
 ctgtgtaaa tacatgaaaa aaaaaaaaaa aa 5457  
 35  
 <210> 61  
 <211> 453  
 <212> PRT  
 40 <213> Homo sapiens  
  
 <400> 61  
 45 Met Lys Leu Leu Val Ile Leu Leu Phe Ser Gly Leu Ile Thr Gly Phe  
 -15 -10 -5 1  
 Arg Ser Asp Ser Ser Ser Ser Leu Pro Pro Lys Leu Leu Val Ser  
 5 10 15  
 50 Phe Asp Gly Phe Arg Ala Asp Tyr Leu Lys Asn Tyr Glu Phe Pro His  
 20 25 30  
 55

Leu Gln Asn Phe Ile Lys Glu Gly Val Leu Val Glu His Val Lys Asn  
 35 40 45  
 5 Val Phe Ile Thr Lys Thr Phe Pro Asn His Tyr Ser Ile Val Thr Gly  
 50 55 60 65  
 Leu Tyr Glu Glu Ser His Gly Ile Val Ala Asn Ser Met Tyr Asp Ala  
 70 75 80  
 10 Val Thr Lys Lys His Phe Ser Asp Ser Asn Asp Lys Asp Pro Phe Trp  
 85 90 95  
 Trp Asn Glu Ala Val Pro Ile Trp Val Thr Asn Gln Leu Gln Glu Asn  
 100 105 110  
 15 Arg Ser Ser Ala Ala Ala Met Trp Pro Gly Thr Asp Val Pro Ile His  
 115 120 125  
 Asp Thr Ile Ser Ser Tyr Phe Met Asn Tyr Asn Ser Ser Val Ser Phe  
 130 135 140 145  
 Glu Glu Arg Leu Asn Asn Ile Thr Met Trp Leu Asn Asn Ser Asn Pro  
 150 155 160  
 25 Pro Val Thr Phe Ala Thr Leu Tyr Trp Glu Glu Pro Asp Ala Ser Gly  
 165 170 175  
 His Lys Tyr Gly Pro Glu Asp Lys Glu Asn Met Ser Arg Val Leu Lys  
 180 185 190  
 30 Lys Ile Asp Asp Leu Ile Gly Asp Leu Val Gln Arg Leu Lys Met Leu  
 195 200 205  
 Gly Leu Trp Glu Asn Leu Asn Val Ile Ile Thr Ser Asp His Gly Met  
 210 215 220 225  
 35 Thr Gln Cys Ser Gln Asp Arg Leu Ile Asn Leu Asp Ser Cys Ile Asp  
 230 235 240  
 His Ser Tyr Tyr Thr Leu Ile Asp Leu Ser Pro Val Ala Ala Ile Leu  
 245 250 255  
 40 Pro Lys Ile Asn Arg Thr Glu Val Tyr Asn Lys Leu Lys Asn Cys Ser  
 260 265 270  
 45 Pro His Met Asn Val Tyr Leu Lys Glu Asp Ile Pro Asn Arg Phe Tyr  
 275 280 285  
 Tyr Gln His Asn Asp Arg Ile Gln Pro Ile Ile Leu Val Ala Asp Glu  
 290 295 300 305  
 50 Gly Trp Thr Ile Val Leu Asn Glu Ser Ser Gln Lys Leu Gly Asp His  
 310 315 320  
 55

Gly Tyr Asp Asn Ser Leu Pro Ser Met His Pro Phe Leu Ala Ala His  
 325 330 335  
 5 Gly Pro Ala Phe His Lys Gly Tyr Lys His Ser Thr Ile Asn Ile Val  
 340 345 350  
 Asp Ile Tyr Pro Met Met Cys His Ile Leu Gly Leu Lys Pro His Pro  
 355 360 365  
 10 Asn Asn Gly Thr Phe Gly His Thr Lys Cys Leu Leu Val Asp Gln Trp  
 370 375 380 385  
 Cys Ile Asn Leu Pro Glu Ala Ile Ala Ile Val Ile Gly Ser Leu Leu  
 15 390 395 400  
 Val Leu Thr Met Leu Thr Cys Leu Ile Ile Ile Met Gln Asn Arg Leu  
 405 410 415  
 20 Ser Val Pro Arg Pro Phe Ser Arg Leu Gln Leu Gln Glu Asp Asp Asp  
 420 425 430  
 Asp Pro Leu Ile Gly  
 435  
 25  
 <210> 62  
 <211> 1359  
 <212> DNA  
 30 <213> Homo sapiens  
  
 <400> 62  
 35 atgagttat tagtaatact ttgttttct ggacttataa ctggttttag aagtgctct 60  
 tccctagtt tggcaccctaa gttactacta gttcccttg atggttcag agctgattat 120  
 ctgaagaaat atgaatttcc tcatctccag aattttatca aagaagggtt ttggttagag 180  
 calgttaaan atgtttttat cacaaaaaca ttccaaacc actacagtat tgtgacaggc 240  
 40 ttgtatgaag aaagccatgg cattgtggct aattccatgt atgatgcagt cacaaagaa 300  
 cacttttcg actctaata caaggatcct ttltgggtgg atgaggcagt acctatttg 360  
 gtgaccaatc agcttcagga aaacagatca agtgcgctg ctatgtggcc tggtaactgt 420  
 45 gtacccatc acgataccat ctcttctat ttatgaatt acaactcctc agtgtcat 480  
 gaggaagac taaataatat tactatgtgg cttaacatt cgaaccacc agtcaccttt 540  
 gcaacactat attgggaaga accagatgca agtggccaca aatagggacc tgaagataa 600  
 gaaacttgn gcaggtgtt gaaatattt gttgtctta tgggtgact agtccaaatg 660  
 50 ctatgatgt tgggtctat ggaatctt ttgtgatca ttacagtga tcatgggtg 720  
 acccagttt ctatggacag actgataac ctggttctt gattcagta ttcatctac 780

55

actcttatag attttagccc agttgcigca atacttccca aaataaatag aacagaggtt 840  
 tataacaaac tgaanaactg tagccctcat atgaatgttt atctcaaaga agacattcct 900  
 5 aacagatttt attaccaaca taatgaicga attcagccca ttattttggt tgcgatgaa 960  
 ggcigggaca ttgtgctaaa tgaatcatca caaaaattag gtgaccatgg ttatgataat 1020  
 tctttgccta gtaatgatcc atttctagct gccacaggac ctgcatttca caaaggctac 1080  
 aagcatagca caattaacat tgtggatatt tatccaatga tgtgccacat cctgggattt 1140  
 10 aaaccacatc ccaataatgg gaccttgggt catactaagt gcttgttagt tgaccagtgg 1200  
 tgcattaatc tcccagaagc catcgcatg gttatcgggt cactcttgggt gtttaaccatg 1260  
 ctaacatgcc tcataataat catgcagaat agactttctg tacctcgicc attttctcga 1320  
 15 cttcagctac aagaagaiga tgaatgatcc ttaattggg 1359

<210> 63  
 <211> 2044  
 20 <212> DNA  
 <213> Homo sapiens

25 <200>  
 <221> CDS  
 <222> (70)..(1428)

30 <220>  
 <221> sig peptide  
 <222> (70)..(114)

35 <220>  
 <221> mat peptide  
 <222> (115)..(1428)

40 <400> 63  
 gtccgcgca ttggaangai gcgaccgcy cggttggaac cctgattgct gtccttcac 60  
 45 gtgttcatt atg aag tta tta gla ala ctt ttg ttt tct gga ctt ata 108  
 Met Lys Leu Leu Val Ile Leu Leu Phe Ser Gly Leu Ile  
 -15 -10 -5  
 50 act ggt ttt nga agt gac tct tcc tct agt ttg cca cct aag tta cta 156  
 Thr Gly Phe Arg Ser Asp Ser Ser Ser Ser Leu Pro Pro Lys Leu Leu  
 1 5 10

55

	cta gta tcc ttt gat ggc ttc aga gct gat tat ctg aag aac tat gaa	204
	Leu Val Ser Phe Asp Gly Phe Arg Ala Asp Tyr Leu Lys Asn Tyr Glu	
5	15 20 25 30	
	ttt cct cat ctc cag aat ttt atc aaa gaa ggt gtt ttg gta gag cat	252
	Phe Pro His Leu Gln Asn Phe Ile Lys Glu Gly Val Leu Val Glu His	
10	35 40 45	
	GTT AAA AAT GTT TTT ATC ACA AAA ACA TTT CCA AAC CAC TAC AGT ATT	300
	Val Lys Asn Val Phe Ile Thr Lys Thr Phe Pro Asn His Tyr Ser Ile	
	50 55 60	
15	gtg aca ggc ttg tat gaa gaa agc cat ggc att gtg gct aat tcc atg	348
	Val Thr Gly Leu Tyr Glu Glu Ser His Gly Ile Val Ala Asn Ser Met	
	65 70 75	
20	tat gat gca gtc aca aag aaa cac ttt tct gac tct aat gac aag gat	396
	Tyr Asp Ala Val Thr Lys Lys His Phe Ser Asp Ser Asn Asp Lys Asp	
	80 85 90	
25	cct ttt tgg tgg aat gag gca gta cct att tgg gtg acc aat cag ctt	444
	Pro Phe Trp Trp Asn Glu Ala Val Pro Ile Trp Val Thr Asn Gln Leu	
	95 100 105 110	
30	cag gaa aac aga tca agt gct gct gct atg tgg cct ggt act gat gta	492
	Gln Glu Asn Arg Ser Ser Ala Ala Ala Met Trp Pro Gly Thr Asp Val	
	115 120 125	
35	ccc att cac gat acc atc tct tcc tat ttt atg aat tac aac tcc tca	540
	Pro Ile His Asp Thr Ile Ser Ser Tyr Phe Met Asn Tyr Asn Ser Ser	
	130 135 140	
40	gtg tca ttt gag gaa aga cta aat aat att act atg tgg cta aac aat	588
	Val Ser Phe Glu Glu Arg Leu Asn Asn Ile Thr Met Trp Leu Asn Asn	
	145 150 155	
45	tcg aac cca cca gtc acc ttt gca aca cta tat tgg gaa gaa cca gat	636
	Ser Asn Pro Pro Val Thr Phe Ala Thr Leu Tyr Trp Glu Glu Pro Asp	
	160 165 170	
50	gca agt ggc cac aaa tac gga cct gaa gnt aaa gaa aac atg agc aga	684
	Ala Ser Gly His Lys Tyr Gly Pro Glu Asp Lys Glu Asn Met Ser Arg	
	175 180 185 190	
55	gtg ttg aaa aaa atn gat gnt ctt atc ggt gac tta gtc can agh ctc	732
	Val Leu Lys Lys Ile Asp Asp Leu Ile Gly Asp Leu Val Gln Arg Leu	
	195 200 205	

	aag atg tta ggg cta tgg gaa aat ctt aat gtg atc att aca agt gat	780
5	Lys Met Leu Gly Leu Trp Glu Asn Leu Asn Val Ile Ile Thr Ser Asp	
	210 215 220	
	cat ggg atg acc cag tgt tct cag gac aga ctg ata aac ctg gat tcc	828
10	His Gly Met Thr Gln Cys Ser Gln Asp Arg Leu Ile Asn Leu Asp Ser	
	225 230 235	
	tgc atc gat cat tca tac tac act ctt ata gat ttg agc cca gtt gct	876
15	Cys Ile Asp His Ser Tyr Tyr Thr Leu Ile Asp Leu Ser Pro Val Ala	
	240 245 250	
	gca ata ctt ccc aaa ata aat aga aca gag gtt tat aac aaa ctg aaa	924
	Ala Ile Leu Pro Lys Ile Asn Arg Thr Glu Val Tyr Asn Lys Leu Lys	
	255 260 265 270	
20	aac tgt agc cct cat atg aat gtt tat ctc aaa gaa gac att cct aac	972
	Asn Cys Ser Pro His Met Asn Val Tyr Leu Lys Glu Asp Ile Pro Asn	
	275 280 285	
	aga ttt tat tac caa cat aat gat cga att cag ccc att att ttg gtt	1020
25	Arg Phe Tyr Tyr Gln His Asn Asp Arg Ile Gln Pro Ile Ile Leu Val	
	290 295 300	
	gcc gat gaa ggc tgg aca att gtg cta aat gaa tca tca caa aan tta	1068
30	Ala Asp Glu Gly Trp Thr Ile Val Leu Asn Glu Ser Ser Gln Lys Leu	
	305 310 315	
	ggc gat cat ggt tat gat aat tct ttg cct agt atg cat cca ttt cta	1116
35	Gly Asp His Gly Tyr Asp Asn Ser Leu Pro Ser Met His Pro Phe Leu	
	320 325 330	
	gct gcc cac gga cct gca ttt cac aaa ggc tac aag cat agc aca att	1164
40	Ala Ala His Gly Pro Ala Phe His Lys Gly Tyr Lys His Ser Thr Ile	
	335 340 345 350	
	aac att gtg gat att tat cca atg atg tgc cac atc ctg gga tta aaa	1212
	Asn Ile Val Asp Ile Tyr Pro Met Met Cys His Ile Leu Gly Leu Lys	
	355 360 365	
45	cca cat ccc aat aat ggg acc ttt ggt cat act aag tgc ttg tta gtt	1260
	Pro His Pro Asn Asn Gly Thr Phe Gly His Thr Lys Cys Leu Leu Val	
	370 375 380	
50	gac cag tgg tgc att aat ctc cca gaa gcc atc ggc att gtt atc ggt	1308
	Asp Gln Trp Cys Ile Asn Leu Pro Glu Ala Ile Ala Ile Val Ile Gly	
	385 390 395	

55

tca ctc ttg gtg tta acc atg cta aca tgc ctc ata ata atc atg cag 1356  
 Ser Leu Leu Val Leu Thr Met Leu Thr Cys Leu Ile Ile Ile Met Gln  
 5                   400                   405                   410  
 aat aga ctt tct gta cct cgt cca ttt tct cga ctt cag cta caa gaa 1404  
 Asn Arg Leu Ser Val Pro Arg Pro Phe Ser Arg Leu Gln Leu Gln Glu  
 10                   415                   420                   425                   430  
 gat gat gat gat ccc tta att ggg tgacatgtc tagggcttat acaaagtgc 1458  
 Asp Asp Asp Asp Pro Leu Ile Gly  
 435  
 15                   tttgattaat cacaaaacta agaatacatc caaagaatag tgttgtaact atgaaaaaga 1518  
 atactttgaa agacaaagaa cttagactaa gcatgttaaa attattactt tgttttcctt 1578  
 gtgttttgtt tcggtgcatt tgctaataag ataacgctga ccatagtaaa attgttagta 1638  
 aatcattagg taacatcttg tggtaggaan tcattaggta acatcaatcc taactagaaa 1698  
 20                   tactaaaaat ggcttttgag aaaaatactt cctctgcttg tattttgcga tgaagatgtg 1758  
 atacatcttt aatgaaaaat ataccaaaat ttagtaggca tgtttttcta ataattttat 1818  
 atatttgtaa agaaaacaac agaaatcttt atgcaatttg tgaattttgt atattagggg 1878  
 25                   ggaaaagctt cctatatattt tatatttacc ttaatttagt ttgtatctca agtaccctct 1938  
 tgaggtagga aatgctctgt gatggtaaat aaaaattggag cagacagaaa agatatagca 1998  
 aatgaagaaa tatitttaagg aaacctatll gaaaaaaa aacaaa 2044  
 30  
 <210> 64  
 <211> 708  
 <212> PRT  
 35                   <213> Homo sapiens  
 <400> 64  
 40                   Met Lys Asp Met Pro Leu Arg Ile His Val Leu Leu Gly Leu Ala Ile  
 -22               -20                               -15                               -10  
 Thr Thr Leu Val Gln Ala Val Asp Lys Lys Val Asp Cys Pro Arg Leu  
 -5                               1                               5                               10  
 45                   Cys Thr Cys Glu Ile Arg Pro Trp Phe Thr Pro Arg Ser Ile Tyr Met  
 15                               20                               25  
 Glu Ala Ser Thr Val Asp Cys Asn Asp Leu Gly Leu Leu Thr Phe Pro  
 30                               35                               40  
 50                   Ala Arg Leu Pro Ala Asn Thr Gln Ile Leu Leu Leu Gln Thr Asn Asn  
 15                               50                               55

55

Ile Ala Lys Ile Glu Tyr Ser Thr Asp Phe Pro Val Asn Leu Thr Gly  
 60 65 70  
 5 Leu Asp Leu Ser Gln Asn Asn Leu Ser Ser Val Thr Asn Ile Asn Val  
 75 80 85 90  
 Lys Lys Met Pro Gln Leu Leu Ser Val Tyr Leu Glu Glu Asn Lys Leu  
 95 100 105  
 10 Thr Glu Leu Pro Glu Lys Cys Leu Ser Glu Leu Ser Asn Leu Gln Glu  
 110 115 120  
 Leu Tyr Ile Asn His Asn Leu Leu Ser Thr Ile Ser Pro Gly Ala Phe  
 125 130 135  
 15 Ile Gly Leu His Asn Leu Leu Arg Leu His Leu Asn Ser Asn Arg Leu  
 140 145 150  
 Gln Met Ile Asn Ser Lys Trp Phe Asp Ala Leu Pro Asn Leu Glu Ile  
 155 160 165 170  
 20 Leu Met Ile Gly Glu Asn Pro Ile Ile Arg Ile Lys Asp Met Asn Phe  
 175 180 185  
 25 Lys Pro Leu Ile Asn Leu Arg Ser Leu Val Ile Ala Gly Ile Asn Leu  
 190 195 200  
 Thr Glu Ile Pro Asp Asn Ala Leu Val Gly Leu Glu Asn Leu Glu Ser  
 205 210 215  
 30 Ile Ser Phe Tyr Asp Asn Arg Leu Ile Lys Val Pro His Val Ala Leu  
 220 225 230  
 Gln Lys Val Val Asn Leu Lys Phe Leu Asp Leu Asn Lys Asn Pro Ile  
 235 240 245 250  
 35 Asn Arg Ile Arg Arg Gly Asp Phe Ser Asn Met Leu His Leu Lys Glu  
 255 260 265  
 Leu Gly Ile Asn Asn Met Pro Glu Leu Ile Ser Ile Asp Ser Leu Ala  
 270 275 280  
 40 Val Asp Asn Leu Pro Asp Leu Arg Lys Ile Glu Ala Thr Asn Asn Pro  
 285 290 295  
 Arg Leu Ser Tyr Ile His Pro Asn Ala Phe Phe Arg Leu Pro Lys Leu  
 300 305 310  
 Glu Ser Leu Met Leu Asn Ser Asn Ala Leu Ser Ala Leu Tyr His Gly  
 315 320 325 330  
 50 Thr Ile Glu Ser Leu Pro Asn Leu Lys Glu Ile Ser Ile His Ser Asn  
 335 340 345

55



	Pro	Ile	Arg	Cys	Asp	Cys	Val	Ile	Arg	Trp	Met	Asn	Met	Asn	Lys	Thr
5	Asn	Ile	Arg	Phe	Met	Glu	Pro	Asp	Ser	Leu	Phe	Cys	Val	Asp	Pro	Pro
	Glu	Phe	Gln	Gly	Gln	Asn	Val	Arg	Gln	Val	His	Phe	Arg	Asp	Met	Met
10																
	Glu	Ile	Cys	Leu	Pro	Leu	Ile	Ala	Pro	Glu	Ser	Phe	Pro	Ser	Asn	Leu
	Asn	Val	Glu	Ala	Gly	Ser	Tyr	Val	Ser	Phe	His	Cys	Arg	Ala	Thr	Ala
15																
	Glu	Pro	Gln	Pro	Glu	Ile	Tyr	Trp	Ile	Thr	Pro	Ser	Gly	Gln	Lys	Leu
20	Leu	Pro	Asn	Thr	Leu	Thr	Asp	Lys	Phe	Tyr	Val	His	Ser	Glu	Gly	Thr
	Leu	Asp	Ile	Asn	Gly	Val	Thr	Pro	Lys	Glu	Gly	Gly	Leu	Tyr	Thr	Cys
25	Ile	Ala	Thr	Asn	Leu	Val	Gly	Ala	Asp	Leu	Lys	Ser	Val	Met	Ile	Lys
	Val	Asp	Gly	Ser	Phe	Pro	Gln	Asp	Asn	Asn	Gly	Ser	Leu	Asn	Ile	Lys
30																
	Ile	Arg	Asp	Ile	Gln	Ala	Asn	Ser	Val	Leu	Val	Ser	Trp	Lys	Ala	Ser
35	Ser	Lys	Ile	Leu	Lys	Ser	Ser	Val	Lys	Trp	Thr	Ala	Phe	Val	Lys	Thr
	Glu	Asn	Ser	His	Ala	Ala	Gln	Ser	Ala	Arg	Ile	Pro	Ser	Asp	Val	Lys
40	Val	Tyr	Asn	Leu	Thr	His	Leu	Asn	Pro	Ser	Thr	Glu	Tyr	Lys	Ile	Cys
	Ile	Asp	Ile	Pro	Thr	Ile	Tyr	Gln	Lys	Asn	Arg	Lys	Lys	Cys	Val	Asn
45	Val	Thr	Thr	Lys	Gly	Leu	His	Pro	Asp	Gln	Lys	Glu	Tyr	Glu	Lys	Asn
	Asn	Thr	Thr	Thr	Leu	Met	Ala	Cys	Leu	Gly	Gly	Leu	Leu	Gly	Ile	Ile
50																
	Gly	Val	Ile	Cys	Leu	Ile	Ser	Cys	Leu	Ser	Pro	Glu	Met	Asn	Cys	Asp

Gly Gly His Ser Tyr Val Arg Asn Tyr Leu Gln Lys Pro Thr Phe Ala  
 635                      640                      645                      650  
 5    Leu Gly Glu Leu Tyr Pro Pro Leu Ile Asn Leu Trp Glu Ala Gly Lys  
                          655                      660                      665  
 Glu Lys Ser Thr Ser Leu Lys Val Lys Ala Thr Val Ile Gly Leu Pro  
 10                      670                      675                      680  
 Thr Asn Met Ser  
                          685  
  
 15    <210> 65  
          <211> 2124  
          <212> DNA  
 20    <213> Homo sapiens  
  
          <400> 65  
 atgaaggaca tgcactccg aattcatgig ctacttggcc tagctatcac tacactagta 60  
 25    caagctgtag ataaaaaagl ggattgtcca cggttatgta cgtgtgaaat caggccttgg 120  
          ttacaccca gatccatita taiggaagca tclacagigg atigtaatga tttaggcttt 180  
          ttaactttcc cagccagatt gccagctaac acacagattc ttclcttaca gactaacaat 240  
 30    attgcaaaaa ttgaatactc cacagacttt ccagtaaac ttactggcct ggatttatct 300  
 caaaacaatt tatcttcagt caccaatatt atglaaaaa agatgcttca gctctttct 360  
          ggtacctag aggaaaacaa acttacigaa ctgcttga aaatgctg cgaactgagc 420  
          aacttacaag aactctatat taatcacac ttgctttc caatttacc tggagccttt 480  
 35    attggcttcc ataactttct tgcatttcat ctcaattcna atagattgca gatgatcaac 540  
          agtaagtggg ttgatgtctt tccaaatcga gagattctga tgaatgggga aaatccaatt 600  
          atcagaatca aagacatgaa cttaagcct cttaacatc ttgcagcct ggttatagct 660  
          ggtataaacc tcacagaaat accagataac gcttgggtg gactggaaaa cttagaaagc 720  
 40    atctcttttt acgataacag gcttattaaa gtaccccatg ttgcctttca aaaagtgtga 780  
          aatctcaaat ttttggatct aaatnaaat cctattanta gnatcgaag ggttgatttt 840  
          agcaataagc tacacttaaa agattgggg ataantaata tgcctgagct gatttccatc 900  
 45    gatagcttg ctgtggataa cctgccagat ttaaganna tagaagctac taacaacctt 960  
          agattgtctt acattcacc caatgcatt ttacagctcc ccagcttga atcactatg 1020  
          ctgaacagca atgctctcag tgcctgttgc catgttaccn ttgagctct gccaaacctc 1080  
 50    aaggancten gcttaccnng taacctcnc nggttgatc gtcctaccg ttggttganc 1140  
          atgaacnaaa ccaacattcg attcatggag ccagattcnc tcttttgcgt ggaccacctt 1200  
          gnatccnng gtctgaaatg tgcctgagtg catctcagng ncatgatga aatttgcctc 1260

ccctctatag ctccctgagag ctttcttct aatctaaatg tagaagctgg gagctatgtt 1320  
 tcccttcacl giagagctac tgcagaacca cagcctgaaa tctactggat aacaccttct 1380  
 5 ggicaaaaac tcttgcctaa taccttgaca gacaagtct atgtccattc tgagggaaca 1440  
 ctagatalaa atggcgtaac tcccaaagaa gggggtttat atacttgtat agcaactaac 1500  
 ctagtggcg ctgacttgaa gtctgttatg atcaaagtg atggatcttt tccacaagat 1560  
 10 aacaatggcl ctttgaatat taaaataaga gatattcagg ccaattcagt ttgggtgtcc 1620  
 tggaaagcaa gtctaaaaat tctcaaatct agtgtraaat ggacagcctt tgtcaagact 1680  
 gaaaattctc atgtgcgca aagtgtcga ataccattc atgtcaaggt atataatctt 1740  
 acitcctga atccatcaac tgagtataaa atttgtattg atattccac catctatcag 1800  
 15 aaaaacagaa aaaaatgtgt aaatgtcacc accaaaggtt tgcacctga tcaaaaagag 1860  
 tatgaaaaga ataataccac aacatttatg gcctgtcttg gaggccttct ggggtatttt 1920  
 ggtgtgalat gtcctatcag ctgcctctct ccagaaatga actgtgatgg tggacacagc 1980  
 20 tatgtgagga attacttaca gaaaccaacc ttgcatttag gtgagcttta tccctctctg 2040  
 ataaatctct gggaagcagg aaaaagaaaa agtacatcac tgaagtaaa agcaactgtt 2100  
 ataggtttac caacaaatat gtcc 2124

25 <210> 66  
 <211> 3068  
 <212> DNA  
 30 <213> Homo sapiens  
  
 <200>  
 <221> CDS  
 35 <222> (89-1).. (3017)  
  
 <220>  
 40 <221> sig peptide  
 <222> (89-1).. (959)  
  
 <220>  
 45 <221> mat peptide  
 <222> (960).. (3017)

50 <400> 66  
 gtctgaagck atggctcct ctctgggagk tgggggggt tcaattatla atgaccgtg 60  
 akcaagcagc acctgtcag tgtgacact gatcgggtga acgatgccc aciaacccc 120

55

atggaacaa ggaataata agccagctca caggatctct ctctactgga ttgagagcct 180  
 cagcctgccg actgagaaaa agagttccag gaaaaagaag gaatcccggc tgcagcctcc 240  
 5 tgccttccct tatattttta aatagagaga taagattgcg tgcattgttg catactata 300  
 gtatatatt tgtacacttt gttacacaga cacacaaatg cacctattta taccgggcaa 360  
 gaacacaacc atgtgattat ctcaaccaag gaactgagga atccagcagc caaggacatc 420  
 10 ggaggtgggc tagcactgaa actgcctttc aagacgagga agaggaggag aaagagaag 480  
 aagaggaaga tgttgggcaa catttatita acatgctcca cagcccgac cctggcatca 540  
 tgcctctatt cctgcaataa ctgaagaagc atgggatita aatattttac ttctaataa 600  
 atgaattact caatctctca tgaccatcta tacatactcc acctcaaaa agtacaatca 660  
 15 tattatatca ttaaggaaat agtaaccttc tctctccaa taigcatgac attttggac 720  
 aatgcaattg tggcactggc acttatttca gtgaagaaaa actttgtgt tctatggcat 780  
 tcatcattg acaaatgcaa gcattctctt tatcaatcag ctctattga acttactagc 840  
 20 actgactgtg gaatccttaa gggcccatia cattctgaa gaagaaagct aag atg 896  
 Met  
 -22  
 aag gac atg cca ctc cga att cat gtg cta ctt ggc cta gct atc act 944  
 25 Lys Asp Met Pro Leu Arg Ile His Val Leu Leu Gly Leu Ala Ile Thr  
 -20 -15 -10  
 aca cta gta caa gct gta gat aaa aaa gtg gat tgt cca cgg tta tgt 992  
 30 Thr Leu Val Gln Ala Val Asp Lys Lys Val Asp Cys Pro Arg Leu Cys  
 -5 1 5 10  
 acg tgt gaa atc agg cct tgg ttt aca ccc aga tcc att tat atg gaa 1040  
 Thr Cys Glu Ile Arg Pro Trp Phe Thr Pro Arg Ser Ile Tyr Met Glu  
 35 15 20 25  
 gca tct nca glg gat tgt aat gat tta ggt ctt tta act ttc cca gcc 1088  
 Ala Ser Thr Val Asp Cys Asn Asp Leu Gly Leu Leu Thr Phe Pro Ala  
 40 30 35 40  
 aga ttg cca gct aac aca cag att ctt ctc cta cag act aac aat att 1136  
 Arg Leu Pro Ala Asn Thr Gln Ile Leu Leu Leu Gln Thr Asn Asn Ile  
 45 45 50 55  
 gca aaa att gaa tac tcc aca gac ttt cca gta aac ctt act ggc ctg 1184  
 Ala Lys Ile Glu Tyr Ser Thr Asp Phe Pro Val Asn Leu Thr Gly Leu  
 60 65 70 75  
 50 gat tta tct cha aac aat tta tct tcn gtc acc nat att nat gla aaa 1232  
 Asp Leu Ser Gln Asn Asn Leu Ser Ser Val Thr Asn Ile Asn Val Lys  
 80 85 90

55

aag atg cct cag ctc ctt tct gtg tac cta gag gaa aac aaa ctt act 1280  
 Lys Met Pro Gln Leu Leu Ser Val Tyr Leu Glu Glu Asn Lys Leu Thr  
 5                   95                   100                   105  
 gaa ctg cct gaa aaa tgt ctg tcc gaa ctg agc aac tta caa gaa ctc 1328  
 Glu Leu Pro Glu Lys Cys Leu Ser Glu Leu Ser Asn Leu Gln Glu Leu  
 10                   110                   115                   120  
 tat att aat cac aac ttg ctt tct aca att tca cct gga gcc ttt att 1376  
 Tyr Ile Asn His Asn Leu Leu Ser Thr Ile Ser Pro Gly Ala Phe Ile  
 15                   125                   130                   135  
 ggc cta cat aat ctt ctt cga ctt cat ctc aat tca aat aga ttg cag 1424  
 Gly Leu His Asn Leu Leu Arg Leu His Leu Asn Ser Asn Arg Leu Gln  
 20                   140                   145                   150                   155  
 atg atc aac agt aag tgg ttt gat gct ctt cca aat cta gag att ctg 1472  
 Met Ile Asn Ser Lys Trp Phe Asp Ala Leu Pro Asn Leu Glu Ile Leu  
 25                   160                   165                   170  
 atg att ggg gaa aat cca att atc aga atc aaa gac atg aac ttt aag 1520  
 Met Ile Gly Glu Asn Pro Ile Ile Arg Ile Lys Asp Met Asn Phe Lys  
 30                   175                   180                   185  
 cct ctt atc aat ctt cgc agc ctg gtt ata gct ggt ata aac ctc aca 1568  
 Pro Leu Ile Asn Leu Arg Ser Leu Val Ile Ala Gly Ile Asn Leu Thr  
 35                   190                   195                   200  
 gaa ata cca gat aac gcc ttg gtt gga ctg gaa aac tta gaa agc atc 1616  
 Glu Ile Pro Asp Asn Ala Leu Val Gly Leu Glu Asn Leu Glu Ser Ile  
 40                   205                   210                   215  
 tct ttt tac gat aac agg ctt att aaa gta ccc cat gtt gct ctt cna 1664  
 Ser Phe Tyr Asp Asn Arg Leu Ile Lys Val Pro His Val Ala Leu Gln  
 45                   220                   225                   230                   235  
 aaa gtt gta aat ctc aaa ttt ttg gat cta aat aaa aat cct att aat 1712  
 Lys Val Val Asn Leu Lys Phe Leu Asp Leu Asn Lys Asn Pro Ile Asn  
 50                   240                   245                   250  
 aga ata cga agg ggt gat ttt ngc nat atg cta cac tta aaa gag ttg 1760  
 Arg Ile Arg Arg Gly Asp Phe Ser Asn Met Leu His Leu Lys Glu Leu  
 55                   255                   260                   265  
 ggg ata aat nat atg cct gag ctg att tcc atc gat agt ctt gct gtg 1808  
 Gly Ile Asn Asn Met Pro Glu Leu Ile Ser Ile Asp Ser Leu Ala Val  
 270                   275                   280

	gat aac ctg cca gat tta aga aaa ata gaa gct act aac aac cct aga	1856
	Asp Asn Leu Pro Asp Leu Arg Lys Ile Glu Ala Thr Asn Asn Pro Arg	
5	285                      290                      295	
	ttg tct tac att cac ccc aat gca ttt ttc aga ctc ccc aag ctg gaa	1904
	Leu Ser Tyr Ile His Pro Asn Ala Phe Phe Arg Leu Pro Lys Leu Glu	
	300                      305                      310                      315	
10	tca ctc atg ctg aac agc aat gct ctc agt gcc ctg tac cat ggt acc	1952
	Ser Leu Met Leu Asn Ser Asn Ala Leu Ser Ala Leu Tyr His Gly Thr	
	320                      325                      330	
15	att gag tct ctg cca aac ctc aag gaa atc agc ata cac agt aac ccc	2000
	Ile Glu Ser Leu Pro Asn Leu Lys Glu Ile Ser Ile His Ser Asn Pro	
	335                      340                      345	
20	atc agg tgt gac tgt gtc atc cgt tgg atg aac atg aac aaa acc aac	2048
	Ile Arg Cys Asp Cys Val Ile Arg Trp Met Asn Met Asn Lys Thr Asn	
	350                      355                      360	
25	att cga ttc atg gag cca gat tca ctg ttt tgc gtg gac cca cct gaa	2096
	Ile Arg Phe Met Glu Pro Asp Ser Leu Phe Cys Val Asp Pro Pro Glu	
	365                      370                      375	
30	ttc caa ggt cag aat gtt cgg caa gtg cat ttc agg gac atg atg gaa	2144
	Phe Gln Gly Gln Asn Val Arg Gln Val His Phe Arg Asp Met Met Glu	
	380                      385                      390                      395	
	att tgt ctc cct ctt ata gct cct gag agc ttt cct tct aat cta aat	2192
	Ile Cys Leu Pro Leu Ile Ala Pro Glu Ser Phe Pro Ser Asn Leu Asn	
35	400                      405                      410	
	gta gaa gct ggg agc tat gtt tcc ttt cac tgt aga gct act gca gaa	2240
	Val Glu Ala Gly Ser Tyr Val Ser Phe His Cys Arg Ala Thr Ala Glu	
	415                      420                      425	
40	cca cag cct gaa atc tac tgg ata aca cct tct ggt caa aac ctc ttg	2288
	Pro Gln Pro Glu Ile Tyr Trp Ile Thr Pro Ser Gly Gln Lys Leu Leu	
	430                      435                      440	
45	cct aat acc ctg aca gac aag ttc tat gtc cat tct gng gga aca cta	2336
	Pro Asn Thr Leu Thr Asp Lys Phe Tyr Val His Ser Glu Gly Thr Leu	
	445                      450                      455	
50	gat ata aat ggc gta nct ccc naa gaa ggg ggt tta tat nct tgt ata	2384
	Asp Ile Asn Gly Val Thr Pro Lys Glu Gly Gly Leu Tyr Thr Cys Ile	
	460                      465                      470                      475	

	gca act aac cta gtt ggc gct gac ttg aag tct gtt atg atc aaa gtg	2432
	Ala Thr Asn Leu Val Gly Ala Asp Leu Lys Ser Val Met Ile Lys Val	
5	480 485 490	
	gat gga tct ttt cca caa gat aac aat ggc tct ttg aat att aaa ata	2480
	Asp Gly Ser Phe Pro Gln Asp Asn Asn Gly Ser Leu Asn Ile Lys Ile	
10	495 500 505	
	aga gat att cag gcc aat tca gtt ttg gtg tcc tgg aaa gca agt tct	2528
	Arg Asp Ile Gln Ala Asn Ser Val Leu Val Ser Trp Lys Ala Ser Ser	
	510 515 520	
15	aaa att ctc aaa tct agt gtt aaa tgg aca gcc ttt gtc aag act gaa	2576
	Lys Ile Leu Lys Ser Ser Val Lys Trp Thr Ala Phe Val Lys Thr Glu	
	525 530 535	
20	aat tct cat gct gcg caa agt gct cga ata cca tct gat gtc aag gta	2624
	Asn Ser His Ala Ala Gln Ser Ala Arg Ile Pro Ser Asp Val Lys Val	
	540 545 550 555	
	tat aat ctt act cat ctg aat cca tca act gag tat aaa att tgt att	2672
25	Tyr Asn Leu Thr His Leu Asn Pro Ser Thr Glu Tyr Lys Ile Cys Ile	
	560 565 570	
	gat att ccc acc atc tat cag aaa aac aga aaa aaa tgt gta aat gtc	2720
30	Asp Ile Pro Thr Ile Tyr Gln Lys Asn Arg Lys Lys Cys Val Asn Val	
	575 580 585	
	acc acc aac ggt ttg cac cct gat caa aac gag tat gaa aag aat aat	2768
	Thr Thr Lys Gly Leu His Pro Asp Gln Lys Glu Tyr Glu Lys Asn Asn	
35	590 595 600	
	acc aca aca ctt atg gcc tgt ctt gga ggc ctt ctg ggg att att ggt	2816
	Thr Thr Thr Leu Met Ala Cys Leu Gly Gly Leu Leu Gly Ile Ile Gly	
40	605 610 615	
	gtg ala tgt ctt atc agc tgc ctc tct cca gaa atg aac tgt gat ggt	2864
	Val Ile Cys Leu Ile Ser Cys Leu Ser Pro Glu Met Asn Cys Asp Gly	
	620 625 630 635	
45	gga cac agc tat gtg agg aat tac tta cag aaa cca acc ttt gca tta	2912
	Gly His Ser Tyr Val Arg Asn Tyr Leu Gln Lys Pro Thr Phe Ala Leu	
	640 645 650	
50	ggt gag ctt tat cct cct ctg ata aat ctc tgg gaa gca gga aaa gaa	2960
	Gly Glu Leu Tyr Pro Pro Leu Ile Asn Leu Trp Glu Ala Gly Lys Glu	
	655 660 665	

55

aaa agt aca tca ctg aaa gla aaa gca act gtt ata ggt tta cca aca 3008  
 Lys Ser Thr Ser Leu Lys Val Lys Ala Thr Val Ile Gly Leu Pro Thr  
 5 670 675 680  
 aat atg tcc taaaaaccac caaggaaacc taticcaaaa atgaacaaaa 3057  
 Asn Met Ser  
 10 685  
 aaaaaaaaa a 3068  
  
 <210> 67  
 15 <211> 255  
 <212> PRT  
 <213> Homo sapiens  
 20  
 <400> 67  
 Met Ser Tyr Tyr Gly Ser Ser Tyr His Ile Ile Asn Ala Asp Ala Lys  
 1 5 10 15  
 25 Tyr Pro Gly Tyr Pro Pro Glu His Ile Ile Ala Glu Lys Arg Arg Ala  
 20 25 30  
 Arg Arg Arg Leu Leu His Lys Asp Gly Ser Cys Asn Val Tyr Phe Lys  
 35 40 45  
 30 His Ile Phe Gly Glu Trp Gly Ser Tyr Val Val Asp Ile Phe Thr Thr  
 50 55 60  
 Leu Val Asp Thr Lys Trp Arg His Met Phe Val Ile Phe Ser Leu Ser  
 35 65 70 75 80  
 Tyr Ile Leu Ser Trp Leu Ile Phe Gly Ser Val Phe Trp Leu Ile Ala  
 85 90 95  
 40 Phe His His Gly Asp Leu Leu Asn Asp Pro Asp Ile Thr Pro Cys Val  
 100 105 110  
 Asp Asn Val His Ser Phe Thr Gly Ala Phe Leu Phe Ser Leu Glu Thr  
 115 120 125  
 45 Gln Thr Thr Ile Gly Tyr Gly Tyr Arg Cys Val Thr Glu Glu Cys Ser  
 130 135 140  
 Val Ala Val Leu Met Val Ile Leu Gln Ser Ile Leu Ser Cys Ile Ile  
 50 145 150 155 160  
 Asn Thr Phe Ile Ile Gly Ala Ala Leu Ala Lys Met Ala Thr Ala Arg  
 165 170 175

55



Lys Arg Ala Gln Thr Ile Arg Phe Ser Tyr Phe Ala Leu Ile Gly Met  
 180 185 190  
 5 Arg Asp Gly Lys Leu Cys Leu Met Trp Arg Ile Gly Asp Phe Arg Pro  
 195 200 205  
 Asn His Val Val Glu Gly Thr Val Arg Ala Gln Leu Leu Arg Tyr Thr  
 210 215 220  
 10 Glu Asp Ser Glu Gly Arg Met Thr Met Ala Phe Lys Asp Leu Lys Leu  
 225 230 235 240  
 Val Asn Asp Gln Ile Ile Leu Val Thr Pro Val Thr Ile Val Pro  
 15 245 250 255  
  
 <210> 68  
 20 <211> 765  
 <212> DNA  
 <213> Homo sapiens  
  
 25 <400> 68  
 atgagctatt acggcagcag ctatcatatt atcaatgcgg acgcaaaata cccaggctac 60  
 ccgccagagc acattatagc tgagaagaga agagcaagaa gacgattact tcacaaagat 120  
 30 ggcagctgta atgtctactt caagcacalt ttgggagaat ggggaagcta tgtgggtgac 180  
 atcttcacca ctcttgigga caccaagtgg cgccatalgt ttgtgatatt tctttatct 240  
 tatattctct cgtggltgat attlggctct gicctttggc tcatagccct tcatcatggc 300  
 gatctatlaa atgntccaga catcacacct tglgttgaca acgtccattc ttcacaggg 360  
 35 gccttttltg tctccctaga gacccnaacc accataggat atggttatcg ctgtgttact 420  
 gaagaatgtt ctgtgcccgt gctcatggtg atctctccagt ccatcttaag ttgcataata 480  
 aataccctta tcatlggagc tgcctlggcc aaatggcaa ctgcicgaaa gagagcccaa 540  
 40 accattcgtt tcagctactt tgcactata ggtatgagag atgggaagct ttgcctcatg 600  
 tggcgattg gtgatttctg gccaaaccac gtggtagaag gaacagttag agcccaactt 660  
 ctccgclala caguagacag tgaaggagg atgacgatgg catttaaga cctcnaatta 720  
 45 gtcaacgacc aaatcatcct ggicaccccg gtaactattg tccca 765  
  
 <210> 69  
 <211> 907  
 50 <212> DNA  
 <213> Homo sapiens  
  
 55

&lt;200&gt;

&lt;221&gt; CDS

5

&lt;222&gt; (78).. (842)

&lt;400&gt; 69

caaaccaaga aatagcaaca agtctagaat tcttactact acaaaactca cctggatccc 60  
 10 taagggcaca gcaaaga atg agc tat tac ggc agc agc tat cat att atc 110  
 Met Ser Tyr Tyr Gly Ser Ser Tyr His Ile Ile  
 1 5 10  
 15 aat gcg gac gca aaa tac cca ggc tac ccg cca gag cac att ata gct 158  
 Asn Ala Asp Ala Lys Tyr Pro Gly Tyr Pro Pro Glu His Ile Ile Ala  
 15 20 25  
 20 gag aag aga aga gca aga aga cga tta ctt cac aaa gat ggc agc tgt 206  
 Glu Lys Arg Arg Ala Arg Arg Arg Leu Leu His Lys Asp Gly Ser Cys  
 30 35 40  
 aat gtc tac ttc aag cac att ttt gga gaa tgg gga agc tat gtg gtc 254  
 25 Asn Val Tyr Phe Lys His Ile Phe Gly Glu Trp Gly Ser Tyr Val Val  
 45 50 55  
 gac atc ttc acc act ctt gtg gac acc aag tgg cgc cat atg ttt gtg 302  
 Asp Ile Phe Thr Thr Leu Val Asp Thr Lys Trp Arg His Met Phe Val  
 30 60 65 70 75  
 ata ttt tct tta tct tat att ctc tcg tgg ttg ata ttt ggc tct gtc 350  
 Ile Phe Ser Leu Ser Tyr Ile Leu Ser Trp Leu Ile Phe Gly Ser Val  
 35 80 85 90  
 ttt tgg ctc ata gcc ttt cat cat ggc gat cta tta aat gat cca gac 398  
 Phe Trp Leu Ile Ala Phe His His Gly Asp Leu Leu Asn Asp Pro Asp  
 95 100 105  
 40 atc aca cct tgt gtt gac aac gtc cat tct ttc aca ggg gcc ttt ttg 416  
 Ile Thr Pro Cys Val Asp Asn Val His Ser Phe Thr Gly Ala Phe Leu  
 110 115 120  
 45 ttc tcc ctg gag acc caa acc acc ata gga tat ggt tat cgc tgt gtt 491  
 Phe Ser Leu Glu Thr Gln Thr Thr Ile Gly Tyr Gly Tyr Arg Cys Val  
 125 130 135  
 act gaa gaa tgt tct gtg gcc gtg ctc atg gtg atc ctc cag tcc atc 512  
 50 Thr Glu Glu Cys Ser Val Ala Val Leu Met Val Ile Leu Gln Ser Ile  
 140 145 150 155

55

tta agt tgc atc ata aat acc ttt atc att gga gct gcc ttg gcc aaa 590  
 Leu Ser Cys Ile Ile Asn Thr Phe Ile Ile Gly Ala Ala Leu Ala Lys  
 5 160 165 170  
 atg gca act gct cga aag aga gcc caa acc att cgt ttc agc tac ttt 638  
 Met Ala Thr Ala Arg Lys Arg Ala Gln Thr Ile Arg Phe Ser Tyr Phe  
 10 175 180 185  
 gca ctt ata ggt atg aga gat ggg aag ctt tgc ctc atg tgg cgc att 686  
 Ala Leu Ile Gly Met Arg Asp Gly Lys Leu Cys Leu Met Trp Arg Ile  
 190 195 200  
 15 ggt gat ttt cgg cca aac cac gtg gta gaa gga aca gtt aga gcc caa 734  
 Gly Asp Phe Arg Pro Asn His Val Val Glu Gly Thr Val Arg Ala Gln  
 205 210 215  
 20 ctt ctc cgc tat aca gaa gac agt gaa ggg agg atg acg atg gca ttt 782  
 Leu Leu Arg Tyr Thr Glu Asp Ser Glu Gly Arg Met Thr Met Ala Phe  
 220 225 230 235  
 aaa gac ctc aaa tta gtc aac gac caa atc atc ctg gtc acc ccg gta 830  
 25 Lys Asp Leu Lys Leu Val Asn Asp Gln Ile Ile Leu Val Thr Pro Val  
 240 245 250  
 act att gtc cca tgaccctgcc aaatccccc ctgtgagaaa cacccaaaaa 882  
 30 Thr Ile Val Pro  
 255  
 aaaaaaaaaa aaaaaaaaaa aaaaaa 907  
 35 <210> 70  
 <211> 859  
 <212> PRT  
 40 <213> Homo sapiens  
 <400> 70  
 Met Ala Cys Arg Trp Ser Thr Lys Glu Ser Pro Arg Trp Arg Ser Ala  
 45 -27 -25 -20 -15  
 Leu Leu Leu Leu Phe Leu Ala Gly Val Tyr Gly Asn Gly Ala Leu Ala  
 -10 -5 1 5  
 50 Glu His Ser Glu Asn Val His Ile Ser Gly Val Ser Thr Ala Cys Gly  
 10 15 20  
 Glu Thr Pro Glu Gln Ile Arg Ala Pro Ser Gly Ile Ile Thr Ser Pro

25 30 35  
 Gly Trp Pro Ser Glu Tyr Pro Ala Lys Ile Asn Cys Ser Trp Phe Ile  
 5 40 45 50  
 Arg Ala Asn Pro Gly Glu Ile Ile Thr Ile Ser Phe Gln Asp Phe Asp  
 55 60 65  
 Ile Gln Gly Ser Arg Arg Cys Asn Leu Asp Trp Leu Thr Ile Glu Thr  
 10 70 75 80 85  
 Tyr Lys Asn Ile Glu Ser Tyr Arg Ala Cys Gly Ser Thr Ile Pro Pro  
 90 95 100  
 15 Pro Tyr Ile Ser Ser Gln Asp His Ile Trp Ile Arg Phe His Ser Asp  
 105 110 115  
 Asp Asn Ile Ser Arg Lys Gly Phe Arg Leu Ala Tyr Phe Ser Gly Lys  
 120 125 130  
 20 Ser Glu Glu Pro Asn Cys Ala Cys Asp Gln Phe Arg Cys Gly Asn Gly  
 135 140 145  
 Lys Cys Ile Pro Glu Ala Trp Lys Cys Asn Asn Met Asp Glu Cys Gly  
 25 150 155 160 165  
 Asp Ser Ser Asp Glu Glu Ile Cys Ala Lys Glu Ala Asn Pro Pro Thr  
 170 175 180  
 30 Ala Ala Ala Phe Gln Pro Cys Ala Tyr Asn Gln Phe Gln Cys Leu Ser  
 185 190 195  
 Arg Phe Thr Lys Val Tyr Thr Cys Leu Pro Glu Ser Leu Lys Cys Asp  
 200 205 210  
 35 Gly Asn Ile Asp Cys Leu Asp Leu Gly Asp Glu Ile Asp Cys Asp Val  
 215 220 225  
 Pro Thr Cys Gly Gln Trp Leu Lys Tyr Phe Tyr Gly Thr Phe Asn Ser  
 230 235 240 245  
 40 Pro Asn Tyr Pro Asp Phe Tyr Pro Pro Gly Ser Asn Cys Thr Trp Leu  
 250 255 260  
 Ile Asp Thr Gly Asp His Arg Lys Val Ile Leu Arg Phe Thr Asp Phe  
 45 265 270 275  
 Lys Leu Asp Gly Thr Gly Tyr Gly Asp Tyr Val Lys Ile Tyr Asp Gly  
 280 285 290  
 50 Leu Glu Glu Asn Pro His Lys Leu Leu Arg Val Leu Thr Ala Phe Asp  
 295 300 305  
 Ser His Ala Pro Leu Thr Val Val Ser Ser Ser Gly Gln Ile Arg Val

	310	315	320	325
	His Phe Cys Ala Asp Lys Val Asn Ala Ala Arg Gly Phe Asn Ala Thr			
5		330	335	340
	Tyr Gln Val Asp Gly Phe Cys Leu Pro Trp Glu Ile Pro Cys Gly Gly			
		345	350	355
10	Asn Trp Gly Cys Tyr Thr Glu Gln Gln Arg Cys Asp Gly Tyr Trp His			
		360	365	370
	Cys Pro Asn Gly Arg Asp Glu Thr Asn Cys Thr Met Cys Gln Lys Glu			
		375	380	385
15	Glu Phe Pro Cys Ser Arg Asn Gly Val Cys Tyr Pro Arg Ser Asp Arg			
	390	395	400	405
	Cys Asn Tyr Gln Asn His Cys Pro Asn Gly Ser Asp Glu Lys Asn Cys			
		410	415	420
20	Phe Phe Cys Gln Pro Gly Asn Phe His Cys Lys Asn Asn Arg Cys Val			
		425	430	435
	Phe Glu Ser Trp Val Cys Asp Ser Gln Asp Asp Cys Gly Asp Gly Ser			
25		440	445	450
	Asp Glu Glu Asn Cys Pro Val Ile Val Pro Thr Arg Val Ile Thr Ala			
		455	460	465
30	Ala Val Ile Gly Ser Leu Ile Cys Gly Leu Leu Leu Val Ile Ala Leu			
	470	475	480	485
	Gly Cys Thr Cys Lys Leu Tyr Ser Leu Arg Met Phe Glu Arg Arg Ser			
		490	495	500
35	Phe Glu Thr Gln Leu Ser Arg Val Glu Ala Glu Leu Leu Arg Arg Glu			
		505	510	515
	Ala Pro Pro Ser Tyr Gly Gln Ile Ala Gln Gly Leu Ile Pro Pro			
		520	525	530
40	Val Glu Asp Phe Pro Val Cys Ser Pro Asn Gln Ala Ser Val Leu Glu			
		535	540	545
	Asn Leu Arg Leu Ala Val Arg Ser Gln Leu Gly Phe Thr Ser Val Arg			
45	550	555	560	565
	Leu Pro Met Ala Gly Arg Ser Ser Asn Ile Trp Asn Arg Ile Phe Asn			
		570	575	580
	Phe Ala Arg Ser Arg His Ser Gly Ser Leu Ala Leu Val Ser Ala Asp			
50		585	590	595
	Gly Asp Glu Val Val Pro Ser Gln Ser Thr Ser Arg Glu Pro Glu Arg			

55

	600	605	610
	Asn His Thr His Arg Ser Leu Phe Ser Val Glu Ser Asp Asp Thr Asp		
5	615	620	625
	Thr Glu Asn Glu Arg Arg Asp Met Ala Gly Ala Ser Gly Gly Val Ala		
	630	635	640 645
10	Ala Pro Leu Pro Gln Lys Val Pro Pro Thr Thr Ala Val Glu Ala Thr		
	650	655	660
	Val Gly Ala Cys Ala Ser Ser Ser Thr Gln Ser Thr Arg Gly Gly His		
	665	670	675
15	Ala Asp Asn Gly Arg Asp Val Thr Ser Val Glu Pro Pro Ser Val Ser		
	680	685	690
	Pro Ala Arg His Gln Leu Thr Ser Ala Leu Ser Arg Met Thr Gln Gly		
20	695	700	705
	Leu Arg Trp Val Arg Phe Thr Leu Gly Arg Ser Ser Ser Leu Ser Gln		
	710	715	720 725
	Asn Gln Ser Pro Leu Arg Gln Leu Asp Asn Gly Val Ser Gly Arg Glu		
25	730	735	740
	Asp Asp Asp Asp Val Glu Met Leu Ile Pro Ile Ser Asp Gly Ser Ser		
	745	750	755
30	Asp Phe Asp Val Asn Asp Cys Ser Arg Pro Leu Leu Asp Leu Ala Ser		
	760	765	770
	Asp Gln Gly Gln Gly Leu Arg Gln Pro Tyr Asn Ala Thr Asn Pro Gly		
	775	780	785
35	Val Arg Pro Ser Asn Arg Asp Gly Pro Cys Glu Arg Cys Gly Ile Val		
	790	795	800 805
	His Thr Ala Gln Ile Pro Asp Thr Cys Leu Glu Val Thr Leu Lys Asn		
40	810	815	820
	Glu Thr Ser Asp Asp Glu Ala Leu Leu Leu Cys		
	825	830	
45	<210> 71		
	<211> 2577		
	<212> DNA		
50	<213> Homo sapiens		
	<400> 71		

55

atggcctgtc gctggagcac aaaagagctt ccgcggtgga ggtctgcgtt gctcttgcct 60  
 ttccctgcctg ggggtgtacgg aaatgggtgt cttgcagaac attctgaaaa tgtgcatatt 120  
 5 tcaggagtgt caacigtctg tggagagact ccagagcaaa tacgagcacc aagtggcata 180  
 atcacaagcc caggctggcc ttctgaatat cctgcaaaaa tcaactgtag ctggttcata 240  
 agggcaaac caggcgaaat cattactata agttttcagg atttgatat tcaagatcc 300  
 10 agaagggtgca atttggactg gttagacaata gaaacataca agaalaatga aagttacaga 360  
 gcttgtggtt ccacaattcc acctccgtat atctcttcac aagaccacat ctggattagg 420  
 ttctattcgg atgacaacat cctagaaag ggtttcagac tggcatattt ttcaggga 480  
 tctgaggaa ccaattgtgc ttgtatcag ttctgtgtg gtaattgaaa gtgtatacca 540  
 15 gaagccigga aatgtaata catggaatga tgtggagata gttccgatga agagatctgt 600  
 gccaaagaag caaatcctcc aactgcgtc gcttttcaac cctgtgctta caaccagttc 660  
 cagtgtttat cccgttttac caaagtttac acctgcctcc ccgaatcttt aaaaatgtat 720  
 gggaacattg actgccttga cctaggagat gagatagact gtgatgtgcc aacatgtggg 780  
 20 caatggctaa aatatittta tggtaattt aattctccca attatccaga cttttatctt 840  
 cctggaagca attgcacctg gtaaatagac actgggtatc accgtaaagt cattttacgc 900  
 ttcatigact ttaaacitga tggtaattt taaggatgt atgtcaaaa ataatgtgga 960  
 25 ttgaggaga atccacacaa gcttttgcgt gttgtgacag cttttgattc tcatgcacct 1020  
 cttacagtgt ttctttctt tggacagata aggttacatt ttgtgtctga taaagtgaat 1080  
 gctgcaagg gatttaatgc tacttacaa gtatgtgggt tctgtttgcc atgggaata 1140  
 30 cctgtggag gtaactggg gtgttatact gagcagcagc gttgtgatgg gtattggcat 1200  
 tgcctaatg gaaggatga aaccaattgt acctgtgcc agaaggaga atttccatgt 1260  
 tcccgaatg gtgtcttga tctctgtct gatcgtgca actaccaga tcatgccca 1320  
 aatggctcag atgaaaaaa ctgtttttt tgccaaccag gaaatttcca ttgtaaaac 1380  
 35 aatcgttgtg tgttgaag tgggtgtgt gattctcaag atgactgtgg tgaatgcagc 1440  
 galgaagaaa attgcccagt aatcgtgctt achagagta tcatgtctgc cgtctagggt 1500  
 agctctatct gttgctgtt actcgtcata gcatgggat gtacttgtaa gctttattct 1560  
 ctgagaatgt ttgaagaag atcatttga acacagtgt caagagtgga agcagaattg 1620  
 40 tlaagaagag aagctcttc ctctgtatga caattgatt ctgagggtt aattccacca 1680  
 gtgaagatt ttcgttttg ttacattat caggcttctg ttttgaaaa tctgaggcta 1740  
 gcgttactgt ctgacttgg atttactta gtcaggcttc ctatggcagg cagatcaagc 1800  
 45 aacatttga accgtattt taattttga agatcagtc attctgggtc attggtttg 1860  
 gctcagcag atggatgta ggttgcctt agtcaguga ccagtagaga acctgagaga 1920  
 aatcatatc acagaagttt gtttccgtg ggtctgtat atacagacac agaaatgag 1980  
 50 agnagnata tggcaggagc atcgtgtgt gttcagctc ctttgcctca aaatgtccct 2040  
 cccacatcgg cagtagnaag gncugltggt gctgtgtca gttctctaac tcnagtlacc 2100  
 cgtgtgtggt atgcatata tttgaagggt gttcaggtg tggacccccc aatgtgtgt 2160

ccagcacgic accagcttac aagtcactc agtcgtatga ctcaggggct acgtgggta 2220  
 cgttttacat taggacgac aagttccca agtcagaacc agatccttt gagacaactt 2280  
 5 gataatgggg taagtggaag agaagaatgat gatgatgttg aaatgctaata tccaatttct 2340  
 gatggatctt cagacttga tgtgaatgac tgcctccagac ctcttcttga tcttgcccta 2400  
 gatcaaggac aagggttag acaaccatat aatgcaaca atcctggagi aaggccaagt 2460  
 aatcgagatg gcccttctga gcgctgtgtt atgtccaca ctgccagat accagacact 2520  
 10 tgcctagaag taacactgaa aaacgaacg agtgatgatg aggttttgtt actttgt 2577

<210> 72

15 <211> 3088

<212> DNA

<213> Homo sapiens

20

<200>

<221> CDS

<222> (41)..(2617)

25

<220>

<221> sig peptide

<222> (41)..(121)

30

<200>

<221> mat peptide

<222> (122)..(2617)

35

<400>

ctcctccgic tctctctctc tctctctc tgcctgggtt atg gcc tgt cgc tgg 55  
 40 Met Ala Cys Arg Trp  
 -27 -25  
 agc aca ann gag tct cgg cgg tgg agg tct gcg ttg ctc ttg ctt ttc 103  
 45 Ser Thr Lys Glu Ser Pro Arg Trp Arg Ser Ala Leu Leu Leu Leu Phe  
 -20 -15 -10  
 ctc gct ggg gtg tac gga aat ggt gct ctt gca gaa cat tct gaa aat 151  
 50 Leu Ala Gly Val Tyr Gly Asn Gly Ala Leu Ala Glu His Ser Glu Asn  
 -5 1 5 10  
 gtg cat att tca gga gtg tcn act gct tgt gga gag act cca gag cat 199

55



	Val His Ile Ser Gly Val Ser Thr Ala Cys Gly Glu Thr Pro Glu Gln	
	15 20 25	
5	ata cga gca cca agt ggc ata atc aca agc cca ggc tgg cct tct gaa	247
	Ile Arg Ala Pro Ser Gly Ile Ile Thr Ser Pro Gly Trp Pro Ser Glu	
	30 35 40	
10	tat cct gca aaa atc aac tgt agc tgg ttc ata agg gca aac cca ggc	295
	Tyr Pro Ala Lys Ile Asn Cys Ser Trp Phe Ile Arg Ala Asn Pro Gly	
	45 50 55	
15	gaa atc att act ata agt ttt cag gat ttt gat att caa gga tcc aga	343
	Glu Ile Ile Thr Ile Ser Phe Gln Asp Phe Asp Ile Gln Gly Ser Arg	
	60 65 70	
	agg tgc aat ttg gac tgg ttg aca ata gaa aca tac aag aat att gaa	391
20	Arg Cys Asn Leu Asp Trp Leu Thr Ile Glu Thr Tyr Lys Asn Ile Glu	
	75 80 85 90	
	agt tac aga gct tgt ggt tcc aca att cca cct ccg tat atc tct tca	439
	Ser Tyr Arg Ala Cys Gly Ser Thr Ile Pro Pro Pro Tyr Ile Ser Ser	
25	95 100 105	
	caa gac cac atc tgg att agg ttt cat tcc gat gac aac atc tct aga	487
	Gln Asp His Ile Trp Ile Arg Phe His Ser Asp Asp Asn Ile Ser Arg	
30	110 115 120	
	aag ggt ttc aga ctg gca tat ttt tca ggg aaa tct gag gaa cca aat	535
	Lys Gly Phe Arg Leu Ala Tyr Phe Ser Gly Lys Ser Glu Glu Pro Asn	
	125 130 135	
35	tgt gct tgt gat cag ttt cgt tgt ggt aat gga aag tgt ata cca gaa	583
	Cys Ala Cys Asp Gln Phe Arg Cys Gly Asn Gly Lys Cys Ile Pro Glu	
	140 145 150	
40	gcc tgg aaa tgt aat aac atg gat gaa tgt gga gal agt tcc gat gaa	631
	Ala Trp Lys Cys Asn Asn Met Asp Glu Cys Gly Asp Ser Ser Asp Glu	
	155 160 165 170	
	gag atc tgt gcc aaa gaa gca aat cct cca act gct gct gct ttt caa	679
45	Glu Ile Cys Ala Lys Glu Ala Asn Pro Pro Thr Ala Ala Ala Phe Gln	
	175 180 185	
	ccc tgt gct tac aac cag ttc cag tgt ttn tcc cgt ttt acc aaa gtt	727
50	Pro Cys Ala Tyr Asn Gln Phe Gln Cys Leu Ser Arg Phe Thr Lys Val	
	190 195 200	
	tac act tgc etc ccc gan tct ttn aaa tgt gat ggg aac att gac tgc	775

55

Tyr Thr Cys Leu Pro Glu Ser Leu Lys Cys Asp Gly Asn Ile Asp Cys  
 205 210 215  
 5 ctt gac cta gga gat gag ata gac tgt gat gtg cca aca tgt ggg caa 823  
 Leu Asp Leu Gly Asp Glu Ile Asp Cys Asp Val Pro Thr Cys Gly Gln  
 220 225 230  
 10 tgg cta aaa tat ttt tat ggt act ttt aat tct ccc aat tat cca gac 871  
 Trp Leu Lys Tyr Phe Tyr Gly Thr Phe Asn Ser Pro Asn Tyr Pro Asp  
 235 240 245 250  
 15 ttt tat cct cct gga agc aat tgc acc tgg tta ata gac act ggt gat 919  
 Phe Tyr Pro Pro Gly Ser Asn Cys Thr Trp Leu Ile Asp Thr Gly Asp  
 255 260 265  
 cac cgt aaa gtc att tta cgc ttc act gac ttt aaa ctt gat ggt act 967  
 His Arg Lys Val Ile Leu Arg Phe Thr Asp Phe Lys Leu Asp Gly Thr  
 270 275 280  
 ggt tal ggt gat tat gtc aaa ata tat gat gga tta gag gag aat cca 1015  
 Gly Tyr Gly Asp Tyr Val Lys Ile Tyr Asp Gly Leu Glu Glu Asn Pro  
 285 290 295  
 25 cac aag ctt ttg cgt gtg ttg aca gct ttt gat tct cat gca cct ctt 1063  
 His Lys Leu Leu Arg Val Leu Thr Ala Phe Asp Ser His Ala Pro Leu  
 300 305 310  
 30 aca gtl gtl tct tct tct gga cag ata agg gta cat ttt tgt gct gat 1111  
 Thr Val Val Ser Ser Ser Gly Gln Ile Arg Val His Phe Cys Ala Asp  
 315 320 325 330  
 35 aaa glg aat gct gca agg gga ttt aat gct act tac caa gta gat ggg 1159  
 Lys Val Asn Ala Ala Arg Gly Phe Asn Ala Thr Tyr Gln Val Asp Gly  
 335 340 345  
 40 ttc tgl ttg cca tgg gaa ata ccc tgt gga ggt aac tgg ggg tgt tat 1207  
 Phe Cys Leu Pro Trp Glu Ile Pro Cys Gly Gly Asn Trp Gly Cys Tyr  
 350 355 360  
 act gag cag cag cgt tgt gat ggg tat tgg cat tgc cca aat gga agg 1255  
 Thr Glu Gln Gln Arg Cys Asp Gly Tyr Trp His Cys Pro Asn Gly Arg  
 365 370 375  
 gnt gaa ucc aat tgt acc atg tgc cag aag gaa gaa ttt cca tgt tcc 1303  
 Asp Glu Thr Asn Cys Thr Met Cys Gln Lys Glu Glu Phe Pro Cys Ser  
 380 385 390  
 50 cga aat ggt gtc tgt tat cct cgt tct gat cgc tgc aac tnc cpg aat 1351

55

	Arg Asn Gly Val Cys Tyr Pro Arg Ser Asp Arg Cys Asn Tyr Gln Asn	
	395                      400                      405                      410	
5	cat tgc cca aat ggc tca gat gaa aaa aac tgc ttt ttt tgc caa cca	1399
	His Cys Pro Asn Gly Ser Asp Glu Lys Asn Cys Phe Phe Cys Gln Pro	
	415                      420                      425	
10	gga aat ttc cat tgt aaa aac aat cgt tgt gtg ttt gaa agt tgg gtg	1447
	Gly Asn Phe His Cys Lys Asn Asn Arg Cys Val Phe Glu Ser Trp Val	
	430                      435                      440	
15	tgt gat tct caa gat gac tgt ggt gat ggc agc gat gaa gaa aat tgc	1495
	Cys Asp Ser Gln Asp Asp Cys Gly Asp Gly Ser Asp Glu Glu Asn Cys	
	445                      450                      455	
20	cca gta atc gtg cct aca aga gtc atc act gct gcc gtc ata ggg agc	1543
	Pro Val Ile Val Pro Thr Arg Val Ile Thr Ala Ala Val Ile Gly Ser	
	460                      465                      470	
25	ctc atc tgt ggc ctg tta ctc gtc ata gca ttg gga tgt act tgt aag	1591
	Leu Ile Cys Gly Leu Leu Leu Val Ile Ala Leu Gly Cys Thr Cys Lys	
	475                      480                      485                      490	
30	ctt tat tct ctg aga atg ttt gaa aga aga tca ttt gaa aca cag ttg	1639
	Leu Tyr Ser Leu Arg Met Phe Glu Arg Arg Ser Phe Glu Thr Gln Leu	
	495                      500                      505	
35	tca aga gtg gaa gca gaa tlg tta aga aga gaa gct cct ccc tgc tat	1687
	Ser Arg Val Glu Ala Glu Leu Leu Arg Arg Glu Ala Pro Pro Ser Tyr	
	510                      515                      520	
40	gga caa tlg att gct cug ggt tta att cca cca gtt gaa gat ttt cct	1735
	Gly Gln Leu Ile Ala Gln Gly Leu Ile Pro Pro Val Glu Asp Phe Pro	
	525                      530                      535	
45	glt tgt tca cct aat cag gct tct gtt ttg gaa aat ctg agg cta gcg	1783
	Val Cys Ser Pro Asn Gln Ala Ser Val Leu Glu Asn Leu Arg Leu Ala	
	540                      545                      550	
50	gta cga tct cag ctt gga ttt nct tca gtc agg ctt cct atg gca ggc	1831
	Val Arg Ser Gln Leu Gly Phe Thr Ser Val Arg Leu Pro Met Ala Gly	
	555                      560                      565                      570	
55	aga tca agc aac att tgg aac cgt att ttt aat ttt gca aga tca cgt	1879
	Arg Ser Ser Asn Ile Trp Asn Arg Ile Phe Asn Phe Ala Arg Ser Arg	
	575                      580                      585	
	cat tct ggg tcn ttg gct ttg gtc tca gca gat gga gat gag gtt gtc	1927

His Ser Gly Ser Leu Ala Leu Val Ser Ala Asp Gly Asp Glu Val Val  
 590 595 600  
 5 cct agt cag agt acc agt aga gaa cct gag aga aat cat act cac aga 1975  
 Pro Ser Gln Ser Thr Ser Arg Glu Pro Glu Arg Asn His Thr His Arg  
 605 610 615  
 10 agt ttg ttt tcc gtg gag tct gat gat aca gac aca gaa aat gag aga 2023  
 Ser Leu Phe Ser Val Glu Ser Asp Asp Thr Asp Thr Glu Asn Glu Arg  
 620 625 630  
 aga gat atg gca gga gca tct ggt ggg gtt gca gct cct ttg cct caa 2071  
 15 Arg Asp Met Ala Gly Ala Ser Gly Gly Val Ala Ala Pro Leu Pro Gln  
 635 640 645 650  
 aaa gtc cct ccc aca acg gca gta gaa gcg aca gta gga gca tgt gca 2119  
 20 Lys Val Pro Pro Thr Thr Ala Val Glu Ala Thr Val Gly Ala Cys Ala  
 655 660 665  
 agt tcc tca act cag agt acc cga ggt ggc cat gca gat aat gga agg 2167  
 Ser Ser Ser Thr Gln Ser Thr Arg Gly Gly His Ala Asp Asn Gly Arg  
 670 675 680  
 25 gat gtg aca agt gtg gaa ccc cca agt gtg agt cca gca cgt cac cag 2215  
 Asp Val Thr Ser Val Glu Pro Pro Ser Val Ser Pro Ala Arg His Gln  
 685 690 695  
 30 ctt aca agt gca ctc agt cgt atg act cag ggg cta cgc tgg gta cgt 2263  
 Leu Thr Ser Ala Leu Ser Arg Met Thr Gln Gly Leu Arg Trp Val Arg  
 700 705 710  
 35 ttt aca tta gga cga tca agt tcc cta agt cag aac cag agt cct ttg 2311  
 Phe Thr Leu Gly Arg Ser Ser Ser Leu Ser Gln Asn Gln Ser Pro Leu  
 715 720 725 730  
 aga caa ctt gat aat ggg gta agt gga aga gaa gat gat gat gat gtt 2359  
 40 Arg Gln Leu Asp Asn Gly Val Ser Gly Arg Glu Asp Asp Asp Asp Val  
 735 740 745  
 gaa atg cta att cca att tct gat gga tct tca gac ttt gat gtg aat 2407  
 45 Glu Met Leu Ile Pro Ile Ser Asp Gly Ser Ser Asp Phe Asp Val Asn  
 750 755 760  
 gac tgc tcc agn cct ctt ctt gnt ctt gcc tca gat can gga can ggg 2455  
 Asp Cys Ser Arg Pro Leu Leu Asp Leu Ala Ser Asp Gln Gly Gln Gly  
 765 770 775  
 50 ctt agn can cca tat aat gcn aca aat cct gga gta agc cca agt aat 2503

55

Leu Arg Gln Pro Tyr Asn Ala Thr Asn Pro Gly Val Arg Pro Ser Asn  
 780 785 790  
 5 cga gat ggc ccc tgt gag cgc tgt ggt att gtc cac act gcc cag ata 2551  
 Arg Asp Gly Pro Cys Glu Arg Cys Gly Ile Val His Thr Ala Gln Ile  
 795 800 805 810  
 10 cca gac act tgc tta gaa gta aca ctg aaa aac gaa acg agt gat gat 2599  
 Pro Asp Thr Cys Leu Glu Val Thr Leu Lys Asn Glu Thr Ser Asp Asp  
 815 820 825  
 gag gct ttg tta ctt tgt taggtacgaa tcacataagg gagattgtat 2647  
 15 Glu Ala Leu Leu Leu Cys  
 830  
 acaagttgga gcaatatcca ttattatttt tgaacttta cagttaaact agttttagtt 2707  
 20 taaaaagaaa aaatgcaggg tgatttcitta ttattatatg ttagccctgca tggttaaatt 2767  
 cgacaacttg taactctatg aacttagagt ttactatitt agcagctaaa aatgcatcac 2827  
 atattcatal tgttcaataa tgcctttica ttgtttctg attgttttca tctgataact 2887  
 gtagttcact gtgaaatgt ggcctgctga acccatttga ttgtcatttt tatctatcct 2947  
 25 atgttaaatg gtttgttttt acaaaataat acccttatitt aattgaaacg tttatgcttt 3007  
 tgccaacaca tcttgtaact taatatacta gatgttaagg ttgttaatgt acaaaaaaaaa 3067  
 aaaaaaaaaa a 3088  
 30  
 <210> 73  
 <211> 687  
 <212> PRT  
 35 <213> Homo sapiens  
 <400> 73  
 40 Met Thr Pro Gln Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu Ser Leu  
 -25 -20 -15 -10  
 Leu Phe Leu Val Gln Gly Ala His Gly Arg Gly His Arg Glu Asp Phe  
 -5 1 5  
 45 Arg Phe Cys Ser Gln Arg Asn Gln Thr His Arg Ser Ser Leu His Tyr  
 10 15 20  
 Lys Pro Thr Pro Asp Leu Arg Ile Ser Ile Glu Asn Ser Glu Glu Ala  
 25 30 35  
 50 Leu Thr Val His Ala Pro Phe Pro Ala Ala His Pro Ala Ser Arg Ser  
 40 45 50 55

Phe Pro Asp Pro Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp Asn Arg  
 60 65 70  
 5 His Ala Gly Arg Leu His Leu Leu Tyr Gly Lys Arg Asp Phe Leu Leu  
 75 80 85  
 Ser Asp Lys Ala Ser Ser Leu Leu Cys Phe Gln His Gln Glu Glu Ser  
 90 95 100  
 10 Leu Ala Gln Gly Pro Pro Leu Leu Ala Thr Ser Val Thr Ser Trp Trp  
 105 110 115  
 Ser Pro Gln Asn Ile Ser Leu Pro Ser Ala Ala Ser Phe Thr Phe Ser  
 15 120 125 130 135  
 Phe His Ser Pro Pro His Thr Ala Ala His Asn Ala Ser Val Asp Met  
 140 145 150  
 20 Cys Glu Leu Lys Arg Asp Leu Gln Leu Leu Ser Gln Phe Leu Lys His  
 155 160 165  
 Pro Gln Lys Ala Ser Arg Arg Pro Ser Ala Ala Pro Ala Ser Gln Gln  
 170 175 180  
 25 Leu Gln Ser Leu Glu Ser Lys Leu Thr Ser Val Arg Phe Met Gly Asp  
 185 190 195  
 Met Val Ser Phe Glu Glu Asp Arg Ile Asn Ala Thr Val Trp Lys Leu  
 30 200 205 210 215  
 Gln Pro Thr Ala Gly Leu Gln Asp Leu His Ile His Ser Arg Gln Glu  
 220 225 230  
 Glu Glu Gln Ser Glu Ile Met Glu Tyr Ser Val Leu Leu Pro Arg Thr  
 35 235 240 245  
 Leu Phe Gln Arg Thr Lys Gly Arg Arg Gly Glu Ala Glu Lys Arg Leu  
 250 255 260  
 40 Leu Leu Val Asp Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser  
 265 270 275  
 Ser Gln Val Leu Gly Glu Lys Val Leu Gly Ile Val Val Gln Asn Thr  
 280 285 290 295  
 45 Lys Val Ala Asn Leu Thr Gln Pro Val Val Leu Thr Phe Gln His Gln  
 300 305 310  
 Leu Gln Pro Lys Asn Val Thr Leu Gln Cys Val Phe Trp Val Glu Asp  
 315 320 325  
 50 Pro Thr Leu Ser Ser Pro Gly His Trp Ser Ser Ala Gly Cys Glu Thr  
 330 335 340  
 55

Val Arg Arg Glu Thr Gln Thr Ser Cys Phe Cys Asn His Leu Thr Tyr  
 345 350 355  
 5 Phe Ala Val Leu Met Val Ser Ser Val Glu Val Asp Ala Val His Lys  
 360 365 370 375  
 His Tyr Leu Ser Leu Leu Ser Tyr Val Gly Cys Val Val Ser Ala Leu  
 10 380 385 390  
 Ala Cys Leu Val Ser Ile Ala Ala Tyr Leu Cys Ser Arg Arg Lys Pro  
 395 400 405  
 Arg Asp Tyr Thr Ile Lys Val His Met Asn Leu Leu Leu Ala Val Phe  
 15 410 415 420  
 Leu Leu Asp Thr Ser Phe Leu Leu Ser Glu Pro Val Ala Leu Thr Gly  
 425 430 435  
 Ser Glu Ala Gly Cys Arg Ala Ser Ala Ile Phe Leu His Phe Ser Leu  
 20 440 445 450 455  
 Leu Thr Cys Leu Ser Trp Met Gly Leu Glu Gly Tyr Asn Leu Tyr Arg  
 460 465 470  
 25 Leu Val Val Glu Val Phe Gly Thr Tyr Val Pro Gly Tyr Leu Leu Lys  
 475 480 485  
 Leu Ser Ala Met Gly Trp Gly Phe Pro Ile Phe Leu Val Thr Leu Val  
 30 490 495 500  
 Ala Leu Val Asp Val Asp Asn Tyr Gly Pro Ile Ile Leu Ala Val His  
 505 510 515  
 Arg Thr Pro Glu Gly Val Ile Tyr Pro Ser Met Cys Trp Ile Arg Asp  
 35 520 525 530 535  
 Ser Leu Val Ser Tyr Ile Thr Asn Leu Gly Leu Phe Ser Leu Val Phe  
 540 545 550  
 40 Leu Phe Asn Met Ala Met Leu Ala Thr Met Val Val Gln Ile Leu Arg  
 555 560 565  
 Leu Arg Pro His Thr Gln Lys Trp Ser His Val Leu Thr Leu Leu Gly  
 570 575 580  
 45 Leu Ser Leu Val Leu Gly Leu Pro Trp Ala Leu Ile Phe Phe Ser Phe  
 585 590 595  
 Ala Ser Gly Thr Phe Gln Leu Val Val Leu Tyr Leu Phe Ser Ile Ile  
 50 600 605 610 615  
 Thr Ser Phe Gln Gly Phe Leu Ile Phe Ile Trp Tyr Trp Ser Met Arg  
 620 625 630

55

Leu Gln Ala Arg Gly Gly Pro Ser Pro Leu Lys Ser Asn Ser Asp Ser

635

640

645

5

Ala Arg Leu Pro Ile Ser Ser Gly Ser Thr Ser Ser Arg Ile

650

655

660

10

&lt;210&gt; 74

&lt;211&gt; 2061

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

15

&lt;400&gt; 74

20

25

30

35

40

45

50

55

atgactcccc agtcgtgct gcagacgaca ctgttctctc tgagtcctgt ctctctgggc 60  
 caaggtgccc acggcagggg ccacagggaa gactttctgt tctgcagcca gcggaaccag 120  
 acacacagga gcagcctcca ctacaaaccc acaccagacc tgcgcattct catcgagaac 180  
 tccgaagagg ccttcacagt ccatgccctt ttcctgcag cccaccctgc ttcctgatcc 240  
 ttcctgacc ccaggggctt ctaccacttc tgcctctact ggaaccgaca tgcctggaga 300  
 ttacatcttc tctatggcaa gcgtgacttc ttgttgagtg acaaagcttc tagcctcttc 360  
 tgcttccagc accaggagga gagcctggct cagggccccc cgtctttagc cacttctgtc 420  
 acctcctggt ggagccctca gaacatcagc ctgcccagtg ccgccagctt cacttcttcc 480  
 ttcacagtc ctcccacac ggccgcctac aatgccctcg tggacatgtg cgagctcaaa 540  
 agggacctcc agctgtcag ccagttcttg aagcatcccc agaaggcttc aaggaggccc 600  
 tgggtgccc ccgccagcca gcagttgag agcttgaggt cgaactgac ctctgtgaga 660  
 ttcatggggg acatgggtgc ctctgaggag gaccggatca acgccacggt gtggaagctc 720  
 cagcccacag ccggcctcca ggacctgcac atccactccc ggcaggggga ggagcagagc 780  
 gagatcatgg agtactcggt gctgtctgtt cgaacactct tccagaggac gaaaggccgg 840  
 aggggggagg ctgagaagag acctctcttg gtagcttca gcagccahgc cctgttccag 900  
 gacaagaatt ccagccaagl cctgggtgag aaggtcttgg ggaattgtgt acagaacacc 960  
 aaagttagcca acctacagga gccctgggtg ctacacttcc agcaccagct acagccgaag 1020  
 aatgtgactc tgcattgtgt gtcttgggtt gaagacccca catlgagcag cccggggcat 1080  
 tggagcagtg ctgggtgtga gaccgtcagg agagaacccc aaacatcttg ctcttgcac 1140  
 cacttgacct accttgaggt gctgattgtc tctctggttg aggtggagct cgtgcacaag 1200  
 cactlaccga gccctctctc ctacgtgggc tglgtctgt ctgccctggc ctgcttgc 1260  
 agcattgccc cctacctctg ctccaggagg aaacctcggt acatcacctt cuaggtgcac 1320  
 algaacctgc tgcgtggcgt ctctctgttg gacacagct tctgtctcag cgagccgggt 1380  
 gccctgacag gctctgaggt tggctgccc gccagtgcca tctctctgca ctctctctg 1440  
 ctctctctcc ttcctggtt ggcctctgag ggtctacacc tctaccgact ctggtgtgag 1500



gtctttggca cctatgtccc tggctacctc ctcaagctga gcgccatggg ctggggcttc 1560  
 cccatcttcc tggtagcgt ggtggccctg glggaigigg acaactatgg ccccatcacc 1620  
 5 ttggctgtgc ataggactcc agaggggcgc atctaccctt ccatgtgtcg gatccgggac 1680  
 tccctggica gctacatcac caacctgggc ctcttcagcc tgggttttct gttcaacatg 1740  
 gccatgctag ccacatggt ggtgcagatc ctgcggctgc gccccacac ccaaaagtgg 1800  
 10 tcacatgtgc tgacactgtt ggccctcagc ctggctcttg gcctgcccctg ggccttgatc 1860  
 ttcttctctt ttgcttctgg caccctccag ctgtctgtcc tctacctttt cagcatcacc 1920  
 acctccttcc aaggcttctt catcttcacc tggtagctgt ccatgcggct gcaggcccgg 1980  
 ggtggccctt cccctctgaa gagcaactca gacagcgcca ggctcccat cagctcgggc 2040  
 15 agcacctcgt ccagccgcat c 2061

<210> 75

20 <211> 3564

<212> DNA

<213> Homo sapiens

25 <200>

<221> CDS

<222> (43)..(2103)

30 <220>

<221> sig peptide

<222> (43)..(117)

35 <221> mat peptide

<222> (118)..(2103)

40 <400> 75

attacaggtg gtagcttcca agagtagctc cgtcggagga aa atg act ccc cag 54

Met Thr Pro Gln

45 -25

tcg ctg ctg cag acg acn ctg ttc ctg ctg agt ctg ctc ttc ctg gtc 102

Ser Leu Leu Gln Thr Thr Leu Phe Leu Leu Ser Leu Leu Phe Leu Val

50 -20 -15 -10

caa ggt gcc cag gcc agc gcc cag agc gaa gac ttt cgc ttc tgc agc 150

Gln Gly Ala His Gly Arg Gly His Arg Glu Asp Phe Arg Phe Cys Ser

55

	-5	1	5	10	
	cag cgg aac cag aca cac agg agc agc ctc cac tac aaa ccc aca cca				198
5	Gln Arg Asn Gln Thr His Arg Ser Ser Leu His Tyr Lys Pro Thr Pro				
	15	20	25		
	gac ctg cgc atc tcc atc gag aac tcc gaa gag gcc ctc aca gtc cat				246
10	Asp Leu Arg Ile Ser Ile Glu Asn Ser Glu Glu Ala Leu Thr Val His				
	30	35	40		
	gcc cct ttc cct gca gcc cac cct gct tcc cga tcc ttc cct gac ccc				294
15	Ala Pro Phe Pro Ala Ala His Pro Ala Ser Arg Ser Phe Pro Asp Pro				
	45	50	55		
	agg gcc ctc tac cac ttc tgc ctc tac tgg aac cga cat gct ggg aga				342
	Arg Gly Leu Tyr His Phe Cys Leu Tyr Trp Asn Arg His Ala Gly Arg				
20	60	65	70	75	
	tta cat ctt ctc tat ggc aag cgt gac ttc ttg ctg agt gac aaa gcc				390
	Leu His Leu Leu Tyr Gly Lys Arg Asp Phe Leu Leu Ser Asp Lys Ala				
	80	85	90		
25	tct agc ctc ctc tgc ttc cag cac cag gag gag agc ctg gct cag gcc				438
	Ser Ser Leu Leu Cys Phe Gln His Gln Glu Glu Ser Leu Ala Gln Gly				
	95	100	105		
30	ccc ccg ctg tta gcc act tct gtc acc tcc tgg tgg agc cct cag aac				486
	Pro Pro Leu Leu Ala Thr Ser Val Thr Ser Trp Trp Ser Pro Gln Asn				
	110	115	120		
	atc agc ctg ccc agt gcc gcc agc ttc acc ttc tcc ttc cac agt cct				534
35	Ile Ser Leu Pro Ser Ala Ala Ser Phe Thr Phe Ser Phe His Ser Pro				
	125	130	135		
	ccc cac acg gcc gct cac aat gcc tgg gtg gac atg tgc gag ctc aaa				582
40	Pro His Thr Ala Ala His Asn Ala Ser Val Asp Met Cys Glu Leu Lys				
	140	145	150	155	
	agg gac ctc cag ctg ctc agc cag ttc ctg aag cat ccc cag aag gcc				630
	Arg Asp Leu Gln Leu Leu Ser Gln Phe Leu Lys His Pro Gln Lys Ala				
45	160	165	170		
	tca agg agg ccc tgg gct gcc ccc gcc agc cag cag ttg cag agc ctg				678
	Ser Arg Arg Pro Ser Ala Ala Pro Ala Ser Gln Gln Leu Gln Ser Leu				
	175	180	185		
50	gag tgg aaa ctg acc tct gtg agt ttc atg ggg gac atg gtg tcc ttc				726
	Glu Ser Lys Leu Thr Ser Val Arg Phe Met Gly Asp Met Val Ser Phe				

55

	190	195	200	
	gag gag gac cgg atc aac gcc acg gtg tgg aag ctc cag ccc aca gcc			774
5	Glu Glu Asp Arg Ile Asn Ala Thr Val Trp Lys Leu Gln Pro Thr Ala			
	205	210	215	
	ggc ctc cag gac ctg cac atc cac tcc cgg cag gag gag gag cag agc			822
10	Gly Leu Gln Asp Leu His Ile His Ser Arg Gln Glu Glu Glu Gln Ser			
	220	225	230	235
	gag atc atg gag tac tcg gtg ctg ctg cct cga aca ctc ttc cag agg			870
15	Glu Ile Met Glu Tyr Ser Val Leu Leu Pro Arg Thr Leu Phe Gln Arg			
	240	245	250	
	acg aaa ggc cgg agg ggg gag gct gag aag aga ctc ctc ctg gtg gac			918
	Thr Lys Gly Arg Arg Gly Glu Ala Glu Lys Arg Leu Leu Leu Val Asp			
20	255	260	265	
	ttc agc agc caa gcc ctg ttc cag gac aag aat tcc agc caa gtc ctg			966
	Phe Ser Ser Gln Ala Leu Phe Gln Asp Lys Asn Ser Ser Gln Val Leu			
	270	275	280	
25	ggg gag aag gtc ttg ggg att gtg gta cag aac acc aaa gta gcc aac			1014
	Gly Glu Lys Val Leu Gly Ile Val Val Gln Asn Thr Lys Val Ala Asn			
	285	290	295	
30	ctc acg gag ccc gtg gtg ctc acc ttc cag cac cag cta cag ccg aag			1062
	Leu Thr Glu Pro Val Val Leu Thr Phe Gln His Gln Leu Gln Pro Lys			
	300	305	310	315
	aat gtg act ctg cau tgt gtg ttc tgg gtt gaa gac ccc aca ttg agc			1110
35	Asn Val Thr Leu Gln Cys Val Phe Trp Val Glu Asp Pro Thr Leu Ser			
	320	325	330	
	agc ccg ggg cat tgg agc agt gct ggg tgt gag acc gtc agg aga gaa			1158
40	Ser Pro Gly His Trp Ser Ser Ala Gly Cys Glu Thr Val Arg Arg Glu			
	335	340	345	
	acc caa aca tcc tgc ttc tgc aac cac ttg acc tac ttt gca gtg ctg			1206
	Thr Gln Thr Ser Cys Phe Cys Asn His Leu Thr Tyr Phe Ala Val Leu			
45	350	355	360	
	atg gtc tcc tcg gtg gag gtg gac gcc gtg cac aag cac tac ctg agc			1254
	Met Val Ser Ser Val Glu Val Asp Ala Val His Lys His Tyr Leu Ser			
	365	370	375	
50	ctc ctc tcc tac gtg ggc tgt gtc gtc tct gcc ctg gcc tgc ctt gtc			1302
	Leu Leu Ser Tyr Val Gly Cys Val Val Ser Ala Leu Ala Cys Leu Val			
55				

	380	385	390	395	
5	agc att gcc gcc tac ctc tgc tcc agg agg aaa cct cgg gac tac acc				1350
	Ser Ile Ala Ala Tyr Leu Cys Ser Arg Arg Lys Pro Arg Asp Tyr Thr				
	400	405	410		
10	atc aag gtg cac atg aac ctg ctg ctg gcc gtc ttc ctg ctg gac acg				1398
	Ile Lys Val His Met Asn Leu Leu Leu Ala Val Phe Leu Leu Asp Thr				
	415	420	425		
15	agc ttc ctg ctc agc gag ccg gtg gcc ctg aca ggc tct gag gct ggc				1446
	Ser Phe Leu Leu Ser Glu Pro Val Ala Leu Thr Gly Ser Glu Ala Gly				
	430	435	440		
20	tgc cga gcc agt gcc atc ttc ctg cac ttc tcc ctg ctc acc tgc ctt				1494
	Cys Arg Ala Ser Ala Ile Phe Leu His Phe Ser Leu Leu Thr Cys Leu				
	445	450	455		
25	tcc tgg atg ggc ctc gag ggg tac aac ctc tac cga ctc gtg gtg gag				1542
	Ser Trp Met Gly Leu Glu Gly Tyr Asn Leu Tyr Arg Leu Val Val Glu				
	460	465	470	475	
30	gtc ttt ggc acc tat gtc cct ggc tac cta ctc aag ctg agc gcc atg				1590
	Val Phe Gly Thr Tyr Val Pro Gly Tyr Leu Leu Lys Leu Ser Ala Met				
	480	485	490		
35	ggc tgg ggc ttc ccc atc ttt ctg gtg acg ctg gtg gcc ctg gtg gat				1638
	Gly Trp Gly Phe Pro Ile Phe Leu Val Thr Leu Val Ala Leu Val Asp				
	495	500	505		
40	gtg gac aac tat ggc ccc atc atc ttg gct gtg cat agx act cca gag				1686
	Val Asp Asn Tyr Gly Pro Ile Ile Leu Ala Val His Arg Thr Pro Glu				
	510	515	520		
45	ggc gtc atc tac cct tcc atg tgc tgg atc cgg gac tcc ctg gtc agc				1734
	Gly Val Ile Tyr Pro Ser Met Cys Trp Ile Arg Asp Ser Leu Val Ser				
	525	530	535		
50	tac atc acc aac ctg ggc ctc ttc agc ctg gtg ttt ctg ttc aac atg				1782
	Tyr Ile Thr Asn Leu Gly Leu Phe Ser Leu Val Phe Leu Phe Asn Met				
	540	545	550	555	
55	gcc atg cta gcc acc atg gtg gtg cag atc ctg cgg ctg cgc ccc cnc				1830
	Ala Met Leu Ala Thr Met Val Val Gln Ile Leu Arg Leu Arg Pro His				
	560	565	570		
60	acc cna ang tgg tcn cnt gta ctg nca ctg ctg ggc ctc ngt ctg gtc				1878
	Thr Gln Lys Trp Ser His Val Leu Thr Leu Leu Gly Leu Ser Leu Val				

575 580 585  
 5 ctt ggc ctg ccc tgg gcc ttg atc ttc ttc tcc ttt gct tct ggc acc 1926  
 Leu Gly Leu Pro Trp Ala Leu Ile Phe Phe Ser Phe Ala Ser Gly Thr  
 590 595 600  
 10 ttc cag ctt gtc gtc etc tac ctt ttc agc atc atc acc tcc ttc caa 1974  
 Phe Gln Leu Val Val Leu Tyr Leu Phe Ser Ile Ile Thr Ser Phe Gln  
 605 610 615  
 15 ggc ttc etc atc ttc atc tgg tac tgg tcc atg cgg ctg cag gcc cgg 2022  
 Gly Phe Leu Ile Phe Ile Trp Tyr Trp Ser Met Arg Leu Gln Ala Arg  
 620 625 630 635  
 20 ggt ggc ccc tcc cct ctg aag agc aac tca gac agc gcc agg etc ccc 2070  
 Gly Gly Pro Ser Pro Leu Lys Ser Asn Ser Asp Ser Ala Arg Leu Pro  
 640 645 650  
 25 atc agc tgg ggc agc acc tgg tcc agc cgc atc taggcctcca gccaccctgc 2123  
 Ile Ser Ser Gly Ser Thr Ser Ser Ser Arg Ile  
 655 660  
 30 ccaigtgatg aagcagagat gcggcctcgt cgcacactgc cigtggcccc cgagccaggc 2183  
 ccagcccccag gccagtcagc cgcagacttt ggaaagccca acgaccatgg agagatgggc 2243  
 cgttgcctatg gtggacggac tcccgggctg ggcttttgaa ttggccttgg ggactactcg 2303  
 35 gccttcactc agctccacag ggactcagaa glgcgcgcc atgctgccta gggtactcgc 2363  
 cccacatcig tcccaaccca gcggaggcc tggctctctc ttacaacccc tgggcccage 2423  
 cctcatatgt gggggccagg ccttggatct tgagggtctg gcacatcctt aatccctgc 2483  
 ccttgccttg gacagaaatg tggctccagt tgcctcgtct ctcgtggctc cctgagggc 2543  
 40 actcgcac ctcctcatt ttaacctcag gtggcaccca gggcgaalg ggcccagggc 2603  
 agaccctcag ggccagagcc ctggcggagg agaggccctt tggcaggagc acagcagcag 2663  
 ctgcctacc tctgagccca ggccccctcc ctcccacgc ccccagtc cccctccatc 2723  
 45 ttcctgggg ttcctcct cteccagggc ctcttgcct ctccttcac agctgggggt 2783  
 ccccattcc aatgctgtt ttggggagt ggtttccagg agctgcctgg tgcctcgt 2843  
 aatgtttgt ctactcaca agcctcggcc tgcctcag ccaggtcgg taccgatcg 2903  
 tggcctggc taggtccctc tgcctcctg ggccttcta tgagctcat tgccttgc 2963  
 50 caccctgacc aagcacacgc ctacagggg cctcagcct ctctgaagc cctcttgg 3023  
 caagaactgt ggaccatgcc agtcccgct ggttccatc cctccactcc aaggactgag 3083  
 actgacctc ctggtgaca ctggctaga gctgacact ctctnagag gttctctcca 3143  
 agcccccaat tagctccagg cgcctcggc cgcctcctt ggttctctt gctccacaaa 3203  
 55 cactcaggg taggtctg gcttctga ggttgaggg acacagatga cctactgt 3263  
 cctctctct gccacatc agtctgtat gtaagcctg ctgagcctt gactctctg 3323

agctacagg acaggagcc atcattcctg cctgggaatc ciggagact tccigcagg 3383  
 gtcagcgttc aatcttgacc ttgaagatgg gaaggatgtt cttttacgt accaattc 3443  
 5 ttgtcttttg atattaaaaa gaagtacatg ttcattgtag agaatttgg aacigttaga 3503  
 gagaatcaag aagaaaaata aaatcagct gttgtaatcg cctagcaaaa aaaaaaana 3563  
 a 3564

10

&lt;210&gt; 76

&lt;211&gt; 704

&lt;212&gt; PRT

15

&lt;213&gt; Homo sapiens

&lt;400&gt; 76

20

Met Phe Thr Phe Leu Leu Thr Cys Ile Phe Leu Pro Leu Leu Arg Gly  
 -16 -15 -10 -5

25

His Ser Leu Phe Thr Cys Glu Pro Ile Thr Val Pro Arg Cys Met Lys  
 1 5 10 15

Met Ala Tyr Asn Met Thr Phe Phe Pro Asn Leu Met Gly His Tyr Asp  
 20 25 30

30

Gln Ser Ile Ala Ala Val Glu Met Glu His Phe Leu Pro Leu Ala Asn  
 35 40 45

Leu Glu Cys Ser Pro Asn Ile Glu Thr Phe Leu Cys Lys Ala Phe Val  
 50 55 60

35

Pro Thr Cys Ile Glu Gln Ile His Val Val Pro Pro Cys Arg Lys Leu  
 65 70 75 80

Cys Glu Lys Val Tyr Ser Asp Cys Lys Lys Leu Ile Asp Thr Phe Gly  
 85 90 95

40

Ile Arg Trp Pro Glu Glu Leu Glu Cys Asp Arg Leu Gln Tyr Cys Asp  
 100 105 110

Glu Thr Val Pro Val Thr Phe Asp Pro His Thr Glu Phe Leu Gly Pro  
 115 120 125

45

Gln Lys Lys Thr Glu Gln Val Gln Arg Asp Ile Gly Phe Trp Cys Pro  
 130 135 140

50

Arg His Leu Lys Thr Ser Gly Gly Gln Gly Tyr Lys Phe Leu Gly Ile  
 145 150 155 160

Asp Gln Cys Ala Pro Pro Cys Pro Asn Met Tyr Phe Lys Ser Asp Glu

55

	165	170	175
	Leu Glu Phe Ala Lys Ser Phe Ile Gly Thr Val Ser Ile Phe Cys Leu		
5	180	185	190
	Cys Ala Thr Leu Phe Thr Phe Leu Thr Phe Leu Ile Asp Val Arg Arg		
	195	200	205
10	Phe Arg Tyr Pro Glu Arg Pro Ile Ile Tyr Tyr Ser Val Cys Tyr Ser		
	210	215	220
	Ile Val Ser Leu Met Tyr Phe Ile Gly Phe Leu Leu Gly Asp Ser Thr		
	225	230	235
15	Ala Cys Asn Lys Ala Asp Glu Lys Leu Glu Leu Gly Asn Thr Val Val		
	245	250	255
	Leu Asp Ser Gln Asn Lys Ala Cys Thr Val Leu Phe Met Leu Leu Tyr		
20	260	265	270
	Phe Phe Thr Met Ala Gly Thr Val Trp Trp Val Ile Leu Thr Ile Thr		
	275	280	285
	Trp Phe Leu Ala Ala Gly Arg Lys Trp Ser Cys Glu Ala Ile Glu Gln		
25	290	295	300
	Lys Ala Val Trp Phe His Ala Val Ala Trp Gly Thr Pro Gly Phe Leu		
	305	310	315
30	Thr Val Met Leu Leu Ala Met Asn Lys Val Glu Gly Asp Asn Ile Ser		
	325	330	335
	Gly Val Cys Phe Val Gly Leu Tyr Asp Leu Asp Ala Ser Arg Tyr Phe		
	340	345	350
35	Val Leu Leu Pro Leu Cys Leu Cys Val Phe Val Gly Leu Ser Leu Leu		
	355	360	365
	Leu Ala Gly Ile Ile Ser Leu Asn His Val Arg Gln Val Ile Gln His		
40	370	375	380
	Asp Gly Arg Asn Gln Glu Lys Leu Lys Lys Phe Met Ile Arg Ile Gly		
	385	390	395
	Val Phe Ser Gly Leu Tyr Leu Val Pro Leu Val Thr Leu Leu Gly Cys		
45	405	410	415
	Tyr Val Tyr Glu Gln Val Asn Arg Ile Thr Trp Glu Ile Thr Trp Val		
	420	425	430
	Ser Asp His Cys Arg Gln Tyr His Ile Pro Cys Pro Tyr Gln Ala Lys		
50	435	440	445
	Ala Lys Ala Arg Pro Glu Leu Ala Leu Phe Met Ile Lys Tyr Leu Met		

55

450                      455                      460  
 Thr Leu Ile Val Gly Ile Ser Ala Val Phe Trp Val Gly Ser Lys Lys  
 5    465                      470                      475                      480  
 Thr Cys Thr Glu Trp Ala Gly Phe Phe Lys Arg Asn Arg Lys Arg Asp  
                     485                      490                      495  
 10    Pro Ile Ser Glu Ser Arg Arg Val Leu Gln Glu Ser Cys Glu Phe Phe  
                     500                      505                      510  
 Leu Lys His Asn Ser Lys Val Lys His Lys Lys Lys His Tyr Lys Pro  
                     515                      520                      525  
 15    Ser Ser His Lys Leu Lys Val Ile Ser Lys Ser Met Gly Thr Ser Thr  
                     530                      535                      540  
 Gly Ala Thr Ala Asn His Gly Thr Ser Ala Val Ala Ile Thr Ser His  
 20    545                      550                      555                      560  
 Asp Tyr Leu Gly Gln Glu Thr Leu Thr Glu Ile Gln Thr Ser Pro Glu  
                     565                      570                      575  
 Thr Ser Met Arg Glu Val Lys Ala Asp Gly Ala Ser Thr Pro Arg Leu  
 25    580                      585                      590  
 Arg Glu Gln Asp Cys Gly Glu Pro Ala Ser Pro Ala Ala Ser Ile Ser  
                     595                      600                      605  
 30    Arg Leu Ser Gly Glu Gln Val Asp Gly Lys Gly Gln Ala Gly Ser Val  
                     610                      615                      620  
 Ser Glu Ser Ala Arg Ser Glu Gly Arg Ile Ser Pro Lys Ser Asp Ile  
 35    625                      630                      635                      640  
 Thr Asp Thr Gly Leu Ala Gln Ser Asn Asn Leu Gln Val Pro Ser Ser  
                     645                      650                      655  
 Ser Glu Pro Ser Ser Leu Lys Gly Ser Thr Ser Leu Leu Val His Pro  
 40    660                      665                      670  
 Val Ser Gly Val Arg Lys Glu Gln Gly Gly Gly Cys His Ser Asp Thr  
                     675                      680                      685  
  
 45    <210> 77  
       <211> 2112  
       <212> DNA  
 50    <213> Homo sapiens  
  
       <400> 77  
  
 55



atgtttacat ttttgttgac gtgtatTTTT ctacccctcc taagagggca cagtctcttc 60  
 accgtgtaac caattactgt tcccgatgt atgaaaatgg cctacaacat gacgtttttc 120  
 5 cctaacttga tgggtcatta tgaccagagt atlgccgcgg tggaaatgga gcattttctt 180  
 cctctcgcaa atctggaatg ttcaccaaac attgaaactt tctctcgcaa agcattttgta 240  
 ccaacctgca tagaacaat tcatgtggtt ccaccttgtc gtaaaccttg tgagaaagta 300  
 10 tattctgatt gcaaaaaatt aattgacact tttgggatcc gatggcctga ggagcttgaa 360  
 tgtgacagat tacaatactg tgatgagact gtacctgtaa cttttgatcc acacacagaa 420  
 tttcttggtc ctgagaagaa aacagaacaa gtccaaagag acattggatt ttggtgtcca 480  
 aggcatttta agacttctgg gggacaagga tataagtctc tgggaatga ccagtgtgcg 540  
 15 cctccatgcc ccaacatgta ttttaaaagt gatgagctag agtttgcaa aagttttatt 600  
 ggaacagtgt caatattttg tctttgtgca actctgttca ctttcttac ttttttaatt 660  
 gatgttagaa gattcagata cccagagaga ccaattatat attactcgt ctgttacagc 720  
 attgtatctc ttatgtactt cattggattt ttgctaggcg atagcacagc ctgcaataag 780  
 20 gcagatgaga agctagaact tggtaacact gtgttcttag accttcaaaa taaggcttgc 840  
 accgttttgt tcatgtcttt gtatttttc acaatggctg gcactgtgtg gtgggtgatt 900  
 ctaccatta ctgtgtctt agctgcagga agaaaatgga gtgtgaagc catcgagcaa 960  
 25 aaagcagtgt ggtttcatgc tgttgcatgg ggaacaccag gtltctgac tgttatgtt 1020  
 ctgtctatga acaagttga aggagacaac attagtgag tttgtttgt tggcctttat 1080  
 gacctggatg ctctctgcta ctttgtactc ttgccactgt gcccttgtgt gtttgttggg 1140  
 ctctctcttc ttttagctgg cattatttcc ttaaatcatg ttcgacaagt catacaacat 1200  
 30 galggccgga accaagaaaa actaaagaaa ttatgattc gaattggagt cticagcggc 1260  
 ttgtatcttg tgccattagt gacacttctc ggaatgttacc tctatgaca agtgaacagg 1320  
 attaccctggg agataacttg ggtctctgal catgtctgc agtaccatat cccatgtctt 1380  
 35 latcaggcaa aagcaaaagc tgcaccagaa ttggccttat ttatgataaa ataccctgag 1440  
 acattaattg ttggcatctc tgcgtctctc tgggttggaa gcaaaaagac atgcacagaa 1500  
 tgggttgggt tttttaaag aaatcgcaag agagatccaa tcagtgaaag tcaagagta 1560  
 ctacaggaat catgtgagtt tttcttaaag cacaattcta aagttaaaca caaaaagag 1620  
 40 cactataaac caagttcaca caagctgaag gtcatlcca aatccatggg aaccagcaca 1680  
 ggagctacag caaatcatgg cacttctgca gtagcaatta ctagccatga ttacctagga 1740  
 caagaacat tgacagaaat ccaaacctca ccagnnacat caatgagaga ggtgaagcag 1800  
 45 gacggagctc gcaccccccag gtttaagaga caggacttgc gtgaacctgc ctgcaccaga 1860  
 gcatccatct ccagactctc tggggaacag gtgcncggga agggccaggc aggcagtgta 1920  
 tctgaagtg cgcggagtga aggaaggatt agtccnnnngn tgnatattac tgacacttgc 1980  
 ctgncncaga gcaacaattt gcaggctccc agtcttctag naccagcng ctctnnngtt 2040  
 50 tccacatctc tgcctgttca cccggttcca ggtgtgagaa ntagcagng aggtgtgtgt 2100  
 callcngta ct 2112

<210> 78  
 <211> 3492  
 5 <212> DNA  
 <213> Homo sapiens

10 <200>  
 <221> CDS  
 <222> (6).. (2117)

15 <220>  
 <221> sig peptide  
 <222> (6).. (53)

20 <220>  
 <221> mat peptide  
 <222> (54).. (2117)

25 <400> 78  
 tggaa atg ttt aca ttt ttg ttg acg tgt att ttt cta ccc ctc cta 47  
 Met Phe Thr Phe Leu Leu Thr Cys Ile Phe Leu Pro Leu Leu  
 -16 -15 -10 -5  
 aga ggg cac agt ctc ttc acc tgt gaa cca att act gtt ccc aga tgt 95  
 Arg Gly His Ser Leu Phe Thr Cys Glu Pro Ile Thr Val Pro Arg Cys  
 35 1 5 10  
 atg aaa atg gcc tac aac atg acg ttt ttc cct aat ctg atg ggt cat 143  
 Met Lys Met Ala Tyr Asn Met Thr Phe Phe Pro Asn Leu Met Gly His  
 40 15 20 25 30  
 tat gac cag agt att gcc gcg gtg gaa atg gag cat ttt ctt cct ctc 191  
 Tyr Asp Gln Ser Ile Ala Ala Val Glu Met Glu His Phe Leu Pro Leu  
 45 35 40 45  
 gca aat ctg gaa tgt tca cca uac att gaa act ttc ctc tgc aaa gca 239  
 Ala Asn Leu Glu Cys Ser Pro Asn Ile Glu Thr Phe Leu Cys Lys Ala  
 50 50 55 60  
 ttt gla cca acc tgc ata gaa cau att cat glg gtt cca cct tgt cgt 287  
 Phe Val Pro Thr Cys Ile Glu Gln Ile His Val Val Pro Pro Cys Arg

55

	65	70	75	
5	aaa ctt tgt gag aaa gta tat tct gat tgc aaa aaa tta att gac act			335
	Lys Leu Cys Glu Lys Val Tyr Ser Asp Cys Lys Lys Leu Ile Asp Thr			
	80	85	90	
10	ttt ggg atc cga tgg cct gag gag ctt gaa tgt gac aga tta caa tac			383
	Phe Gly Ile Arg Trp Pro Glu Glu Leu Glu Cys Asp Arg Leu Gln Tyr			
	95	100	105	110
15	tgt gat gag act gtt cct gta act ttt gat cca cac acn gaa ttt ctt			431
	Cys Asp Glu Thr Val Pro Val Thr Phe Asp Pro His Thr Glu Phe Leu			
	115	120	125	
20	ggt cct cag aag aaa acn gaa caa gtc caa aga gac att gga ttt tgg			479
	Gly Pro Gln Lys Lys Thr Glu Gln Val Gln Arg Asp Ile Gly Phe Trp			
	130	135	140	
25	tgt cca agg cat ctt aag act tct ggg gga caa gga tat aag ttt ctg			527
	Cys Pro Arg His Leu Lys Thr Ser Gly Gly Gln Gly Tyr Lys Phe Leu			
	145	150	155	
30	gga att gac cag tgt gcg cct cca tgc ccc aac atg tat ttt aaa agt			575
	Gly Ile Asp Gln Cys Ala Pro Pro Cys Pro Asn Met Tyr Phe Lys Ser			
	160	165	170	
35	gat gag cta gag ttt gca aaa agt ttt att gga acn gtt tca ata ttt			623
	Asp Glu Leu Glu Phe Ala Lys Ser Phe Ile Gly Thr Val Ser Ile Phe			
	175	180	185	190
40	tgt ctt tgt gca act ctg ttc acn ttc ctt act ttt tta att gat gtt			671
	Cys Leu Cys Ala Thr Leu Phe Thr Phe Leu Thr Phe Leu Ile Asp Val			
	195	200	205	
45	aga aga ttc aga tac cca gag agn cca att ata tat tac tct gtc tgt			719
	Arg Arg Phe Arg Tyr Pro Glu Arg Pro Ile Ile Tyr Tyr Ser Val Cys			
	210	215	220	
50	tac agc att gta tct ctt atg tac ttc att gga ttt ttg cta ggc gat			767
	Tyr Ser Ile Val Ser Leu Met Tyr Phe Ile Gly Phe Leu Leu Gly Asp			
	225	230	235	
55	agc acn gcc tgc aat aag gca gat gag aag cta gaa ctt ggt aac act			815
	Ser Thr Ala Cys Asn Lys Ala Asp Glu Lys Leu Glu Leu Gly Asn Thr			
	240	245	250	
	gtt gtc cta gac tct caa aat aac gct tgc acc gtt ttg ttc atg ctt			863

Val Val Leu Asp Ser Gln Asn Lys Ala Cys Thr Val Leu Phe Met Leu  
 255                      260                      265                      270  
 5    ttg tat ttt ttc aca atg gct ggc act gtg tgg tgg gtg att ctt acc    911  
     Leu Tyr Phe Phe Thr Met Ala Gly Thr Val Trp Trp Val Ile Leu Thr  
                          275                      280                      285  
 10    att act tgg ttc tta gct gca gga aga aaa tgg agt tgt gaa gcc atc    959  
     Ile Thr Trp Phe Leu Ala Ala Gly Arg Lys Trp Ser Cys Glu Ala Ile  
                          290                      295                      300  
 15    gag caa aaa gca gtg tgg ttt cat gct gtt gca tgg gga aca cca ggt    1007  
     Glu Gln Lys Ala Val Trp Phe His Ala Val Ala Trp Gly Thr Pro Gly  
                          305                      310                      315  
 20    ttc ctg act gtt atg ctt ctt gct atg aac aaa gtt gaa gga gac aac    1055  
     Phe Leu Thr Val Met Leu Leu Ala Met Asn Lys Val Glu Gly Asp Asn  
                          320                      325                      330  
 25    att agt gga gtt tgc ttt gtt ggc ctt tat gac ctg gat gct tct cgc    1103  
     Ile Ser Gly Val Cys Phe Val Gly Leu Tyr Asp Leu Asp Ala Ser Arg  
                          335                      340                      345                      350  
 30    tac ttt gla ctc ttg cca ctg tgc ctt tgt gtg ttt gtt ggg ctc tct    1151  
     Tyr Phe Val Leu Leu Pro Leu Cys Leu Cys Val Phe Val Gly Leu Ser  
                          355                      360                      365  
 35    ctt ctt tta gct ggc att att tcc tta aat cat gtt cga caa gtc ata    1199  
     Leu Leu Leu Ala Gly Ile Ile Ser Leu Asn His Val Arg Gln Val Ile  
                          370                      375                      380  
 40    cna cni gat ggc cgg aac caa gaa aaa cta aag aaa ttt atg att cga    1247  
     Gln His Asp Gly Arg Asn Gln Glu Lys Leu Lys Lys Phe Met Ile Arg  
                          385                      390                      395  
 45    att gga gtc ttc agc ggc ttg tat ctt gtg cca tta gtg aca ctt ctc    1295  
     Ile Gly Val Phe Ser Gly Leu Tyr Leu Val Pro Leu Val Thr Leu Leu  
                          400                      405                      410  
 50    gga tgt tac gtc tat gag caa gtg aac agg att acc tgg gag ata act    1343  
     Gly Cys Tyr Val Tyr Glu Gln Val Asn Arg Ile Thr Trp Glu Ile Thr  
                          415                      420                      425                      430  
 55    tgg gtc tct gat cat tgt cgt cag tac cat ntc cca tgt cct tat cag    1391  
     Trp Val Ser Asp His Cys Arg Gln Tyr His Ile Pro Cys Pro Tyr Gln  
                          435                      440                      445  
     gca aaa gen aaa gct cga cca gaa tlg gct tta ttt atg ntn aua tac    1439

Ala Lys Ala Lys Ala Arg Pro Glu Leu Ala Leu Phe Met Ile Lys Tyr  
450 455 460  
5 ctg atg aca tta att gtt ggc atc tct gct gtc ttc tgg gtt gga agc 1487  
Leu Met Thr Leu Ile Val Gly Ile Ser Ala Val Phe Trp Val Gly Ser  
465 470 475  
10 aaa aag aca tgc aca gaa tgg gct ggg ttt ttt aaa cga aat cgc aag 1535  
Lys Lys Thr Cys Thr Glu Trp Ala Gly Phe Phe Lys Arg Asn Arg Lys  
480 485 490  
15 aga gat cca atc agt gaa agt cga aga gta cta cag gaa tca tgt gag 1583  
Arg Asp Pro Ile Ser Glu Ser Arg Arg Val Leu Gln Glu Ser Cys Glu  
495 500 505 510  
20 ttt ttc tta aag cac aat tct aaa gtt aaa cac aaa aag aag cac tat 1631  
Phe Phe Leu Lys His Asn Ser Lys Val Lys His Lys Lys Lys His Tyr  
515 520 525  
25 aaa cca agt tca cac aag ctg aag gtc att tcc aaa tcc atg gga acc 1679  
Lys Pro Ser Ser His Lys Leu Lys Val Ile Ser Lys Ser Met Gly Thr  
530 535 540  
30 agc aca gga gct aca gca aat cat ggc act tct gca gta gca att act 1727  
Ser Thr Gly Ala Thr Ala Asn His Gly Thr Ser Ala Val Ala Ile Thr  
545 550 555  
35 agc cat gat tac cta gga caa gaa act ttg acn gaa atc caa acc tca 1775  
Ser His Asp Tyr Leu Gly Gln Glu Thr Leu Thr Glu Ile Gln Thr Ser  
560 565 570  
40 cca gaa acn tca atg aga gag gtg nnn gcc gac gga gct agc acc ccc 1823  
Pro Glu Thr Ser Met Arg Glu Val Lys Ala Asp Gly Ala Ser Thr Pro  
575 580 585 590  
45 agg tta aga gaa cag gac tgt ggt gaa cct gcc tgg cca gca gca tcc 1871  
Arg Leu Arg Glu Gln Asp Cys Gly Glu Pro Ala Ser Pro Ala Ala Ser  
595 600 605  
50 atc tcc aga ctc tct ggg gaa cag gtc gac ggg aag ggc cag gca ggc 1919  
Ile Ser Arg Leu Ser Gly Glu Gln Val Asp Gly Lys Gly Gln Ala Gly  
610 615 620  
55 agt gta tct gaa agt gcg cgg agt gaa gga agg att agt cca aag agt 1967  
Ser Val Ser Glu Ser Ala Arg Ser Glu Gly Arg Ile Ser Pro Lys Ser  
625 630 635  
gat att act gac act ggc ctg gca cag agc aac aat ttg cag gtc ccc 2015

Asp Ile Thr Asp Thr Gly Leu Ala Gln Ser Asn Asn Leu Gln Val Pro  
 640 645 650  
 5 agt tct tca gaa cca agc agc ctc aaa ggt tcc aca tct ctg ctt gtt 2063  
 Ser Ser Ser Glu Pro Ser Ser Leu Lys Gly Ser Thr Ser Leu Leu Val  
 655 660 665 670  
 10 cac ccg gtt tca gga gtg aga aaa gag cag gga ggt ggt tgt cat tca 2111  
 His Pro Val Ser Gly Val Arg Lys Glu Gln Gly Gly Gly Cys His Ser  
 675 680 685  
 gat act tgaagaacat tttctctcgt tactcagaag caaatttggt ttacactgga 2167  
 15 Asp Thr  
 agtgacctat gcactgtttt gtaagaatca ctgttacgtt cttcttttgc acttaaagtt 2227  
 gcattgccia ctgtttatact ggaaaaaata gagttcaaga ataattatgac tcatttcaca 2287  
 caaaggttaa tgacaacaat atacctgaaa acagagatgt gcaggttaat aatatttttt 2347  
 20 taatagtgtg ggaggacaga gtagaggaa tcttcccttt ctatttatga agattctact 2407  
 ctgtgtaaga gtattttaag atgtactatg ctattttact tttttgatat aaaatcaaga 2467  
 tatttctttg ctgaagtatt taaatcttat ccttgtatct ttttatacat atttgaaaaa 2527  
 25 aagcttatat gtatttgaac tttttgaaa tctatttcaa gtatttttat catgctattg 2587  
 tgatatttta gcacttttgt agcttttaca ctgaatttct aagaaaatig taaaatagtc 2647  
 ttcttttata ctgtaaaaaa agatatacca aaaagtctta taataggaat ttaactttta 2707  
 aaaccacatt attgatacct taccatctaa aatgtgtgat ttttatagtc tctttttagg 2767  
 30 aatttcacag auctaaatta tgtagctgaa ataagggtct tactcaaga ggtccacta 2827  
 ttgatigtat tatgtgtctc actgatcttt ctgcatattt aaaalauaat gtcctaaagg 2887  
 gtagtagac aanaigttag tcttttgtat attaggccaa gtgcaatiga ctctcccttt 2947  
 35 ttaatgttcc atgaccaccc attgattgta ttataaccac ttacagtllc ttatatlttt 3007  
 tgttttaact ttgttttttt aacattttaga alattacatt ttgtattala cagtaccttt 3067  
 ctccagacatt ttglagaatt catllcggca gctcactagg attllgciga acaltanaaa 3127  
 gtgtgatagc gatatttagtg ccaatcaaat ggaaaaaagg tagtctaat aaacaagaca 3187  
 40 caacgttttt atacaacata cttttaaata ttaaggagtt ttcttaattt lgtttcctat 3247  
 taagtattat tctttgggca agattttctg atgcttttga ttttctctca atttagcatt 3307  
 tgccttttgg tttttctctt atttagcatt ctgttaaggc acaaaaacta tgtactgtat 3367  
 45 gggaantglt glaatatla ccttttccac attttaaca gacaactttg aatacaaaaa 3427  
 ctttgttttg tglgtctttt lcallantaa aattatcttt gtataaghaa naaaahnaaa 3487  
 aaaa 3492  
 50 <210> 79  
 <211> 551  
 55

&lt;212&gt; PRT

5

&lt;400&gt; 79

10

15

20

25

30

35

40

45

50

55

Met Leu Cys Ser Leu Leu Leu Cys Glu Cys Leu Leu Val Ala Gly

-18 -15 -10 -5

Tyr Ala His Asp Asp Asp Trp Ile Asp Pro Thr Asp Met Leu Asn Tyr

1 5 10

Asp Ala Ala Ser Gly Thr Met Arg Lys Ser Gln Ala Lys Tyr Gly Ile

15 20 25 30

Ser Gly Glu Lys Asp Val Ser Pro Asp Leu Ser Cys Ala Asp Glu Ile

35 40 45

Ser Glu Cys Tyr His Lys Leu Asp Ser Leu Thr Tyr Lys Ile Asp Glu

50 55 60

Cys Glu Lys Lys Lys Arg Glu Asp Tyr Glu Ser Gln Ser Asn Pro Val

65 70 75

Phe Arg Arg Tyr Leu Asn Lys Ile Leu Ile Glu Ala Gly Lys Leu Gly

80 85 90

Leu Pro Asp Glu Asn Lys Gly Asp Met His Tyr Asp Ala Glu Ile Ile

95 100 105 110

Leu Lys Arg Glu Thr Leu Leu Glu Ile Gln Lys Phe Leu Asn Gly Glu

115 120 125

Asp Trp Lys Pro Gly Ala Leu Asp Asp Ala Leu Ser Asp Ile Leu Ile

130 135 140

Asn Phe Lys Phe His Asp Phe Glu Thr Trp Lys Trp Arg Phe Glu Asp

145 150 155

Ser Phe Gly Val Asp Pro Tyr Asn Val Leu Met Val Leu Leu Cys Leu

160 165 170

Leu Cys Ile Val Val Leu Val Ala Thr Glu Leu Trp Thr Tyr Val Arg

175 180 185 190

Trp Tyr Thr Gln Leu Arg Arg Val Leu Ile Ile Ser Phe Leu Phe Ser

195 200 205

Leu Gly Trp Asn Trp Met Tyr Leu Tyr Lys Leu Ala Phe Ala Gln His

210 215 220

Gln Ala Glu Val Ala Lys Met Glu Pro Leu Asn Asn Val Cys Ala Lys

225 230 235

Lys Met Asp Trp Thr Gly Ser Ile Trp Glu Trp Phe Arg Ser Ser Trp  
 240 245 250  
 5 Thr Tyr Lys Asp Asp Pro Cys Gln Lys Tyr Tyr Glu Leu Leu Leu Val  
 255 260 265 270  
 Asn Pro Ile Trp Leu Val Pro Pro Thr Lys Ala Leu Ala Val Thr Phe  
 10 275 280 285  
 Thr Thr Phe Val Thr Glu Pro Leu Lys His Ile Gly Lys Gly Thr Gly  
 290 295 300  
 Glu Phe Ile Lys Ala Leu Met Lys Glu Ile Pro Ala Leu Leu His Leu  
 15 305 310 315  
 Pro Val Leu Ile Ile Met Ala Leu Ala Ile Leu Ser Phe Cys Tyr Gly  
 320 325 330  
 20 Ala Gly Lys Ser Val His Val Leu Arg His Ile Gly Gly Pro Glu Ser  
 335 340 345 350  
 Glu Pro Pro Gln Ala Leu Arg Pro Arg Asp Arg Arg Arg Gln Glu Glu  
 355 360 365  
 25 Ile Asp Tyr Arg Pro Asp Gly Gly Ala Gly Asp Ala Asp Phe His Tyr  
 370 375 380  
 Arg Gly Gln Met Gly Pro Thr Glu Gln Gly Pro Tyr Ala Lys Thr Tyr  
 385 390 395  
 30 Glu Gly Arg Arg Glu Ile Leu Arg Glu Arg Asp Val Asp Leu Arg Phe  
 400 405 410  
 Gln Thr Gly Asn Lys Ser Pro Glu Val Leu Arg Ala Phe Asp Val Pro  
 35 415 420 425 430  
 Asp Ala Glu Ala Arg Glu His Pro Thr Val Val Pro Ser His Lys Ser  
 435 440 445  
 40 Pro Val Leu Asp Thr Lys Pro Lys Glu Thr Gly Gly Ile Leu Gly Glu  
 450 455 460  
 Gly Thr Pro Lys Glu Ser Ser Thr Glu Ser Ser Gln Ser Ala Lys Pro  
 465 470 475  
 45 Val Ser Gly Gln Asp Thr Ser Gly Asn Thr Glu Gly Ser Pro Ala Ala  
 480 485 490  
 Glu Lys Ala Gln Leu Lys Ser Glu Ala Ala Gly Ser Pro Asp Gln Gly  
 495 500 505 510  
 50 Ser Thr Tyr Ser Pro Ala Arg Gly Val Ala Gly Pro Arg Gly Gln Asp  
 515 520 525  
 55



Pro Val Ser Ser Pro Cys Gly

530

5

&lt;210&gt; 80

&lt;211&gt; 1653

10

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 80

15

atgctgtgtt ctttgcctct ttgtgaatgt ctgttgcctg tagctgggta tgcctatgat 60

gatgactgga ttgacccac agacatgctt aactatgatg ctgcttcagg aacaatgaga 120

aaatctcagg caaatatgg tatttcaggg gaaaaggatg tcagtcctga cttgtcatgt 180

20

gctgatgaaa tatcagaatg ttatcacaaa ctgattctt taacttataa gattgatgag 240

tgtgaaaaga aaaagaggga agactatgaa agtcaaagca atcctgtttt taggagatac 300

ttaataaga ttttaattga agctggaaag cttggacttc ctgatgaaa caaaggcga 360

atgcattatg atgctgagat tatcttataa agagaaactt tgttagaaat acagaagt 420

25

ctcaatggag aagaciggaa accaggtgcc ttggatgatg caclaagta tattttaatt 480

aattttaagt ttcatgattt tgaacaatgg aagtgccgat tcaagattc ctttggagt 540

gatccatata atgtgttaat ggtacttctt tgtctgctct gcalcgtgg 600

30

accgagctgt ggacatatgt acgttggtag actcagtga gacgtgtttt aatcaccagc 660

tttctgttca gtttgggatg gaattggatg tatttatata agctagcttt tgcacagcat 720

caggcigaag tcgccaagat gggccatla aacaalggt gggccuanaa gatggactgg 780

actggaagta tcgggaatg gtttagaagt tcatggacct atangnatga cccatgccaa 840

35

aaatactatg agctcttact aglcaacctt atttgggttg tcccacnac aaaggcactt 900

gcagttacat tcaccacatt tgaacggag ccattgaagc atattggaa aggnactggg 960

gaatttatta aagcactcat gaaggnaatt ccagcgtgc tcaatcttc agtctgata 1020

40

attatggcat tagccatctt gatttcttgc tatgggtctg gaaaatcagt tcatgtgctg 1080

agacatatag ggggtcctga gagcgacctt cccagggcag ttggccacg gatataga 1140

cggcaggagg aatttgatta tagacctgtt ggtggagcag gttgtccga ttccattat 1200

aggggccaaa tgggcccnc tggcaaggc ctttatgcc aacgtatga gggtagaaga 1260

45

gagatttga gagagagaga tgttgcctg agatttcag ctggcucuaa gggccctgaa 1320

gtgtccggg cttttagt accagacgca gggcagcag agcatccac ggtgttacc 1380

agtataaat cactgtttt ggttacaag cccaaggga cagggtgnaa cttggggaa 1440

50

ggcacaccg angatggcgt tctgttgcg agccgtcgt ccaagccgt cttgtgccaa 1500

gacatcag ggtatcag aggttacc cccagggaa aggccagct caatctgaa 1560

gcccagggc gcccagcca agccagcca taccgccc cagggtgtt ggtgtacca 1620

55

cgtggacagg atccggtcag cagccccigt ggc

1653

5

&lt;210&gt; 81

&lt;211&gt; 2000

&lt;212&gt; DNA

10

&lt;213&gt; Homo sapiens

&lt;200&gt;

15

&lt;221&gt; CDS

&lt;222&gt; (82)..(1734)

&lt;220&gt;

20

&lt;221&gt; sig peptide

&lt;222&gt; (82)..(135)

&lt;220&gt;

25

&lt;221&gt; mat peptide

&lt;222&gt; (136)..(1734)

30

&lt;400&gt; 81

gcggcgccnn gctgtgcgac cctctcgcg gccggcctgg gcaggigtct tctcgagag 60

gcaggcagkg gatcccgac g atg ctg tgt tct ttt ctc ctt tgt gaa tgt 111

Met Leu Cys Ser Leu Leu Leu Cys Glu Cys

35

-18 -15 -10

ctg ttg ctg gta gct ggt tat gct cat gat gat gac tgg att gac ccc 159

Leu Leu Leu Val Ala Gly Tyr Ala His Asp Asp Asp Trp Ile Asp Pro

40

-5 1 5

aca gac atg ctt aac tat gat gct gct tca gga aca atg aga aaa tct 207

Thr Asp Met Leu Asn Tyr Asp Ala Ala Ser Gly Thr Met Arg Lys Ser

10 15 20

45

cag gca aaa tat ggt att tca ggg gaa aag gat gtc agt cct gac ttg 255

Gln Ala Lys Tyr Gly Ile Ser Gly Glu Lys Asp Val Ser Pro Asp Leu

25 30 35 40

50

tca tgt gct gat gaa ata tca gaa tgt tat cac aac ctt gat tct tta 303

Ser Cys Ala Asp Glu Ile Ser Glu Cys Tyr His Lys Leu Asp Ser Leu

45 50 55

55

	act tat aag att gat gag tgt gaa aag aaa aag agg gaa gac tat gaa	351
	Thr Tyr Lys Ile Asp Glu Cys Glu Lys Lys Lys Arg Glu Asp Tyr Glu	
5	60 65 70	
	agt caa agc aat cct gtt ttt agg aga tac tta aat aag att tta att	399
	Ser Gln Ser Asn Pro Val Phe Arg Arg Tyr Leu Asn Lys Ile Leu Ile	
10	75 80 85	
	gaa gct gga aag ctt gga ctt cct gat gaa aac aaa ggc gat atg cat	447
	Glu Ala Gly Lys Leu Gly Leu Pro Asp Glu Asn Lys Gly Asp Met His	
	90 95 100	
15	tat gat gct gag att atc ctt aaa aga gaa act ttg tta gaa ata cag	495
	Tyr Asp Ala Glu Ile Ile Leu Lys Arg Glu Thr Leu Leu Glu Ile Gln	
	105 110 115 120	
20	aag ttt ctc aat gga gaa gac tgg aaa cca ggt gcc ttg gat gat gca	543
	Lys Phe Leu Asn Gly Glu Asp Trp Lys Pro Gly Ala Leu Asp Asp Ala	
	125 130 135	
25	cta agt gat att tta att aat ttt aag ttt cat gat ttt gaa aca tgg	591
	Leu Ser Asp Ile Leu Ile Asn Phe Lys Phe His Asp Phe Glu Thr Trp	
	140 145 150	
	aag tgg cga ttc gaa gat tcc ttt gga gtg gat cca tat aat gtg tta	639
30	Lys Trp Arg Phe Glu Asp Ser Phe Gly Val Asp Pro Tyr Asn Val Leu	
	155 160 165	
	atg gta ctt ctt tgt ctg ctc tgc atc glg gtt tta gtg gct acc gag	687
	Met Val Leu Leu Cys Leu Leu Cys Ile Val Val Leu Val Ala Thr Glu	
35	170 175 180	
	ctg tgg aca tal gta cgt lgg tac act cag ttg aga cgt gtt tta atc	735
	Leu Trp Thr Tyr Val Arg Trp Tyr Thr Gln Leu Arg Arg Val Leu Ile	
40	185 190 195 200	
	atc agc ttt ctg ttc agt ttg gga tgg aat lgg atg tat tta tat aag	783
	Ile Ser Phe Leu Phe Ser Leu Gly Trp Asn Trp Met Tyr Leu Tyr Lys	
	205 210 215	
45	cta gct ttt gca cag cat cag gct gaa gtc gcc aag atg gag cca tta	831
	Leu Ala Phe Ala Gln His Gln Ala Glu Val Ala Lys Met Glu Pro Leu	
	220 225 230	
50	aac aat gtg tgt gcc aac aag atg gac tgg act gga agt atc lgg gaa	879
	Asn Asn Val Cys Ala Lys Lys Met Asp Trp Thr Gly Ser Ile Trp Glu	
	235 240 245	
55		

	tgg ttt aga agt tca tgg acc tat aag gat gac cca tgc caa aaa tac	927
	Trp Phe Arg Ser Ser Trp Thr Tyr Lys Asp Asp Pro Cys Gln Lys Tyr	
5	250 255 260	
	tat gag ctc tta cta gtc aac cct att tgg ttg gtc cca cca aca aag	975
	Tyr Glu Leu Leu Leu Val Asn Pro Ile Trp Leu Val Pro Pro Thr Lys	
10	265 270 275 280	
	gca ctt gca gtt aca ttc acc aca ttt gta acg gag cca ttg aag cat	1023
	Ala Leu Ala Val Thr Phe Thr Thr Phe Val Thr Glu Pro Leu Lys His	
	285 290 295	
15	att gga aaa gga act ggg gaa ttt att aaa gca ctc atg aag gaa att	1071
	Ile Gly Lys Gly Thr Gly Glu Phe Ile Lys Ala Leu Met Lys Glu Ile	
	300 305 310	
20	cca gcg ctg ctt cat ctt cca gtg ctg ata att atg gca tta gcc atc	1119
	Pro Ala Leu Leu His Leu Pro Val Leu Ile Ile Met Ala Leu Ala Ile	
	315 320 325	
	ctg agt ttc tgc tat ggt gct gga aaa tca gtt cat gtg ctg aga cat	1167
25	Leu Ser Phe Cys Tyr Gly Ala Gly Lys Ser Val His Val Leu Arg His	
	330 335 340	
	ata ggc ggt cct gag agc gaa cct ccc cag gca ctt cgg cca cgg gat	1215
30	Ile Gly Gly Pro Glu Ser Glu Pro Pro Gln Ala Leu Arg Pro Arg Asp	
	345 350 355 360	
	aga aga cgg cag gag gaa att gat tat aga cct gnt ggt gca ggt	1263
	Arg Arg Arg Gln Glu Glu Ile Asp Tyr Arg Pro Asp Gly Gly Ala Gly	
35	365 370 375	
	gat gcc gat ttc cat tat agg ggc caa atg ggc ccc act gag caa ggc	1311
	Asp Ala Asp Phe His Tyr Arg Gly Gln Met Gly Pro Thr Glu Gln Gly	
	380 385 390	
40	cct tat gcc aaa acg tat gag ggt aga aga gag att ttg aga gag aga	1359
	Pro Tyr Ala Lys Thr Tyr Glu Gly Arg Arg Glu Ile Leu Arg Glu Arg	
	395 400 405	
45	gat gtt gac ttg aga ttt cag act ggc aac aag agc cct gaa gtg ctc	1407
	Asp Val Asp Leu Arg Phe Gln Thr Gly Asn Lys Ser Pro Glu Val Leu	
	410 415 420	
50	cgg gca ttt gat gta cca gac gca gag gca cca gaa cat ccc aag gtg	1455
	Arg Ala Phe Asp Val Pro Asp Ala Glu Ala Arg Glu His Pro Thr Val	
	425 430 435 440	

	gta ccc agt cat.aaa tca cctgtt ttg gat aca aag ccc aag gag aca	1503
5	Val Pro Ser His Lys Ser Pro Val Leu Asp Thr Lys Pr Lys Glu Thr	
	445 450 455	
	ggg gga atc ctg ggg gaa ggc aca ccg aaa gaa agc agt act gaa agc	1551
	Gly Gly Ile Leu Gly Glu Gly Thr Pro Lys Glu Ser Ser Thr Glu Ser	
10	460 465 470	
	agc cag tgc gcc aag cct gtc tct ggc caa gac aca tca ggg aat aca	1599
	Ser Gln Ser Ala Lys Pro Val Ser Gly Gln Asp Thr Ser Gly Asn Thr	
15	475 480 485	
	gaa ggt tca ccc gca gcg gaa aag gcc cag ctc aag tct gaa gcc gca	1647
	Glu Gly Ser Pro Ala Ala Glu Lys Ala Gln Leu Lys Ser Glu Ala Ala	
	490 495 500	
20	ggc agc cca gac caa ggc agc aca tac agc ccc gca aga ggt gtg gct	1695
	Gly Ser Pro Asp Gln Gly Ser Thr Tyr Ser Pro Ala Arg Gly Val Ala	
	505 510 515 520	
25	gga cca cgt gga cag gat ccg gtc agc agc ccc tgt ggc tagaggaaca	1744
	Gly Pro Arg Gly Gln Asp Pro Val Ser Ser Pro Cys Gly	
	525 530	
30	ccagcacaaa cgacagccctc aagtctctt cgagctttat atccatttgg ggaagaagtc	1804
	tactttgaca gctagcaagg cgucalgcan cgtttgttga atgatgacag caattcagga	1864
	aagacttaaa tatgaagca aatignacac atcggttgtt tttatcaga aaagagatga	1924
	gatgagataa gactttgttla ttgactagcc aataigicat taaaattaag gttlaaaaaa	1984
35	aaaaaaaaa aaaaaa	2000
	<p>&lt;210&gt; 82</p> <p>&lt;211&gt; 35</p> <p>&lt;212&gt; DNA</p> <p>&lt;213&gt; Artificial Sequence</p>	
45	<p>&lt;220&gt;</p> <p>&lt;221&gt; difference</p> <p>&lt;222&gt; (37).. (15)</p> <p>&lt;223&gt; XhoI-random 9mer to synthesize double strands cDNA</p>	
50	<p>&lt;400&gt; 82</p> <p>cgattgtaatt cttagacctgc ctgagagnnnn nnnnn</p>	

5  
 <210> 83  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

10  
 <220>  
 <221> modified base  
 <222> (1)  
 <223> biotin-conjugated ON056-F1 primer

15  
 <400> 83  
 aacatgaatc ttctgctcgt cctggct

20  
 <210> 84  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

25  
 <220>  
 <221> modified base  
 <222> (1)  
 <223> biotin-conjugated ON034-F1 primer

30  
 <400> 84  
 tgaagcccat cctctcctcg cctttacg

35  
 <210> 85  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

40  
 <220>  
 <221> ON003-F1 primer

45  
 <400> 85

50  
 <210> 86  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

55  
 <220>  
 <221> modified base  
 <222> (1)  
 <223> biotin-conjugated ON034-F1 primer

60  
 <400> 86  
 tgaagcccat cctctcctcg cctttacg

caaaaccac aagaaattca ccaaggc

5

<210> 86

<211> 23

<212> DNA

<213> Artificial Sequence

10

<220>

<223> OX003-F2 primer

15

<400> 86

tcaccaaggc taacatggtg gcc

20

<210> 87

<211> 27

<212> DNA

25

<213> Artificial Sequence

<220>

<223> OA052-F1 primer

30

<400> 87

atgcctagaa gaggactgat tcctcac

35

<210> 88

<211> 27

<212> DNA

40

<213> Artificial Sequence

<220>

<223> OC001-F1 primer

45

<400> 88

atgagggaag ggaaccttct gctgagc

50

<210> 89

55

5  
 <211> 18  
 <212> DNA  
 <213> Artificial Sequence

10  
 <220>  
 <223> OC004-F2 primer

15  
 <400> 89  
 tgagcttcca gagctgtc

20  
 <210> 90  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

25  
 <220>  
 <223> OM017-F3 primer

30  
 <400> 90  
 gggaaatgaa acatttctgt aacctgc

35  
 <210> 91  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

40  
 <220>  
 <223> OM017-F1 primer

45  
 <400> 91  
 atgaaacatt tctgtaacct gcttltgt

50  
 <210> 92  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

55



5  
 <220>  
 <223> OM101-F3 primer

10  
 <400> 92  
 tgaagttgca gataatgagg acttacc

15  
 <210> 93  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

20  
 <220>  
 <223> OM101-F1 primer

25  
 <400> 93  
 atgaggactt accattatat accatta

30  
 <210> 94  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

35  
 <220>  
 <223> OM126-F3 primer

40  
 <400> 94  
 aggaaggatg aggaagacca ggctctg

45  
 <210> 95  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

50  
 <220>  
 <221> modified base

55

5  
 <222> (1)  
 <223> biotin-conjugated OM160-F1 primer

10  
 <400> 95  
 atgccttcagt ggaggagaag acactgc

15  
 <210> 96  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

20  
 <220>  
 <223> OMA016-F1 primer

25  
 <400> 96  
 agaaatggtg aatgcctgct ggltgtg

30  
 <210> 97  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

35  
 <220>  
 <223> OMB130-F1 primer

40  
 <400> 97  
 tcctctgact ttctctctgc aagctcc

45  
 <210> 98  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

50  
 <220>  
 <223> OMB112-F2 primer

55

	<400> 98
	gcccgaaggtc aaggagatgg tacggat
5	
	<210> 99
	<211> 28
10	<212> DNA
	<213> Artificial Sequence
	<220>
15	<223> OMB142-F1 primer
	<400> 99
20	ggagatggta cggatcttaa ggactgtg
	<210> 100
	<211> 27
25	<212> DNA
	<213> Artificial Sequence
	<220>
30	<223> OTB033-F1 primer
	<400> 100
35	tgcactatcc aaaagctcca tgtacac
	<210> 101
40	<211> 19
	<212> DNA
	<213> Artificial Sequence
45	<220>
	<223> OTB003-F2 primer
50	<400> 101
	ccatgtacac agtgggggc
55	

5	<p>&lt;210&gt; 102</p> <p>&lt;211&gt; 27</p> <p>&lt;212&gt; DNA</p> <p>&lt;213&gt; Artificial Sequence</p>
10	<p>&lt;220&gt;</p> <p>&lt;223&gt; OVB100-F1 primer</p>
15	<p>&lt;400&gt; 102</p> <p>cacttgggtgt ttgatttacc taagcac</p>
20	<p>&lt;210&gt; 103</p> <p>&lt;211&gt; 27</p> <p>&lt;212&gt; DNA</p> <p>&lt;213&gt; Artificial Sequence</p>
25	<p>&lt;220&gt;</p> <p>&lt;223&gt; OAF062-F2 primer</p>
30	<p>&lt;400&gt; 103</p> <p>gagtttcgta agcaaaatag aggacag</p>
35	<p>&lt;210&gt; 104</p> <p>&lt;211&gt; 27</p> <p>&lt;212&gt; DNA</p> <p>&lt;213&gt; Artificial Sequence</p>
40	<p>&lt;220&gt;</p> <p>&lt;223&gt; OAF062-F3 primer</p>
45	<p>&lt;400&gt; 104</p> <p>tagaggacag aaatgcagtt catgtaac</p>
50	<p>&lt;210&gt; 105</p> <p>&lt;211&gt; 28</p> <p>&lt;212&gt; DNA</p>
55	

<213> Artificial Sequence

5

<220>

<223> OAF075-F1 primer

10

<400> 105

gacatgaggt ggatactgtt catgggg

15

<210> 106

<211> 28

<212> DNA

<213> Artificial Sequence

20

<220>

<223> OAG119-F1 primer

25

<400> 106

tggcgtgtaa ctatgcctca catgttc

30

<210> 107

<211> 28

<212> DNA

<213> Artificial Sequence

35

<220>

<223> OAH040-F1 primer

40

<400> 107

ttagccccc catgttgata gaacccc

45

<210> 108

<211> 28

<212> DNA

<213> Artificial Sequence

50

<220>

55

<223> OAH058-F1 primer

5

<400> 108

acaatgttgg cctgtctgca agcttgtg

10

<210> 109

<211> 27

<212> DNA

<213> Artificial Sequence

15

<220>

<221> modified base

20

<222> (1)

<223> biotin-conjugated OM011-F1 primer

25

<400> 109

gaagtgactc ttctctagt ttgccac

30

<210> 110

<211> 27

<212> DNA

<213> Artificial Sequence

35

<220>

<221> modified base

40

<222> (1)

<223> biotin-conjugated OM028-F1 primer

45

<400> 110

atgaaggaca tgccactccg aattcat

50

<210> 111

<211> 27

<212> DNA

<213> Artificial Sequence

55

5  
 <220>  
 <221> difference  
 <223> OMB092-F1 primer

10  
 <400> 111  
 actcacctgg atccctaagg gcacagc

15  
 <210> 112  
 <211> 28  
 <212> DNA  
 <213> Artificial Sequence

20  
 <220>  
 <223> OMB092-F2 primer

25  
 <400> 112  
 agaatgagct attacggcag cagctatc

30  
 <210> 113  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

35  
 <220>  
 <223> OMB108-F1 primer

40  
 <400> 113  
 ctctctccat ctgctgtggt tatggcc

45  
 <210> 111  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

50  
 <220>  
 <223> OMB108-F2 primer

55

5  
 <400> 114  
 tggttatggc ctgtcgctgg ag

10  
 <210> 115  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

15  
 <220>  
 <221> modified base  
 <222> (1)  
 <223> biotin-conjugated OT007-F1 primer

20  
 <400> 115  
 aaaatgactc cccagtcgct gctgcag

25  
 <210> 116  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

30  
 <220>  
 <223> OAG051-F1 primer

35  
 <400> 116  
 ggaaatgttt acatttttgt tgacgtg

40  
 <210> 117  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

45  
 <220>  
 <221> modified base  
 <222> (1)

50  
 <220>  
 <221> modified base  
 <222> (1)

55



<223> biotin-conjugated OLB068-F1 primer

5

<400> 117

cactcatgaa ggaaattcca gcgcigc

10

# Claims

15


1. A substantially purified form of the polypeptide comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79, homologue thereof, fragment thereof or homologue of the fragment.
2. A polypeptide according to claim 1 comprising the amino acid sequence shown in SEQ ID NOS. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76 or 79.
3. A cDNA encoding the polypeptide according to claim 1.
4. A cDNA according to claim 3 comprising the nucleotide sequence shown in SEQ ID NOS. 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35, 38, 41, 44, 47, 50, 53, 56, 59, 62, 65, 68, 71, 74, 77 or 80, or a fragment cDNA selectively hybridized to the cDNA.
5. A cDNA according to claim 3 comprising the nucleotide sequence shown in SEQ ID NOS. 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78 or 81, or a fragment cDNA selectively hybridized to the cDNA.
6. A replication or expression vector carrying the cDNA according to claims 3 to 5.
7. A host cell transformed with the replication or expression vector according to claim 6.
8. A method for producing the polypeptide according to claim 1 or 2 which comprises culturing a host cell according to claim 7 under a condition effective to express the polypeptide according to claim 1 or 2.
9. A monoclonal or polyclonal antibody against the polypeptide according to claim 1 or 2.
10. A pharmaceutical composition containing the polypeptide according to claim 1 or 2 or the antibody according to claim 9, in association with pharmaceutically acceptable diluent and/or carrier.

45

50

55

**FIG. 1**



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/JP98/04514

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl. <sup>8</sup> C07K14/47, C12N15/12, C12P21/02, C12P21/08, C07K16/18, A61K39/395, A61K38/17, A61K48/00 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl. <sup>8</sup> C07K14/47, C12N15/12, C12P21/02, C12P21/08, C07K16/18, A61K39/395, A61K38/17, A61K48/00 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) SwissPort/PIR/GeneSeq, Genbank/EMBL/DBJ/GeneSeq, WPI (DIALOG), BIOSIS (DIALOG)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Okamura, W. et al., "Direct evidence for the elevated synthesis and secretion of procathepsin L in the distal caput epididymis of boar", <i>Biochim Biophys Acta</i> (1995) vol. 1245, No. 2 p.221-226	1-10
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 27 January, 1999 (27. 01. 99)		Date of mailing of the international search report 2 February, 1999 (02. 02. 99)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP98/04514

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
Claims 1 to 10, provided the internal search report covers, among the inventions related to these claims, only those inventions which relate to a polypeptide comprising the amino acid sequence represented by SEQ ID NO:
- Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP98/04514

Continuation of Box No. II of continuation of first sheet (1)

1 and a process for producing the same, a cDNA encoding the same, a replication or expression vector comprising the cDNA, a host cell transformed with the vector, a monoclonal or polyclonal antibody against the polypeptide, and a pharmaceutical composition containing the polypeptide and/or the antibody.

## Concerning claims 1 to 10

According to the disclosure in the description of the present invention, "polypeptides respectively comprising the amino acid sequence represented by SEQ ID NO: 1, 4, 7, ... 76 or 79 or polypeptides respectively comprising the homolog, fragment or homolog of the fragment of the above polypeptides" as set forth in claim 1 and "the polypeptides as set forth in claim 1 respectively comprising the amino acid sequence represented by SEQ ID NO: 1, 4, 7, ... 76 or 79" as set forth in claim 2 are assumed to be polypeptides having 27 kinds of utterly different functions and constitutions, except for the common feature that they are secretory or membrane proteins, and a plurality of such secretory or membrane proteins are well known. Therefore, the fact of being secretory or membrane proteins is not considered special technical features in common among these 27 kinds of polypeptides.

Such being the case, each of the above claims is considered to describe 27 inventions. When the unity of invention is taken into account concerning the 27 inventions based on the above consideration, these polypeptides are considered neither those attaining common purposes nor those having common principal parts, and thus it does not appear that there is a technical relationship among these 27 inventions involving one or more of the same or corresponding special technical features. As a result, claims 1 and 2 are not considered fulfilling the requirement of unity of invention.

For the same reason, the requirement of unity of invention is not considered fulfilled as regards the cDNA as set forth in claims 3, 4 and 5, the replication or expression vector in claim 6, the host cell in claim 7, the process for producing a polypeptide in claim 8, the monoclonal or polyclonal antibody in claim 9, and the pharmaceutical composition in claim 10.